Bispecific binding molecules binding to VEGF and Ang2

Abstract

Bispecifc binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS

[0001] This application is a continuation of U.S. Ser. No. 16/515,231, filed Jul. 18, 2019, which is a continuation of U.S. Ser. No. 15/350,364, filed Nov. 14, 2016 which issued as U.S. Pat. No. 10,414,828, on Sept. 17, 2019, which is a division of U.S. patent application Ser. No. 13/433,359, filed Mar. 29, 2012, which issued as U.S. Pat. No. 9,527,925, on Dec. 27, 2016, all of which is incorporated by reference herein.

SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Apr. 10, 2019, named 12-0332-US-2_SL.txt and is 503,868 bytes in size.

FIELD OF THE INVENTION

[0003] The invention relates to the field of human therapy, in particular cancer therapy and agents and compositions useful in such therapy.

BACKGROUND OF THE INVENTION

[0004] When tumors reach a critical size of approximately 1 mm.sup.3 they become dependent on angiogenesis for maintaining blood supply with oxygen and nutritients to allow for further growth. Anti-angiogenesis therapies have become an important treatment option for several types of tumors. These therapies have focused on blocking the VEGF pathway (Ferrara et al., Nat Rev Drug Discov. 2004 May; 3(5):391-400.) by neutralizing VEGF (Avastin) or its receptors (Sutent and Sorafinib). Recent studies in mice have shown, that Angiopoietin2 (Ang2), a ligand of the Tie2 receptor, controls vascular remodeling by enabling the functions of other angiogenic factors, such as VEGF. Ang2 is primarily expressed by endothelial cells, strongly induced by hypoxia and other angiogenic factors and has been demonstrated to regulate tumor vessel plasticity, allowing vessels to respond to VEGF and FGF2 (Augustin et al., Nat Rev Mol Cell Biol. 2009 March; 10(3):165-77.). Consistent with this role, the deletion or inhibition of Ang2 results in reduced angiogenesis (Gale et al., Dev Cell. 2002 September; 3(3):302-4.) (Falcon et al., Am J Pathol. 2009 November; 175(5):2159-70.). Elevated Ang2 serum concentrations have been reported for patients with colorectal cancer, NSCLC and melanoma (Goede et al., Br J Cancer. 2010 Oct. 26; 103(9):1407-14),(Park et al., Chest. 2007 July; 132(1): 200-6.), (Helfrich et al., Clin Cancer Res. 2009 Feb. 15; 15(4):1384-92.). In CRC cancer Ang2 serum levels correlate with therapeutic response to anti-VEGF therapy.

[0005] The Ang-Tie system consists of 2 receptors (Tie1 and Tie2) and 3 ligands (Ang1, Ang2 and Ang4) (Augustin et al., Nat Rev Mol Cell Biol. 2009 March; 10(3):165-77.). Tie2, Ang1 and Ang2 are the best studied members of this family, Tie1 is an orphan receptor and the role of Ang4 for vascular remodelling still needs to be defined. Ang2 and Ang1 mediate opposing functions upon Tie2 binding and activation. Ang2-mediated Tie2 activation results in endothelial cell activation, pericyte dissociation, vessel leakage and induction of vessel sprouting. In contrast to Ang2, Ang1 signaling maintains vessel integrity by recruitment of pericytes, thereby maintaining endothelial cell quiescence.

[0006] Angiopoietin 2 (Ang2) is a secreted, 66 kDa ligand for the Tie2 receptor tyrosine kinase (Augustin et al., Nat Rev Mol Cell Biol. 2009 March; 10(3):1 65-77.). Ang2 consists of an N-terminal coiled-coil domain and a C-terminal fibrinogen-like domain, the latter is required for Tie2 interaction. Ang2 is primarily expressed by endothelial cells and strongly induced by hypoxia and other angiogenic factors, including VEGF. Tie2 is found on endothelial cells, haematopoietic stem cells and tumor cells. Ang2-Tie2 has been demonstrated to regulate tumor vessel plasticity, allowing vessels to respond to VEGF and FGF2.

[0007] In vitro Ang2 has been shown to act as a modest mitogen, chemoattractant and inducer of tube formation in human umbilical vein endothelial cells (HUVEC). Ang2 induces tyrosine phosphorylation of ectopically expressed Tie2 in fibroblasts and promotes downstream signaling events, such as phosphorylation of ERK-MAPK, AKT and FAK in HUVEC. An antagonistic role of Ang2 in Ang1-induced endothelial cell responses has been described.

[0008] Ang2 -deficiency has been shown to result in a profound lymphatic patterning defect in mice. Although the loss of Ang2 is dispensable for embryonic vascular development, Ang2 -deficient mice have persistent vascular defects in the retina and kidney. Together with the dynamic pattern of Ang2 expression at sites of angiogenesis (for example ovary), these findings indicate that Ang2 controls vascular remodeling by enabling the functions of other angiogenic factors, such as VEGF.

[0009] The Ang2-Tie2 system exerts crucial roles during the angiogenic switch and later stages of tumor angiogenesis. Ang2 expression is strongly up-regulated in the tumor-associated endothelium. Reduced growth of tumors has been observed when implanted into Ang2-deficient mice, especially during early stages of tumor growth. Therapeutic blocking of Ang2 with Ang2 mAbs has shown broad efficacy in a variety of tumor xenograft models. Additive effects of Ang2 mAbs with inhibitors of VEGFR2 (mAbs and small molecular weight inhibitors) have been described.

[0010] As described in e.g. US2008/0014196 and WO2008/101985, angiogenesis is implicated in the pathogenesis of a number of disorders, including solid tumors and metastasis as well as eye diseases. One of the most important pro-angiogenic factors is vascular endothelial growth factor (VEGF), also termed VEGF-A or vascular permeability factor (VPF). VEGF belongs to a gene family that includes placenta growth factor (PIGF), VEGF-B, VEGF-C, VEGF-D, VEGF-E and VEGF-F. Alternative splicing of mRNA of a single gene of human VEGF results in at least six isoforms (VEGF121, VEGF145, VEGF165, VEGF183, VEGF189, and VEGF206), VEGF165 being the most abundant isoform.

[0011] Two VEGF tyrosine kinase receptors (VEGFR) have been identified that interact with VEGF, i.e. VEGFR-1 (also known as Flt-1) and VEGFR-2 (also known as KDR or FIK-1). VEGFR-1 has the highest affinity for VEGF, while VEGFR- 2 has a somewhat lower affinity for VEGF. Ferrara (Endocrine Rev. 2004, 25: 581-611) provide a detailed description of VEGF, the interaction with its receptors and its function in normal and pathological processes can be found in Hoeben et al. Pharmacol. Rev. 2004, 56: 549-580.

[0012] VEGF has been reported to be a pivotal regulator of both normal and abnormal angiogenesis (Ferrara and Davis-Smyth, Endocrine Rev. 1997, 18: 4-25; Ferrara J. MoL Med. 1999, 77: 527-543). Compared to other growth factors that contribute to the processes of vascular formation, VEGF is unique in its high specificity for endothelial cells within the vascular system.

[0013] VEGF mRNA is overexpressed by the majority of human tumors. In the case of tumor growth, angiogenesis appears to be crucial for the transition from hyperplasia to neoplasia, and for providing nourishment for the growth and metastasis of the tumor (Folkman et al., 1989, Nature 339-58), which allows the tumor cells to acquire a growth advantage compared to the normal cells. Therefore, anti-angiogenesis therapies have become an important treatment option for several types of tumors. These therapies have focused on blocking the VEGF pathway (Ferrara et al., Nat Rev Drug Discov. 2004 May; 3(5): 391-400.

[0014] VEGF is also involved in eye diseases. The concentration of VEGF in eye fluids is highly correlated with the presence of active proliferation of blood vessels in patients with diabetic and other ischemia-related retinopathies. Furthermore, recent studies have demonstrated the localization of VEGF in choroidal neovascular membranes in patients affected by age-related macular degeneration (AMD). Up-regulation of VEGF has also been observed in various inflammatory disorders. VEGF has been implicated in the pathogenesis of rheutatoid arthritis, an inflammatory disease in which angiogenesis plays a significant role.

[0015] The elucidation of VEGF and its role in angiogenesis and different processes has provided a potential new target of therapeutic intervention. The function of VEGF has been inhibited by small molecules that block or prevent activation of VEGF receptor tyrosine kinases (Schlaeppi and Wood, 1999, Cancer Metastasis Rev., 18: 473-481) and consequently interfere with the VEGF receptor signal transduction pathway. Cytotoxic conjugates containing bacterial or plant toxins can inhibit the stimulating effect of VEGF on tumor angiogenesis. VEGF-DT385 toxin conjugates (diphtheria toxin domains fused or chemically conjugated to VEGF165), for example, efficiently inhibit tumor growth in vivo. Tumor growth inhibition could also be achieved by delivering a Flk-1 mutant or soluble VEGF receptors by a retrovirus.

[0016] VEGF-neutralizing antibodies, such as A4.6.I and MV833, have been developed to block VEGF from binding to its receptors and have shown preclinical antitumor activity (Kim et al. Nature 1993, 362: 841-844; Folkman Nat. Med. 1995, 1: 27-31; Presta et al. Cancer Res. 1997, 57: 4593-4599; Kanai et al. Int. J. Cancer 1998, 77: 933-936; Ferrara and Alitalo Nat. Med. 1999, 5: 1359-1364; 320, 340. For a review of therapeutic anti-VEGF approaches trials, see Campochiaro and Hackett (Oncogene 2003, 22: 6537-6548).

[0017] Most clinical experience has been obtained with A4.6.1, also called bevacizumab (Avastin.RTM.; Genentech, San Francisco, Calif.).

[0018] WO2008/101985 describes immunoglobulin single variable domains from camelides (VHHs or "Nanobodies.RTM.", as defined herein) that bind to VEGF, and their use in the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization.

[0019] It has been an object of the present invention to provide novel anti-angiogenic binding molecules for human therapy.

[0020] It has been a further object of the invention to provide methods for the prevention, treatment, alleviation and/or diagnosis of such diseases, disorders or conditions, involving the use and/or administration of such binding molecules and compositions comprising them. In particular, it is has been an object of the invention to provide such pharmacologically active binding molecules, compositions and/or methods that provide advantages compared to the agents, compositions and/or methods currently used and/or known in the art. These advantages include improved therapeutic and/or pharmacological properties and/or other advantageous properties, e.g. for manufacturing purposes, especially as compared to conventional antibodies as those described above, or fragments thereof.

BRIEF SUMMARY OF THE INVENTION

[0021] According to a first aspect, there are provided bispecific binding molecules, preferably bispecific immunoglobulins, preferably immunoglobulin single variable domains like VHHs and domain antibodies, which comprise at least one VEGF-binding component and at least one Ang2-binding component in a single molecule. Preferably, said bispecific binding molecules further comprise a serum albumin binding component.

[0022] More specifically, a bispecific binding molecule of the invention essentially comprises (i) a Ang2-binding component specifically binding to at least one epitope of Ang2 and (ii) a VEGF-binding component specifically binding to at least an epitope of VEGF, wherein the components are linked to each other in such a way that they simultaneously bind to Ang2 and VEGF or that they bind to either Ang2 or VEGF at a time.

[0023] According to preferred aspects of the invention, the two components comprise one or more immunoglobulin single variable domains that may be, independently of each other, VHHs or domain antibodies, and/or any other sort of immunoglobulin single variable domains, such as VL domains, as defined herein, provided that each of these immunoglobulin single variable domains will bind the antigen, i.e. Ang2 or VEGF, respectively.

[0024] According to a preferred embodiment, the immunoglobulin single variable domains are of the same type, in particular, all immunoglobulin single variable domains are VHHs or domain antibodies.

[0025] According to a particularly preferred embodiment, all immunoglobulin single variable domains are VHHs, preferably humanized (or "sequence-optimized", as defined herein) VHHs. Accordingly, the invention relates to bispecific binding molecules comprising an (optionally humanized or sequence-optimized) anti-Ang2 VHH and an (optionally humanized or sequence-optimized) anti-VEGF VHH.

[0026] However, it will be clear to the skilled person that the teaching herein may be applied analogously to bispecific binding molecules including other anti-Ang2 or anti-VEGF immunoglobulin single variable domains, such as domain antibodies.

[0027] In another aspect, the invention relates to nucleic acids encoding the bispecific binding molecules of the invention as well as host cells containing same.

[0028] The invention further relates to a product or composition containing or comprising at least one bispecific binding molecule of the invention and optionally one or more further components of such compositions.

[0029] The invention further relates to methods for preparing or generating the bispecific binding molecules, nucleic acids, host cells, products and compositions described herein.

[0030] The invention further relates to applications and uses of the bispecific binding molecules, nucleic acids, host cells, products and compositions described herein, as well as to methods for the prevention and/or treatment for diseases and disorders that can be modulated by inhibition of Ang2.

[0031] It has been found that the Ang2-binding component of the bispecific binding molecules according to the present invention binds to and antagonizes Ang2 with a potency at least 5,000 times higher, preferably 10,000 times higher than to Ang1 or Ang4. This will largely avoid blocking activation of Ang1-mediated signalling, which would counter the intended anti-angiogenetic effect.

[0032] It has further been found that the VEGF-binding component of the bi-specific binding molecules according to the present invention binds to VEGF-A with an affinity of at least 1,000 times higher, preferebly at least 5,000 times higher, more preferably at least 10,000 times higher than to VEGF-B, VEGF-C, VEGF-D or PLGF. Due to the highly preferential binding to VEGF-A the signaling of VEGFR3, which modulates of lymph angiogenesis, is not interfered with.

[0033] In a preferred embodiment the bispecific binding molecules of the present invention are provided as linked VHH domains. Such molecules are significantly smaller than conventional antibodies and have thus the potential for penetrating into a tumor deeper than such conventional antibodies. This benefit is further accentuated by the specific sequences disclosed herein after being free of glycosylation sites.

[0034] Further, due to the bispecific nature (VEGF- and Ang2-binding components in one molecule) the tumor penetration of both functionalities will be necessarily equal, which will ensure that the beneficial effects of the combined antagonism of VEGF and Ang2 will be provided within the whole depth of penetration of the tumor. This is an advantage over the combination of individual antagonists against these targets, since the depth of penetration of individual antagonists will always vary to some degree.

[0035] Another advantage of a preferred bispecific binding molecules of the present invention is their increased serum half-like due to a serum albumin binding component such as a serum albumin binding molecule as described herein.

[0036] These and other aspects, embodiments, advantages and applications of the invention will become clear from the further description hereinbelow.

[0037] Definitions

[0038] Unless indicated or defined otherwise, all terms used have their usual meaning in the art, which will be clear to the skilled person. Reference is for example made to the standard handbooks, such as Sambrook et al, "Molecular Cloning: A Laboratory Manual" (2nd Ed.), Vols. 1-3, Cold Spring Harbor Laboratory Press (1989); Lewin, "Genes IV", Oxford University Press, New York, (1990), and Roitt et al., "Immunology" (2.sup.nd Ed.), Gower Medical Publishing, London, New York (1989), as well as to the general background art cited herein; Furthermore, unless indicated otherwise, all methods, steps, techniques and manipulations that are not specifically described in detail can be performed and have been performed in a manner known per se, as will be clear to the skilled person. Reference is for example again made to the standard handbooks, to the general background art referred to above and to the further references cited therein.

[0039] The term "bispecific binding molecule" refers to a molecule comprising at least one Ang2-binding molecule (or "Ang2-binding component") and at least one VEGF-binding molecule (or "VEGF-binding component"). A bispecific binding molecule may contain more than one Ang2-binding molecule and/or more than one VEGF-binding molecule, i.e. in the case that the bispecific binding molecule contains a biparatopic (as defined below) Ang2-binding molecule and/or a biparatopic VEGF-binding molecule, in the part of the molecule that binds to Ang2 or to VEGF, i.e. in its "Ang2-binding component" (or anti-Ang2 component) or "VEGF-binding component" (or anti-VEGF component), respectively. The word "bispecific" in this context is however not to be construed as to exclude further binding components with binding specificity to molecules other than VEGF and Ang2 from the bispecific binding molecule. Non-limiting examples of such further binding components are binding components binding to serum albumin.

[0040] Unless indicated otherwise, the terms "immunoglobulin" and "immunoglobulin sequence"--whether used herein to refer to a heavy chain antibody or to a conventional 4-chain antibody--are used as general terms to include both the full-size antibody, the individual chains thereof, as well as all parts, domains or fragments thereof (including but not limited to antigen-binding domains or fragments such as VHH domains or VH/VL domains, respectively). In addition, the term "sequence" as used herein (for example in terms like "immunoglobulin sequence", "antibody sequence", "(single) variable domain sequence", "VHH sequence" or "protein sequence"), should generally be understood to include both the relevant amino acid sequence as well as nucleic acid sequences or nucleotide sequences encoding the same, unless the context requires a more limited interpretation.

[0041] The term "domain" (of a polypeptide or protein) as used herein refers to a folded protein structure which has the ability to retain its tertiary structure independently of the rest of the protein. Generally, domains are responsible for discrete functional properties of proteins, and in many cases may be added, removed or transferred to other proteins without loss of function of the remainder of the protein and/or of the domain.

[0042] The term "immunoglobulin domain" as used herein refers to a globular region of an antibody chain (such as e.g. a chain of a conventional 4-chain antibody or of a heavy chain antibody), or to a polypeptide that essentially consists of such a globular region. Immunoglobulin domains are characterized in that they retain the immunoglobulin fold characteristic of antibody molecules, which consists of a 2-layer sandwich of about 7 antiparallel beta-strands arranged in two beta-sheets, optionally stabilized by a conserved disulphide bond. An immunoglobulin domain comprises (a) variable domain(s), i.e., one or more immunoglobulin variable domains.

[0043] The term "immunoglobulin variable domain" as used herein means an immunoglobulin domain essentially consisting of four "framework regions" which are referred to in the art and hereinbelow as "framework region 1" or "FR1"; as "framework region 2" or"FR2"; as "framework region 3" or "FR3"; and as "framework region 4" or "FR4", respectively; which framework regions are interrupted by three "complementarity determining regions" or "CDRs", which are referred to in the art and hereinbelow as "complementarity determining region 1" or "CDR1"; as "complementarity determining region 2" or "CDR2";

[0044] and as "complementarity determining region 3" or "CDR3", respectively. Thus, the general structure or sequence of an immunoglobulin variable domain can be indicated as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. It is the immunoglobulin variable domain(s) that confer specificity to an antibody for the antigen by carrying the antigen-binding site. In the context of the present invention immunoglobulin single variable domains like VHHs and domain antibodies are preferred.

[0045] The term "immunoglobulin single variable domain" as used herein means an immunoglobulin variable domain which is capable of specifically binding to an epitope of the antigen without pairing with an additional variable immunoglobulin domain. One example of immunoglobulin single variable domains in the meaning of the present invention are "domain antibodies", such as the immunoglobulin single variable domains VH and VL (VH domains and VL domains). Another example of immunoglobulin single variable domains are "VHH domains" (or simply "VHHs") from camelids, as defined hereinafter.

[0046] In view of the above definition, the antigen-binding domain of a conventional 4-chain antibody (such as an IgG, IgM, IgA, IgD or IgE molecule; known in the art) or of a Fab fragment, a F(ab')2 fragment, an Fv fragment such as a disulphide linked Fv or a scFv fragment, or a diabody (all known in the art) derived from such conventional 4-chain antibody, would normally not be regarded as an immunoglobulin single variable domain, as, in these cases, binding to the respective epitope of an antigen would normally not occur by one (single) immunoglobulin domain but by a pair of (associating) immunoglobulin domains such as light and heavy chain variable domains, i.e. by a VH-VL pair of immunoglobulin domains, which jointly bind to an epitope of the respective antigen.

[0047] "VHH domains", also known as VHHs, VHH domains, VHH antibody fragments, and VHH antibodies, have originally been described as the antigen binding immunoglobulin (variable) domain of "heavy chain antibodies" (i.e. of "antibodies devoid of light chains"; Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa E B, Bendahman N, Hamers R.: "Naturally occurring antibodies devoid of light chains"; Nature 363, 446-448 (1993)). The term "VHH domain" has been chosen in order to distinguish these variable domains from the heavy chain variable domains that are present in conventional 4-chain antibodies (which are referred to herein as "V.sub.H domains" or "VH domains") and from the light chain variable domains that are present in conventional 4-chain antibodies (which are referred to herein as "V.sub.L domains" or "VL domains"). VHH domains can specifically bind to an epitope without an additional antigen binding domain (as opposed to VH or VL domains in a conventional 4-chain antibody, in which case the epitope is recognized by a VL domain together with a VH domain). VHH domains are small, robust and efficient antigen recognition units formed by a single immunoglobulin domain.

[0048] In the context of the present invention, the terms VHH domain, VHH, V.sub.HH domain, VHH antibody fragment, VHH antibody, as well as "Nanobody.RTM." and "Nanobody.RTM. domain" ("Nanobody" being a trademark of the company Ablynx N.V.; Ghent; Belgium) are used interchangeably and are representatives of immunoglobulin single variable domains (having the structure FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 and specifically binding to an epitope without requiring the presence of a second immunoglobulin variable domain), and which are distinguished from VH domains by the so-called "hallmark residues", as defined in e.g. WO2009/109635, FIG. 1.

[0049] The amino acid residues of a immunoglobulin single variable domain, e.g. a VHH, are numbered according to the general numbering for V.sub.H domains given by Kabat et al. ("Sequence of proteins of immunological interest", US Public Health Services, NIH Bethesda, Md., Publication No. 91), as applied to VHH domains from Camelids, as shown e.g. in FIG. 2 of Riechmann and Muyldermans, J. Immunol. Methods 231, 25-38 (1999). According to this numbering

[0050] FR1 comprises the amino acid residues at positions 1-30,

[0051] CDR1 comprises the amino acid residues at positions 31-35,

[0052] FR2 comprises the amino acids at positions 36-49,

[0053] CDR2 comprises the amino acid residues at positions 50-65,

[0054] FR3 comprises the amino acid residues at positions 66-94,

[0055] CDR3 comprises the amino acid residues at positions 95-102, and

[0056] FR4 comprises the amino acid residues at positions 103-113.

[0057] However, it should be noted that--as is well known in the art for VH domains and for VHH domains--the total number of amino acid residues in each of the CDRs may vary and may not correspond to the total number of amino acid residues indicated by the Kabat numbering (that is, one or more positions according to the Kabat numbering may not be occupied in the actual sequence, or the actual sequence may contain more amino acid residues than the number allowed for by the Kabat numbering). This means that, generally, the numbering according to Kabat may or may not correspond to the actual numbering of the amino acid residues in the actual sequence.

[0058] Alternative methods for numbering the amino acid residues of VH domains, which methods can also be applied in an analogous manner to VHH domains, are known in the art. However, in the present description, claims and figures, the numbering according to Kabat and applied to VHH domains as described above will be followed, unless indicated otherwise.

[0059] The total number of amino acid residues in a VHH domain will usually be in the range of from 110 to 120, often between 112 and 115. It should however be noted that smaller and longer sequences may also be suitable for the purposes described herein.

[0060] Immunoglobulin single variable domains, e.g. VHHs and domain antibodies, according to the preferred embodiments of the invention, have a number of unique structural characteristics and functional properties which makes them highly advantageous for use in therapy as functional antigen-binding molecules. In particular, and without being limited thereto, VHH domains (which have been "designed" by nature to functionally bind to an antigen without pairing with a light chain variable domain) can function as single, relatively small, functional antigen-binding structural units.

[0061] Due to their unique properties, immunoglobulin single variable domains, as defined herein, like VHHs or VHs (or VLs)--either alone or as part of a larger polypeptide, e.g. a biparatopic molecule--offer a number of significant advantages:

[0062] only a single domain is required to bind an antigen with high affinity and with high selectivity, so that there is no need to have two separate domains present, nor to assure that these two domains are present in the right spacial conformation and configuration (i.e. through the use of especially designed linkers, as with scFv's);

[0063] immunoglobulin single variable domains can be expressed from a single nucleic acid molecule and do not require any post-translational modification (like glycosylation;

[0064] immunoglobulin single variable domains can easily be engineered into multivalent and multispecific formats (as further discussed herein);

[0065] immunoglobulin single variable domains have high specificity and affinity for their target, low inherent toxicity and can be administered via alternative routes than infusion or injection;

[0066] immunoglobulin single variable domains are highly stable to heat, pH, proteases and other denaturing agents or conditions and, thus, may be prepared, stored or transported without the use of refrigeration equipments;

[0067] immunoglobulin single variable domains are easy and relatively inexpensive to prepare, both on small scale and on a manufacturing scale. For example, immunoglobulin single variable domains can be produced using microbial fermentation (e.g. as further described below) and do not require the use of mammalian expression systems, as with for example conventional antibodies;

[0068] immunoglobulin single variable domains are relatively small (approximately 15 kDa, or 10 times smaller than a conventional IgG) compared to conventional 4-chain antibodies and antigen-binding fragments thereof, and therefore show high(er) penetration into tissues (including but not limited to solid tumors and other dense tissues) and can be administered in higher doses than such conventional 4-chain antibodies and antigen-binding fragments thereof;

[0069] VHHs have specific so-called "cavity-binding properties" (inter alia due to their extended CDR3 loop, compared to VH domains from 4-chain antibodies) and can therefore also access targets and epitopes not accessible to conventional 4-chain antibodies and antigen-binding fragments thereof;

[0070] VHHs have the particular advantage that they are highly soluble and very stable and do not have a tendency to aggregate (as with the mouse-derived antigen-binding domains described by Ward et al., Nature 341: 544-546 (1989)).

[0071] The immunoglobulin single variable domains of the invention are not limited with respect to a specific biological source from which they have been obtained or to a specific method of preparation. For example, obtaining VHHs may include the following steps:

[0072] (1) isolating the VHH domain of a naturally occurring heavy chain antibody; or screening a library comprising heavy chain antibodies or VHHs and isolating VHHs therefrom;

[0073] (2) expressing a nucleic acid molecule encoding a VHH with the naturally occurring sequence;

[0074] (3) "humanizing" (as described herein) a VHH, optionally after affinity maturation, with a naturally occurring sequence or expressing a nucleic acid encoding such humanized VHH;

[0075] (4) "camelizing" (as described below) a immunoglobulin single variable heavy domain from a naturally occurring antibody from an animal species, in particular a species of mammal, such as from a human being, or expressing a nucleic acid molecule encoding such camelized domain;

[0076] (5) "camelizing" a VH, or expressing a nucleic acid molecule encoding such a camelized VH;

[0077] (6) using techniques for preparing synthetically or semi-synthetically proteins, polypeptides or other amino acid sequences;

[0078] (7) preparing a nucleic acid molecule encoding a VHH domain using techniques for nucleic acid synthesis, followed by expression of the nucleic acid thus obtained;

[0079] (8) subjecting heavy chain antibodies or VHHs to affinity maturation, to mutagenesis (e.g. random mutagenesis or site-directed mutagenesis) and/or any other technique(s) in order to increase the affinity and/or specificity of the VHH; and/or (9) combinations or selections of the foregoing steps.

[0080] Suitable methods and techniques for performing the above-described steps are known in the art and will be clear to the skilled person. By way of example, methods of obtaining VHH domains binding to a specific antigen or epitope have been described in WO2006/040153 and WO2006/122786.

[0081] According to specific embodiments, the immunoglobulin single variable domains of the invention or present in the polypeptides of the invention are VHH domains with an amino acid sequence that essentially corresponds to the amino acid sequence of a naturally occurring VHH domain, but that has been "humanized" or "sequence-optimized" (optionally after affinity-maturation), i.e. by replacing one or more amino acid residues in the amino acid sequence of said naturally occurring VHH sequence by one or more of the amino acid residues that occur at the corresponding position(s) in a variable heavy domain of a conventional 4-chain antibody from a human being. This can be performed using methods known in the art, which can by routinely used by the skilled person.

[0082] A humanized VHH domain may contain one or more fully human framework region sequences, and, in an even more specific embodiment, may contain human framework region sequences derived from the human germline Vh3 sequences DP-29, DP-47, DP-51, or parts thereof, or be highly homologous thereto, optionally combined with JH sequences, such as JHS. Thus, a humanization protocol may comprise the replacement of any of the VHH residues with the corresponding framework 1, 2 and 3 (FRI, FR2 and FR3) residues of germline VH genes such as DP 47, DP 29 and DP 51) either alone or in combination. Suitable framework regions (FR) of the immunoglobulin single variable domains of the invention can be selected from those as set out e.g. in WO2006/004678 and specifically, include the so-called "KERE" (SEQ ID NO: 276) and "GLEW" (SEQ ID NO: 277) classes. Examples are immunoglobulin single variable domains having the amino acid sequence G-L-E-W (SEQ ID NO: 277) at about positions 44 to 47, and their respective humanized counterparts. A humanized VHH domain may contain one or more fully human framework region sequences.

[0083] By way of example, a humanizing substitution for VHHs belonging to the 103 P,R,S-group and/or the GLEW-group (SEQ ID NO: 277) (as defined below) is 108Q to 108L. Methods for humanizing immunoglobulin single variable domains are known in the art.

[0084] Binding immunoglobulin single variable domains with improved properties in view of therapeutic application, e.g. enhanced affinity or decreased immunogenicity, may be obtained from individual binding molecules by techniques known in the art, such as affinity maturation (for example, starting from synthetic, random or naturally occurring immunoglobulin sequences), CDR grafting, humanizing, combining fragments derived from different immunoglobulin sequences, PCR assembly using overlapping primers, and similar techniques for engineering immunoglobulin sequences well known to the skilled person; or any suitable combination of any of the foregoing, also termed "sequence optimization", as described herein. Reference is, for example, made to standard handbooks, as well as to the further description and Examples.

[0085] If appropriate, a binding molecule with increased affinity may be obtained by affinity-maturation of another binding molecule, the latter representing, with respect to the affinity-matured molecule, the "parent" binding molecule.

[0086] Methods of obtaining VHHs that bind to a specific antigen or epitope have been described earlier, e.g. in WO2006/040153 and WO2006/122786. As also described therein in detail, VHH domains derived from camelids can be "humanized" (also termed "sequence-optimized" herein, "sequence-optimizing" may, in addition to humanization, encompass an additional modification of the sequence by one or more mutations that furnish the VHH with improved properties, such as the removal of potential post translational modification sites) by replacing one or more amino acid residues in the amino acid sequence of the original VHH sequence by one or more of the amino acid residues that occur at the corresponding position(s) in a VH domain from a conventional 4-chain antibody from a human being. A humanized VHH domain can contain one or more fully human framework region sequences, and, in an even more specific embodiment, can contain human framework region sequences derived from DP-29, DP-47, DP-51, or parts thereof, optionally combined with JH sequences, such as JH5.

[0087] Domain antibodies, also known as "Dab"s and "dAbs" (the terms "Domain Antibodies" and "dAbs" being used as trademarks by the GlaxoSmithKline group of companies) have been described in e.g. Ward, E. S., et al.: "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli"; Nature 341: 544-546 (1989); Holt, L. J. et al.: "Domain antibodies: proteins for therapy"; TRENDS in Biotechnology 21(11): 484-490 (2003); and WO2003/002609.

[0088] Domain antibodies essentially correspond to the VH or VL domains of antibodies from non-camelid mammals, in particular human 4-chain antibodies. In order to bind an epitope as a single antigen binding domain, i.e. without being paired with a VL or VH domain, respectively, specific selection for such antigen binding properties is required, e.g. by using libraries of human single VH or VL domain sequences.

[0089] Domain antibodies have, like VHHs, a molecular weight of approximately 13 to approximately 16 kDa and, if derived from fully human sequences, do not require humanization for e.g. therapeutical use in humans. As in the case of VHH domains, they are well expressed also in prokaryotic expression systems, providing a significant reduction in overall manufacturing cost.

[0090] Furthermore, it will also be clear to the skilled person that it is possible to "graft" one or more of the CDR's mentioned above onto other "scaffolds", including but not limited to human scaffolds or non-immunoglobulin scaffolds. Suitable scaffolds and techniques for such CDR grafting are known in the art.

[0091] The terms "epitope" and "antigenic determinant", which can be used interchangeably, refer to the part of a macromolecule, such as a polypeptide, that is recognized by antigen-binding molecules, such as conventional antibodies or the polypeptides of the invention, and more particularly by the antigen-binding site of said molecules. Epitopes define the minimum binding site for an immunoglobulin, and thus represent the target of specificity of an immunoglobulin.

[0092] A polypeptide (such as an immunoglobulin, an antibody, an immunoglobulin single variable domain of the invention, or generally an antigen-binding molecule or a fragment thereof) that can "bind to" or "specifically bind to", that "has affinity for" and/or that "has specificity for" a certain epitope, antigen or protein (or for at least one part, fragment or epitope thereof) is said to be "against" or "directed against" said epitope, antigen or protein or is a "binding" molecule with respect to such epitope, antigen or protein. In this context, a VEGF-binding component may also be referred to as "VEGF-neutralizing".

[0093] Generally, the term "specificity" refers to the number of different types of antigens or epitopes to which a particular antigen-binding molecule or antigen-binding protein (such as an immunoglobulin single variable domain of the invention) molecule can bind. The specificity of an antigen-binding molecule can be determined based on its affinity and/or avidity. The affinity, represented by the equilibrium constant for the dissociation of an antigen with an antigen-binding protein (KD), is a measure for the binding strength between an epitope and an antigen-binding site on the antigen-binding protein: the lesser the value of the KD, the stronger the binding strength between an epitope and the antigen-binding molecule (alternatively, the affinity can also be expressed as the affinity constant (KA), which is 1/KD). As will be clear to the skilled person (for example on the basis of the further disclosure herein), affinity can be determined in a manner known per se, depending on the specific antigen of interest. Avidity is the measure of the strength of binding between an antigen-binding molecule (such as an immunoglobulin, an antibody, an immunoglobulin single variable domain or a polypeptides containing it and the pertinent antigen. Avidity is related to both the affinity between an epitope and its antigen binding site on the antigen-binding molecule and the number of pertinent binding sites present on the antigen-binding molecule.

[0094] The part of an antigen-binding molecule that recognizes the epitope is called a paratope.

[0095] Unless indicated otherwise, the term "VEGF-binding molecule" or "Ang2-binding molecule" includes anti-VEGF or anti-Ang2 antibodies, anti-VEGF antibody or anti-Ang2 antibody fragments, "anti-VEGF antibody-like molecules" or "anti-Ang2 antibody-like molecules", as defined herein, and conjugates with any of these. Antibodies include, but are not limited to, monoclonal and chimerized monoclonal antibodies. The term "antibody" encompasses complete immunoglobulins, like monoclonal antibodies produced by recombinant expression in host cells, as well as antibody fragments or "antibody-like molecules", including single-chain antibodies and linear antibodies, so-called "SMIPs" ("Small Modular Immunopharmaceuticals"), as e.g described in WO2002/056910; Antibody-like molecules include immunoglobulin single variable domains, as defined herein. Other examples for antibody-like molecules are immunoglobulin super family antibodies (IgSF), or CDR-grafted molecules.

[0096] "Ang2-binding molecule" or "VEGF-binding molecule" respectively, refers to both monovalent target-binding molecules (i.e. molecules that bind to one epitope of the respective target) as well as to bi- or multivalent binding molecules (i.e. binding molecules that bind to more than one epitope, e.g. "biparatopic" molecules as defined hereinbelow). Ang2(or VEGF)-binding molecules containing more than one Ang2(or VEGF)-binding immunoglobulin single variable domain are also termed "formatted" binding molecules, they may, within the target-binding component, in addition to the immunoglobulin single variable domains, comprise linkers and/or moieties with effector functions, e.g. half-life-extending moieties like albumin-binding immunoglobulin single variable domains, and/or a fusion partner like serum albumin and/or an attached polymer like PEG.

[0097] The term "biparatopic Ang2(or VEGF)-binding molecule" or "biparatopic immunoglobulin single variable domain" as used herein shall mean a binding molecule comprising a first immunoglobulin single variable domain and a second immunoglobulin single variable domain as herein defined, wherein the two molecules bind to two non-overlapping epitopes of the respective antigen. The biparatopic binding molecules are composed of immunoglobulin single variable domains which have different specificities with respect to the epitope. The part of an antigen-binding molecule (such as an antibody or an immunoglobulin single variable domain of the invention) that recognizes the epitope is called a paratope.

[0098] A formatted binding molecule may, albeit less preferred, also comprise two identical immunoglobulin single variable domains or two different immunoglobulin single variable domains that recognize the same or overlapping epitopes or their respective antigen. In this case, with respect to VEGF, the two immunoglobulin single variable domains may bind to the same or an overlapping epitope in each of the two monomers that form the VEGF dimer.

[0099] Typically, the binding molecules of the invention will bind with a dissociation constant (KD) of 10E-5 to 10E-14 moles/liter (M) or less, and preferably 10E-7 to 10E-14 moles/liter (M) or less, more preferably 10E-8 to 10E-14 moles/liter, and even more preferably 10E-11 to 10E-13, as measured e.g. in a Biacore or in a Kinexa assay), and/or with an association constant (KA) of at least 10E7 ME-1, preferably at least 10E8 ME-1, more preferably at least 10E9 ME-1, such as at least 10E11 ME-1. Any KD value greater than 10E-4 M is generally considered to indicate non-specific binding.

[0100] Preferably, a polypeptide of the invention will bind to the desired antigen, i.e. VEGF or Ang2, respectively, with a KD less than 500 nM, preferably less than 200 nM, more preferably less than 10 nM, such as less than 500 pM. Specific binding of an antigen-binding protein to an antigen or epitope can be determined in any suitable manner known per se, including, for example, the assays described herein, Scatchard analysis and/or competitive binding assays, such as radioimmunoassays (RIA), enzyme immunoassays (EIA) and sandwich competition assays, and the different variants thereof known per se in the art.

[0101] Amino acid residues will be indicated according to the standard three-letter or one-letter amino acid code, as generally known and agreed upon in the art. When comparing two amino acid sequences, the term "amino acid difference" refers to insertions, deletions or substitutions of the indicated number of amino acid residues at a position of the reference sequence, compared to a second sequence. In case of substitution(s), such substitution(s) will preferably be conservative amino acid substitution(s), which means that an amino acid residue is replaced with another amino acid residue of similar chemical structure and which has little or essentially no influence on the function, activity or other biological properties of the polypeptide. Such conservative amino acid substitutions are well known in the art, for example from WO1998/49185, wherein conservative amino acid substitutions preferably are substitutions in which one amino acid within the following groups (i)-(v) is substituted by another amino acid residue within the same group: (i) small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr, Pro and Gly; (ii) polar, negatively charged residues and their (uncharged) amides: Asp, Asn, Glu and Gln; (iii) polar, positively charged residues: His, Arg and Lys; (iv) large aliphatic, nonpolar residues: Met, Leu, Ile, Val and Cys; and (v) aromatic residues: Phe, Tyr and Trp. Particularly preferred conservative amino acid substitutions are as follows: Ala into Gly or into Ser; Arg into Lys; Asn into Gln or into His; Asp into Glu; Cys into Ser; Gln into Asn; Glu into Asp; Gly into Ala or into Pro; His into Asn or into Gln; Ile into Leu or into Val; Leu into Ile or into Val; Lys into Arg, into Gln or into Glu; Met into Leu, into Tyr or into Ile; Phe into Met, into Leu or into Tyr; Ser into Thr; Thr into Ser; Trp into Tyr; Tyr into Trp or into Phe; Val into Ile or into Leu.

[0102] A polypeptide or nucleic acid molecule is considered to be "(in) essentially isolated (form)"--for example, when compared to its native biological source and/or the reaction medium or cultivation medium from which it has been obtained--when it has been separated from at least one other component with which it is usually associated in said source or medium, such as another protein/polypeptide, another nucleic acid, another biological component or macromolecule or at least one contaminant, impurity or minor component. In particular, a polypeptide or nucleic acid molecule is considered "essentially isolated" when it has been purified at least 2-fold, in particular at least 10-fold, more in particular at least 100-fold, and up to 1000-fold or more. A polypeptide or nucleic acid molecule that is "in essentially isolated form" is preferably essentially homogeneous, as determined using a suitable technique, such as a suitable chromatographical technique, such as polyacrylamide gel electrophoresis.

[0103] "Sequence identity" between two VEGF-binding molecule sequences or between two Ang2-binding molecule sequences indicates the percentage of amino acids that are identical between the sequences. It may be calculated or determined as described in paragraph f) on pages 49 and 50 of WO2008/020079. "Sequence similarity" indicates the percentage of amino acids that either are identical or that represent conservative amino acid substitutions.

[0104] Alternative methods for numbering the amino acid residues of VH domains, which methods can also be applied in an analogous manner to VHH domains, are known in the art. However, in the present description, claims and figures, the numbering according to Kabat and applied to VHH domains as described above will be followed, unless indicated otherwise.

[0105] An "affinity-matured" VEGF-binding molecule or Ang2-binding molecule, in particular a VHH or a domain antibody, has one or more alterations in one or more CDRs which result in an improved affinity for VEGF or Ang2, as compared to the respective parent VEGF-binding molecule or Ang2-binding molecule. Afffinity-matured VEGF-binding molecules or Ang2-binding molecules of the invention may be prepared by methods known in the art, for example, as described by Marks et al., 1992, Biotechnology 10: 779-783, or Barbas, et al., 1994, Proc. Nat. Acad. Sci, USA 91: 3809-3813.; Shier et al., 1995, Gene 169:147-155; Yelton et al., 1995, Immunol. 155: 1994-2004; Jackson et al., 1995, J. Immunol. 154(7):3310-9; and Hawkins et al., 1992, J. Mol. Biol. 226(3): 889 896; KS Johnson and RE Hawkins, "Affinity maturation of antibodies using phage display", Oxford University Press 1996.

[0106] For the present invention, an "amino acid sequences of SEQ ID NO: x": includes, if not otherwise stated, an amino acid sequence that is 100% identical with the sequence shown in the respective SEQ ID NO: x;

[0107] a) amino acid sequences that have at least 80% amino acid identity with the sequence shown in the respective SEQ ID NO: x;

[0108] b) amino acid sequences that have 3, 2, or 1 amino acid differences with the sequence shown in the respective SEQ ID NO: x.

[0109] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth/proliferation. Examples of cancer to be treated with a bispecific binding molecule of the invention, include but are not limited to carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More particular examples of such cancers, as suggested for treatment with VEGF antagonists in US 2008/0014196, include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, gastric cancer, melanoma, and various types of head and neck cancer. Dysregulation of angiogenesis can lead to many disorders that can be treated by compositions and methods of the invention. These disorders include both non-neoplastic and neoplastic conditions. Neoplasties include but are not limited those described above.

[0110] Non-neoplastic disorders include, but are not limited to, as suggested for treatment with VEGF antagonists in US2008/0014196, undesired or aberrant hypertrophy, arthritis, rheumatoid arthritis (RA), psoriasis, psoriatic plaques, sarcoidosis, atherosclerosis, atherosclerotic plaques, diabetic and other proliferative retinopathies including retinopathy of prematurity, retrolental fibroplasia, neovascular glaucoma, age-related macular degeneration, diabetic macular edema, corneal neovascularization, corneal graft neovascularization, corneal graft rejection, retinal/choroidal neovascularization, neovascularization of the angle (rubeosis), ocular neovascular disease, vascular restenosis, arteriovenous malformations (AVM), meningioma, hemangioma, angiofibroma, thyroid hyperplasias (including Grave's disease), corneal and other tissue transplantation, chronic inflammation, lung inflammation, acute lung injury/ARDS, sepsis, primary pulmonary hypertension, malignant pulmonary effusions, cerebral edema (e.g., associated with acute stroke/closed head injury/trauma), synovial inflammation, pannus formation in RA, myositis ossificans, hypertropic bone formation, osteoarthritis (OA), refractory ascites, polycystic ovarian disease, endometriosis, 3.sup.rd spacing of fluid diseases (pancreatitis, compartment syndrome, burns, bowel disease), uterine fibroids, premature labor, chronic inflammation such as IBD (Crohn's disease and ulcerative colitis), renal allograft rejection, inflammatory bowel disease, nephrotic syndrome, undesired or aberrant tissue mass growth (non-cancer), hemophilic joints, hypertrophic scars, inhibition of hair growth, Osier-Weber syndrome, pyogenic granuloma retrolental fibroplasias, scleroderma, trachoma, vascular adhesions, synovitis, dermatitis, preeclampsia, ascites, pericardial effusion (such as that associated with pericarditis), and pleural effusion.

DETAILED DESCRIPTION OF THE INVENTION

[0111] In a first aspect, the present invention relates to a bispecific binding molecule comprising at least one Ang2-binding component and at least one VEGF-binding component.

[0112] In a preferred embodiment, the present invention relates to a bispecific binding molecule comprising at least one VEGF-binding component and at least one Ang2-binding component which further comprises at least a further binding component, preferably a serum albumin binding component (serum albumin binding molecule).

[0113] In a preferred embodiment, the serum albumin binding component of the binding molecule of the present invention is an isolated immunoglobulin single variable domain or a polypeptide containing one or more of said immunoglobulin single variable domains, wherein said immunoglobulin single variable domain consists of four framework regions and three complementarity determining regions CDR1, CDR2 and CDR3, respectively, and wherein said CDR3 has an amino acid sequence selected from amino acid sequences shown in SEQ ID NOs: 257, 260, 263, 266, 269, 272, or 275.

[0114] More preferably, said one or more immunoglobulin single variable domain of the serum albumin binding component contain

[0115] a. a CDR3 with an amino acid sequence selected from a first group of amino acid sequences shown in SEQ ID NOs: SEQ IDs NOs: 257, 260, 263, 266, 269, 272, or 275;

[0116] b. a CDR1 with an amino acid sequences selected from a second group of amino acid sequences shown SEQ ID NOs:255, 258, 261, 264, 267, 270, or 273;

[0117] c. a CDR2 with an amino acid sequences selected from a second group of amino acid sequences shown SEQ ID NOs:256, 259, 262, 265, 268, 271, or 274.

[0118] In a more preferred embodiment, said one or more immunoglobulin single variable domains of the serum albumin binding component are VHHs, preferably having an amino acid sequence shown in SEQ ID NOs: 98 or 254.

[0119] According to preferred embodiments, said Ang2-binding component and said VEGF-binding component comprise at least one Ang2-binding immunoglobulin single variable domain and at least one VEGF-binding immunoglobulin single variable domain, respectively.

[0120] In a preferred aspect, said Ang2-binding component and said VEGF-binding component each comprise at least one VEGF-binding immunoglobulin single variable domain and at least one Ang2-binding immunoglobulin single variable domain, respectively, wherein each of said immunoglobulin single variable domains has four framework regions and three complementarity determining regions CDR1, CDR2 and CDR3, respectively.

[0121] Thus, the anti-Ang2 and/or the anti-VEGF component contained in the bispecific binding molecules of the invention may include two (or more) anti-Ang2 (or anti-VEGF, respectively) immunoglobulin single variable domains, wherein the immunoglobulin single variable domains are directed against different epitopes within the Ang2 (or VEGF) target. Thus, the two immunoglobulin single variable domains in a bispecific binding molecule will have different antigen specificity and therefore different CDR sequences.

[0122] Such bivalent binding molecules are also named "biparatopic single domain antibody constructs" (if the immunoglobulin single variable domains consist or essentially consist of single domain antibodies), or "biparatopic VHH constructs" (if the immunoglobulin single variable domains consist or essentially consist of VHHs), respectively, as the two immunoglobulin single variable domains will include two different paratopes.

[0123] In the bispecific binding molecule of the invention, one or both of the binding molecules may be bivalent; e.g. the VEGF-binding component may be biparatopic and the Ang2-binding component may be one immunoglobulin single variable domain, or the VEGF-binding component may be one immunoglobulin single variable domain and the Ang2-binding component may be biparatopic.

[0124] In bispecific binding molecules of the invention, it is preferably the VEGF-binding component that contains a bivalent VEGF-binding immunoglobulin single variable domain, e.g. a biparatopic VHH.

[0125] Such VEGF-binding immunoglobulin single variable domain may be two or more VEGF-binding VHHs, which are

[0126] a. identical VHHs that are capable of blocking the interaction between recombinant human VEGF and the recombinant human VEGFR-2 with an inhibition rate of 60% or

[0127] b. different VHHs that bind to non-overlapping epitopes of VEGF, wherein at least one VHH is capable of blocking the interaction between recombinant human VEGF and the recombinant human VEGFR-2 with an inhibition rate of 60% and wherein at least one VHH is capable of blocking said interaction with an inhibition rate of 60%.

[0128] The VEGF-binding component comprising at least a variable domain with four framework regions and three complementarity determining regions CDR1, CDR2 and CDR3, respectively, wherein said CDR3 has the amino acid sequence Ser Arg Ala Tyr Xaa Ser Xaa Arg Leu Arg Leu Xaa Xaa Thr Tyr Xaa Tyr as shown in SEQ ID NO: 1, wherein

[0129] Xaa at position 5 is Gly or Ala;

[0130] Xaa at position 7 is Ser or Gly;

[0131] Xaa at position 12 is Gly, Ala or Pro;

[0132] Xaa at position 13 is Asp or Gly;

[0133] Xaa at position 16 is Asp or Glu; and

[0134] wherein said VEGF-binding component is capable of blocking the interaction of human recombinant VEGF165 with the human recombinant VEGFR-2 with an inhibition rate of .gtoreq.60%.

[0135] According to preferred embodiments, Xaa at position 5 is Gly, Xaa at position 7 is Ser, Xaa at position 12 is Ala, and Xaa at position 13 is Asp.

[0136] In particular, said CDR3 has a sequence selected from

TABLE-US-00001 SEQ ID NO: 2 SRAYGSSRLRLGDTYDY, SEQ ID NO: 3 SRAYGSSRLRLADTYDY; SEQ ID NO: 4 SRAYGSSRLRLADTYEY; SEQ ID NO: 5 SRAYGSGRLRLADTYDY; SEQ ID NO: 6 SRAYASSRLRLADTYDY; SEQ ID NO: 7 SRAYGSSRLRLPDTYDY; SEQ ID NO: 8 SRAYGSSRLRLPGTYDY.

[0137] According to certain embodiments, a VEGF-binding component comprises one or more immunoglobulin single variable domains each containing

[0138] a. a CDR3 with an amino acid sequence selected from a first group of sequences shown in SEQ ID NO: 2 to 8;

[0139] b. a CDR1 and a CDR2 with an amino acid sequences that is contained, as indicated in Table 3, in a sequence selected from a second group of amino acid sequences shown in SEQ ID NOs: 9 to 46, wherein said second sequence contains the respective CDR3 selected according to a).

[0140] According to preferred embodiments, the immunoglobulin single variable domains are VHHs.

[0141] According to specific embodiments, the VHHs have amino acid sequences selected from sequences shown in SEQ ID NOs: 9-46.

[0142] According to another specific embodiment, the VHHs have amino acid sequences selected from SEQ ID NOs: 15, SEQ ID NO: 18 and SEQ ID NO: 25.

[0143] The invention also relates to VEGF-binding component that have been obtained by affinity maturation and/or sequence optimization of an above-defined VHH, e.g. to a

[0144] VHH that has been obtained by sequence optimization of a VHH having an amino acid sequence shown in SEQ ID NO: 18. Examples are VHHs having amino acid sequences selected from sequences shown in SEQ ID NOs: 47-57.

[0145] According to certain embodiments, a VEGF-binding domain of the invention may be formatted, as herein defined, e.g. it may be biparatopic or comprise two identical immunoglobulin single variable domains. Such VEGF-binding components may comprise two or more VHHs, which are

[0146] a) identical VHHs that are capable of blocking the interaction between recombinant human VEGF and the recombinant human VEGFR-2 with an inhibition rate of 60% or

[0147] b) different VHHs that bind to non-overlapping epitopes of VEGF, wherein at least one VHH is capable of blocking the interaction between recombinant human VEGF and the recombinant human VEGFR-2 with an inhibition rate of .gtoreq.60% and wherein at least one VHH binds is capable of blocking said interaction with an inhibition rate of .ltoreq.60%.

[0148] The percentage of blocking said interaction at an inhibition rate of .gtoreq.60% or .ltoreq.60%, respectively, refers to an inhibition rate as determined by an Amplified Luminescent Proximity Homogeneous Assay (AlphaScreen.RTM.), a competition ELISA, a plasmon resonance (SPR) based assay (Biacore.RTM.) as used in the Examples.

[0149] In the following, the ability of VHHs according to a) is also termed "receptor-blocking", while the ability of VHHs according to b) is also termed "non-receptor-blocking".

[0150] Preferably, the receptor-blocking VHHs have an inhibition rate of 80%, more preferably 90%; the most preferred VHHs being complete receptor blockers, i.e. have an inhibition rate of 100%.

[0151] A VEGF-binding component may contain two or more identical VHHs a) selected from VHHs having amino acid sequences shown in SEQ ID NOs: 9-46 or VHHs that have been obtained by affinity maturation and/or sequence optimization of such VHH. The VHH may be selected from VHHs having the amino acid shown in SEQ ID NO: 18 or SEQ ID NO: 47-57.

[0152] According to preferred embodiments, a formatted VEGF-binding component comprises two VHHs each having the amino acid sequence shown in SEQ ID NO: 57.

[0153] In formatted VEGF-binding components comprising two different VHHs

[0154] a) said one or more VHHs with an inhibition rate of 60% are selected from

[0155] i. VHHs having an amino acid sequence selected from amino acid sequences shown in SEQ ID NOs: 9-46 or

[0156] ii. VHHs that have been obtained by affinity maturation and/or sequence optimization of such VHHs, and wherein

[0157] b) said one or more VHHs with an inhibition rate of 60% are selected from

[0158] i. SEQ ID NOs: 58-124 or

[0159] ii. VHHs that have been obtained by affinity maturation and/or sequence optimization of such VHH.

[0160] According to preferred embodiments, two VHHs are contained in polypeptides with amino acid sequences shown in SEQ ID NOs: 128-168, separated by linker sequences as indicated in Table 15.

[0161] In a preferred VEGF-binding component VHH a) i. has an amino acid sequence shown in SEQ ID NO: 18 and VHH b) i. has an amino acid sequence shown in SEQ ID NO: 64.

[0162] In other preferred VEGF-binding components VHHs according to a) ii. are selected from VHHs having an amino acid sequence shown in SEQ ID NOs: 47-57 and VHHs according to b) ii. are selected from VHHs having an amino acid sequence shown in SEQ ID NOs: 125-127 .

[0163] Particularly preferred is a biparatopic VEGF-binding component comprising two VHHs, one of them having the amino acid shown in SEQ ID NO: 57 and one of them having the amino acid shown in SEQ ID NO: 127.

[0164] The Ang2-binding component comprises at least a variable domain with four framework regions and three complementarity determining regions CDR1, CDR2 and CDR3, respectively, wherein said CDR3 has an amino acid sequence selected from amino acid sequences shown in SEQ ID NOs: 226, 229, 232, 235, 238, 241, 244, 247, 250, or 253.

[0165] In a second aspect, said Ang2-binding component is an isolated immunoglobulin single variable domain or a polypeptide containing one or more of said immunoglobulin single variable domains, wherein said immunoglobulin single variable domain consists of four framework regions and three complementarity determining regions CDR1, CDR2 and CDR3, respectively, and wherein said CDR3 has an amino acid sequence selected from amino acid sequences shown in SEQ ID NOs: 226, 229, 232, 235, 238, 241, 244, 247, 250, or 253.

[0166] In a further aspect, said immunoglobulin single variable domain of the Ang2-binding component contains

[0167] a. a CDR3 with an amino acid sequence selected from a first group of amino acid sequences shown in SEQ ID NOs: SEQ IDs NOs: 226, 229, 232, 235, 238, 241, 244, 247, 250, or 253 (see also Table 49);

[0168] b. a CDR1 with an amino acid sequences that is contained, as indicated in Table 36-A, 38-A, 41-A, or 45-A, as partial sequence in a sequence selected from a second group of amino acid sequences shown SEQ ID NOs: 224, 227, 230, 233, 236, 239, 242, 245, 248, or 251 (see also Table 49);

[0169] c. a CDR2 with an amino acid sequences that is contained, as indicated in Table 36-A, 38-A, 41-A, or 45-A, as partial sequence in a sequence selected from a second group of amino acid sequences shown SEQ ID NOs: 225, 228, 231, 234, 237, 240, 243, 246, 249, or 252 (see also Table 49).

[0170] Preferably, the immunoglobulin single variable domain of the Ang2-binding component is a VHH, preferably having amino acid sequence selected from amino acid sequences shown in SEQ ID NOs: 214, 215, 216, 217, 218, 219, 220, 221, 222, or 223.

[0171] In another preferred embodiment, the immunoglobulin single variable domain of the Ang2-binding component has been obtained by affinity maturation or humanization of an immunoglobulin single variable domain as described herein.

[0172] Similarly, the present invention also relates to a VHH which has been obtained by affinity maturation or humanization of a VHH of the Ang2-binding component as described herein.

[0173] The present invention thus also relates to an Ang2-binding VHH with an amino acid sequence selected from acid sequences shown in SEQ ID NOs: 214, 215, 216, 217, 218, 219, 220, 221, 222, or 223.

[0174] Suitable parent Ang2-binding components for affinity maturation are, by way of example, the above-described VHHs with amino acid sequences shown in SEQ ID NOs:214, 215, 216, 217, 21 i8, or 219.

[0175] Accordingly, the invention also relates to Ang2-binding molecules that have been obtained by affinity maturation and/or sequence optimization of an above-defined VHH, e.g. to a VHH that has been obtained by sequence optimization of a VHH having an amino acid sequence shown as SEQ ID NOs: 217, 218, 219, 220, 221, 222, or 223. The "source" amino acid sequences that were used to generate the latter VHHs are shown in SEQ ID NOs: 214, 215, or 216. Also these amino acid sequences are suitable Ang2-binding components that can be applied in the binding molecules of the present invention.

[0176] As described herein, the binding molecule of the present invention preferably comprises at least one serum albumin binding component. Particularly preferred binding molecules thus have at least one VEGF-binding component, at least one Ang2-binding component and at least one serum albumin binding component. The order of these three binding components could be any possible order such as the order set out in FIG. 20B, 23B, 23D, 26B, 26C, 29G, 30B, 30C, or 38; or in FIG. 20A, 23A, 26A, or 30A, e.g. the VEGF-, Ang2-or serum albumin binding component can be N-terminal or C-terminal. Notably, "1D01" (SEQ ID No: 214), "11B07", "00027" (SEQ ID No:216), "00908", "7G08" (SEQ ID No:215), "00919", "00921" (SEQ ID No: 220), "00928" (SEQ ID No:221), "00932", "00933", "00934", "00935", "00936", "00937", "00938" (SEQ ID No:222), or "00956" (SEQ ID No:223) as referred to in the legend of the aforementioned Tables and Figures stand for Ang2-binding components, while "00038" stands for a VEGF-binding component and "ALB11" stands for a serum albumin binding component. None of them is to be construed to a specific sequence, but stands for a Ang2-, VEGF- and serum albumin binding component in general when used in the context of possible set-ups of binding molecules of the present invention.

[0177] However, it is preferred that the serum albumin binding component is in between the VEGF- and Ang2-binding component (or vice versa), while it is particularly preferred that at least one VEGF-binding component is N-terminal, followed by at least one serum albumin binding component, followed by at least one Ang2-binding component at the C-Terminus. This set-up is shown to be specifically useful.

[0178] The present invention relates thus in a preferred aspect to binding molecules comprising at least one VEGF-binding component, at least one Ang2-binding component and at least one serum albumin binding component having an amino acid sequence selected from the amino acid sequences shown in SEQ ID NOs: 180-213.

[0179] "At least one" binding component (VEGF, Ang2 or serum albumin) when used herein includes that a binding molecule of the present invention may contain one, two, three, four or five VEGF-, Ang2-, and/or serum albumin binding components (i.e., entities/units) which are preferably represented by an immunoglobulin singly variable domain as described herein.

[0180] The VEGF- and/or Ang2-binding components with improved properties in view of therapeutic application, e.g. enhanced affinity or decreased immunogenicity, may be obtained from individual VEGF-or Ang2-binding components of the invention by techniques known in the art, such as affinity maturation (for example, starting from synthetic, random or naturally occurring immunoglobulin sequences), CDR grafting, humanizing, combining fragments derived from different immunoglobulin sequences, PCR assembly using overlapping primers, and similar techniques for engineering immunoglobulin sequences well known to the skilled person; or any suitable combination of any of the foregoing, also termed "sequence optimization", as described herein. Reference is, for example, made to standard handbooks, as well as to the further description and Examples.

[0181] If appropriate, a VEGF-or Ang2-binding component of the invention with increased affinity may be obtained by affinity-maturation of another VEGF-or Ang2-binding component, the latter representing, with respect to the affinity-matured molecule, the "parent" VEGF-binding component.

[0182] In VEGF or Ang2 VHHs of the invention that start with EVQ, the N-terminal E may be replaced by a D (which is often a result of sequence-optimization) or it may be missing (as for expression of the VHH in E. coli). For formatted VEGF-binding components, this usually applies only to the VHH that is situated N-terminally.

[0183] A preferred, but non-limiting humanizing substitution for VEGF VHH domains belonging to the 103 P,R,S-group and/or the GLEW-group (SEQ ID NO: 277) (as defined below) is 108Q to 108L. Methods for humanizing immunoglobulin single variable domains are known in the art.

[0184] According to another embodiment, the immunoglobulin single variable domain is a domain antibody, as defined herein.

[0185] In yet another embodiment, the representatives of the class of VEGF-and/or Ang2-binding immunoglobulin single variable domains of the invention have amino acid sequences that correspond to the amino acid sequence of a naturally occurring VH domain that has been "camelized", i.e. by replacing one or more amino acid residues in the amino acid sequence of a naturally occurring variable heavy chain from a conventional 4-chain antibody by one or more amino acid residues that occur at the corresponding position(s) in a VHH domain of a heavy chain antibody. This can be performed in a manner known per se, which will be clear to the skilled person, and reference is additionally be made to WO1994/04678. Such camelization may preferentially occur at amino acid positions which are present at the VH-VL interface and at the so-called Camelidae Hallmark residues (see for example also WO1994/04678). A detailed description of such "humanization" and "camelization" techniques and preferred framework region sequences consistent therewith can additionally be taken from e.g. pp. 46 and pp. 98 of WO2006/040153 and pp. 107 of WO2006/122786.

[0186] The VEGF-binding components of the invention, e.g. immunoglobulin single variable domains, have specificity for VEGF in that they comprise one or more immunoglobulin single variable domains specifically binding to one or more epitopes within the VEGF molecule. The same is true for Ang2-binding components of the invention.

[0187] Specific binding of an VEGF-binding component to its antigen VEGF can be determined in any suitable manner known per se, including, for example, the assays described herein, Scatchard analysis and/or competitive binding assays, such as radioimmunoassays (RIA), enzyme immunoassays (EIA and ELISA) and sandwich competition assays, and the different variants thereof known per se in the art. The same is true for an Ang2-binding component when binding to its antigen.

[0188] With regard to the antigen VEGF, a VEGF-binding component of the invention, e.g. an immunoglobulin single variable domain, is not limited with regard to the species. Thus, the immunoglobulin single variable domains of the invention preferably bind to human VEGF, if intended for therapeutic purposes in humans. However, immunoglobulin single variable domains that bind to VEGF from another mammalian species are also within the scope of the invention. An immunoglobulin single variable domain of the invention binding to one species form of VEGF may cross-react with VEGF, which has a different sequence than the human one, from one or more other species. For example, immunoglobulin single variable domains of the invention binding to human VEGF may exhibit cross reactivity with VEGF from one or more other species of primates and/or with VEGF from one or more species of animals that are used in animal models for diseases, for example monkey, mouse, rat, rabbit, pig, dog, and in particular in animal models for diseases and disorders associated with VEGF-mediated effects on angiogenesis (such as the species and animal models mentioned herein). Immunoglobulin single variable domains of the invention that show such cross-reactivity are advantageous in a research and/or drug development, since it allows the immunoglobulin single variable domains of the invention to be tested in acknowledged disease models such as monkeys, in particular Cynomolgus or Rhesus, or mice and rats.

[0189] Preferably, in view of cross-reactivity with one or more VEGF molecules from species other than human that is/are intended for use as an animal model during development of a therapeutic VEGF antagonist, a VEGF-binding component recognizes an epitope in a region of the VEGF of interest that has a high degree of identity with human VEGF.

[0190] An immunoglobulin single variable domain of the invention recognizes an epitope which is, totally or in part, located in a region of VEGF that is relevant for binding to its receptor, in particular to VEGFR-2, which has been shown to be the receptor whose activation is causally involved in the neovascularisation of tumors. According to preferred aspects, immunoglobulin single variable domains of the invention block VEGF receptor activation, in particular VEGFR-2 activation, at least partially, preferably substantially and most preferably totally.

[0191] As described above, the ability of a VEGF-binding component to block the interaction between VEGF and its receptors, in particular the VEGFR-2, can be determined by an Amplified Luminescent Proximity Homogeneous Assay (AlphaScreen.RTM.), a competition ELISA, or a plasmon resonance (SPR) based assay (Biacore.RTM.), as described in the Examples.

[0192] Preferably, an immunoglobulin single variable domain of the invention binds to VEGF with an affinity less than 500 nM, preferably less than 200 nM, more preferably less than 10 nM, such as less than 500 pM (as determined by Surface Plasmon Resonance analysis, as described in Example 5.7). The same is true for an immunoglobulin single variable domain of the invention binds to angiopoietin.

[0193] Preferably, the immunoglobulin single variable domains of the invention have IC.sub.50 values, as measured in a competition ELISA assay as described in Example 5.1. in the range of 10.sup.-6 to 10.sup.-10 moles/litre or less, more preferably in the range of 10.sup.-8 to 10.sup.-10 moles/litre or less and even more preferably in the range of 10.sup.-9 to 10.sup.-10 moles/litre or less.

[0194] According to a non-limiting but preferred embodiment of the invention, VEGF-binding immunoglobulin single variable domains of the invention bind to VEGF with an dissociation constant (K.sub.D) of 10.sup.-5 to 10.sup.-12 moles/liter (M) or less, and preferably 10.sup.-7 to 10.sup.-12 moles/liter (M) or less and more preferably 10.sup.-8 to 10.sup.-12 moles/liter (M), and/or with an association constant (K.sub.A) of at least 10.sup.7 M.sup.-1, preferably at least 10.sup.8 M.sup.-1, more preferably at least 10.sup.9 M.sup.-1, such as at least 10.sup.12 M.sup.-1; and in particular with a KD less than 500 nM, preferably less than 200 nM, more preferably less than 10 nM, such as less than 500 pM. The K.sub.D and K.sub.A values of the immunoglobulin single variable domain of the invention against VEGF can be determined. The same is true for an Ang2-binding immunoglobulin single variable domain of the invention.

[0195] Biparatopic VEGF-binding components comprising two or more immunoglobulin single variable domains essentially consist of or comprise (i) a first immunoglobulin single variable domain specifically binding to a first epitope of VEGF and (ii) a second immunoglobulin single variable domain specifically binding to a second epitope of VEGF, wherein the first epitope of VEGF and the second epitope of VEGF are not identical epitopes. In other words, such polypeptide of the invention comprises or essentially consist of two or more immunoglobulin single variable domains that are directed against at least two non-overlapping epitopes present in VEGF, wherein said immunoglobulin single variable domains are linked to each other in such a way that they are capable of simultaneously binding VEGF. In this sense, the polypeptide of the invention can also be regarded as a "bivalent" or "multivalent" immunoglobulin construct, and especially as a "multivalent immunoglobulin single variable domain construct", in that the polypeptide contains at least two binding sites for VEGF. (Such constructs are also termed "formatted" VEGF binding molecules, e.g. "formatted" VHHs). The same is true for biparatopic Ang2-binding components, mutatis mutandis.

[0196] Such VEGF-or Ang2-binding component of the invention includes (at least) two anti-VEGF or Ang2 immunoglobulin single variable domains, respectively, wherein (the) two immunoglobulin single variable domains are preferably directed against non-overlapping epitopes within the VEGF molecule or angiopoietin molecule, respectively. Thus, these two immunoglobulin single variable domains will have a different antigen specificity and therefore different CDR sequences. For this reason, such polypeptides of the invention will herein also be named "biparatopic polypeptides", or "biparatopic domain antibody constructs" (if the immunoglobulin single variable domains consist or essentially consist of domain antibodies), or "biparatopic VHH constructs" (if the immunoglobulin single variable domains consist or essentially consist of VHHs), respectively, as the two immunoglobulin single variable domains will include two different paratopes.

[0197] If a polypeptide of the invention is a biparatopic molecule as defined herein, at least one of the immunoglobulin single variable domain components binds to an epitope such that the interaction between recombinant human VEGF and recombinant humen VEGFR-2 is blocked at an inhibition rate of .gtoreq.80%. As has been shown in experiments of the invention, certain formatted molecules contain two VHHs that both block the VEGFR2 receptor at an inhibition rate of .gtoreq.80%. Certain VHHs of the invention block the VEGFR-2 at an inhibition rate of 100%, i.e. they are complete blockers.

[0198] In both cases, additional sequences and moieties may be present within the VEGF-binding components of the invention, e.g. N-terminally, C-terminally, or located between the two immunoglobulin single variable domains, e.g. linker sequences and sequences providing for effector functions, as set out in more detail herein.

[0199] According to another, albeit less preferred embodiment, a VEGF-binding component of the invention may include more than two anti-VEGF immunoglobulin single variable domains, i.e. three, four or even more anti-VEGF VHHs. In this case, at least two of the anti-VEGF immunoglobulin single variable domains are directed against non-overlapping epitopes within the VEGF molecule, wherein any further immunoglobulin single variable domain may bind to any of the two non-overlapping epitopes and/or a further epitope present in the VEGF molecule.

[0200] According to the invention, the two or more immunoglobulin single variable domains can be, independently of each other, VHHs or domain antibodies, and/or any other sort of immunoglobulin single variable domains, such as VL domains, as defined herein, provided that these immunoglobulin single variable domains will bind the antigen, i.e. VEGF or angiopoietin, respectively.

[0201] The detailed description of the binding components is primarily provided for the VEGF-binding component. However, all features and options outlined herein for the VEGF-binding component also apply equivalently for the Ang2-binding component, mutatis mutandis.

[0202] According to preferred embodiments, the binding molecules present in the bispecific binding molecules (the Ang2-binding molecules within the Ang2-binding component or the VEGF-binding molecules within the VEGF-binding component or the two adjacent Ang2- and VEGF-binding components) may be connected with each other directly (i.e. without use of a linker) or via a linker. The linker is preferably a linker peptide and will be selected so as to allow binding of the two different binding molecules to each of non-overlapping epitopes of the targets, either within one and the same target molecule, or within two different molecules.

[0203] In the case of biparatopic binding molecules, selection of linkers within the Ang2- or the VEGF-binding component will inter alia depend on the epitopes and, specifically, the distance between the epitopes on the target to which the immunoglobulin single variable domains bind, and will be clear to the skilled person based on the disclosure herein, optionally after some limited degree of routine experimentation.

[0204] Two binding molecules (two VHHs or domain antibodies or VHH and a domain antibody), or two binding components, may be linked to each other via an additional VHH or domain antibody, respectively (in such binding molecules, the two or more immunoglobulin single variable domains may be linked directly to said additional immunoglobulin single variable domain or via suitable linkers). Such an additional VHH or domain antibody may for example be a VHH or domain antibody that provides for an increased half-life. For example, the latter VHH or domain antibody may be one that is capable of binding to a (human) serum protein such as (human) serum albumin or (human) transferrin.

[0205] Alternatively, the two or more immunoglobulin single variable domains that bind to the respective target may be linked in series (either directly or via a suitable linker) and the additional VHH or domain antibody (which may provide for increased half-life) may be connected directly or via a linker to one of these two or more aforementioned immunoglobulin sequences.

[0206] Suitable linkers are described herein in connection with specific polypeptides of the invention and may--for example and without limitation--comprise an amino acid sequence, which amino acid sequence preferably has a length of 9 or more amino acids, more preferably at least 17 amino acids, such as about 20 to 40 amino acids. However, the upper limit is not critical but is chosen for reasons of convenience regarding e.g. biopharmaceutical production of such polypeptides.

[0207] The linker sequence may be a naturally occurring sequence or a non-naturally occurring sequence. If used for therapeutic purposes, the linker is preferably non-immunogenic in the subject to which the bispecific binding molecule of the invention is administered.

[0208] One useful group of linker sequences are linkers derived from the hinge region of heavy chain antibodies as described in WO1996/34103 and WO1994/04678.

[0209] Other examples are poly-alanine linker sequences such as Ala- Ala- Ala.

[0210] Further preferred examples of linker sequences are Gly/Ser linkers of different length such as (gly.sub.xser.sub.y).sub.z linkers, including (gly.sub.4ser).sub.3 (SEQ ID NO:278), (gly.sub.4ser).sub.4(SEQ ID NO: 279), (gly.sub.4ser) (SEQ ID NO: 280), (gly.sub.3ser) (SEQ ID NO: 281), gly.sub.3, and (gly.sub.3ser.sub.2)3 (SEQ ID NO: 282).

[0211] Some non-limiting examples of linkers are contained in bispecific binding molecules of the invention shown in Table 15 (SEQ ID NOs 128-168), e.g. the linkers

TABLE-US-00002 (35GS; SEQ ID NO: 169) GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS; (9GS; SEQ ID NO: 170) GGGGSGGGS; (40GS; SEQ ID NO: 171) GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS.

[0212] If a formatted bispecific binding molecule of the invention is modified by the attachment of a polymer, for example of a polyethylene glycol PEG (polyethylene glycol) moiety, the linker sequence preferably includes an amino acid residue, such as a cysteine or a lysine, allowing such modification, e.g. PEGylation, in the linker region.

[0213] Examples of linkers useful for for PEGylation are:

TABLE-US-00003 ("GS9,C5", SEQ ID NO: 172) GGGGCGGGS; ("GS25,C5, SEQ ID NO: 173) GGGGCGGGGSGGGGSGGGGSGGGGS ("GS27,C14", SEQ ID NO: 174) GGGSGGGGSGGGGCGGGGSGGGGSGGG, ("GS35,C15", SEQ ID NO: 175) GGGGSGGGGSGGGGCGGGGSGGGGSGGGGSGGGGS, and ("GS35,C5", SEQ ID NO: 176) GGGGCGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS.

[0214] Furthermore, the linker may also be a poly(ethylene glycol) moiety, as shown in e.g. WO2004/081026.

[0215] In another embodiment, the immunoglobulin single variable domains are linked to each other via another moiety (optionally via one or two linkers), such as another polypeptide which, in a preferred but non-limiting embodiment, may be a further immunoglobulin single variable domain as described above. Such moiety may either be essentially inactive or may have a biological effect such as improving the desired properties of the polypeptide or may confer one or more additional desired properties to the polypeptide. For example, and without limitation, the moiety may improve the half-life of the protein or polypeptide, and/or may reduce its immunogenicity or improve any other desired property.

[0216] According to a preferred embodiment, a bispecific binding molecule of the invention includes, especially when intended for use or used as a therapeutic agent, a moiety which extends the half-life of the polypeptide of the invention in serum or other body fluids of a patient. The term "half-life" is defined as the time it takes for the serum concentration of the (modified) polypeptide to reduce by 50%, in vivo, for example due to degradation of the polypeptide and/or clearance and/or sequestration by natural mechanisms.

[0217] More specifically, such half-life extending moiety can be covalently linked to or fused to an immunoglobulin single variable domain and may be, without limitation, an Fc portion, an albumin moiety, a fragment of an albumin moiety, an albumin binding moiety, such as an anti-albumin immunoglobulin single variable domain, a transferrin binding moiety, such as an anti-transferrin immunoglobulin single variable domain, a polyoxyalkylene molecule, such as a polyethylene glycol molecule, an albumin binding peptide or a hydroxyethyl starch (HES) derivative.

[0218] In another embodiment, the bispecific binding molecule of the invention comprises a moiety which binds to an antigen found in blood, such as serum albumin, serum immunoglobulins, thyroxine-binding protein, fibrinogen or transferrin, thereby conferring an increased half-life in vivo to the resulting polypeptide of the invention. According to a specifically preferred embodiment, such moiety is an albumin-binding immunoglobulin and, especially preferred, an albumin-binding immunoglobulin single variable domain such as an albumin-binding VHH domain.

[0219] If intended for use in humans, such albumin-binding immunoglobulin single variable domain preferably binds to human serum albumin and preferably is a humanized albumin-binding VHH domain.

[0220] Immunoglobulin single variable domains binding to human serum albumin are known in the art and are described in further detail in e.g. WO2006/122786. Specifically, useful albumin binding VHHs are ALB 1 and its humanized counterpart, ALB 8 (WO2009/095489). Other albumin binding VHH domains mentioned in the above patent publication may, however, be used as well.

[0221] A specifically useful albumin binding VHH domain is ALB8 which consists of or contains the amino acid sequence shown in SEQ ID NO: 98 or 254.

[0222] According to a further embodiment of the invention, the two immunoglobulin single variable domains, in preferably VHHs, may be fused to a serum albumin molecule, such as described e.g. in WO2001/79271 and WO2003/59934. As e.g. described in WO2001/79271, the fusion protein may be obtained by conventional recombinant technology: a DNA molecule coding for serum albumin, or a fragment thereof, is joined to the DNA coding for the bispecific binding molecule, the obtained construct is inserted into a plasmid suitable for expression in the selected host cell, e.g. a yeast cell like Pichia pastoris or a bacterial cell, and the host cell is then transfected with the fused nucleotide sequence and grown under suitable conditions. The sequence of a useful HSA is shown in SEQ ID NO: 99.

[0223] According to another embodiment, a half-life extending modification of a polypeptide of the invention (such modification also reducing immunogenicity of the polypeptide) comprises attachment of a suitable pharmacologically acceptable polymer, such as straight or branched chain poly(ethylene glycol) (PEG) or derivatives thereof (such as methoxypoly(ethylene glycol) or mPEG). Generally, any suitable form of PEGylation can be used, such as the PEGylation used in the art for antibodies and antibody fragments (including but not limited to domain antibodies and scFv's); reference is made, for example, to: Chapman, Nat. Biotechnol., 54, 531-545 (2002); Veronese and Harris, Adv. Drug Deliv. Rev. 54, 453-456 (2003); Harris and Chess, Nat. Rev. Drug. Discov. 2 (2003); and WO2004/060965.

[0224] Various reagents for PEGylation of polypeptides are also commercially available, for example from Nektar Therapeutics, USA, or NOF Corporation, Japan, such as the Sunbright.RTM. EA Series, SH Series, MA Series, CA Series, and ME Series, such as Sunbright.RTM. ME-100MA, Sunbright.RTM. ME-200MA, and Sunbright.RTM. ME-400MA.

[0225] Preferably, site-directed PEGylation is used, in particular via a cysteine-residue (see for example Yang et al., Protein Engineering 16, 761-770 (2003)). For example, for this purpose, PEG may be attached to a cysteine residue that naturally occurs in a polypeptide of the invention, a polypeptide of the invention may be modified so as to suitably introduce one or more cysteine residues for attachment of PEG, or an amino acid sequence comprising one or more cysteine residues for attachment of PEG may be fused to the N- and/or C-terminus of a polypeptide of the invention, all using techniques of protein engineering known per se to the skilled person.

[0226] Preferably, for the polypeptides of the invention, a PEG is used with a molecular weight of more than 5 kDa, such as more than 10 kDa and less than 200 kDa, such as less than 100 kDa; for example in the range of 20 kDa to 80 kDa.

[0227] With regard to PEGylation, its should be noted that generally, the invention also encompasses any bispecific binding molecule that has been PEGylated at one or more amino acid positions, preferably in such a way that said PEGylation either (1) increases the half-life in vivo; (2) reduces immunogenicity; (3) provides one or more further beneficial properties known per se for PEGylation; (4) does not essentially affect the affinity of the polypeptide for its target (e.g. does not reduce said affinity by more than 50%, and more preferably not by more than 10%, as determined by a suitable assay described in the art); and/or (4) does not affect any of the other desired properties of the bispecific binding molecules of the invention. Suitable PEG-groups and methods for attaching them, either specifically or non-specifically, will be clear to the skilled person. Various reagents for PEGylation of polypeptides are also commercially available, for example from Nektar Therapeutics, USA, or NOF Corporation, Japan, such as the Sunbright.RTM. EA Series, SH Series, MA Series, CA Series, and ME Series, such as Sunbright.RTM. ME-100MA, Sunbright.RTM. ME-200MA, and Sunbright.RTM. ME-400MA.

[0228] According to an especially preferred embodiment of the invention, a PEGylated polypeptide of the invention includes one PEG moiety of linear PEG having a molecular weight of 40 kDa or 60 kDa, wherein the PEG moiety is attached to the polypeptide in a linker region and, specifially, at a Cys residue at position 5 of a GS9-linker peptide as shown in SEQ ID NO:93, at position 14 of a GS27-linker peptide as shown in SEQ ID NO:95, or at position 15 of a GS35-linker peptide as shown in SEQ ID NO:96, or at position 5 of a 35GS-linker peptide as shown in SEQ ID NO:97.

[0229] A bispecific binding molecule of the invention may be PEGylated with one of the PEG reagents as mentioned above, such as "Sunbright.RTM. ME-400MA", as shown in the following chemical formula:

##STR00001##

[0230] Bispecific binding molecules that contain linkers and/or half-life extending functional groups are shown in SEQ ID NO: 81 and in FIG. 48.

[0231] According to another embodiment, the immunoglobulin single variable domains are domain antibodies, as defined herein.

[0232] Immunoglobulin single variable domains present in the bispecific binding molecules of the invention may also have sequences that correspond to the amino acid sequence of a naturally occurring VH domain that has been "camelized", i.e. by replacing one or more amino acid residues in the amino acid sequence of a naturally occurring variable heavy chain from a conventional 4-chain antibody by one or more amino acid residues that occur at the corresponding position(s) in a VHH domain of a heavy chain antibody. This can be performed in a manner known per se, which will be clear to the skilled person, and reference is additionally be made to WO1994/04678. Such camelization may preferentially occur at amino acid positions which are present at the VH-VL interface and at the so-called Camelidae Hallmark residues (see for example also WO1994/04678). A detailed description of such "humanization" and "camelization" techniques and preferred framework region sequences consistent therewith can additionally be taken from e.g. pp. 46 and pp. 98 of WO2006/040153 and pp. 107 of WO2006/122786.

[0233] The binding components have specificity for Ang2 or VEGF, respectively, in that they comprise in a preferred embodiment one or more immunoglobulin single variable domains specifically binding to one or more epitopes within the Ang2 molecule or within the VEGF molecule, respectively.

[0234] Specific binding of a binding component to its antigen Ang2 or VEGF can be determined in any suitable manner known per se, including, for example, the assays described herein, Scatchard analysis and/or competitive binding assays, such as radioimmunoassays (RIA), enzyme immunoassays (EIA and ELISA) and sandwich competition assays, and the different variants thereof known per se in the art.

[0235] With regard to the antigen Ang2 or VEGF, respectively, an immunoglobulin single variable domain is not limited with regard to the species. Thus, the immunoglobulin single variable domains preferably bind to human Ang2 or to human VEGF, respectively, if intended for therapeutic purposes in humans. However, immunoglobulin single variable domains that bind to Ang2 or VEGF, respectively, from another mammalian species, or polypeptides containing them, are also within the scope of the invention. An immunoglobulin single variable domain binding to one species form of Ang2 or VEGF may cross-react with the respective antigen from one or more other species. For example, immunoglobulin single variable domains binding to the human antigen may exhibit cross reactivity with the respective antigen from one or more other species of primates and/or with the antigen from one or more species of animals that are used in animal models for diseases, for example monkey (in particular Cynomolgus or Rhesus), mouse, rat, rabbit, pig, dog or) and in particular in animal models for diseases and disorders that can be modulated by inhibition of Ang2 (such as the species and animal models mentioned herein). Immunoglobulin single variable domains of the invention that show such cross-reactivity are advantageous in a research and/or drug development, since it allows the immunoglobulin single variable domains of the invention to be tested in acknowledged disease models such as monkeys, in particular Cynomolgus or Rhesus, or mice and rats.

[0236] Also, the binding components are not limited to or defined by a specific domain or an antigenic determinant of the antigen against which they are directed. Preferably, in view of cross-reactivity with one or more antigen molecules from species other than human that is/are intended for use as an animal model during development of a therapeutic Ang2/VEGF antagonist, a binding component recognizes an epitope in a region of the the respective antigen that has a high degree of identity with the human antigen. By way of example, in view of using a mouse model, an anti-Ang2 immunoglobulin single variable domain contained in the bispecific binding molecules of the invention recognizes an epitope which is, totally or in part, located within the FLD domain of Ang2, which shows a high identity between human and mouse.

[0237] Preferably, the VEGF-binding component binds to the VEGF isoforms VEGF165 and/or VEGF121.

[0238] In another aspect, the invention relates to nucleic acid molecules that encode bispecific binding molecules of the invention. Such nucleic acid molecules will also be referred to herein as "nucleic acids of the invention" and may also be in the form of a genetic construct, as defined herein. A nucleic acid of the invention may be genomic DNA, cDNA or synthetic DNA (such as DNA with a codon usage that has been specifically adapted for expression in the intended host cell or host organism). According to one embodiment of the invention, the nucleic acid of the invention is in essentially isolated form, as defined hereabove.

[0239] The nucleic acid of the invention may also be in the form of, may be present in and/or may be part of a vector, such as for example a plasmid, cosmid or YAC. The vector may especially be an expression vector, i.e. a vector that can provide for expression of the bispecific binding molecule in vitro and/or in vivo (i.e. in a suitable host cell, host organism and/or expression system). Such expression vector generally comprises at least one nucleic acid of the invention that is operably linked to one or more suitable regulatory elements, such as promoter(s), enhancer(s), terminator(s), and the like. Such elements and their selection in view of expression of a specific sequence in a specific host are common knowledge of the skilled person. Specific examples of regulatory elements and other elements useful or necessary for expressing bispecific binding molecules of the invention, such as promoters, enhancers, terminators, integration factors, selection markers, leader sequences, reporter genes, and the like, are disclosed e.g. on pp. 131 to 133 of WO2006/040153.

[0240] The nucleic acids of the invention may be prepared or obtained in a manner known per se (e.g. by automated DNA synthesis and/or recombinant DNA technology), based on the information on the amino acid sequences for the polypeptides of the invention given herein, and/or can be isolated from a suitable natural source.

[0241] In another aspect, the invention relates to host cells that express or that are capable of expressing one or more bispecific binding molecules of the invention; and/or that contain a nucleic acid of the invention. According to a particularly preferred embodiment, said host cells are bacterial cells; other useful cells are yeast cells, fungal cells or mammalian cells.

[0242] Suitable bacterial cells include cells from gram-negative bacterial strains such as strains of Escherichia coli, Proteus, and Pseudomonas, and gram-positive bacterial strains such as strains of Bacillus, Streptomyces, Staphylococcus, and Lactococcus. Suitable fungal cell include cells from species of Trichoderma, Neurospora, and Aspergillus. Suitable yeast cells include cells from species of Saccharomyces (for example Saccharomyces cerevisiae), Schizosaccharomyces (for example Schizosaccharomyces pombe), Pichia (for example Pichia pastoris and Pichia methanolica), and Hansenula.

[0243] Suitable mammalian cells include for example CHO cells, BHK cells, HeLa cells, COS cells, and the like. However, amphibian cells, insect cells, plant cells, and any other cells used in the art for the expression of heterologous proteins can be used as well.

[0244] The invention further provides methods of manufacturing a bispecific binding molecule of the invention, such methods generally comprising the steps of:

[0245] culturing host cells comprising a nucleic acid capable of encoding a bispecific binding molecule under conditions that allow expression of the bispecific binding molecule of the invention; and

[0246] recovering or isolating the polypeptide expressed by the host cells from the culture; and

[0247] optionally further purifying and/or modifying and/or formulating the bispecific binding molecule of the invention.

[0248] For production on an industrial scale, preferred host organisms include strains of E. coli, Pichia pastoris, and S. cerevisiae that are suitable for large scale expression, production and fermentation, and in particular for large scale pharmaceutical expression, production and fermentation.

[0249] The choice of the specific expression system depends in part on the requirement for certain post-translational modifications, more specifically glycosylation. The production of a bispecific binding molecule of the invention for which glycosylation is desired or required would necessitate the use of mammalian expression hosts that have the ability to glycosylate the expressed protein. In this respect, it will be clear to the skilled person that the glycosylation pattern obtained (i.e. the kind, number and position of residues attached) will depend on the cell or cell line that is used for the expression.

[0250] Bispecific binding molecules of the invention may be produced either in a cell as set out above intracellullarly (e.g. in the cytosol, in the periplasma or in inclusion bodies) and then isolated from the host cells and optionally further purified; or they can be produced extracellularly (e.g. in the medium in which the host cells are cultured) and then isolated from the culture medium and optionally further purified.

[0251] Methods and reagents used for the recombinant production of polypeptides, such as specific suitable expression vectors, transformation or transfection methods, selection markers, methods of induction of protein expression, culture conditions, and the like, are known in the art. Similarly, protein isolation and purification techniques useful in a method of manufacture of a polypeptide of the invention are well known to the skilled person.

[0252] In a further aspect, the invention relates to a peptide having an amino acid sequence of a CDR3 contained in an anti-VEGF-VHH having an amino acid sequence selected from sequences shown in SEQ ID NOs: 9 to 57 or SEQ ID NOs: 58-127, respectively, and a nucleic acid molecule encoding same.

[0253] These peptides correspond to CDR3s derived from the VHHs of the invention. They, in particular the nucleic acid molecules encoding them, are useful for CDR grafting in order to replace a CDR3 in an immunoglobulin chain, or for insertion into a non-immunoglobulin scaffold, e.g. a protease inhibitor, DNA-binding protein, cytochrome b562, a helix-bundle protein, a disulfide-bridged peptide, a lipocalin or an anticalin, thus conferring target-binding properties to such scaffold. The method of CDR-grafting is well known in the art and has been widely used, e.g. for humanizing antibodies (which usually comprises grafting the CDRs from a rodent antibody onto the Fv frameworks of a human antibody).

[0254] In order to obtain an immunoglobulin or a non-immunoglobulin scaffold containing a CDR3 of the invention, the DNA encoding such molecule may be obtained according to standard methods of molecular biology, e.g. by gene synthesis, by oligonucleotide annealing or by means of overlapping PCR fragments, as e.g. described by Daugherty et al., 1991, Nucleic Acids Research, Vol. 19, 9, 2471-2476. A method for inserting a VHH CDR3 into a non-immunoglobulin scaffold has been described by Nicaise et al., 2004, Protein Science, 13, 1882-1891.

[0255] The invention further relates to a product or composition containing or comprising at least one bispecific binding molecule of the invention and optionally one or more further components of such compositions known per se, i.e. depending on the intended use of the composition.

[0256] For pharmaceutical use, a bispecific binding molecule of the invention may be formulated as a pharmaceutical preparation or composition comprising at least one bispecific binding molecule of the invention and at least one pharmaceutically acceptable carrier, diluent or excipient and/or adjuvant, and optionally one or more further pharmaceutically active polypeptides and/or compounds. By means of non-limiting examples, such a formulation may be in a form suitable for oral administration, for parenteral administration (such as by intravenous, intramuscular or subcutaneous injection or intravenous infusion), for topical administration, for administration by inhalation, by a skin patch, by an implant, by a suppository, etc. Such suitable administration forms--which may be solid, semi-solid or liquid, depending on the manner of administration--as well as methods and carriers for use in the preparation thereof, will be clear to the skilled person, and are further described herein.

[0257] Thus, in a further aspect, the invention relates to a pharmaceutical composition that contains at least one bispecific binding molecule, in particular one immunoglobulin single variable domain, of the invention and at least one suitable carrier, diluent or excipient (i.e. suitable for pharmaceutical use), and optionally one or more further active substances.

[0258] The bispecific binding molecules of the invention may be formulated and administered in any suitable manner known per se: Reference, in particular for the immunoglobulin single variable domains, is for example made to WO2004/041862, WO2004/041863, WO2004/041865, WO2004/041867 and WO2008/020079, as well as to the standard handbooks, such as Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Company, USA (1990), Remington, the Science and Practice of Pharmacy, 21.sup.th Edition, Lippincott Williams and Wilkins (2005); or the Handbook of Therapeutic Antibodies (S. Dubel, Ed.), Wiley, Weinheim, 2007 (see for example pages 252-255).

[0259] For example, an immunoglobulin single variable domain of the invention may be formulated and administered in any manner known per se for conventional antibodies and antibody fragments (including ScFv's and diabodies) and other pharmaceutically active proteins. Such formulations and methods for preparing the same will be clear to the skilled person, and for example include preparations suitable for parenteral administration (for example intravenous, intraperitoneal, subcutaneous, intramuscular, intraluminal, intra-arterial or intrathecal administration) or for topical (i.e. transdermal or intradermal) administration.

[0260] Preparations for parenteral administration may for example be sterile solutions, suspensions, dispersions or emulsions that are suitable for infusion or injection. Suitable carriers or diluents for such preparations for example include, without limitation, sterile water and pharmaceutically acceptable aqueous buffers and solutions such as physiological phosphate-buffered saline, Ringer's solutions, dextrose solution, and Hank's solution; water oils; glycerol; ethanol; glycols such as propylene glycol or as well as mineral oils, animal oils and vegetable oils, for example peanut oil, soybean oil, as well as suitable mixtures thereof. Usually, aqueous solutions or suspensions will be preferred.

[0261] Thus, the bispecific binding molecule of the invention may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. For oral therapeutic administration, the bispecific binding molecule of the invention may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of the binding molecule of the invention. Their percentage in the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of the bispecific binding molecule of the invention in such therapeutically useful compositions is such that an effective dosage level will be obtained.

[0262] The tablets, pills, capsules, and the like may also contain binders, excipients, disintegrating agents, lubricants and sweetening or flavouring agents, for example those mentioned on pages 143-144 of WO2008/020079. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the binding molecules of the invention, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the bispecific binding molecules of the invention may be incorporated into sustained-release preparations and devices.

[0263] Preparations and formulations for oral administration may also be provided with an enteric coating that will allow the constructs of the invention to resist the gastric environment and pass into the intestines. More generally, preparations and formulations for oral administration may be suitably formulated for delivery into any desired part of the gastrointestinal tract. In addition, suitable suppositories may be used for delivery into the gastrointestinal tract.

[0264] The bispecific binding molecules of the invention may also be administered intravenously or intraperitoneally by infusion or injection, as further described on pages 144 and 145 of WO2008/020079.

[0265] For topical administration of the bispecific binding molecules of the invention, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid, as further described on page 145 of WO2008/020079.

[0266] Generally, the concentration of the bispecific binding molecules of the invention in a liquid composition, such as a lotion, will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.1-5 wt-%, preferably about 0.5-2.5 wt-%.

[0267] The amount of the bispecific binding molecules of the invention required for use in treatment will vary not only with the particular binding molecule selected, but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician. Also, the dosage of the binding molecules of the invention varies depending on the target cell, tumor, tissue, graft, or organ.

[0268] The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.

[0269] An administration regimen may include long-term, daily treatment. By "long-term" is meant at least two weeks and preferably, several weeks, months, or years of duration. Necessary modifications in this dosage range may be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein. See Remington's Pharmaceutical Sciences (Martin, E. W., ed. 4), Mack Publishing Co., Easton, Pa. The dosage can also be adjusted by the individual physician in the event of any complication.

[0270] According to a further embodiment, the invention relates to the use of bispecific binding molecules, e.g. immunoglobulin single variable domains, for therapeutic purposes, such as

[0271] for the prevention, treatment and/or alleviation of a disorder, disease or condition, especially in a human being, that is associated with VEGF- and/or Ang2-mediated effects on angiogenesis or that can be prevented, treated or alleviated by modulating the Notch signaling pathway and/or the Tie2 signalling pathway with a bispecific binding molecule according to the invention,

[0272] in a method of treatment of a patient in need of such therapy, such method comprising administering, to a subject in need thereof, a pharmaceutically active amount of at least one bispecific binding molecule of the invention, e.g. an immunoglobulin single variable domain, or a pharmaceutical composition containing same;

[0273] for the preparation of a medicament for the prevention, treatment or alleviation of disorders, diseases or conditions associated with VEGF- and/or Ang2-mediated effects on angiogenesis;

[0274] as an active ingredient in a pharmaceutical composition or medicament used for the above purposes.

[0275] According to a specific aspect, said disorder disorder, disease or condition is a cancer or cancerous disease, as defined herein.

[0276] According to another aspect, the disease is an eye disease associated with VEGF- and/or Ang2-mediated effects on angiogenesis or which can be treated or alleviated by modulating the Notch signaling pathway with a bispecific binding molecule.

[0277] Depending on the cancerous disease to be treated, a bispecific binding molecule of the invention may be used on its own or in combination with one or more additional therapeutic agents, in particular selected from chemotherapeutic agents like DNA damaging agents or therapeutically active compounds that inhibit angiogenesis, signal transduction pathways or mitotic checkpoints in cancer cells.

[0278] The additional therapeutic agent may be administered simultaneously with, optionally as a component of the same pharmaceutical preparation, or before or after administration of the binding molecule.

[0279] In certain embodiments, the additional therapeutic agent may be, without limitation (and in the case of the receptors, including the respective ligands), one or more inhibitors selected from the group of inhibitors of EGFR, VEGFR, HER2-neu, Her3, AuroraA, AuroraB, PLK and PI3 kinase, FGFR, PDGFR, Raf, Ras, KSP, PDK1, PTK2, IGF-R or I R.

[0280] Further examples of additional therapeutic agents are inhibitors of CDK, Akt, src/bcr abl, cKit, cMet/HGF, c-Myc, Flt3, HSP90, hedgehog antagonists, inhibitors of JAK/STAT, MEK, mTor, NFkappaB, the proteasome, Rho, an inhibitor of wnt signaling or an inhibitor of the ubiquitination pathway or another inhibitor of the Notch signaling pathway.

[0281] Examples for Aurora inhibitors are, without limitation, PHA-739358, AZD-1152, AT 9283, CYC-116, R-763, VX-680, VX-667, MLN-8045, PF-3814735.

[0282] An example for a PLK inhibitor is GSK-461364.

[0283] Examples for raf inhibitors are BAY-73-4506 (also a VEGFR inhibitor), PLX 4032, RAF-265 (also in addition a VEGFR inhibitor), sorafenib (also in addition a VEGFR inhibitor), and XL 281.

[0284] Examples for KSP inhibitors are ispinesib, ARRY-520, AZD-4877, CK-1122697, GSK 246053A, GSK-923295, MK-0731, and SB-743921.

[0285] Examples for a src and/or bcr-abl inhibitors are dasatinib, AZD-0530, bosutinib, XL 228 (also an IGF-1 R inhibitor), nilotinib (also a PDGFR and cKit inhibitor), imatinib (also a cKit inhibitor), and NS-187.

[0286] An example for a PDK1 inhibitor is BX-517.

[0287] An example for a Rho inhibitor is BA-210.

[0288] Examples for PI3 kinase inhibitors are PX-866, BEZ-235 (also an mTor inhibitor), XL 418 (also an Akt inhibitor), XL-147, and XL 765 (also an mTor inhibitor).

[0289] Examples for inhibitors of cMet or HGF are XL-184 (also an inhibitor of VEGFR, cKit, Flt3), PF-2341066, MK-2461, XL-880 (also an inhibitor of VEGFR), MGCD-265 (also an inhibitor of VEGFR, Ron, Tie2), SU-11274, PHA-665752, AMG-102, and AV-299.

[0290] An example for a c-Myc inhibitor is CX-3543.

[0291] Examples for Flt3 inhibitors are AC-220 (also an inhibitor of cKit and PDGFR), KW 2449, lestaurtinib (also an inhibitor of VEGFR, PDGFR, PKC), TG-101348 (also an inhibitor of JAK2), XL-999 (also an inhibitor of cKit, FGFR, PDGFR and VEGFR), sunitinib (also an inhibitor of PDGFR, VEGFR and cKit), and tandutinib (also an inhibitor of PDGFR, and cKit).

[0292] Examples for HSP90 inhibitors are tanespimycin, alvespimycin, IPI-504 and CNF 2024.

[0293] Examples for JAK/STAT inhibitors are CYT-997 (also interacting with tubulin), TG 101348 (also an inhibitor of Flt3), and XL-019.

[0294] Examples for MEK inhibitors are ARRY-142886, PD-325901, AZD-8330, and XL 518.

[0295] Examples for mTor inhibitors are temsirolimus, AP-23573 (which also acts as a VEGF inhibitor), everolimus (a VEGF inhibitor in addition). XL-765 (also a PI3 kinase inhibitor), and BEZ-235 (also a PI3 kinase inhibitor).

[0296] Examples for Akt inhibitors are perifosine, GSK-690693, RX-0201, and triciribine.

[0297] Examples for cKit inhibitors are AB-1010, OSI-930 (also acts as a VEGFR inhibitor), AC-220 (also an inhibitor of Flt3 and PDGFR), tandutinib (also an inhibitor of Flt3 and PDGFR), axitinib (also an inhibitor of VEGFR and PDGFR), XL-999 (also an inhibitor of Flt3, PDGFR, VEGFR, FGFR), sunitinib (also an inhibitor of Flt3, PDGFR, VEGFR), and XL-820 (also acts as a VEGFR- and PDGFR inhibitor), imatinib (also a bcr-abl inhibitor), nilotinib (also an inhibitor of bcr-abl and PDGFR).

[0298] Examples for hedgehog antagonists are IPI-609 and CUR-61414.

[0299] Examples for CDK inhibitors are seliciclib, AT-7519, P-276, ZK-CDK (also inhibiting VEGFR2 and PDGFR), PD-332991, R-547, SNS-032, PHA-690509, and AG 024322.

[0300] Examples for proteasome inhibitors are bortezomib, carfilzomib, and NPI-0052 (also an inhibitor of NFkappaB).

[0301] An example for an NFkappaB pathway inhibitor is NPI-0052.

[0302] An example for an ubiquitination pathway inhibitor is HBX-41108.

[0303] In preferred embodiments, the additional therapeutic agent is an anti-angiogenic agent.

[0304] Examples for anti-angiogenic agents are inhibitors of the FGFR, PDGFR and VEGFR or the respective ligands (e.g VEGF inhibitors like pegaptanib or the anti-VEGF antibody bevacizumab), EGFL7 inhibitors, such as anti-EGFL7 MAb, angiopoietinl/2 inhibitors such as AMG386, and thalidomides, such agents being selected from, without limitation, bevacizumab, motesanib, CDP-791, SU-14813, telatinib, KRN-951, ZK-CDK (also an inhibitor of CDK), ABT-869, BMS-690514, RAF-265, IMC-KDR, IMC-18F1, IMiDs (immunomodulatory drugs), thalidomide derivative CC-4047, lenalidomide, ENMD 0995, IMC-D11, Ki 23057, brivanib, cediranib, XL-999 (also an inhibitor of cKit and Flt3), 163, CP 868596, IMC 3G3, R-1530 (also an inhibitor of Flt3), sunitinib (also an inhibitor of cKit and Flt3), axitinib (also an inhibitor of cKit), lestaurtinib (also an inhibitor of Flt3 and PKC), vatalanib, tandutinib (also an inhibitor of Flt3 and cKit), pazopanib, GW 786034, PF-337210, IMC-1121B, AVE-0005, AG-13736, E-7080, CHIR 258, sorafenib tosylate (also an inhibitor of Raf), RAF-265 (also an inhibitor of Raf), vandetanib, CP-547632, OSI-930, AEE-788 (also an inhibitor of EGFR and Her2), BAY-57-9352 (also an inhibitor of Raf), BAY-73-4506 (also an inhibitor of Raf), XL 880 (also an inhibitor of cMet), XL-647 (also an inhibitor of EGFR and EphB4), XL 820 (also an inhibitor of cKit), and nilotinib (also an inhibitor of cKit and brc-abl).

[0305] The additional therapeutic agent may also be selected from EGFR inhibitors, it may be a small molecule EGFR inhibitor or an anti-EGFR antibody. Examples for anti-EGFR antibodies, without limitation, are cetuximab, panitumumab, matuzumab; an example for a small molecule EGFR inhibitor is gefitinib. Another example for an EGFR modulator is the EGF fusion toxin.

[0306] Among the EGFR and Her2 inhibitors useful for combination with the bispecific binding molecule of the invention are lapatinib, gefitinib, erlotinib, cetuximab, trastuzumab, nimotuzumab, zalutumumab, vandetanib (also an inhibitor of VEGFR), pertuzumab, XL-647, HKI-272, BMS-599626 ARRY-334543, AV 412, mAB-806, BMS-690514, JNJ-26483327, AEE-788 (also an inhibitor of VEGFR), ARRY-333786, IMC-11F8, Zemab.

[0307] Other agents that may be advantageously combined in a therapy with the bispecific binding molecule of the invention are tositumumab and ibritumomab tiuxetan (two radiolabelled anti-CD20 antibodies), alemtuzumab (an anti-CD52 antibody), denosumab, (an osteoclast differentiation factor ligand inhibitor), galiximab (a CD80 antagonist), ofatumumab (a CD20 inhibitor), zanolimumab (a CD4 antagonist), SGN40 (a CD40 ligand receptor modulator), rituximab (a CD20 inhibitor), mapatumumab (a TRAIL-1 receptor agonist), REGN421(SAR1 53192) or OMP-21M18 (DII4 inhibitors).

[0308] Other chemotherapeutic drugs that may be used in combination with the bispecific binding molecule of the present invention are selected from, but not limited to hormones, hormonal analogues and antihormonals (e.g. tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, flutamide, nilutamide, bicalutamide, cyproterone acetate, finasteride, buserelin acetate, fludrocortisone, fluoxymesterone, medroxyprogesterone, octreotide, arzoxifene, pasireotide, vapreotide), aromatase inhibitors (e.g. anastrozole, letrozole, liarozole, exemestane, atamestane, formestane), LHRH agonists and antagonists (e.g. goserelin acetate, leuprolide, abarelix, cetrorelix, deslorelin, histrelin, triptorelin), antimetabolites (e.g. antifolates like methotrexate, pemetrexed, pyrimidine analogues like 5 fluorouracil, capecitabine, decitabine, nelarabine, and gemcitabine, purine and adenosine analogues such as mercaptopurine thioguanine, cladribine and pentostatin, cytarabine, fludarabine); antitumor antibiotics (e.g. anthracyclines like doxorubicin, daunorubicin, epirubicin and idarubicin, mitomycin-C, bleomycin dactinomycin, plicamycin, mitoxantrone, pixantrone, streptozocin); platinum derivatives (e.g. cisplatin, oxaliplatin, carboplatin, lobaplatin, satraplatin); alkylating agents (e.g. estramustine, meclorethamine, melphalan, chlorambucil, busulphan, dacarbazine, cyclophosphamide, ifosfamide, hydroxyurea, temozolomide, nitrosoureas such as carmustine and lomustine, thiotepa); antimitotic agents (e.g. vinca alkaloids like vinblastine, vindesine, vinorelbine, vinflunine and vincristine; and taxanes like paclitaxel, docetaxel and their formulations, larotaxel; simotaxel, and epothilones like ixabepilone, patupilone, ZK-EPO); topoisomerase inhibitors (e.g. epipodophyllotoxins like etoposide and etopophos, teniposide, amsacrine, topotecan, irinotecan) and miscellaneous chemotherapeutics such as amifostine, anagrelide, interferone alpha, procarbazine, mitotane, and porfimer, bexarotene, celecoxib.

[0309] The efficacy of bispecific binding molecule of the invention or polypeptides, and of compositions comprising the same, can be tested using any suitable in vitro assay, cell-based assay, in vivo assay and/or animal model known per se, or any combination thereof, depending on the specific disease or disorder of interest. Suitable assays and animal models will be clear to the skilled person, and for example include the assays described herein and used in the Examples below, e.g. a proliferation assay.

[0310] The data obtained in the experiments of the invention confirm that bispecific binding molecules of the invention have properties that are superior to those of binding molecules of the prior art. Among such properties are complete inhibition of the VEGF165-VEGFR2 interaction and a low IC50, as can e.g. be taken from the ELISA data of FIG. 1 and Table 5 as well as the IC50 (nM) values for VHHs in the AlphaScreen assay as shown in FIGS. 3, 17, 18 and Table 7; and the affinity KD (nM) of purified VHHs on recombinant human VEGF and mouse VEGF in Table 9, 10 and FIG. 5. Also, as shown in Table 13, VEGF binders of the invention have high potency, i.e. in the subnanomolar range, in the HUVEC proliferation assay. This indicates that bispecific binding molecules of the invention are promising candidates to have therapeutic efficacy in diseases and disorders associated with VEGF-mediated effects on angiogenesis, such as cancer.

[0311] According to another embodiment of the invention, there is provided a method of diagnosing a disease by

[0312] a) contacting a sample with a binding molecule of the invention as defined above, and

[0313] b) detecting binding of said binding molecule to said sample, and

[0314] c) comparing the binding detected in step (b) with a standard, wherein a difference in binding relative to said sample is diagnostic of a disease or disorder associated with VEGF- and/or Ang2-mediated effects on angiogenesis.

[0315] For this and other uses, it may be useful to further modify a bispecific binding molecule of the invention, such as by introduction of a functional group that is one part of a specific binding pair, such as the biotin-(strept)avidin binding pair. Such a functional group may be used to link the binding molecule of the invention to another protein, polypeptide or chemical compound that is bound to the other half of the binding pair, i.e. through formation of the binding pair. For example, a bispecific binding molecule of the invention may be conjugated to biotin, and linked to another protein, polypeptide, compound or carrier conjugated to avidin or streptavidin. For example, such a conjugated bispecific binding molecule of the invention may be used as a reporter, for example in a diagnostic system where a detectable signal-producing agent is conjugated to avidin or streptavidin.

BRIEF DESCRIPTION OF THE FIGURES

[0316] FIG. 1: Purified monovalent VHHs block the hVEGF165/hVEGFR2-Fc interaction (ELISA)

[0317] FIG. 2: Purified monovalent VHHs block the hVEGF165/hVEGFR1-Fc interaction (ELISA)

[0318] FIG. 3: Purified monovalent VHHs block the hVEGF165/hVEGFR2-Fc interaction (AlphaScreen)

[0319] FIG. 4: Purified monovalent VHHs block the hVEGF165/hVEGFR1-Fc interaction (AlphaScreen)

[0320] FIG. 5: Binding of monovalent VHHs to recombinant human and mouse VEGF (ELISA)

[0321] FIG. 6: Binding of monovalent VHHs to human VEGF121

[0322] FIG. 7: Purified VHHs do not bind to VEGFB, VEGFC, VEGFD and PIGF

[0323] FIG. 8: Formatted VHHs block hVEGF165/hVEGFR2-Fc interaction (ELISA)

[0324] FIG. 9: Formatted VHHs block hVEGF165/hVEGFR1-Fc interaction (ELISA)

[0325] FIG. 10: Formatted VHHs block hVEGF165/hVEGFR2-Fc interaction (AlphaScreen)

[0326] FIG. 11:Formatted VHHs block hVEGF165/hVEGFR1-Fc interaction (AlphaScreen)

[0327] FIG. 12: Formatted VHHs block mVEGF164/mVEGFR2-Fc interaction (AlphaScreen)

[0328] FIG. 13: Formatted VHHs bind to mouse and human VEGF

[0329] FIG. 14A-14H: Formatted VHHs do not bind to VEGFB, VEGFC, VEGFD and PIGF

[0330] FIG. 15: Formatted VHHs bind to VEGF121

[0331] FIG. 16: Sequence alignment of VHH VEGFBII23B04 (SEQ ID NO:18) with human VH3/JH (SEQ ID NO:179)

[0332] germline consensus sequence

[0333] FIG. 17: VHH variants of VEGFBII23B04 block hVEGF165/hVEGFR2-Fc interaction (AlphaScreen)

[0334] FIG. 18: Sequence-optimized clones of VEGFBII23B04 block the hVEGF165/hVEGFR2-Fc interaction (AlphaScreen)

[0335] FIG. 19: Sequence alignment of VHH VEGFBII5B05 (SEQ ID NO: 64) with human VH3/JH (SEQ ID NO: 179)

[0336] germline consensus sequence

[0337] FIG. 20 A-20C: Description bivalent Ang2 VHHs: A.discloses "9GS" and "9 GlySer" as SEQ ID NO: 170 and "40GS" and "40 GlySer" as SEQ ID NO: 171; B. Expression levels of all bivalent VHHs is depicted in FIG. 20 A; C. IC.sub.50 values (pM) in human Ang2/human Tie2, mouse Ang2/mouse Tie2, cyno Ang2/cyno Tie2 and hAng1/hTie2 competition ELISA.

[0338] FIG. 21-1A to 21-1D; 21-2A to 21-2D; 21-3A to 21-3D: Purified bivalent Ang2 VHHs blocking hAng2-hTie2 (25-1), mAng2-mTie2 (25-2) and cAng2-cTie2 (25-3) interaction (ELISA)

[0339] FIG. 22: Purified bivalent Ang2 VHHs blocking hAng1-hTie2 interaction (ELISA)

[0340] FIG. 23A-23D: A. Description trivalent VEGFxAng2 bispecific VHHs (FIG. 23 discloses "9GS" and "9 GlySer" as SEQ ID NO: 170); B. Expression levels are indicated for all four bispecific VHHs depicted in FIG. 23 A; C. IC.sub.50 values (nM) in human VEGF165/human VEGFR2 competition AlphaScreen: D. IC.sub.50 values (pM) in human Ang2/human Tie2 competition ELISA * * *

[0341] FIG. 24A-24D: Purified trivalent VEGFxAng2 Nanobodies blocking hVEGF-hVEGFR2 interaction (AlphaScreen)

[0342] FIG. 25A-25D: Purified trivalent VEGFxAng2 VHHs blocking hAng2-hTie2 interaction (ELISA)

[0343] FIG. 26A-26C: A. Description trivalent and tetravalent VEGFxAng2 bispecific VHHs (FIG. 26 discloses "9GS" and "9 GlySer" as SEQ ID NO: 170); B. Expression levels all ten bispecific VHHs as depicted in FIG. 26A are shown; C. IC50 values (nM) in human VEGF165/human VEGFR2 and human VEGF165/human VEGFR1 competition AlphaScreen

[0344] FIG. 27-1A to 27-1H; 27-2A to 27-2H: Purified trivalent and tetravalent VEGFxAng2 VHHs blocking hVEGF-hVEGFR2 (31-1) and hVEGF-hVEGFR1 (31-2) interaction (AlphaScreen)

[0345] FIG. 28-1A to 28-1H; 28-2A to 28-2G; 28-3A to 28-3G: Purified trivalent and tetravalent VEGFxAng2 VHHs blocking hAng2-hTie2 (32-1), mAng2-mTie2 (32-2) and cAng2-cTie2 (32-3) interaction (ELISA)

[0346] FIG. 29A-29G: A-F. Purified trivalent and tetravalent VEGFxAng2 VHHs blocking hAng2 mediated HUVEC survival; G. IC.sub.50 values (pM) and % inhibition in human Ang2/human Tie2, mouse Ang2/mouse Tie2 and cyno Ang2/cyno Tie2 competition ELISA and IC.sub.50 (nM) values and % inhibition in hAng2 mediated HUVEC survival.

[0347] FIG. 30A-30D: A. Description sequence optimized and affinity VEGFxAng2 bispecific VHHs (FIG. 30 discloses "9GS" and "9 GlySer" as SEQ ID NO: 170); B. Expression levels of all 14 bispecific VHHs as depicted in (A); C. IC.sub.50 values (nM) in human VEGF165/human VEGFR2 and human VEGF165/human VEGFR1 competition AlphaScreen; D. Overview of kinetic parameters of the bispecific VHHs on human VEGF165 in hVEGF165 Biacore assay.

[0348] FIG. 31-1A to 31-1C; 31-2A to 31-2C: Purified VEGFANGBII00022-25-28 VEGFxAng2 VHHs blocking hVEGF-hVEGFR2 (35-1) and hVEGF-hVEGFR1 (35-2) interaction (AlphaScreen)

[0349] FIG. 32A-32B: Purified VEGFANGBII00022-25-28 VEGFxAng2 VHHs binding to human VEGF165 (36-1) and hVEGF121 (36-2) (ELISA)

[0350] FIG. 33A-33B: Purified VEGFANGBII00022-25-28 VEGFxAng2 VHHs binding to (A) mouse and (B) rat VEGF164 (ELISA)

[0351] FIG. 34A-34D: Purified VEGFANGBII00022-25-28 VEGFxAng2 VHHs binding to (A) human VEGF-B, (B) human VEGF-C, (C) human VEGF-D and (D) human PIGF (ELISA)

[0352] FIG. 35-1A to 35-1C; 35-2A to 35-2C; 35-3A to 35-3C: Purified VEGFANGBII00022-25-28 VEGFxAng2 VHHs blocking hAng2-hTie2 (39-1), mAng2-mTie2 (39-2) and cAng2-cTie2 (39-3) interaction (ELISA)

[0353] FIG. 36A-36C: Purified VEGFANGBII00022-25-28 VEGFxAng2 VHHs blocking hAng1-hTie2 interaction (ELISA)

[0354] FIG. 37A-37C: Purified VEGFANGBII00022-25-28 VEGFxAng2 VHHs blocking hAng2 mediated HUVEC survival.

[0355] FIG. 38: A summary of IC.sub.50 values and % inhibition: 1050 values (pM) in human Ang2/human Tie2, mouse Ang2/mouse Tie2 and cyno Ang2/cyno Tie2 competition ELISA, hAng1 ELISA and IC50 values (nM) in hAng2 mediated HUVEC survival assay.

[0356] Materials and Methods:

[0357] a) Production and Functionality Testing of VEGF109

[0358] A cDNA encoding the receptor binding domain of human vascular endothelial growth factor isoform VEGF165 (GenBank: AAM03108.1; AA residues 27-135) is cloned into pET28a vector (Novagen, Madison, Wis.) and overexpressed in E. coli (BL21 Star DE3) as a His-tagged insoluble protein. Expression is induced by addition of 1 mM IPTG and allowed to continue for 4 hours at 37.degree. C. Cells are harvested by centrifugation and lysed by sonication of the cell pellet. Inclusion bodies are isolated by centrifugation. After a washing step with 1% Triton X 100 (Sigma-Aldrich), proteins are solubilized using 7.5M guanidine hydrochloride and refolded by consecutive rounds of overnight dialysis using buffers with decreasing urea concentrations from 6M till OM. The refolded protein is purified by ion exchange chromatography using a MonoQ5/50GL (Amersham BioSciences) column followed by gel filtration with a Superdex75 10/300 GL column (Amersheim BioSciences). The purity and homogeneity of the protein is confirmed by SDS-PAGE and Westen blot. In addition, binding activity to VEGFR1, VEGFR2 and Bevacizumab is monitored by ELISA. To this end, 1 .mu.g/mL of recombinant human VEGF109 is immobilized overnight at 4.degree. C. in a 96-well MaxiSorp plate (Nunc, Wiesbaden, Germany). Wells are blocked with a casein solution (1%). Serial dilutions of VEGFR1, VEGFR2 or Bevacizumab are added to the VEGF109 coated plate and binding is detected using alkaline phosphatase (AP) conjugated goat anti-human IgG, Fc specific (Jackson Immuno Research Laboratories Inc., West Grove, Pa., USA) and a subsequent enzymatic reaction in the presence of the substrate PNPP (p-nitrophenylphosphate) (Sigma-Aldrich). VEGF109 could bind to VEGFR1, VEGFR2 and Bevacizumab, indicating that the produced VEGF109 is active.

[0359] b) KLH Conjugation of VEGF165 and Functionality Testing of KLH-Conjugated VEGF165

[0360] Recombinant human VEGF165 (R&D Systems, Minneapolis, Minn., USA) is conjugated to mariculture keyhole limpet hemocyanin (mcKLH) using the Imject Immunogen EDC kit with mcKLH (Pierce, Rockford, Ill., USA) according to the manufacturer's instructions. Efficient conjugation of the polypeptide to mcKLH is confirmed by SDS-PAGE. Functionality of the conjugated protein is checked by ELISA: 2 .mu.g/mL of KLH conjugated VEGF165 is immobilized overnight at 4.degree. C. in a 96-well MaxiSorp plate (Nunc, Wiesbaden, Germany). Wells are blocked with a casein solution (1%). Serial dilutions of VEGFR1 or VEGFR2 are added and binding is detected using a horseradish peroxidase (HRP)-conjugated goat anti-human IgG, Fc specific (Jackson Immuno Research Laboratories Inc., West Grove, Pa., USA) and a subsequent enzymatic reaction in the presence of the substrate TMB (3,3',5,5'-tetramentylbenzidine) (Pierce, Rockford, Ill., USA). The KLH conjugated protein could still interact with VEGFR1, VEGFR2 and Bevacizumab, confirming that the relevant epitopes onVEGF165 are still accessible.

EXAMPLE 1

[0361] Immunization with Different VEGF Formats Induces a Humoral Immune Response in Ilama

[0362] 1.1 Immunizations

[0363] After approval of the Ethical Committee of the faculty of Veterinary Medicine (University Ghent, Belgium), 4 llamas (designated No. 264, 265, 266, 267) are immunized according to standard protocols with 6 intramuscular injections (100 or 50 .mu.g/dose at weekly intervals) of recombinant human VEGF109. The first injection at day 0 is formulated in Complete Freund's Adjuvant (Difco, Detroit, Mich., USA), while the subsequent injections are formulated in Incomplete Freund's Adjuvant (Difco, Detroit, Mich., USA). In addition, four llamas (designated No. 234, 235, 280 and 281) are immunized according to the following protocol: 5 intramuscular injections with KLH-conjugated human VEGH165 (100 or 50 .mu.g/dose at biweekly intervals) followed by 4 intramuscular injections of human VEGF109 (first dose of 100 .mu.g followed 2 weeks later with three 50 .mu.g/dose at weekly interval).

[0364] 1.2 Evaluation of VEGF-Induced Immune Responses in Ilama

[0365] To monitor VEGF specific serum titers, an ELISA assay is set up in which 2 .mu.g/mL of recombinant human VEGF165 or VEGF109 is immobilized overnight at 4.degree. C. in a 96-well MaxiSorp plate (Nunc, Wiesbaden, Germany). Wells are blocked with a casein solution (1%). After addition of serum dilutions, bound total IgG is detected using horseradish peroxidase (HRP)-conjugated goat anti-llama immunoglobulin (Bethyl Laboratories Inc., Montgomery, TX, USA) and a subsequent enzymatic reaction in the presence of the substrate TMB (3,3',5,5'-tetramentylbenzidine) (Pierce, Rockford, IL, USA). For llamas 264, 265, 266 and 267, an additional ELISA is performed in which the isotype-specific responses against VEGF165 and VEGF109 are evaluated. Isotype specific responses are detected using mouse mAbs specifically recognizing conventional llama IgG1 and the heavy-chain only llama IgG2 and IgG3 [Daley et al. (2005). Clin. Diagn. Lab. Imm. 12:380-386] followed by a rabbit anti-mouse-HRP conjugate (DAKO). ELISAs are developed using TMB as chromogenic substrate and absorbance is measured at 450nm. The serum titers for each llama are depicted in Table 1.

TABLE-US-00004 TABLE 1 Antibody-mediated specific serum response against VEGF165 and VEGF109 ELISA (recombinant protein solid phase coated) Recombinant human Recombinant human EGF165 VEGF109 Llama Immunogen Total IgG IgG1 IgG2 IgG3 Total IgG IgG1 IgG2 IgG3 234 VEGF165-KLH + ++ n/d n/d n/d ++ n/d n/d n/d VEGF109 235 VEGF165-KLH + ++ n/d n/d n/d ++ n/d n/d n/d VEGF109 280 VEGF165-KLH + + n/d n/d n/d + n/d n/d n/d VEGF109 281 VEGF165-KLH + + n/d n/d n/d + n/d n/d n/d VEGF109 264 VEGF109 n/d ++ + + ++ ++ + + 265 VEGF109 n/d ++ + + + ++ + + 266 VEGF109 n/d ++ + +/- ++ ++ + +/- 267 VEGF109 n/d +/- - - +/- +/- - - n/d, not determined

EXAMPLE 2

[0366] Cloning of the Heavy-Chain Only Antibody Fragment Repertoires and Preparation of Phage

[0367] Following the final immunogen injection, immune tissues as the source of B-cells that produce the heavy-chain antibodies are collected from the immunized llamas. Typically, two 150-mi blood samples, collected 4 and 8 days after the last antigen injection, and one lymph node biopsy, collected 4 days after the last antigen injection are collected per animal. From the blood samples, peripheral blood mononuclear cells (PBMCs) are prepared using Ficoll-Hypaque according to the manufacturer's instructions (Amersham Biosciences, Piscataway, N.J., USA). From the PBMCs and the lymph node biopsy, total RNA is extracted, which is used as starting material for RT-PCR to amplify the VHH encoding DNA segments, as described in W02005/044858. For each immunized llama, a library is constructed by pooling the total RNA isolated from all collected immune tissues of that animal. In short, the PCR-amplified VHH repertoire is cloned via specific restriction sites into a vector designed to facilitate phage display of the VHH library. The vector is derived from pUC119 and contains the LacZ promoter, a M13 phage gill protein coding sequence, a resistance gene for ampicillin or carbenicillin, a multiple cloning site and a hybrid gIII-pelB leader sequence (pAX050). In frame with the VHH coding sequence, the vector encodes a C-terminal c-myc tag and a His6 tag (SEQ ID NO: 283). Phage are prepared according to standard protocols and stored after filter sterilization at 4.degree. C. for further use.

EXAMPLE 3

[0368] Selection of VEGF-Specific VHHs Via Phage Display

[0369] VHH phage libraries are used in different selection strategies applying a multiplicity of selection conditions. Variables include i) the VEGF protein format (rhVEGF165, rhVEGF109 or rmVEGF164), ii) the antigen presentation method (solid phase: directly coated or via a biotin-tag onto Neutravidin-coated plates; solution phase: incubation in solution followed by capturing on Neutravidin-coated plates), iii) the antigen concentration and iv) the elution method (trypsin or competitive elution using VEGFR2). All selections are carried out in Maxisorp 96-well plates (Nunc, Wiesbaden, Germany).

[0370] Selections are performed as follows: Phage libraries are incubated at RT with variable concentrations of VEGF antigen, either in solution or immobilized on a solid support. After 2hrs of incubation and extensive washing, bound phage are eluted. In case trypsin is used for phage elution, the protease activity is immediately neutralized by addition of 0.8 mM protease inhibitor AEBSF. Phage outputs that show enrichment over background are used to infect E. coli. Infected E. coli cells are either used to prepare phage for the next selection round (phage rescue) or plated on agar plates (LB+amp+glucose.sup.2%) for analysis of individual VHH clones. In order to screen a selection output for specific binders, single colonies are picked from the agar plates and grown in 1 mL 96-deep-well plates. The lacZ-controlled VHH expression is induced by adding IPTG (0.1-1 mM final). Periplasmic extracts (in a volume of .about.80 .mu.L) are prepared according to standard methods.

EXAMPLE 4

[0371] Identification of VEGF-binding and VEGF receptor-blocking VHHs Periplasmic extracts are tested for binding to human VEGF165 by ELISA. In brief, 2 .mu.g/mL of recombinant human VEGF165 is immobilized overnight at 4.degree. C. in a 96-well MaxiSorp plate (Nunc, Wiesbaden, Germany). Wells are blocked with a casein solution (1%). After addition of typically a 10-fold dilution of the periplasmic extracts, VHH binding is detected using a mouse anti-myc (Roche) and an anti-mouse-HRP conjugate (DAKO). Clones showing ELISA signals of >3-fold above background are considered as VEGF binding VHHs.

[0372] In addition, periplasmic extracts are screened in a human VEGF165/human VEGFR2 AlphaScreen assay (Amplified Luminescent Proximity Homogeneous Assay) to assess the blocking capacity of the VHHs. Human VEGF165 is biotinylated using Sulfo-NHS-LC-Biotin (Pierce, Rockford, Ill., USA). Human VEGFR2/Fc chimera (R&D Systems, Minneapolis, Minn., USA) is captured using an anti-humanFc VHH which is coupled to acceptor beads according to the manufacturer's instructions (Perkin Elmer, Waltham, Mass., US). To evaluate the neutralizing capacity of the VHHs, periplasmic extracts are diluted 1/25 in PBS buffer containing 0.03% Tween 20 (Sigma-Aldrich) and preincubated with 0.4 nM biotinylated human VEGF165 for 15 minutes at room temperature (RT). To this mixture the acceptor beads (10 .mu.g/ml) and 0.4 nM VEGFR2-huFc are added and further incubated for 1 hour at RT in the dark. Subsequently donor beads (10 .mu.g/ml) are added followed by incubation of 1 hour at RT in the dark. Fluorescence is measured by reading plates on the Envision Multi label Plate reader (Perkin Elmer, Waltham, Mass., USA) using an excitation wavelength of 680 nm and an emission wavelength between 520 nm and 620 nm. Periplasmic extract containing irrelevant VHH is used as negative control. Periplasmic extracts containing anti-VEGF165 VHHs which are able to decrease the fluorescence signal with more than 60% relative to the signal of the negative control are identified as a hit. All hits identified in the AlphaScreen are confirmed in a competition ELISA. To this end, 1 .mu.g/mL of human VEGFR2 chimera (R&D Systems, Minneapolis, MN, USA) is coated in a 96-well MaxiSorp plate (Nunc, Wiesbaden, Germany). Fivefold dilutions of the periplasmic extracts are incubated in the presence of a fixed concentration (4nM) of biotinylated human VEGF165 in PBS buffer containing 0.1% casein and 0.05% Tween 20 (Sigma-Aldrich). Binding of these VHH/bio-VEGF165 complexes to the human VEGFR2 chimera coated plate is detected using horseradish peroxidase (HRP) conjugated extravidin (Sigma, St Louis, Mo., USA). VHH sequence IDs and the corresponding AA sequences of VEGF-binding (non-receptor-blocking) VHHs and inhibitory (receptor-blocking) VHHs are listed in Table 2 and Table 3, respectively.

TABLE-US-00005 TABLE 2 Sequence IDs and AA sequences of monovalent "non-receptor-blocking" anti-VEGF VHHs (FR, framework; CDR, complementary determining region) VHH ID/ CDR1/ SEQ ID FR1/SEQ ID SEQ ID FR2/SEQ CDR2/SEQ FR3/SEQ ID CDR3/SEQ ID FR4/SEQ NO: NO: NO: ID NO: ID NO: NO: NO: ID NO: VEGFBII EVQLVESGGG SYGMG/ WFRQSPG AISEYSNTYC RFTISRDNTKN SPTILLTTEQW WGQGTQVT 01C02/58 LVQAGGSLRL 284 KEREFVS/ SDSVRG/330 TVYLQMNSLTP YKY/389 VSS/603 SCTASGGSFS/ 517 DDTAIYYCAA/ 466 548 VEGFBII EVQLVESGGG ASDMG/ WFRQAPG AINWSGLSTF RFTISRDNDNG GRIPSSSRFSS WGQGTQVT 01E07/59 LVQAGDSLRL 285 KEREFVA/ YTDSVKG/331 ALYLQMNTLKP PAAYAS/390 VSS/603 SCVATGRTFR/ 518 EDTAVYSCAA/ 467 549 VEGFBII EVQLVESGGG ITVMA/ WFRQAPG AITWSAPTTY RFTISRDNAKN DRFKGRSIVTP WGQGTQVT 03D12/60 LVQAGGSLRL 286 KEREFVA/ YADSVKG/332 TVYLRMNSLKP SDYRY/391 VSS/603 SCTASTSIYT/ 518 EDSAIYYCAA/ 468 550 VEGFBII EVQLVESGGG DITVA/ WYRQAPG TITPSGYTYY RFTISRDNSKN QFY/392 WGQGTQVT 04B08/61 LVQPGGSLRL 287 IQRQLVA/ WDFVKG/333 IVYLQMNSLKP VSS/603 SCAASGSAVG/ 519 EDTAAYYCNT/ 469 551 VEGFBII EVQLVESGGG TDDVG/ WFRQAPG VIRWSTGGTY RFTLSRDNAKN RSRPLGAGAWY WGQGTQVT 05B02/62 LVQAGGSLRL 288 KEREFVA/ TSDSVKG/334 TMYLQMNSLKP SGEKHYNY/393 VSS/603 SCAASGRTFS/ 518 EDTAVYYCAA/ 470 552 VEGFBII EVQLVESGGG HYNMG/ WFRQAPG SIRGGGGSTT RFTISRENAKN TAFYRGPYDYD WGQGTQVT 05B03/63 LAQAGDSLRL 289 KEREFVA/ YANSVKD/335 TVYLQMNSLKP Y/394 VSS/603 SCAASGRSFS/ 518 EDTAVYYCAA/ 471 553 VEGFBII EVQLVESGGG SMA/ WYRQAPG RISSGGTTAY RFTISRDNSKN FSSRPNP/395 WGAGTQVT 05B05/64 LVQPGGSLRL 290 KHRELVA/ VDSVKG/336 TVYLQMNSLKA VSS/604 SCVASGIRFM/ 520 EDTAVYYCNT/ 472 554 VEGFBII EVQLVESGGG NNAMA/ WYRQAPG RISSGGGFTY RFTVSRDNAKN AYRTYNY/396 WGQGTQVT 06G02/65 LVQPGGSLRL 291 KQRELVA/ YLDSVKG/337 TVYLQMNSLKP VSS/603 SCAASGNIFS/ 521 EDTAVYYCNA/ 473 555 VEGFBII EVQLVESGGG ITVMA/ WFRQAPG AITWSAPSSY RFTISRDNAKN DRFKGRSIVTR WGQGTQVT 07A03/66 LVQAGGSLRL 286 KESEFVA/ YADSVKG/338 TVYLQMNSLKP SDYKY/397 VSS/603 SCAASTSIYS/ 522 EDSAIYYCAA/ 474 556 VEGFBII EVQLVESGGG ISVMA/ WFRQAPG AITWSAPTTY RFTISRDNAKN DRFKGRSIVTR WGQGTQVT 07A06/67 LVQAGGSLRL 292 KERAFVA/ YADSVKG/332 TVYLQTNSLKP SDYRY/398 VSS/603 SCAVSTSIYS/ 523 EDSAIYYCAA/ 475 557 VEGFBII EVQLVESGGG NYAMA/ WFRQAPG AINQRGSNTN RFTISRDSAKN STWYGYSTYAR WGQGTQVT 07D08/68 LVQTGGSLRL 293 KEREFVS/ YADSVKG/339 SVFLQMNSLKP REEYRY/399 VSS/603 SCAASGRTFS/ 524 EDTAVYYCAA/ 476 558 VEGFBII EVQLVESGGG DNVMG/ WFRQAAG HISRGGSRTE RFTISRDNTKK SRSVALATARP WGQGTQVT 08D09/69 LVQAGGSLRL 294 KEREFVA/ YAESVKG/340 TMYLQMNSLKP YDY/400 VSS/603 SCAASGRSFS/ 525 EDTAVYYCAA/ 477 559 VEGFBII EVQLVESGGG SYYMG/ WFRQAPG TISWNKISTI RFTVSRDNNKN DASRPTLRIPQ WGQGTPVT 08E07/70 LAQAGGSLRL 295 KEREFVA/ YTDSVKG/341 TVYLQMNNLKP Y/401 VSS/603 SCTTSGLTFS/ 518 EDTAVYYCAA/ 478 560 VEGFBII EVQLVESGGG SDVMG/ WYRQAPG FIRSLGSTYY RFTISRDDAAN RFSGESY/402 WGQGTQVT 08F06/71 LVQPGGSLRL 296 KQRELVA/ AGSVKG/342 TVYLQMNSLKP VSS/605 SCAASGSIVR/ 521 EDTAVYYCNA/ 479 561 VEGFBII EVQLVESGGG LYAMG/ WFRQAPG AITWSAGDTQ RFTISRDNARN RQWGGTYYYHG WGQGTQVT 08F07/72 LVQAGGSLRL 297 REREFLS/ YADSVKG/343 TVNLQMNGLKP SYAY/403 VSS/603 SCAVSGSTFG/ 526 EDTAVYYCAG/ 480 562 VEGFBII EVQLVESGGG SMA/ WYRQAPG RISSEGTTAY RFTISRDNSKN FSSRPNP/395 WGAGTTVT 09A09/73 LVQPGGSLRL 290 KHRELVA/ VDSVKG/344 TVYLQMNSLKA VSS/606 SCVASGIRFM/ 520 EDTAVYYCNT/ 472 554 VEGFBII EVQLVESGGG TDDVG/ WFRQAPG VIRWSTGGTY RFTLSRDNAKN RSRPLGAGAWY WGQGTQVT 09A12/74 LVQAGGSLRL 288 KEREFVA/ TSDSVAG/345 TMYLQMNSLKP TGETRYDS/405 VSS/603 SCAASGRTFS/ 518 EDTAVYYCAA/ 470 552 VEGFBII EVQLVESGGG RYGMG/ WFRQAPG AISEYDNVYT RFTISRDNSKS SPTILLSTDEW WGRGTQVT 09D05/75 LVQPGDSLRL 298 KEREFVI/ ADSVRG/346 TVYLQMNSLKS YKY/406 VSS/607 SCAASGLSFS/ 527 EDTAVYYCAA/ 481 563 VEGFBII EVQLVESGGG TDDVG/ WFRQAPG VIRWSTGGTY RFTLSRDNAKN RSRPLGAGAWY WGQGTQVT 09F05/76 LVQAGGSLRL 288 KEREFVA/ TSDSVKG/334 TMYLQMNSLKP TGETRYNY/407 VSS/603 SCAASGRTFS/ 518 EDTAVYYCAA/ 470 552 VEGFBII EVQLVESGGG NYAMG/ WFRQVPG VITRSPSNTY RFTISRDNAKN HYWNSDSYTYT WGQGTQVT 10C07/77 LVQAGGSLRL 299 REREFVA/ TYDSVKG/347 IVYLQMNSLKP DSRWYNY/408 VSS/603 SCAASARAFS/ 528 EDTAVYYCAA/ 482 564 VEGFBII EVQLVESGGG NYAMG/ WFRQAPG DISSSGINTY RFTISRDNAKN SAWWYSQMARD WGQGTQVT 10E07/78 LVQAGGSLRL 299 KERVLVA/ VADAVKG/348 TVYLQMNSLKP NYRY/409 VSS/603 SCAASGRTFS/ 529 EDTAVYYCAA/ 470 565 VEGFBII EVQLVESGGG RYAMG/ WFRQAPG SINTSGKRTS RFAVSRDNAKN DRFFGSDSNEP WGQGTQVT 10G04/79 LVQAGGSLRL 300 KEREFVA/ YADSMKG/ TGYLQMNSLKL RAYRY/410 VSS/603 SCAASGDTLS/ 518 349 EDTATYYCAA/ 483 566 VEGFBII EVQLVESGGG NYNMG/ WFRQAPG TIRHHGYDTY RFTISRDNAKN KLFWDMDPKTG WGQGTQVT 10G05/80 LVQAGESLRL 301 KEREFVA/ YAESVKG/350 EVYLQMNSLKP FSS/411 VSS/603 SCVASGITFS/ 518 EDTALYSCAK/ 484 567 VEGFBII EVQLVESGGG SYGLG/ WFRQAPG AIGWSGSSTY RFTVSVDNAKN KVRNFNSDWDL WGQGTQVT 11C08/81 LVQAGGSLRL 302 KEREFVA/ YADSVKG/351 TVYLKMNSLEP LTSYNY/412 VSS/603 SCAASGRTLS/ 518 EDTAVYYCAA/ 485 568 VEGFBII EVQLVESGGG SYAIG/ WFRQAPG RISWSGANTY RFTISRGNAKN QTTSKYDNYDA WGQGTQVT 11C11/82 LVQAGGSLML 303 REREFVA/ YADSVKG/ TVYLQMNSLKP RAYGY/413 VSS/603 SCAASGRALS/ 530 352 EDTAAYYCAA/ 486 569 VEGFBII EEQLVESGGG SYAIG/ WFRQAPG RISWSGANTY RFTISRGNAKN QTTSKYDNYDA WGQGTQVT 11D09/83 LVQAGGSLML 303 REREFVA/ YADSVKG/352 TVYLQMNSLKP RAYGY/413 VSS/603 SCAASGRALS/ 530 EDTAAYYCAA/ 487 569 VEGFBII EVQLVESGGG SYAMG/ WFRQAPG TISQSGYSTY RFTISRDNAKN DPFYSYGSPSP WGQGTQVT 11E04/84 LVQAGGSLRL 304 KEREFVA/ YADSVKG/353 TVNLQMNSLKPP YRY/414 VSS/603 SCAASGRTFS/ 518 EDTAVYYCAA/ 470 570 VEGFBII EVQLVESGGG FSAMG/ WFRQAPG AFKWSGSTTY RFTISTDNAKN DRFYTGRYYSS WGQGTQVT 11E05/85 LVQPGGSLRL 305 KEREFVA/ TADYVKG/354 ILFLQMNSLKP DEYDY/415 VSS/603 SCASSGRLFS/ 518 EDTAIYYCAV/ 488 571 VEGFBII EVQLVESGGG ITVMA/ WFRQAPG AITWSAPSSY RFTISRDNAKN DRFKGRSIVTR WGQGTQVT 11F10/86 LVQAGGSLRL 286 KEREFVA/ YADSVKG/ TVYLQVNSLKP SDYRY/416 VSS/603 SCAASTSIYS/ 518 355 EDSAIYYCAA/ 474 572 VEGFBII EVQLVESGGG SLAMG/ WFRQVPG SISQSGITTS RFTISRDSAKN SVFYSTALTRP WGQGTQVT 11F12/87 LVQSGGSLRL 306 KDREFVA/ YADSVKS/356 TVYLQMNLLKP VDYRY/417 VSS/603 SCAASGRSFS/ 531 EDTAVYYCAT/ 489 573 VEGFBII EVQLVESGGG ITVMA/ WFRQAPG AITWSAPTTY RFTISRDNAKN DRFKGRSIVTR WGQGTQVT 11G09/88 LVQAGGSLRL 286 KEREFVA/ SADSVKG/ TVYLQMNSLKP SDYRY/416 VSS/603 SCAASTSIYS/ 518 357 EDSAIYYCAA/ 474 556 VEGFBII EVQLVESGGG KYVMG/ WFRQAPG AITSRDGPTY RFTISGDNTKN DEDLYHYSSYH WGQGTQVT 12A07/89 LVQAGGSLRL 307 NDREFVA/ YADSVKG/358 KIFLQMNSLMP FTRVDLYHY/ VSS/603 SCSVTGRTFN/ 532 EDTAVYYCAI/ 418 490 574 VEGFBII EVQLVESGGG SSWMY/ WVRQAPG RISPGGLFTY RFSVSTDNANN GGAPNYTP/419 RGRGTQVT 12B01/90 LVQPGGSLRL 308 KGLEWVS/ YVDSVKG/359 TLYLQMNSLKP VSS/608 ACAASGFTLS/ 533 EDTALYSCAK/ 491 575 VEGFBII EVQLVESGGG SDVMG/ WYRQAPG FIRSLGSTYY RFTISRDNAAN RFSGESY/402 WGQGTPVT 12C04/91 LVQPGGSLRL 296 KQRELVA/ AGSVKG/342 TVYLQMNNLKP VSS/605 SCAASGSIVR/ 521 EDTAVYYCNA/ 479 576 VEGFBII EVQLVESGGG NYVMG/ WFRQAPG AITSTNGPTY RFTISGDNTKN DEDLYHYSSYH WGQGTQVT 12E10/92 LAQAGGSLRL 309 NEREFVA/ YADSVKG/360 KVFLQMDSLRP YTRVALYHY/ VSS/603 SCTASGRTFN/ 534 EDTAVYYCAI/ 420 492 577 VEGFBII EVQLVESGGG LYAMG/ WFRQAPG AITWSAGDTQ RFTISRDNARN RQWGGTYYYHG WGQGTQVT 12G04/93 LVQSGDSLRL 297 REREFVS/ YADSVKG/343 TVNLQMNGLKP SYAW/421 VSS/603 SCAVSGNTFG/ 535 EDTAVYYCAG/ 493 562 VEGFBII EVQLVESEGG TDDVG/ WFRQAPG VIRWSTGGTY RFTLSRDNAKN RSRPLGAGAWY WGQGTQVT 16C03/94 LVQAGGSLRL 288 KEREFVA/ TSDSVKG/ TMYLQMNSLKP TGENYYNY/ VSS/603 SCAASGRTFS/ 518 334 EDTAVYYCAA/ 422 494 552 VEGFBII EVQLVESGGG GYDMG/ WFRQAPG AITWSGGSTY RFTISRDNAKN GRIWRSRDYDS WGHGTQVT 16F11/95 LVQAGGSLRL 310 KEREFVT/ SPDSVKG/361 TVYLQMNNLTP EKYYDI/423 VSS/609

SCAASGRTSS/ 536 EDTAVYYCAS/ 495 578 VEGFBII EVQLVESGGG AYDMG/ WFRQAPG VISWTNSMTY RFTISRDNAKN DRRRTYSRWRF WGQGTQVT 36C08/96 LVQAGGSLRL 311 KEREFVA/ YADSVKG/362 TVYLQMNSLKP YTGVNDYDY/ VSS/603 SCAASGRTFS/ 518 EDTAVYYCAV/ 424 470 579 VEGFBII EVQLVESGGG AYDMG/ WFRQAPG VISWSGGMTY RFTISRDNAKS DRRRAYSRWRY WGQGTQVT 37F09/97 LVQTGGSLRL 311 KEREFVA/ YADSVQG/363 TVYLQMNSPKP YTGVNDYEF/ VSS/603 SCAASGRTFS/ 518 EDTAVYYCAV/ 425 476 580 VEGFBII EVQLVESGGG AYDMG/ WFRQAPG VISWSGGMTY RFTISRDNAKN DRRRLYSRWRY WGQGTQVT 38A06/98 LVQAGGSLRL 311 KEREFVA/ YADSVKG/364 TVYLQMNSLKP YTGVNDYDY/ VSS/603 SCAASGRTFS/ 518 EDTAVYYCAV/ 426 470 579 VEGFBII EVQLVESGGG AYDMG/ WFRQAPG VISWTGGMTY RFTISRDKAKN DRRRTYSRWRY WGQGTQVT 39H11/99 LVQAGGSLRL 311 KEREFVA/ YADSVKG/365 TVSLQMNSLKP YTGVNEYEY/ VSS/603 SCAASGRTFS/ 518 EDTAVYYCAV/ 427 470 581 VEGFBII EVQLVESGGG AYDMG/ WFRQAPG VISWTGDMTY RFTISRDKAKN DRRRTYSRWRY WGQGTQVT 41B06/ LVQAGGSLRL 311 KEREFVA/ YADSVKG/ TVSLQMNSLKP YTGVNEYEY/ VSS/603 100 SCAASGRTFS/ 518 366 EDTAVYYCAA/ 427 470 582 VEGFBII EVQLVESGGG VYTMG/ WFRQAPG TISRTGDRTS RFTISRENAKN GPIAPSPRPRE WGQGTQVT 41C05/ LVQAGGSLRL 312 KEREFVA/ YANSVKG/367 TVYLQMNSLKP YYY/428 VSS/603 101 SCAASGRTFS/ 518 EDTAVYSCAA/ 470 583 VEGFBII EVQLMESGGG AYDMG/ WFRQAPG VISWTGGMTY RFTISRDKAKN DRRRTYSRWRY WGQGTQVT 41D11/ LVQAGGSLRL 311 KEREFVA/ YADSVKG/ TVSLQMNSLKP YTGVNEYEY/ VSS/603 102 SCAASGRTFS/ 518 365 EDTAVYYCAV/ 427 496 581 VEGFBII EVQLVESGGG AYDMG/ WFRQAPG VISWSGGMTD RFTISRENAKN GRRRAYSRWRY WGQGTQVT 42F10/ LVQAGGSLRL 311 KEREFVA/ YADSVKG/368 TQFLQMNSLKP YTGVNEYDY/ VSS/603 103 SCAASGRTFS/ 518 EDTAVYYCAV/ 429 470 584 VEGFBII EVQLVESGGG SYAMG/ WFRQAPG HINRSGSSTY RFTISRDNAKN GRYYSSDGVPS WGQGTQVT 86C11/ LVQAGDSLRL 304 KERESVA/ YADSVKG/ TVYLQLNSLKP ASFNY/430 VSS/603 104 SCTASGRTFN/ 537 369 EDTAVYYCAA/ 497 585 VEGFBII EVQLVESGGG TWAMA/ WFRQAPG AISWSGSMTY RFIISRDNAQN KTVDYCSAYEC WGRGAQVT 86F11/ LVQAGDSLRL 313 KEREFIS/ YTDSVKG/ TLFLQMNNTAP YARLEYDY/ VSS/610 105 SCFTSARTFD/ 538 370 EDTAVYYCAA/ 431 498 586 VEGFBII EVQLVESGGG STNMG/ WFRQGPG AITLSGTTYY RFTISRDNDKN DPSYYSTSRYT WGQGTQVT 86G08/ LMQTGDSLRL 314 KEREFVA/ AEAVKG/ TVALQMNSLKP KATEYDY/ VSS/603 106 SCAASGLRFT/ 539 371 EDTAVYYCGA/ 432 499 587 VEGFBII EVQLVESGGG TYTMG/ WFRQTPG AIRWTVNITY RFTISRDIVKN QTSAPRSLIRM WGQGTQVT 86G10/ LVQAGGSLRL 315 TEREFVA/ YADSVKG/ TVYLQMNSLKP SNEYPY/433 VSS/603 107 SCAASGRTFN/ 540 372 EDTAVYYCAA/ 500 588 VEGFBII EVQLVESGGG LYTVG/ WFRQAPG YISRSGSNRY RFTLSRDNAKN TSRGLSSLAGE WGRGTQVT 86G11/ LVQAGGSLRL 316 KEREFVA/ YVDSVKG/ TVDLQMNSLKT YNY/434 VSS/607 108 SCAASGLTFS/ 518 373 EDTAVYYCAA/ 501 589 VEGFBII EVQLVESGGG SYRMG/ WFRRTPG SISWTYGSTF RFTMSRDKAKN GAQSDRYNIRS WGQGTQVT 86H09/ LVQAGGSLRL 317 KEDEFVA/ YADSVKG/ AGYLQMNSLKP YDY/435 VSS/603 109 SCTASGSAFK/ 541 374 EDTALYYCAA/ 502 590 VEGFBII EVQLVESGGG TSWMH/ WVRQAPG SIPPVGHFAN RFTISRDNAKN DSAGRT/436 KGQGTQVT 87B07/ LVQPGGSLKL 318 KGLEWVS/ YAPSVKG/ TLFLQMNSLKS VSS/611 110 SCTASGFTFS/ 533 375 EDTAVYYCAK/ 503 591 VEGFBII KVQLVESGGG NYAMD/ WFRQAPG AITRSGGGTY RFTISRDNAKN TRSSTIVVGVG WGKGTLVT 88A01/ LVQAGGSLRL 319 KEREFVA/ YADSVKG/ TVYLQMNSLKP GMEY/437 VSS/612 111 SCAASERTFS/ 518 376 EDTAVYYCAA/ 504 565 VEGFBII EVQLVESGGG DYDIG/ WFRQAPG CITTDVGTTY RFTISSDNAKN DTQDLGLDIFC WGQGTQVT 88A02/ LVQAGGSLRL 320 NEREGVS/ YADSVKG/ TVYLQINDLKP RGNGPFDG/ VSS/603 112 SCAASGFTFG/ 542 377 EDTAIYYCAV/ 438 505 592 VEGFBII EVQLVESGGG DYAIG/ WFRQAPG CISSYDSVTY RFTISRDSAKN EREQLRRRESP SGKGTLVT 88B02/ LVQPGGSLRL 230 KEREGVS/ YADHVKG/ TLYLQMNSLSI HDELLRLCFYG VSS/613 113 SCTASGLNLD/ 543 378 EDTGVYYCAA/ MRY/439 506 593 VEGFBII EVQLVESGGG DYAIG/ WFRQAPG CISSSDTSID RFTFSRDNAKN AFRCSGYELRG WGQGTQVT 88E02/ LVQPGGSLRL 230 KEREAVS/ YTNSVKG/ TVYLQMNSLKP FPT/440 VSS/603 114 SCVASGFRLD/ 544 379 EDTAVYYCAA/ 507 594 VEGFBII EVQLVESGGG SLAVG/ WFRQAPG RITWSGATTY RFTISRDNAKN DRSPNIINVVT WGQGTQVT 88G03/ LVQAGGSLRL 321 KEREFVA/ YADAVKD/ TMYLQMNSLKP AYEYDY/441 VSS/603 115 SCAASGGTFS/ 518 380 EDTAVYYCAA/ 508 595 VEGFBII EVQLVESGGG LYNMG/ WFRQAPG AITSSPMSTY RFSISINNDKT PEGSFRRQYAD WGQGTQVT 88G05/ LVQPGASLRL 322 KEREFVA/ YADSVKG/ TGFLQMNVLKP RAMYDY/442 VSS/603 116 SCAASGDGFT/ 518 381 EDTGVYFCAA/ 509 596 VEGFBII EVQLVESGGG GSDMG/ WFRQSPG AIRLSGSITY RFTISRDNAKN RSTYSYYLALA WGQGTQVT 88G11/ LAQAGGSLRL 323 KEREIVA/ YPDSVKG/ TVYLQMNSLKP DRGGYDY VSS/603 117 SCAASGRTFS/ 545 382 EDTAVYYCAA/ /443 510 565 VEGFBII EVQLVESGGG TYAIG/ WFRQAPG CMSAGDSIPW RFTTSTDNARN ARYHGDYCYYE WGQGTQVT 88H01/ LVQAGGSLRL 324 KEREAVS/ YTASVKG/ TVYLQMNSLKP GYYPF/444 VSS/603 118 SCVASGFTLG/ 544 383 EDTAHYYCAA/ 511 597 VEGFBII EVQLVESGGG TNFMG/ WYRQAPG TITSSSITNY RFTISRDNAKN RWRWSDVEY/ WGKGTLVT 89B04/ LVQAGGSLRL 325 KQRELVA/ VDSVKG/ TVYLQMTSLKP 445 VSS/612 119 SCAASTSISS/ 521 384 EDTAVYYCHA/ 512 598 VEGFBII EVQLVESGGG IFAMR/ WYRQAPG SITRSSITTY RFTPSRDNAKN AIRPELYSVVN WGQGTQVT 89B08/ LVQPGGSLRL 326 KQRELVA/ ADSVKG/ TVSLQMNSLKP DY/446 VSS/603 120 SCAASGTTSS/ 521 385 EDTAVYYCNA/ 513 599 VEGFBII EVQLVESGGG DYNLG/ WFRQAPG VISWRDSFAY RFTISRDNAKN DRVSSRLVLPN WGQGTQVT 89D04/ LVQPGGSLRL 327 KERQFVA/ YAEPVKG/ TVYLQMNSLKP TSPDFGS/ VSS/603 121 SCATSGLTFS/ 546 386 EDTAVYYCAA/ 447 514 565 VEGFBII EVQLVESGGG NAIMG/ WFRQAPG AMNWRGGPTY RFTISGDNTKN DEDLYHYSSYH WGQGTQVT 89F09/ LVQAGDSLRL 328 QEREFVA/ YADSVKG/ TVFLQMNFLKP YSRVDLYHY/ VSS/603 122 SCAASGRTFN/ 547 387 EDTAVYYCAA/ 448 515 600 VEGFBII EVQLVESGGG IFAMR/ WYRQAPG SITRSSITTY RFTLSRDNAKN AIRPELYSVVN WGQGTQVT 89G09/ LVQPGGSLRL 326 KQRELVA/ ADSVKG/ TVSLQMNSLKP DY/446 VSS/603 123 SCAASGTTSS/ 521 385 EDTAVYYCNA/ 513 601 VEGFBII EVQLVESGGG SYAPG/ WFRQAPG AFTRSSNIPY RFTISRDNAHT NLGSTWSRDQR WGQGTQVT 89H08/ LVQAGGSLRL 329 KEREFVA/ YKDSVKG/ VYLQMNSLKPE TYDY/449 VSS/603 124 SCAASGGSFS/ 518 388 DTAIYYCAV/ 516 602

TABLE-US-00006 TABLE 3 Sequence IDs and AA sequences of monovalent receptor-blocking anti-VEGF VHHs (FR, framework; CDR, complementary determining region) SEQ ID NO: 9-46 CDR1/ VHH ID/ FR1/SEQ SEQ FR2/SEQ CDR2/SEQ FR3/SEQ CDR3/SEQ FR4/SEQ SEQ ID NO: ID NO: ID NO: ID NO: ID NO: ID NO: ID NO: ID NO: VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSSGGYI RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 22A10/9 GLVQPGDSL G/450 REFVV/636 YDSVSLEG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCAFSGR 453 TADYYCAA/638 TFS/614 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSGGFIY RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 22A11/10 GLVQPGDSL A/451 REFVV/636 DAVSLEG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCAFSGR 454 TAVYYCAA/639 TFS/614 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSSGGYI RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 22B06/11 GLVQPGDSL G/450 REFVV/636 YDSVSLEG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCAASGR 453 TAVYYCAA/639 TFS/615 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSSGNYK RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 22B07/12 GLVQAGDSL G/450 REFVV/636 YDSVSLEG/ VYLQINSLKPED GDTYDY/2 TVSS/603 RLSCAASGR 455 TAVYYCAA/640 TFS/616 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSGGSIY RFTISRDNTKNT SRAYASSRLRL WGQGTQV 22E04/13 GLVQPGDSL G/450 REFVV/636 DSVSLQG/ VYLQTPSLKPED ADTYDY/6 TVSS/603 KLSCVASGR 456 TAVYYCAA/639 TSS/617 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSGGYIY RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 23A03/14 GLVQPGDSL G/450 REFVV/636 DSVSLQG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCVASGR 457 TAVYYCAA/639 TFS/618 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSGGFIY RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 23A06/15 GLVQPGDSL G/450 REFVV/636 DAVSLEG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCAFSGR 454 TAVYYCAA/639 TFS/619 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISNGGYKY RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 23A08/16 GLVQTGDSL G/450 REFVV/636 DSVSLEG/ VYLQINSLKPED ADTYDY/3 TVSS/603 RLSCVASGR 458 TAVYYCAA/640 TFS/620 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSSGGYI RFTISRDNSKNT SRAYGSSRLRL WGQGTQV 23A09/17 GLVQPGDSL G/450 REFVV/636 YDSVSLEG/ VYLQTPSLKPED PDTYDY/7 TVSS/603 KLSCAFSGR 453 TAVYYCAA/641 TFG/621 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISKGGYKY RFTISKDNAKNT SRAYGSSRLRL WGQGTQV 23B04/18 GLVQTGDSL G/450 REFVV/636 DSVSLEG/ VYLQINSLKPED ADTYEY/4 TVSS/603 RLSCEVSGR 459 TAVYYCAS/642 TFS/622 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSGGFIY RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 23D11/19 GLVQPGDSL A/451 REFVV/636 DAVSLEG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 RLSCAFSGR 454 TAVYYCAA/639 TFS/623 VEGFBII EVQLVESEG SYSM WFRQAQGKE AISSGGYIY RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 23E05/20 GLVQPGDSL G/450 REFVV/636 DSVSLQG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCVASGR 457 TAVYYCAA/639 TSS/624 VEGFBII EMQLVESGG SYSM WFRQAQGKE AISSSGGYI RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 23F02/21 GLVQPGDSL G/450 REFVV/636 YDSVSLEG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCAFSGR 453 TADYYCAA/638 TFS/625 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSSGNYK RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 23F05/22 GLVQAGDSL G/450 REFVV/636 YDSVSLEG/ VYLQINSLKPKD GDTYDY/2 TVSS/603 RLSCAASGR 455 TAVYYCAA/643 TFS/616 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSGGGYI RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 23F11/23 GLVQPGDSL G/450 REFVV/636 YDSVSLEG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCAFSGR 460 TADYYCAA/638 TFS/614 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSSGGYI RFTISRDNSKNT SRAYGSSRLRL WGQGTQV 23G03/24 GLVQPGDSL G/450 REFVV/636 YDSVSLEG/ VYLQTPSLKPED PGTYDY/8 TVSS/603 KLSCAFSGR 453 TAVYYCAA/641 TFG/621 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSGGYIY RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 24C04/25 GLVQPGDSL G/450 REFVV/636 DSVSLQG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCVASGR 457 TAVYYCAA/639 TSS/617 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSGGYKY RFTISRDNTQNT SRAYGSGRLRL WGQGTQV 27D08/26 GLVQTGDSL G/450 REFVV/636 DSVSLEG/ VYLQINSLKPED ADTYDY/5 TVSS/603 RLSCAASGR 461 TAVYYCAA/644 TFS/626 VEGFBII EVQLVESGG SYSM WFRQAQGQE AISSGGYIY RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 27G07/27 GLVQPGDSL G/450 REFVV/637 DSVSLQG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCVASGR 457 TAVYYCAA/639 TSS/617 VEGFBII EVQLVESGG SYSM WFRQAQGQE AISSGGYIY RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 30C09/28 GLVQPGDSL G/450 REFVV/637 DSVSLQG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCIASGR 457 TAVYYCAA/639 TSS/627 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSSGNYK RFTISRDNTKNT SRAYGSSRLRL WGQGTRV 30E07/29 GLVQAGDSL G/450 REFVV/636 YDSVSLEG/ VYLQINSLKPED GDTYDY/2 TVSS/652 RLSCAASGR 455 TAVYYCAA/640 TFS/616 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSSGGYI RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 31C07/30 GLVQTGDSL G/450 REFVV/636 YDSVSLEG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 RLSCAASGG 453 TADYYCAA/638 TFS/628 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSSGGYI RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 39E02/31 GLVQPGDPL G/450 REFVV/636 YDSVSLEG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCAFSGR 453 TADYYCAA/638 TFS/629 VEGFBII EVPLVESGG SYSM WFRQAQGKE AISSSGNYK RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 39G04/32 GLVQAGDSL G/450 REFVV/636 YDSASLEG/ VYLQINSLKPED GDTYDY/2 TVSS/603 RLSCAASGR 462 TAVYYCAA/640 TFS/630 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSGGFIY RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 40F02/33 GLVQPGDSL A/451 REFVV/636 DAVSLEG/ VYLQTPSLKPEG ADTYDY/3 TVSS/603 KLSCAFSGR 454 TAVYYCAA/645 TFS/614 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSSGGYI RFTISRDNTKNA SRAYGSSRLRL WGQGTQV 40G07/34 GLVQPGDSL G/450 REFVV/636 YDSVSLEG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCAFSGR 453 TADYYCAA/646 TFS/614 VEGFBII EVQLMESGG SYSM WFRQAQGKE AISSSGGYI RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 40H10/35 GLVQPGDSL G/450 REFVV/636 YDSVSLEG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCAFSGR 453 TADYYCAA/638 TFS/631 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSGGFIY RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 41B05/36 GLVQPGGSL G/450 REFVV/636 DAVSLEG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 RLSCAFSGR 454 TAVYYCAA/639 TFS/632 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSGGFIY RFTISRENTKNT SRAYGSSRLRL WGQGTQV 41G03/37 GLVQPGDSL A/451 REFVV/636 DAVSLEG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCAFSGR 454 TAVYYCAA/647 TFS/614 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSSGGYI RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 42A05/38 GLVQPGDSL G/450 REFVV/636 YDSVSLEG/ VYLQMPSLKPED ADTYDY/3 TVSS/603 KLSCAFSGR 453 TADYYCAA/648 TFS/614 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSSGGYI RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 42D05/39 GLVQPGDSL G/450 REFVV/636 YDSVSLEG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCAFSGR 453 TAVYYCAA/639 TFS/614 VEGFBII EVQLVESGG SYSV WFRQAQGKE AISSGGYIY RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 42F11/40 GLVQPGDSL G/452 REFVV/636 DSVSLQG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCVASGR 457 TAVYYCAA/639 TSS/617 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSSGGYI RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 56E11/41 GLVQPGDSL G/450 REFVV/636 YDSVSLEG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCAFSGR 453 AADYYCAA/649 TFS/614 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSSGGYI RFTISRDNTRNT SRAYGSSRLRL WGQGTQV 60A09/42 GLVQPGDSL G/450 REFVV/636 YDSVSLEG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCAFSGR 453 TADYYCAA/650 TFS/614 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSGGYKY RFTISRDNTKNT SRAYASSRLRL WGQGTQV 61A01/43 GLVQAGGSL G/450 REFVV/636 DAVSLEG/ VYLQTPSLKPED ADTYDY/6 TVSS/603

RLSCAFSGR 463 TAVYYCAA/639 TFS/633 VEGFBII EVQLVESGG SYSM WFRQAQGKE AISSSGGYI RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 62A09/44 DLVQPGDSL G/450 REFVV/636 YDSVSLEG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCAASGR 453 TAVYYCAA/639 TFS/634 VEGFBII EVQLVESEG SYSM WFRQAQGKE AISSSGNYK RFTISRDNTKNT SRAYGSSRLRL WGQGTQV 62D10/45 GLVQAGDSL G/450 REFVV/636 YDSVSLEG/ VYLQINSLKPED GDTYDY/2 TVSS/603 RLSCAASGR 455 TAVYYCAA/640 TFS/635 VEGFBII EVQLVESGG SYSM WFRQAQGKE AIASGGYIY RFTISRDNTKDT SRAYGSSRLRL WGQGTQV 62F02/46 GLVQPGDSL G/450 REFVV/636 DAVSLEG/ VYLQTPSLKPED ADTYDY/3 TVSS/603 KLSCAFSGR 464 TAVYYCAA/651 TFS/614

[0373] Dissociation rates of inhibitory VHHs are analyzed on Biacore (Biacore T100 instrument, GE Healthcare). HBS-EP+buffer is used as running buffer and experiments are performed at 25.C. Recombinant human VEGF165 is irreversibly captured on a CM5 sensor chip via amine coupling (using EDC and NHS) up to a target level of +/-1500RU. After immobilization, surfaces are deactivated with 10 min injection of 1M ethanolamine pH8.5. A reference surface is activated and deactivated with respectively EDC/NHS and ethanolamine. Periplasmic extracts of VHHs are injected at a 10-fold dilution in running buffer for 2 min at 45 .mu.l/min and allowed to dissociate for 10 or 15 min. Between different samples, the surfaces are regenerated with regeneration buffer. Data are double referenced by subtraction of the curves on the reference channel and of a blank running buffer injection. The of the processed curves is evaluated by fitting a two phase decay model in the Biacore T100 Evaluation software v2.0.1. Values for k.sub.d-fast, k.sub.d-slow and % fast are listed in Table 4.

TABLE-US-00007 TABLE 4 Off-rate determination of anti-VEGF receptor-blocking VHHs with Biacore B- Bind- cell Unique ing line- sequence Representative % level age variant VHH ID k.sub.d(fast) k.sub.d(slow) fast (RU) 1 1 VEGFBII22B07 1.50E-02 7.80E-05 31 328 1 2 VEGFBII23A08 1.30E-02 5.00E-05 19 502 1 3 VEGFBII23B04 8.80E-03 4.00E-05 12 768 1 4 VEGFBII27D08 2.40E-02 8.10E-05 13 225 1 5 VEGFBII24C04 1.30E-02 3.40E-05 17 456 1 6 VEGFBII27G07 1.30E-02 3.80E-05 18 471 1 7 VEGFBII22E04 1.80E-02 1.10E-04 14 520 1 8 VEGFBII23A03 1.50E-02 3.20E-05 15 487 1 9 VEGFBII22B06 3.80E-02 9.00E-05 23 168 1 10 VEGFBII23A09 2.70E-02 4.60E-05 20 247 1 11 VEGFBII23G03 2.80E-02 8.60E-05 28 141 1 12 VEGFBII22A11 2.20E-02 4.70E-05 12 461 1 13 VEGFBII23A06 1.70E-02 3.70E-05 13 547 1 14 VEGFBII23F11 2.70E-02 1.30E-04 22 134 1 15 VEGFBII22A10 3.70E-02 4.00E-05 19 229 1 16 VEGFBII23F05 1.60E-02 1.30E-04 29 198 1 17 VEGFBII23D11 1.90E-02 5.80E-05 13 510 1 18 VEGFBII23F02 n/d n/d n/d n/d 1 19 VEGFBII23E05 1.50E-02 6.90E-05 18 275 1 20 VEGFBII31C07 3.70E-02 1.50E-04 25 77 1 21 VEGFBII30C09 1.50E-02 7.60E-05 19 264 1 22 VEGFBII30E07 1.70E-02 1.30E-04 29 226 1 23 VEGFBII39G04 1.40E-02 7.40E-04 40 210 1 24 VEGFBII41G03 1.20E-02 2.70E-04 20 332 1 25 VEGFBII41B05 1.90E-02 1.20E-04 16 324 1 26 VEGFBII40F02 1.20E-02 9.80E-05 20 258 1 27 VEGFBII39E02 1.90E-02 2.40E-04 13 181 1 28 VEGFBII42D05 3.30E-02 1.50E-04 26 77 1 29 VEGFBII40G07 1.80E-02 3.20E-04 19 139 1 30 VEGFBII42A05 1.60E-02 3.40E-04 25 118 1 31 VEGFBII42F11 9.10E-03 5.00E-04 46 100 1 32 VEGFBII40H10 1.40E-02 2.90E-04 17 200 1 33 VEGFBII62A09 4.10E-02 1.10E-04 23 84 1 34 VEGFBII60A09 3.70E-02 9.30E-05 20 106 1 35 VEGFBII62F02 1.40E-02 8.50E-05 21 205 1 36 VEGFBII62D10 1.90E-02 1.60E-04 40 94 1 37 VEGFBII61A01 7.40E-03 1.70E-04 21 275 1 38 VEGFBII56E11 3.30E-02 1.40E-04 24 76 n/d, not determined

EXAMPLE 5

[0374] Characterization of Purified Anti-VEGF VHHs

[0375] Three inhibitory anti-VEGF VHHs are selected for further characterization as purified protein: VEGFBII23B04, VEGFBII24C4 and VEGFBII23A6. These VHHs are expressed in E. coli TG1 as c-myc, His6-tagged proteins ("His6" disclosed as SEQ ID NO: 283). Expression is induced by addition of 1 mM IPTG and allowed to continue for 4 hours at 37.degree. C. After spinning the cell cultures, periplasmic extracts are prepared by freeze-thawing the pellets. These extracts are used as starting material for VHH purification via IMAC and size exclusion chromatography (SEC). Final VHH preparations show 95% purity as assessed via SDS-PAGE.

[0376] 5.1 Evaluation of Human VEGF165/VEGFR2 Blocking VHHs in Human VEGF165/Human VEGFR2-Fc Blocking ELISA

[0377] The blocking capacity of the VHHs is evaluated in a human VEGF165/human VEGFR2-Fc blocking ELISA. In brief, 1 .mu.g/mL of VEGFR2-Fc chimera (R&D Systems, Minneapolis, Minn., USA) is coated in a 96-well MaxiSorp plate (Nunc, Wiesbaden, Germany). Dilution series (concentration range 1 mM-64 pM) of the purified VHHs in PBS buffer containing 0.1% casein and 0.05% Tween 20 (Sigma) are incubated in the presence of 4 nM biotinlyated VEGF165. Residual binding of bio-VEGF165 to VEGFR2 is detected using horseradish peroxidase (HRP) conjugated extravidin (Sigma, St Louis, Mo., USA) and TMB as substrate. As controls Bevacizumab (Avastin.RTM.) and Ranibizumab (Lucentis.RTM.) are taken along. Dose inhibition curves are shown in FIG. 1; the corresponding IC50 values and % inhibition are summarized in Table 5.

TABLE-US-00008 TABLE 5 IC.sub.50 (nM) values and % inhibition for monovalent VHHs in hVEGF165/hVEGFR2-Fc competition ELISA IC.sub.50 % VHH ID (nM) inhibition VEGFBII23B04 2.1 100 VEGFBII23A06 3.0 100 VEGFBII24C04 2.5 100 Ranibizumab 1.6 100 Bevacizumab 1.7 100

[0378] 5.2 Evaluation of Human VEGF165/VEGFR2 Blocking VHHs in Human VEGF165/Human VEGFR1-Fc Blocking ELISA

[0379] VHHs are also evaluated in a human VEGF165/human VEGFR1-Fc blocking ELISA. In brief, 2 .mu.g/mL of VEGFR1-Fc chimera (R&D Systems, Minneapolis, Minn., USA) is coated in a 96-well MaxiSorp plate (Nunc, Wiesbaden, Germany). Dilution series (concentration range 1 mM-64 pM) of the purified VHHs in PBS buffer containing 0.1% casein and 0.05% Tween 20 (Sigma) are incubated in the presence of 0.5nM biotinlyated VEGF165. Residual binding of bio-VEGF165 to VEGFR1 is detected using horseradish peroxidase (HRP) conjugated extravidin (Sigma, St Louis, Mo., USA) and TMB as substrate. As controls Bevacizumab, Ranibizumab and an irrelevant VHH (2E6) are taken along. Dose inhibition curves are shown in FIG. 2; the corresponding IC.sub.50 values and % inhibition are summarized in Table 6.

TABLE-US-00009 TABLE 6 IC.sub.50 (nM) values and % inhibition of monovalent VHHs in hVEGF165/hVEGFR1-Fc competition ELISA VHH ID IC.sub.50 (nM) % inhibition VEGFBII23B04 0.5 64 VEGFBII23A06 0.9 55 VEGFBII24C04 0.8 71 Ranibizumab 1.2 91 Bevacizumab 1.5 96

[0380] 5.3 Evaluation of the Anti-VEGF165 VHHs in the Human VEGF165/Human VEGFR2-Fc Blocking AlphaScreen

[0381] The blocking capacity of the VHHs is also evaluated in a human VEGF165/human VEGFR2-Fc blocking AlphaScreen. Briefly, serial dilutions of purified VHHs (concentration range: 200 nM-0.7 pM) in PBS buffer containing 0.03% Tween 20 (Sigma) are added to 4 pM bio-VEGF165 and incubated for 15 min. Subsequently VEGFR2-Fc (0.4 nM) and anti-Fc VHH-coated acceptor beads (20 .mu.g/ml) are added and this mixture is incubated for 1 hour in the dark. Finally, streptavidin donor beads (20 .mu.g/ml) are added and after 1 hour of incubation in the dark, fluorescence is measured on the Envision microplate reader. Dose-response curves are shown in the FIG. 3. The IC.sub.50 values for VHHs blocking the human VEGF165-human VEGFR2-Fc interaction are summarized in Table 7.

TABLE-US-00010 TABLE 7 IC.sub.50 (pM) values and % inhibition for VHHs in hVEGF165/hVEGFR2-Fc competition AlphaScreen VHH ID IC.sub.50 (pM) % inhibition VEGFBII23B04 160 100 VEGFBII23A06 250 100 VEGFBII24C04 250 100 Ranibizumab 860 100

[0382] 5.4 Evaluation of the Anti-VEGF165 VHHs in the Human VEGF165/Human VEGFR1-Fc Blocking AlphaScreen

[0383] The blocking capacity of the VHHs is also evaluated in a human VEGF165/human VEGFR1-Fc blocking AlphaScreen. Briefly, serial dilutions of purified VHHs (concentration range: 500 nM-1.8 pM)) in PBS buffer containing 0.03% Tween 20 (Sigma) are added to 0.4 nM bio-VEGF165 and incubated for 15 min. Subsequently VEGFR1-Fc (1 nM) and anti-Fc VHH-coated acceptor beads (20 .mu.g/ml) are added and this mixture is incubated for 1 hour in the dark. Finally, streptavidin donor beads (20 .mu.g/ml) are added and after 1 hour of incubation in the dark, fluorescence is measured on the Envision microplate reader. Dose-response curves are shown in the FIG. 4. The IC.sub.50 values and % inhibition for VHHs blocking the human VEGF165-human VEGFR1-Fc interaction are summarized in Table 8.

TABLE-US-00011 TABLE 8 IC.sub.50 (nM) values for VHHs in hVEGF165/hVEGFR1-Fc competition AlphaScreen VHH ID IC.sub.50 (nM) % inhibition VEGFBII23B04 0.9 41 VEGFBII23A06 0.4 46 VEGFBII24C04 0.2 53 Ranibizumab 3.3 79

[0384] 12-0332-US-4

[0385] 5.5 Determination of the Affinity of the Human VEGF165-VHH Interaction

[0386] Binding kinetics of VHH VEGFB1123B04 with hVEGF165 is analyzed by SPR on a Biacore T100 instrument. Recombinant human VEGF165 is immobilized directly on a CM5 chip via amine coupling (using EDC and NHS). VHHs are analyzed at different concentrations between 10 and 360 nM. Samples are injected for 2 min and allowed to dissociate up to 20 min at a flow rate of 45 .mu.l/min. In between sample injections, the chip surface is regenerated with 100 mM HCl. HBS-EP+ (Hepes buffer pH7.4+EDTA) is used as running buffer. Binding curves are fitted using a Two State Reaction model by Biacore T100 Evaluation Software v2.0.1. The calculated affinities of the anti-VEGF VHHs are listed in Table 9.

TABLE-US-00012 TABLE 9 Affinity K.sub.D (nM) of purified VHHs for recombinant human VEGF165 VEGF165 k.sub.a k.sub.a1 k.sub.a2 k.sub.d k.sub.d1 k.sub.d2 K.sub.D VHH ID (M.sup.-1 s.sup.-1) (M.sup.-1 s.sup.-1) (M.sup.-1 s.sup.-1) (s.sup.-1) (s.sup.-1) (s.sup.-1) (nM) VEGFBII23B04.sup.(a) -- 2.1E+05 1.4E-02 -- 8.6E-03 2.4E-04 0.7 VEGFBII23A06.sup.(a) -- 4.2E+05 2.0E-02 -- 5.7E-02 1.0E-04 0.7 VEGFBII24C04.sup.(a) -- 3.2E+05 1.8E-02 -- 2.6E-02 9.6E-05 0.4 .sup.(a)Heterogeneous binding curve resulting in no 1:1 fit, curves are fitted using a Two State Reaction model by Biacore T100 Evaluation Software v2.0.1

[0387] 5.6 Binding to Mouse VEGF164

[0388] Cross-reactivity to mouse VEGF164 is determined using a binding ELISA. In brief, recombinant mouse VEGF164 (R&D Systems, Minneapolis, MS, USA) is coated overnight at 4.degree. C. at 1 .mu.g/mL in a 96-well MaxiSorp plate (Nunc, Wiesbaden, Germany). Wells are blocked with a casein solution (1% in PBS). VHHs are applied as dilution series (concentration range: 500 nM-32 pM) in PBS buffer containing 0.1% casein and 0.05% Tween 20 (Sigma) and binding is detected using a mouse anti-myc (Roche) and an anti-mouse-HRP conjugate (DAKO) and a subsequent enzymatic reaction in the presence of the substrate TMB (3,3',5,5'-tetramentylbenzidine) (Pierce, Rockford, Ill., USA) (FIG. 5). A mouse VEGF164 reactive mAb is included as positive control. As reference, binding to human VEGF165 is also measured. EC.sub.50 values are summarized in Table 10.

TABLE-US-00013 TABLE 10 EC.sub.50 (pM) values for VHHs in a recombinant human VEGF165 and mouse VEGF164 binding ELISA rhVEGF165 rmVEGF164 VHH ID EC.sub.50 (pM) EC.sub.50 (pM) VEGFBII23B04 297 NB VEGFBII24C04 453 NB VEGFBII23A06 531 NB NB, no binding

[0389] 5.7 Binding to VEGF121

[0390] Binding to recombinant human VEGF121 is assessed via a solid phase binding ELISA. Briefly, recombinant human VEGF121 (R&D Systems, Minneapolis, MS, USA) is coated overnight at 4.degree. C. at 1 .mu.g/mL in a 96-well MaxiSorp plate (Nunc, Wiesbaden, Germany). Wells are blocked with a casein solution (1% in PBS). VHHs are applied as dilution series (concentration range: 500 nM-32 pM) in PBS buffer containing 0.1% casein and 0.05% Tween 20 (Sigma) and binding is detected using a mouse anti-myc (Roche) and an anti-mouse-HRP conjugate (DAKO) and a subsequent enzymatic reaction in the presence of the substrate TMB (3,3',5,5'-tetramentylbenzidine) (Pierce, Rockford, Ill., USA) (FIG. 6). As positive control serial dilutions of the VEGFR2 is taken along. EC.sub.50 values are summarized in Table 11.

TABLE-US-00014 TABLE 11 EC.sub.50 (pM) values for monovalent VHHs in a recombinant human VEGF121 binding ELISA VHH ID EC.sub.50 (pM) VEGFBII23B04 510 VEGFBII24C04 792 VEGFBII23A06 928

[0391] 5.8 Binding to VEGF Family Members VEGFB, VEGFC, VEGFD and PIGF

[0392] Binding to VEGFB, VEGFC, VEGFD and PIGF is assessed via a solid phase binding ELISA. In brief, VEGFB, VEGFC, VEGFD and PIGF (R&D Systems, Minneapolis, MS, USA) are coated overnight at 4.degree. C. at 1 .mu.g/mL in a 96-well MaxiSorp plate (Nunc, Wiesbaden, Germany). Wells are blocked with a casein solution (1% in PBS). VHHs are applied as dilution series (concentration range: 500 nM-32 pM) and binding is detected using a mouse anti-myc (Roche) and an anti-mouse-AP conjugate (Sigma, St Louis, Mo., USA). As positive controls serial dilutions of the appropriate receptors are taken along and detected with horseradish peroxidase (HRP)-conjugated goat anti-human IgG, Fc specific antibody (Jackson Immuno Research Laboratories Inc., West Grove, Pa., USA) and a subsequent enzymatic reaction in the presence of the substrate TMB (3,3',5,5'-tetramentylbenzidine) (Pierce, Rockford, Ill., USA). Dose-response curves of VHHs and controls are shown in FIG. 7. The results show that there was no detectable binding of the selected VHHs to VEGFB, VEGFC, VEGFD or PIGF.

[0393] 5.9 Epitope Binning

[0394] Biacore-based epitope binning experiments are performed to investigate which VEGF binders bind to a similar or overlapping epitope as VEGFBII23B04. To this end, VEGFBII23B04 is immobilized on a CM5 sensor chip. For each sample, human VEGF165 is passed over the chip surface and reversibly captured by VEGFBII23B4. Purified VHHs (100 nM) or periplasmic extracts ( 1/10 diluted) are then injected with a surface contact time of 240 seconds and a flow rate of 10 uL/minute. Between different samples, the surface is regenerated with regeneration buffer (100 mM HCl). Processed curves are evaluated with Biacore T100 Evaluation software. VHHs could be divided within two groups: group one which gave additional binding to VEGFBII23B04 captured VEGF165 and a second group which is not able to simultaneously bind to VEGFBII23B04 captured VEGF165. Table 12-A summarizes the binding epitopes of the tested VHHs.

[0395] The same assay set-up is used to assess whether VEGFR1, VEGFR2, Ranibizumab and Bevacizumab are able to bind to human VEGF-165 simultaneously with VEGFBII23B04. Table 12-B presents the additional binding responses to VEGFBII23B04-captured VEGF165. Only VEGFR2 is not able to bind to VEGFBII23B04-captured VEGF165, underscoring the blocking capacity of VEGFBII23B04 for the VEGF-VEGFR2 interaction. In addition, these data show that the VEGFBII23B04 epitope is different from the Bevacizumab and Ranibizumab epitope.

TABLE-US-00015 TABLE 12-A Epitope binning of anti-VEGF VHHs--simultaneous binding with VEGFBII23604 No or low 1C02 1E07 4B08 8E07 8F07 12A07 12B01 86C11 86F11 86G08 additional 86G10 86G11 87B07 88A01 88A02 88B02 88E02 88G03 88G05 88G11 binding to 88H01 89B04 89D04 89F09 89G09 89H08 24C04 23A6 27G07 23B04 23B04- captured VEGF165* Additional 3D12 5B02 5B03 5B05 6G02 7D08 8D09 8F06 10C07 10E07 binding to 10G04 10G05 11C08 11D09 11E04 11E05 11F12 86H09 41C05 captured 23B04- VEGF165 *indicating same or overlapping epitopes

TABLE-US-00016 TABLE 12-B Epitope binning of VEGFBII23B04-binding of benchmark inhibitors or cognate receptors on VEGFBII23B04 captured VEGF165 Injection Binding step Binding [sample] level (RU) 1 VEGF165 100 nM 1727 2 VEGFBII23B04 100 nM -- 3 Ranibizumab 100 nM 763 4 Bevacizumab 100 nM 1349 5 VEGFR1 100 nM 1011 6 VEGFR2 100 nM --

[0396] 5.10 Characterization of the Anti-VEGF VHHs in the HUVEC Proliferation Assay

[0397] The potency of the selected VHHs is evaluated in a proliferation assay. In brief, primary HUVEC cells (Technoclone) are supplement-starved over night and then 4000 cells/well are seeded in quadruplicate in 96-well tissue culture plates. Cells are stimulated in the absence or presence of VHHs with 33 ng/mL VEGF. The proliferation rates are measured by [.sup.3H] Thymidine incorporation on day 4. The results of the HUVEC proliferation assay are shown in Table.

TABLE-US-00017 TABLE 13 IC.sub.50 (nM) values and % inhibition of monovalent VEGFBII23B04, VEGFBII23A06 and VEGFBII24C04 in VEGF HUVEC proliferation assay VHH ID IC.sub.50 (nM) % inhibition VEGFBII23B04 0.36 91 Bevacizumab 0.21 92 VEGFBII23A06 4.29 73 VEGFBII24C04 3.8 79 Bevacizumab 0.78 78

[0398] 5.11 Characterization of the Anti-VEGF VHHs in the HUVEC Erk Phosphorylation Assay

[0399] The potency of the selected VHHs is assessed in the HUVEC Erk phosphorylation assay. In brief, primary HUVE cells are serum-starved over night and then stimulated in the absence or presence of VHHs with 10 ng/mL VEGF for 5 min. Cells are fixed with 4% Formaldehyde in PBS and ERK phosphorylation levels are measured by ELISA using phosphoERK-specific antibodies (anti-phosphoMAP Kinase pERK1&2, M8159, Sigma) and polyclonal Rabbit Anti-Mouse-Immunoglobulin-HRP conjugate (P0161, Dako). As shown in Table 14, VEGFBII23B04 and Bevacizumab inhibit the VEGF induced Erk phosphoryaltion by at least 90%, with IC.sub.50s<1 nM.

TABLE-US-00018 TABLE 14 IC.sub.50 (nM) values and % inhibition of monovalent VEGFBII23B04 in VEGF HUVEC Erk phosphorylation assay VHH ID IC.sub.50 (nM) % inhibition VEGFBII23B04 0.37 90 Bevacizumab 0.63 98

EXAMPLE 6

[0400] Generation of Multivalent Anti-VEGF Blocking VHHs

[0401] VHH VEGFBII23B04 is genetically fused to either VEGFBII23B04 resulting in a homodimeric VHH (AA sequence see Table 15) or different VEGF binding VHHs resulting in heterodimeric VHHs. To generate the heterodimeric VHHs, a panel of 10 unique VEGF binding VHHs are linked via a 9 or 40 Gly-Ser flexible linker (SEQ ID NOS 170 and 171, respectively) in two different orientations to VEGFBII23B04 (AA sequences see Table 15). Homodimeric VEGFBII23B04 (VEGFBII010) and the 40 heterodimeric bivalent' VHHs are expressed in E. coli TG1 as c-myc, His6-tagged proteins ("His6" disclosed as SEQ ID NO: 283). Expression is induced by addition of 1 mM IPTG and allowed to continue for 4 hours at 37.degree. C. After spinning the cell cultures, periplasmic extracts are prepared by freeze-thawing the pellets. These extracts are used as starting material and VHHs are purified via IMAC and desalting resulting in 90% purity as assessed via SDS-PAGE.

TABLE-US-00019 TABLE 15 Sequence ID, VHH ID and AA sequence of bivalent anti-VEGF VHHs (each of the used linkers is highlighted in one relevant sequence) Sequence ID/ SEQ ID NO: VHH ID AA sequence VEGFBII23B04- VEGFBII010 EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 35GS-23B04/128 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQTGDSLRLSCE VSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVSLEGRFTISKDNAKNTVYLQINSLK PEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS VEGFBII23B04- EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 9GS-4B08/129 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGSEVQLVESGGGLVQPGGSLRLSCAASGSAVGDITVAWYRQAPGIQRQLVATITP SGYTYYWDFVKGRFTISRDNSKNIVYLQMNSLKPEDTAAYYCNTQFYWGQGTQVTVSS VEGFBII23B04- EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 9GS-5B03/130 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGSEVQLVESGGGLAQAGDSLRLSCAASGRSFSHYNMGWFRQAPGKEREFVASIR GGGGSTTYANSVKDRFTISRENAKNTVYLQMNSLKPEDTAVYYCAATAFYRGPYDYDYWGQG TQVTVSS VEGFBII23B04- VEGFBII022 EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 9GS-5B05/131 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGSEVQLVESGGGLVQPGGSLRLSCVASGIRFMSMAWYRQAPGKHRELVARISSG GTTAYVDSVKGRFTISRDNSKNTVYLQMNSLKAEDTAVYYCNTFSSRPNPWGAGTQVTVSS VEGFBII23B04- EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 9GS-6G02/132 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGSEVQLVESGGGLVQPGGSLRLSCAASGNIFSNNAMAWYRQAPGKQRELVARIS SGGGFTYYLDSVKGRFTVSRDNAKNTVYLQMNSLKPEDTAVYYCNAAYRTYNYWGQGTQVTV SS VEGFBII23B04- EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 9GS-10E07/133 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGSEVQLVESGGGLVQAGGSLRLSCAASGRTFSNYAMGWFRQAPGKERVLVADIS SSGINTYVADAVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAASAWWYSQMARDNYRYW GQGTQVTVSS VEGFBII23B04- EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 9GS-12B01/134 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGSEVQLVESGGGLVQPGGSLRLACAASGFTLSSSWMYWVRQAPGKGLEWVSRI SPGGLFTYYVDSVKGRFSVSTDNANNTLYLQMNSLKPEDTALYSCAKGGAPNYTPRGRGTQV TVSS VEGFBII23B04- EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 9GS-86C11/135 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGSEVQLVESGGGLVQAGDSLRLSCTASGRTFNSYAMGWFRQAPGKERESVAHIN RSGSSTYYADSVKGRFTISRDNAKNTVYLQLNSLKPEDTAVYYCAAGRYYSSDGVPSASFNYW GQGTQVTVSS VEGFBII23B04- EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 9GS-86H09/136 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGSEVQLVESGGGLVQAGGSLRLSCTASGSAFKSYRMGWFRRTPGKEDEFVASIS WTYGSTFYADSVKGRFTMSRDKAKNAGYLQMNSLKPEDTALYYCAAGAQSDRYNIRSYDYW GQGTQVTVSS VEGFBII23B04- EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 9GS-87B07/137 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGSEVQLVESGGGLVQPGGSLKLSCTASGFTFSTSWMHWVRQAPGKGLEWVSSIP PVGHFANYAPSVKGRFTISRDNAKNTLFLQMNSLKSEDTAVYYCAKDSAGRTKGQGTQVTVSS VEGFBII23B04- EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 9GS-88A01/138 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGSEVQLVESGGGLVQAGGSLRLSCAASERTFSNYAMDWFRQAPGKEREFVAAIT RSGGGTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAATRSSTIVVGVGGMEYW GKGTQVTVSS VEGFBII23B04- EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 40GS-4B08/139 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGS LRLSCAASGSAVGDITVAWYRQAPGIQRQLVATITPSGYTYYWDFVKGRFTISRDNSKNIVYLQ MNSLKPEDTAAYYCNTQFYWGQGTQVTVSS VEGFBII23B04- EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 40GS-5B03/140 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLAQAGDSL RLSCAASGRSFSHYNMGWFRQAPGKEREFVASIRGGGGSTTYANSVKDRFTISRENAKNTVY LQMNSLKPEDTAVYYCAATAFYRGPYDYDYWGQGTQVTVSS VEGFBII23B04- VEGFBII021 EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 40GS-5B05/141 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGS LRLSCVASGIRFMSMAWYRQAPGKHRELVARISSGGTTAYVDSVKG RFTISRDNSKNTVYLQM NSLKAEDTAVYYCNTFSSRPNPWGAGTQVTVSS VEGFBII23B04- EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 40GS-6G02/142 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGS LRLSCAASGNIFSNNAMAWYRQAPGKQRELVARISSGGGFTYYLDSVKGRFTVSRDNAKNTVY LQMNSLKPEDTAVYYCNAAYRTYNYWGQGTQVTVSS VEGFBII23B04- VEGFBII023 EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 40GS-10E07/143 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQAGGS LRLSCAASGRTFSNYAMGWFRQAPGKERVLVADISSSGINTYVADAVKGRFTISRDNAKNTVYL QMNSLKPEDTAVYYCAASAWWYSQMARDNYRYWGQGTQVTVSS VEGFBII23B04- EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 40GS-12B01/144 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGS LRLACAASGFTLSSSWMYWVRQAPGKGLEWVSRISPGGLFTYYVDSVKGRFSVSTDNANNTL YLQMNSLKPEDTALYSCAKGGAPNYTPRGRGTQVTVSS VEGFBII23B04- EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 40GS-86C11/145 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQAGDSL RLSCTASGRTFNSYAMGWFRQAPGKERESVAHINRSGSSTYYADSVKGRFTISRDNAKNTVYL QLNSLKPEDTAVYYCAAGRYYSSDGVPSASFNYWGQGTQVTVSS VEGFBII23B04- VEGFBII024 EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 40GS-86H09/146 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQAGGS LRLSCTASGSAFKSYRMGWFRRTPGKEDEFVASISWTYGSTFYADSVKGRFTMSRDKAKNAG YLQMNSLKPEDTALYYCAAGAQSDRYNIRSYDYWGQGTQVTVSS VEGFBII23B04- EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 40GS-87B07/147 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGS LKLSCTASGFTFSTSWMHWVRQAPGKGLEWVSSIPPVGHFANYAPSVKGRFTISRDNAKNTLF LQMNSLKSEDTAVYYCAKDSAGRTKGQGTQVTVSS VEGFBII23B04- EVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVS 40GS-88A01/148 LEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQAGGS LRLSCAASERTFSNYAMDWFRQAPGKEREFVAAITRSGGGTYYADSVKGRFTISRDNAKNTVY LQMNSLKPEDTAVYYCAATRSSTIVVGVGGMEYWGKGTQVTVSS VEGFBII4B08-9GS- EVQLVESGGGLVQPGGSLRLSCAASGSAVGDITVAWYRQAPGIQRQLVATITPSGYTYYWDFV 23B04/149 KGRFTISRDNSKNIVYLQMNSLKPEDTAAYYCNTQFYWGQGTQVTVSSGGGGSGGGSEVQLV ESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVSLEGRF TISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS VEGFBII5B03-9GS- EVQLVESGGGLAQAGDSLRLSCAASGRSFSHYNMGWFRQAPGKEREFVASIRGGGGSTTYA 23B04/150 NSVKDRFTISRENAKNTVYLQMNSLKPEDTAVYYCAATAFYRGPYDYDYWGQGTQVTVSSGG GGSGGGSEVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKG GYKYDSVSLEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQ GTQVTVSS VEGFBII5B05-9GS- EVQLVESGGGLVQPGGSLRLSCVASGIRFMSMAWYRQAPGKHRELVARISSGGTTAYVDSVK 23B04/151 GRFTISRDNSKNTVYLQMNSLKAEDTAVYYCNTFSSRPNPWGAGTQVTVSSGGGGSGGGSE VQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVSL EGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS VEGFBII6G02-9GS- EVQLVESGGGLVQPGGSLRLSCAASGNIFSNNAMAWYRQAPGKQRELVARISSGGGFTYYLD 23B04/152 SVKGRFTVSRDNAKNTVYLQMNSLKPEDTAVYYCNAAYRTYNYWGQGTQVTVSSGGGGSGG GSEVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDS VSLEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVS S VEGFBII10E07- EVQLVESGGGLVQAGGSLRLSCAASGRTFSNYAMGWFRQAPGKERVLVADISSSGINTYVAD 9GS-23B04/153 AVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAASAWWYSQMARDNYRYWGQGTQVTVS SGGGGSGGGSEVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAI SKGGYKYDSVSLEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYW GQGTQVTVSS VEGFBII12B01- EVQLVESGGGLVQPGGSLRLACAASGFTLSSSWMYWVRQAPGKGLEWVSRISPGGLFTYYV 9GS-23B04/154 DSVKGRFSVSTDNANNTLYLQMNSLKPEDTALYSCAKGGAPNYTPRGRGTQVTVSSGGGGS GGGSEVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYK YDSVSLEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQ VTVSS VEGFBII86C11- EVQLVESGGGLVQAGDSLRLSCTASGRTFNSYAMGWFRQAPGKERESVAHINRSGSSTYYAD 9GS-23B04/155 SVKGRFTISRDNAKNTVYLQLNSLKPEDTAVYYCAAGRYYSSDGVPSASFNYWGQGTQVTVS SGGGGSGGGSEVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAI SKGGYKYDSVSLEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYW GQGTQVTVSS VEGFBII86H09- EVQLVESGGGLVQAGGSLRLSCTASGSAFKSYRMGWFRRTPGKEDEFVASISWTYGSTFYAD 9GS-23B04/156 SVKGRFTMSRDKAKNAGYLQMNSLKPEDTALYYCAAGAQSDRYNIRSYDYWGQGTQVTVSS GGGGSGGGSEVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAIS KGGYKYDSVSLEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYW GQGTQVTVSS VEGFBII87B07- EVQLVESGGGLVQPGGSLKLSCTASGFTFSTSWMHWVRQAPGKGLEWVSSIPPVGHFANYA 9GS-23B04/157 PSVKGRFTISRDNAKNTLFLQMNSLKSEDTAVYYCAKDSAGRTKGQGTQVTVSSGGGGSGGG SEVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSV SLEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS VEGFBII88A01- EVQLVESGGGLVQAGGSLRLSCAASERTFSNYAMDWFRQAPGKEREFVAAITRSGGGTYYAD 9GS-23B04/158 SVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAATRSSTIVVGVGGMEYWGKGTQVTVSS GGGGSGGGSEVQLVESGGGLVQTGDSLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAIS KGGYKYDSVSLEGRFTISKDNAKNTVYLQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYW GQGTQVTVSS VEGFBII4B08- EVQLVESGGGLVQPGGSLRLSCAASGSAVGDITVAWYRQAPGIQRQLVATITPSGYTYYWDFV 40GS-23B04/159 KGRFTISRDNSKNIVYLQMNSLKPEDTAAYYCNTQFYWGQGTQVTVSSGGGGSGGGGSGGG

GSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQTGDSLRLSCEVSGRTFSSY SMGWFRQAQGKEREFVVAISKGGYKYDSVSLEGRFTISKDNAKNTVYLQINSLKPEDTAVYYC ASSRAYGSSRLRLADTYEYWGQGTQVTVSS VEGFBII5B03- EVQLVESGGGLAQAGDSLRLSCAASGRSFSHYNMGWFRQAPGKEREFVASIRGGGGSTTYA 40GS-23B04/160 NSVKDRFTISRENAKNTVYLQMNSLKPEDTAVYYCAATAFYRGPYDYDYWGQGTQVTVSSGG GGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQTGDSLRL SCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVSLEGRFTISKDNAKNTVYLQIN SLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS VEGFBII5B05- EVQLVESGGGLVQPGGSLRLSCVASGIRFMSMAWYRQAPGKHRELVARISSGGTTAYVDSVK 40GS-23B04/161 GRFTISRDNSKNTVYLQMNSLKAEDTAVYYCNTFSSRPNPWGAGTQVTVSSGGGGSGGGGS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQTGDSLRLSCEVSGRTF SSYSMGWFRQAQGKEREFVVAISKGGYKYDSVSLEGRFTISKDNAKNTVYLQINSLKPEDTAV YYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS VEGFBII6G02- EVQLVESGGGLVQPGGSLRLSCAASGNIFSNNAMAWYRQAPGKQRELVARISSGGGFTYYLD 40GS-23B04/162 SVKGRFTVSRDNAKNTVYLQMNSLKPEDTAVYYCNAAYRTYNYWGQGTQVTVSSGGGGSGG GGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQTGDSLRLSCEVS GRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVSLEGRFTISKDNAKNTVYLQINSLKPE DTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS VEGFBII10E07- VEGFBII025 EVQLVESGGGLVQAGGSLRLSCAASGRTFSNYAMGWFRQAPGKERVLVADISSSGINTYVAD 40GS-23B04/163 AVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAASAWWYSQMARDNYRYWGQGTQVTVS SGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQTGD SLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVSLEGRFTISKDNAKNTVY LQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS VEGFBII12B01- EVQLVESGGGLVQPGGSLRLACAASGFTLSSSWMYWVRQAPGKGLEWVSRISPGGLFTYYV 40GS-23B04/164 DSVKGRFSVSTDNANNTLYLQMNSLKPEDTALYSCAKGGAPNYTPRGRGTQVTVSSGGGGS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQTGDSLRLSCE VSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVSLEGRFTISKDNAKNTVYLQINSLK PEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS VEGFBII86C11- EVQLVESGGGLVQAGDSLRLSCTASGRTFNSYAMGWFRQAPGKERESVAHINRSGSSTYYAD 40GS-23B04/165 SVKGRFTISRDNAKNTVYLQLNSLKPEDTAVYYCAAGRYYSSDGVPSASFNYWGQGTQVTVS SGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQTGD SLRLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVSLEGRFTISKDNAKNTVY LQINSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS VEGFBI186H09- EVQLVESGGGLVQAGGSLRLSCTASGSAFKSYRMGWFRRTPGKEDEFVASISWTYGSTFYAD 40GS-23B04/166 SVKGRFTMSRDKAKNAGYLQMNSLKPEDTALYYCAAGAQSDRYNIRSYDYWGQGTQVTVSS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQTGDSL RLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVSLEGRFTISKDNAKNTVYLQ INSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS VEGFBII87B07- EVQLVESGGGLVQPGGSLKLSCTASGFTFSTSWMHWVRQAPGKGLEWVSSIPPVGHFANYA 40GS-23B04/167 PSVKGRFTISRDNAKNTLFLQMNSLKSEDTAVYYCAKDSAGRTKGQGTQVTVSSGGGGSGGG GSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQTGDSLRLSCEVSGR TFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVSLEGRFTISKDNAKNTVYLQINSLKPEDTA VYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS VEGFBII88A01- EVQLVESGGGLVQAGGSLRLSCAASERTFSNYAMDWFRQAPGKEREFVAAITRSGGGTYYAD 40GS-23B04/168 SVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAATRSSTIVVGVGGMEYWGKGTQVTVSS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQTGDSL RLSCEVSGRTFSSYSMGWFRQAQGKEREFVVAISKGGYKYDSVSLEGRFTISKDNAKNTVYLQ INSLKPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTQVTVSS

[0402] The panel of 40 bivalent VHHs is tested in the VEGFR2 and VEGFR1 blocking AlphaScreen assay, as described in Example 5.3 and 5.4, respectively. Based on potency and maximum level of inhibition, the 5 best bivalent VHHs (VEGFBII021, VEGFBII022, VEGFBI023, VEGFBI024 and VEGFBII025) are chosen for further characterization. An overview of the screening results for the 5 selected bivalent VHHs in the competitive VEGFR2 and VEGFR1 AlphaScreen is shown in Table 16.

TABLE-US-00020 TABLE 16 Potency and efficacy of 5 best bivalent VHHs in the VEGF/VEGFR1 and VEGF/VEGFR2 competition AlphaScreen assay VEGFR2 VEGFR1 VHH ID IC.sub.50 (pM) IC.sub.50 (pM) % inhibition VEGFBII021 9 16 100 VEGFBII022 7 8 100 VEGFBII023 38 44 91 VEGFBII024 12 46 100 VEGFBII025 51 39 82

EXAMPLE 7

[0403] Characterization of Formatted Anti-VEGF VHHs

[0404] VHHs VEGFBII010, VEGFBII021, VEGFBII022, VEGFBII023, VEGFBII024 and VEGFBII025 are compared side-by-side in the VEGFR2 and VEGFR1 blocking ELISA (FIGS. 8 and 9, Table 17 and Table 18 respectively) and AlphaScreen assay (FIGS. 10 and 11, Table 19 and 20) as described in Examples 5.1, 5.2, 5.3 and 5.4, respectively.

TABLE-US-00021 TABLE 17 IC.sub.50 (pM) values and % inhibition for formatted VHHs in hVEGF165/ hVEGFR2-Fc competition ELISA IC.sub.50 % VHH ID (pM) inhibition VEGFBII010 49 100 VEGFBII021 204 100 VEGFBII022 164 100 VEGFBII023 213 100 VEGFBII024 292 100 VEGFBII025 577 100 Bevacizumab 315 100 Ranibizumab 349 100

TABLE-US-00022 TABLE 18 IC.sub.50 (pM) values and % inhibition of formatted VHHs in VEGF165/hVEGFR1-Fc competition ELISA IC.sub.50 % VHH ID (pM) inhibition VEGFBII010 73.5 67 VEGFBII021 254 97 VEGFBII022 225 89 VEGFBII023 279 91 VEGFBII024 326 92 VEGFBII025 735 91 Bevacizumab 484 91 Ranibizumab 594 96

TABLE-US-00023 TABLE 19 IC.sub.50 (pM) values and % inhibition for formatted VHHs in hVEGF165/hVEGFR2-Fc competition AlphaScreen VHH ID IC.sub.50 (pM) % inhibition VEGFBII010 16 100 VEGFBII021 7 100 VEGFBII022 7 100 VEGFBII023 46 100 VEGFBII024 50 100 VEGFBII025 51 100 Ranibizumab 600 100

TABLE-US-00024 TABLE 20 IC.sub.50 (pM) values and % inhibition of formatted VHHs in VEGF165/hVEGFR1-Fc competition AlphaScreen VHH ID IC.sub.50 (pM) % inhibition VEGFBII010 21 70 VEGFBII021 12 100 VEGFBII022 9 98 VEGFBII023 48 87 VEGFBII024 69 98 VEGFBII025 71 82 Ranibizumab 1300 87

[0405] In addition, formatted VHHs are also tested for their capacity to block the mVEGF164/mVEGFR2-huFc interaction. In brief, serial dilutions of purified VHHs (concentration range: 4 .mu.M-14.5 pM) in PBS buffer containing 0.03% Tween 20 (Sigma) are added to 0.1 nM biotinylated mVEGF164 and incubated for 15 min. Subsequently mouse VEGFR2-huFc (0.1 nM) and anti-huFc VHH-coated acceptor beads (20 .mu.g/ml) are added and this mixture is incubated for 1 hour. Finally, streptavidin donor beads (20 .mu.g/ml) are added and after 1 hour of incubation fluorescence is measured on the Envision microplate reader. Dose-response curves are shown in FIG. 12. The IC.sub.50 values for VHHs blocking the mouse VEGF164/VEGFR2-hFC interaction are summarized in Table 21.

TABLE-US-00025 TABLE 21 IC.sub.50 (pM) values and % inhibition for formatted VHHs in mVEGF164/mVEGFR2-hFc competition AlphaScreen VHH ID IC.sub.50 (nM) % inhibition VEGFBII022 108 100 VEGFBII024 -- -- mVEGF164 0.05 100 Ranibizumab -- --

[0406] The formatted VHHs are also tested in ELISA for their ability to bind mVEGF164 and human VEGF165 (Example 5.6; FIG. 13; Table 22); VEGF121 (Example 5.7; FIG. 15; Table 23) and the VEGF family members VEGFB, VEGFC, VEGFD and PIGF (Example 5.8; FIG. 14). Binding kinetics for human VEGF165 are analyzed as described in Example 5.5. The KD values are listed in Table 24.

TABLE-US-00026 TABLE 22 EC.sub.50 (pM) values for formatted VHHs in a recombinant human VEGF165 and mouse VEGF164 binding ELISA rhVEGF165 rmVEGF164 VHH ID EC.sub.50 (pM) EC.sub.50 (pM) VEGFBII010 428 -- VEGFBII021 334 502 VEGFBII022 224 464 VEGFBII023 221 -- VEGFBII024 320 -- VEGFBII025 668 --

TABLE-US-00027 TABLE 23 EC.sub.50 (pM) values for formatted VHHs in a recombinant human VEGF121 binding ELISA rhVEGF121 VHH ID EC.sub.50 (pM) VEGFBII010 920 VEGFBII022 540 VEGFBII024 325 VEGFBII025 475

TABLE-US-00028 TABLE 24 Affinity KD (nM) of purified formatted VHHs for recombinant human VEGF165 K.sub.D VHH ID k.sub.a1 (1/Ms) k.sub.d1 (1/s) k.sub.a2 (1/s) k.sub.d2 (1/s) (nM).sup.(a) VEGFBII010.sup.(b) 4.5E + 05 1.7E - 02 2.9E - 02 1.3E - 04 0.16 VEGFBII021.sup.(b) 1.2E + 06 1.1E - 02 2.3E - 02 1.9E - 04 0.07 VEGFBII022.sup.(b) 1.2E + 06 9.1E - 03 1.4E - 02 2.6E - 04 0.14 VEGFBII023.sup.(b) 3.0E + 05 1.8E - 02 2.4E - 02 2.7E - 04 0.69 VEGFBII024.sup.(b) 3.0E + 05 1.3E - 02 2.6E - 02 2.8E - 04 0.47 VEGFBII025.sup.(b) 3.3E + 05 1.7E - 02 1.8E - 02 3.7E - 04 1.1 .sup.(a)K.sub.D = k.sub.d1/k.sub.a1(k.sub.d2/(k.sub.d2 + k.sub.a2)) .sup.(b)Curves are fitted using a Two State Reaction model by Biacore T100 Evaluation Software v2.0.1

[0407] VHHs VEGFBII010, VEGFBII022, VEGFBII024 and VEGFBII025 are also tested in the VEGF-mediated HUVEC proliferation and Erk phosphorylation assay.

[0408] The potency of the selected formatted VHHs is evaluated in a proliferation assay. In brief, primary HUVEC cells (Technoclone) are supplement-starved over night and then 4000 cells/well are seeded in quadruplicate in 96-well tissue culture plates. Cells are stimulated in the absence or presence of VHHs with 33 ng/mL VEGF. The proliferation rates are measured by [.sup.3H] Thymidine incorporation on day 4. The results shown in Table 25 demonstrate that the formatted VHHs and Bevacizumab inhibit the VEGF-induced HUVEC proliferation by more than 90%, with IC.sub.50s<1 nM.

TABLE-US-00029 TABLE 25 IC.sub.50 (nM) values and % inhibition of formatted VHHs in VEGF HUVEC proliferation assay VHH ID IC.sub.50 (nM) % inhibition VEGFBII010 0.22 95 VEGFBII021 0.40 98 VEGFBII022 0.34 100 VEGFBII023 0.52 98 VEGFBII024 0.38 96 VEGFBII025 0.41 104 Bevacizumab 0.21 92

[0409] The potency of the selected formatted VHHs is assessed in the HUVEC Erk phosphorylation assay. In brief, primary HUVE cells are serum-starved over night and then stimulated in the absence or presence of VHHs with 10 ng/mL VEGF for 5 min. Cells are fixed with 4% Formaldehyde in PBS and ERK phosphorylation levels are measured by ELISA using phosphoERK-specific antibodies (anti-phosphoMAP Kinase pERK1&2, M8159, Sigma) and polyclonal Rabbit Anti-Mouse-Immunoglobulin-HRP conjugate (PO161, Dako). As shown in Table 26, the formatted VHHs and Bevacizumab inhibit the VEGF induced Erk phosphoryaltion by more than 90%, with IC.sub.50s<1 nM.

TABLE-US-00030 TABLE 26 IC.sub.50 (nM) values and % inhibition of formatted VHHs in VEGF HUVEC Erk phosphorylation assay VHH ID IC.sub.50 (nM) % inhibition VEGFBII010 0.19 92 VEGFBII021 0.21 103 VEGFBII022 0.18 94 VEGFBII023 0.25 100 VEGFBII024 0.23 94 VEGFBII025 0.23 99 Bevacizumab 0.63 98

EXAMPLE 8

[0410] Sequence Optimization

[0411] 8.1 Sequence Optimization of VEGFBII23B04

[0412] The amino acid sequence of VEGFBII23B04 is aligned to the human germline sequence VH3-23/JH5, see FIG. 16 (SEQ ID NO: 179)

[0413] The alignment shows that VEGFBII23B04 contains 19 framework mutations relative to the reference germline sequence. Non-human residues at positions 14, 16, 23, 24, 41, 71, 82, 83 and 108 are selected for substitution with their human germline counterparts. A set of 8 VEGFBII23B04 variants is generated carrying different combinations of human residues at these positions (AA sequences are listed in Table 27). One additional variant is constructed in which the potential isomerization site at position D59S60 (CDR2 region, see FIG. 16, indicated as bold italic residues) is removed by introduction of a S60A mutation.

TABLE-US-00031 TABLE 27 AA sequence of sequence-optimized variants of VHH VEGFBII23604 (FR, framework; CDR, complementary determining region) CDR1/ SEQ CDR2/ CDR3/ VHH ID/ FR1/SEQ ID ID SEQ ID SEQ ID FR4/SEQ ID SEQ ID NO: NO: NO: FR2/SEQ ID NO: NO: FR3/SEQ ID NO: NO: NO: VEGFBII EVQLVESGG SYSM WFRQAPGKERE AISKGGY RFTISRDNAKNTVYLQI SRAYGS WGQGTLVTV 111D05/47 GLVQTGGSL G/450 FVV/659 KYDSVSL NSLRPEDTAVYYCAS/ SRLRLAD SS/664 RLSCEASGRT EG/459 660 TYEY/4 FS/653 VEGFBII EVQLVESGG SYSM WFRQAPGKERE AISKGGY RFTISRDNAKNTVYLQ SRAYGS WGQGTLVTV 111G06/48 GLVQPGGSL G/450 FVV/659 KYDSVSL MNSLRPEDTAVYYCAS SRLRLAD/ SS/664 RLSCAASGRT EG/459 661 TYEY/4 FS/654 VEGFBII EVQLVESGG SYSM WFRQAPGKERE AISKGGY RFTISRDNAKNTVYLQI SRAYGS WGQGTLVTV 112D11/49 GLVQPGGSL G/450 FVV/659 KYDSVSL NSLRPEDTAVYYCAS/ SRLRLAD SS/664 RLSCEASGRT EG/459 660 TYEY/4 FS/655 VEGFBII EVQLVESGG SYSM WFRQAPGKERE AISKGGY RFTISKDNAKNTVYLQI SRAYGS WGQGTLVTV 113A08/50 GLVQTGGSL G/450 FVV/659 KYDSVSL NSLRPEDTAVYYCAS/ SRLRLAD SS/664 RLSCEVSGRT EG/459 662 TYEY4 FS/656 VEGFBII EVQLVESGG SYSM WFRQAQGKERE AISKGGY RFTISKDNAKNTVYLQ SRAYGS WGQGTLVTV 113E03/51 GLVQTGDSL G/450 FVV/691 KYDSVSL MNSLRPEDTAVYYCAS/ SRLRLAD SS/664 RLSCEVSGRT EG/459 663 TYEY/4 FS/690 VEGFBII EVQLVESGG SYSM WFRQAPGKERE AISKGGY RFTISKDNAKNTVYLQI SRAYGS WGQGTLVTV 114C09/52 GLVQPGDSL G/450 FVV/659 KYDSVSL NSLRPEDTAVYYCAS/ SRLRLAD SS/664 RLSCEVSGRT EG/459 662 TYEY/4 FS/657 VEGFBII EVQLVESGG SYSM WFRQAPGKERE AISKGGY RFTISRDNAKNTVYLQI SRAYGS WGQGTLVTV 114D02/53 GLVQTGGSL G/450 FVV/659 KYDSVSL NSLRPEDTAVYYCAS/ SRLRLAD SS/664 RLSCEVSGRT EG/459 660 TYEY/4 FS/656 VEGFBII EVQLVESGG SYSM WFRQAQGKERE AISKGGY RFTISKDNAKNTVYLQI SRAYGS WGQGTLVTV 114D03/54 GLVQTGDSL G/450 FVV/691 KYDSVSL NSLRPEDTAVYYCAS/ SRLRLAD SS/664 RLSCAVSGRT EG/459 662 TYEY/4 FS/658 VEGFBII EVQLVESGG SYSM WFRQAQGKERE AISKGGY RFTISKDNAKNTVYLQI SRAYGS WGQGTQVT 118E10/55 GLVQTGDSL G/450 FVV/691 KYDAVSL NSLKPEDTAVYYCAS/ SRLRLAD VSS/665 RLSCEVSGRT EG/465 692 TYEY/4 FS/690

[0414] These variants are characterized as purified proteins in the VEGF165/VEGFR2 AlphaScreen (Example 5.3, FIG. 17). The melting temperature (T.sub.m) of each clone is determined in a thermal shift assay, which is based on the increase in fluorescence signal upon incorporation of Sypro Orange (Invitrogen) (Ericsson et al, Anal. Biochem. 357 (2006), pp 289-298). All variants displayed comparable IC.sub.50 when compared to VEGFBII23B04 and Tm values which are similar or higher when compared to the parental VEGFBII23B04. Table 28 summarizes the IC.sub.50 values and T.sub.m values at pH 7 for the 9 clones tested.

TABLE-US-00032 TABLE 28 IC.sub.50 (pM) values, % inhibition and melting temperature (@pH 7) of sequence-optimized variants of VEGFBII23B04 VHH ID IC.sub.50 (pM) % inhibition T.sub.m @ pH 7 (.degree. C.) VEGFBII23B04 (wt) 169 100 63 VEGFBII111D05 209 100 68 VEGFBII111G06 366 100 71 VEGFBII112D11 221 100 70 VEGFBII113A08 253 100 69 VEGFBII113E03 290 100 68 VEGFBII114C09 215 100 71 VEGFBII114D02 199 100 74 VEGFBII114D03 227 100 64 VEGFBII118E10 189 100 62

[0415] In a second cycle, tolerated mutations from the humanization effort (VEGFBII111G06) and mutations to avoid potential posttranslational modification at selected sites (the D16G, the S60A substitution and an El D mutation) are combined resulting in a sequence-optimized clone derived from VEGFB1123B04: VEGFBI10037. One extra sequence-optimized variant (VEGFB11038) is anticipated which contains the same substitutions as VEGFBI10037, with the exception of the I82M mutation, as this mutation may be associated with a minor drop in potency. The sequences from both sequence-optimized clones are listed in Table 29. VEGFBII0037 and VEGFBII0038 are characterized in the VEGF165/VEGFR2 blocking AlphaScreen (Example 5.3, FIG. 18), the melting temperature is determined in the thermal shift assay as described above and the affinity for binding on VEGF165 is determined in Biacore (Example 5.5). An overview of the characteristics of the 2 sequence-optimized VHHs is presented in Table 30.

TABLE-US-00033 TABLE 29 AA sequences of sequence-optimized variants of VHH VEGFBII23B04 CDR1/ VHH ID/ SEQ CDR 2/ FR SEQ ID FR 1/SEQ ID FR2/SEQ SEQ ID CDR 3/SEQ 4/SEQ NO: ID NO: NO: ID NO: NO: FR3/SEQ ID NO: ID NO: ID NO: VEGFBII0 DVQLVES SYSM WFRQAP AISKG RFTISRDNAKNT SRAYGSSR WGQG 37 GGGLVQP G/450 GKEREF GYKYD VYLQMNSLRPE LRLADTYE TLVTVS 56 GGSLRLS VV/659 AVSLE DTAVYYCAS/661 Y/4 S/664 CAASGRT G/465 FS/666 VEGFBII0 DVQLVES SYSM WFRQAP AISKG RFTISRDNAKNT SRAYGSSR WGQG 38 GGGLVQP G/450 GKEREF GYKYD VYLQINSLRPED LRLADTYE TLVTVS 57 GGSLRLS VV/659 AVSLE TAVYYCAS/660 Y/4 S/664 CAASGRT G/465 FS/666

TABLE-US-00034 TABLE 30 IC.sub.50 (pM) values, % inhibition, melting temperature (@pH 7) and affinity (pM) of sequence-optimized clones VEGFBII037 and VEGFBII038 VHH ID IC.sub.50 (pM) % inhibition T.sub.m (.degree. C.) @ pH 7 K.sub.D (pM) VEGFBII23B04 152 100 63 560 VEGFBII037 300 100 72 270 VEGFBII038 143 100 71 360

[0416] 8.2 Sequence Optimization of VEGFBII5B05

[0417] The amino acid sequence of VEGFBII5B05 is aligned to the human germline sequence VH3-23/JH5, see FIG. 19 (SEQ ID:NO: 179 The alignment shows that VEGFBII5B05 contains 15 framework mutations relative to the reference germline sequence. Non-human residues at positions 23, 60, 83, 105, 108 are selected for substitution with their human germline counterparts while the histidine at position 44 is selected for substitution by glutamine. One humanization variant is constructed carrying the 6 described mutations (AA sequence is listed in Table 31).

TABLE-US-00035 TABLE 31 AA sequences of sequence-optimized variants of VHH VEGFBII5B05 (FR, framework; CDR, complementary determining region) CDR1/ SEQ CDR2/ CDR3/ VHH ID/ FR1/SEQ ID FR2/SEQ SEQ FR3/SEQ ID SEQ FR4/SEQ SEQ ID NO: ID NO: NO: ID NO: ID NO: NO: ID NO: ID NO: VEGFBII119 EVQLVES SM WYRQAP RISSG RFTISRDNS FSSR WGQGTL G11/ GGGLVQ A/ GKQRELV GTTA KNTVYLQMN PNP/ VTVSS/ 125 PGGSLRL 290 A/669 YADS SLRAEDTAV 395 664 SCAASGI VKG/ YYCNT/671 RFM/667 404 VEGFBII120E EVQLVES SM WYRQAP RISSG RFTISRDNS FSSR WGAGT 10/ GGGLVQ A/ GKHRELV GTTA KNTVYLQMN PNP/ QVTVSS/ 126 PGGSLRL 290 A/670 YVDS SLKAEDTAV 395 673 SCVASGI VKG/ YYCNT/672 RFI/668 336

[0418] One additional variant is constructed in which the potential oxidation site at position M30 (CDR1 region, see FIG. 19 indicated as bold italic residue) is removed by introduction of a M30I mutation. Both variants are tested for their ability to bind hVEGF165 using the ProteOn. In brief, a GLC ProteOn Sensor chip is coated with human VEGF165. Periplasmic extracts of the variants are diluted 1/10 and injected across the chip coated with human VEGF165. Off-rates are calculated and compared to the off-rates of the parental VEGFBII5B05. Off-rates from the 2 variants are in the same range as the off-rates from the parental VEGFBII5B05 indicating that all mutations are tolerated (Table 32).

TABLE-US-00036 TABLE 32 Off-rates sequence-optimized variants VEGFBII5605 VHH ID binding level (RU) k.sub.d (1/s) VEGFBII5B05 242 6.15E - 02 VEGFBII119G11 234 7.75E - 02 VEGFBII120E10 257 4.68E - 02

[0419] In a second cycle, mutations from the humanization effort and the M30I substitution are combined resulting in a sequence-optimized clone of VEGFBII5B05, designated VEGFBII032. The sequence is listed in Table 33. Affinity of VEGFBII032 is determined by Biacore (see Example 5.5) and the melting temperature is determined in the thermal shift assay as described above. An overview of the characteristics of the sequence-optimized VHH VEGFBII032 is presented in Table 34.

TABLE-US-00037 TABLE 33 AA sequence of sequence-optimized clone VEGFBII032 (FR, framework; CDR, complementary determining region) CDR1/ VHH ID/ SEQ CDR2/ CDR3/ SEQ ID FR1/SEQ ID FR2/SEQ SEQ FR3/SEQ ID SEQ FR4/SEQ NO: ID NO: NO: ID NO: ID NO: NO: ID NO: ID NO: VEGFBII032/ EVQLVES SM WYRQAP RISSG RFTISRDNS FSSR WGQGTL 127 GGGLVQ A/ GKQRELV GTTA KNTVYLQMN PNP/ VTVSS/ PGGSLRL 290 A/675 YADS SLRAEDTAV 395 664 SCAASGI VKG/ YYCNT/671 RFI/674 404

TABLE-US-00038 TABLE 34 Melting temperature (@pH 7) and affinity (nM) of sequence-optimized clone VEGFBII032 VHH ID T.sub.m (.degree. C.) @ pH 7 K.sub.D (nM) VEGFBII5B05(wt) 69 32 VEGFBII0032 71 44

[0420] The potency of the sequence-optimized clones VEGFBVBII037 and VEGFBII038 is evaluated in a proliferation assay. In brief, primary HUVEC cells (Technoclone) are supplement-starved over night and then 4000 cells/well are seeded in quadruplicate in 96-well tissue culture plates. Cells are stimulated in the absence or presence of VHHs with 33 ng/mL VEGF. The proliferation rates are measured by [.sup.3H] Thymidine incorporation on day 4. The results shown in Table 35, demonstrate that the activity (potency and degree of inhibition) of the parental VHH VEGFBII23B04 is conserved in the sequence optimized clone VEGFBII038.

TABLE-US-00039 TABLE 35 IC.sub.50 (nM) values and % inhibition of the sequence optimized clones VEGFBII037 and VEGFBII038 in VEGF HUVEC proliferation assay VHH ID IC.sub.50 (nM) % inhibition VEGFBII23B04 0.68 92 VEGFBII037 1.54 78 VEGFBII038 0.60 92 Bevacizumab 0.29 94

EXAMPLE 9

[0421] Construction, Production and Characterization of Bivalent VHHs Targeting Ang2

[0422] VHHs 1D01 (SEQ ID No:214), 11B07, 00908 and 00027 (SEQ ID No:216) are genetically fused to 1D01 (SEQ ID No: 214), 11B07, 00908 and 00027 (SEQ ID No:216), respectively, resulting in homodimeric VHHs. The bivalent VHHs are linked via a 9-GlySer (SEQ ID NO: 170) or 40-GlySer (SEQ ID NO: 171) flexible linker. The encoding DNA sequences of the formatted VHHs are cloned in the expression vector pAX172. VHHs are expressed in Pichia pastoris as c-terminally myc-His6 tagged proteins ("His6" disclosed as SEQ ID NO: 283). In brief, BGCM cultures are started from a single colony streak incubated over weekend at 30.degree. C. (250 rpm). After medium switch to BMCM, cultures are incubated until evening at 30.degree. C. (250 rpm) and followed by an induction with 100% methanol. The next day the cultures are induced an additional 3 times (morning, afternoon, evening). The next day cultures are centrifuged for 20 min at 4.degree. C. (1,500.times.g). The His6-tagged VHHs ("His6" disclosed as SEQ ID NO: 283) present in the supernatant are purified through immobilized metal affinity chromatography (IMAC) followed by desalting (DS) and finally gel filtration (GF) to remove any endotoxins/impurities. An overview of the format and sequence of all bivalent VHHs is depicted in FIG. 20 A and Table 36 (linker sequences underlined), SEQ ID Nos 180-185. Expression levels are indicated in FIG. 20B.

[0423] To explore the anti-Ang2 blocking properties in comparison with the monovalent building blocks, bivalent VHHs are analyzed in a human Ang2/hTie2 (FIG. 21-1), mouse Ang2/mTie2 (FIG. 21-2), cyno Ang2/cTie2 (FIG. 21-3) and human Ang1/hTie2 (FIG. 22) competition ELISA. A summary of IC.sub.50 values is shown in FIG. 20C.

TABLE-US-00040 TABLE 36 Sequences of bivalent VHH targeting Ang2 VHH ID AA sequence ANGBII00001 EVQLVESGGGLVQAGGSLRLSCAASGFTFDDYALGWFRQAAGKEREGVSCIRCSDGSTYYADSVKGR FTISSDNAKNTVYLQMNSLKPEDTAVYYCAASIVPRSKLEPYEYDAWGQGTLVTVSSGGGGSGGGSE VQLVESGGGLVQAGGSLRLSCAASGFTFDDYALGWFRQAAGKEREGVSCIRCSDGSTYYADSVKGRF TISSDNAKNTVYLQMNSLKPEDTAVYYCAASIVPRSKLEPYEYDAWGQGTLVTVSS (SEQ ID NO: 180) ANGBII00002 EVQLVESGGGLVQAGGSLRLSCAASGFTFDDYALGWFRQAAGKEREGVSCIRCSDGSTYYADSVKGR FTISSDNAKNTVYLQMNSLKPEDTAVYYCAASIVPRSKLEPYEYDAWGQGTLVTVSSGGGGSGGGGS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQAGGSLRLSCAASGFTFDDYALGWF RQAAGKEREGVSCIRCSDGSTYYADSVKGRFTISSDNAKNTVYLQMNSLKPEDTAVYYCAASIVPRS KLEPYEYDAWGQGTLVTVSS (SEQ ID NO: 181) ANGBII00003 EVQLVESGGGLVQVGDSLRLSCAASGRTFSTYLMVGWFRQAPGKEREFAAGIWSSGDTAYADSVRGR FTISRDNAKNTVYLQMNSLKTEDTAVYYCAGSYDGNYYIPGFYKDWGQGTLVTVSSGGGGSGGGSEV QLVESGGGLVQVGDSLRLSCAASGRTFSTYLMVGWFRQAPGKEREFAAGIWSSGDTAYADSVRGRFT ISRDNAKNTVYLQMNSLKTEDTAVYYCAGSYDGNYYIPGFYKDWGQGTLVTVSS (SEQ ID NO: 182) ANGBII00004 EVQLVESGGGLVQAGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSSIRDNDGSTYYADSVKGR FTISSDNDKNTVYLQMNSLKPEDTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSSGGGGS GGGSEVQLVESGGGLVQAGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSSIRDNDGSTYYADS VKGRFTISSDNDKNTVYLQMNSLKPEDTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSS (SEQ ID NO: 183) ANGBII00005 EVQLVESGGGLVQAGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSSIRDNDGSTYYADSVKGR FTISSDNDKNTVYLQMNSLKPEDTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSSGGGGS GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSEVQLVESGGGLVQAGGSLRLSCAASGFTLDDY AIGWFRQAPGKEREGVSSIRDNDGSTYYADSVKGRFTISSDNDKNTVYLQMNSLKPEDTAVYYCAAV PAGRLRFGEQWYPLYEYDAWGQGTLVTVSS (SEQ ID NO: 184) ANGBII00006 EVQLVESGGGLVQPGGSLRLSCAASGITLDDYAIGWFRQAPGKEREGVSSIRDNGGSTYYADSVKGR FTISSDNSKNTVYLQMNSLRPEDTAVYYCAAVPAGRLRYGEQWYPIYEYDAWGQGTLVTVSSGGGGS GGGSEVQLLESGGGLVQPGGSLRLSCAASGITLDDYAIGWFRQAPGKEREGVSSIRDNGGSTYYADS (SEQ ID NO: 185)

EXAMPLE 10

[0424] Construction, Production and Characterization of Trivalent Bispecific VHHs Targeting VEGF and Ang2 Using Anti-Serum Abumin as Half-Life Extension

[0425] The anti-VEGF VHH VEGFBII00038 (US 2011/0172398 A1) and the anti-Ang2 VHH 00027 (SEQ ID No:216) are used as building blocks to generate bispecific VHHs VEGFANGBII00001-00004. A genetic fusion to a serum albumin binding VHH is used as half-life extension methodology. Building blocks are linked via a triple Ala or 9 Gly-Ser flexible linker (SEQ ID NO: 170). VHHs are produced and purified as described in Example 9. An overview of the format and sequence of all four bispecific VHHs is depicted in FIG. 23 A and Table 38 (linker sequences underlined), SEQ ID Nos 186-189. Expression levels are indicated in FIG. 23B.

TABLE-US-00041 TABLE 38 Sequences of bispecific VHH targeting VEGF and Ang2 VHH ID AA sequence VEGFANGBII00001 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGR FTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGG LVQAGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSSIRDNDGSTYYADSVKGRFTISSDNDKN TVYLQMNSLKPEDTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSS (SEQ ID NO: 186) VEGFANGBII00002 EVQLVESGGGLVQAGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSSIRDNDGSTYYADSVKGR FTISSDNDKNTVYLQMNSLKPEDTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSSGGGGS GGGSEVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADS VKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSDVQLVE SGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRFTISRDN AKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSS (SEQ ID NO: 187) VEGFANGBII00003 EVQLVESGGGLVQAGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSSIRDNDGSTYYADSVKGR FTISSDNDKNTVYLQMNSLKPEDTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSSGGGGS GGGSDVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSL EGRFTISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGS GGGSEVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADS VKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS (SEQ ID NO: 188) VEGFANGBII00004 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSAAAEVQLVE SGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRD NAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSAAAEVQLVESGGGLVQAGGSLRLSC AASGFTLDDYAIGWFRQAPGKEREGVSSIRDNDGSTYYADSVKGRFTISSDNDKNTVYLQMNSLKPE DTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSS (SEQ ID NO: 189)

[0426] To explore the anti-VEGF blocking properties in comparison with the monovalent building block VEGFB1100038, all four bispecific VHHs are analyzed in the VEGF/VEGFR2-Fc (FIG. 22) competition AlphaScreen. The assay is slightly adjusted compared to Example 12.3 described in patent US 2011/0172398 A1. Both human VEGF165 and human VEGFR2-Fc are added at 0.05 nM. This competition assay is also performed after preincubation of the VHH with 25 .mu.M human serum albumin. A summary of IC.sub.50 values and % inhibition is shown in FIG. 23C.

[0427] To explore the anti-Ang2 blocking properties in comparison with the monovalent building block 00027 (SEQ ID No:216) , all four bispecific VHHs are analyzed in a human Ang2/hTie2-Fc (FIG. 25) competition ELISA. This assay is also performed after incubation of the VHH with 0.5 .mu.M human serum albumin. A summary of IC.sub.50 values is shown in FIG. 23D.

EXAMPLE 11

[0428] Construction, Production and Characterization of Trivalent and tetravalent Bispecific VHHs Targeting VEGF and Ang2 Using Anti-Serum Albumin Binding as Half-Life Extension

[0429] Ten bispecific VHHs targeting VEGF and Ang2 are constructed (VEGFANGBII00005-00015). In these constructs monovalent and bivalent 1D01 (SEQ ID NO:214), monovalent and bivalent 7G08 (SEQ ID NO:215) and bivalent 00027 (SEQ ID NO:216) anti-Ang2 building blocks are included. A genetic fusion to a serum albumin binding VHH is used as half-life extension methodology. Building blocks are linked via a 9 Gly-Ser flexible linker (SEQ ID NO: 170). VHHs are produced and purified as described in Example 8. An overview of the format and sequence of all ten bispecific VHHs is depicted in FIG. 26A and Table 41(linker sequences underlined), SEQ ID Nos 190-199. Expression levels are indicated in FIG. 26B.

TABLE-US-00042 TABLE 41 Sequences of bispecific VHH targeting VEGF and Ang2 VHH ID AA sequence VEGFANGBII00005 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGGSLRLSCAASGFALDYYAIGWFRQVPGKEREGVSCISSSDGITYYVDSVKGR FTISRDNAKNTVYLQMNSLKPEDTAVYYCATDSGGYIDYDCMGLGYDYWGQGTLVTVSSGGGGSGGG SEVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKG RFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS (SEQ ID NO: 190) VEGFANGBII00006 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGR FTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGG LVQPGGSLRLSCAASGFALDYYAIGWFRQVPGKEREGVSCISSSDGITYYVDSVKGRFTISRDNAKN TVYLQMNSLKPEDTAVYYCATDSGGYIDYDCMGLGYDYWGQGTLVTVSS (SEQ ID NO: 191) VEGFANGBII00007 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGGSLRLSCAASGFALDYYAIGWFRQVPGKEREGVSCISSSDGITYYVDSVKGR FTISRDNAKNTVYLQMNSLKPEDTAVYYCATDSGGYIDYDCMGLGYDYWGQGTLVTVSSGGGGSGGG SEVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKG RFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGG GLVQPGGSLRLSCAASGFALDYYAIGWFRQVPGKEREGVSCISSSDGITYYVDSVKGRFTISRDNAK NTVYLQMNSLKPEDTAVYYCATDSGGYIDYDCMGLGYDYWGQGTLVTVSS (SEQ ID NO: 192) VEGFANGBII00008 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQAGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSSIRDNDGSTYYADSVKGR FTISSDNDKNTVYLQMNSLKPEDTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSSGGGGS GGGSEVQLVESGGGLVQAGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSSIRDNDGSTYYADS VKGRFTISSDNDKNTVYLQMNSLKPEDTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSSG GGGSGGGSEVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTL YADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS (SEQ ID NO: 193) VEGFANGBII00009 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGR FTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGG LVQAGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSSIRDNDGSTYYADSVKGRFTISSDNDKN TVYLQMNSLKPEDTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSSGGGGSGGGSEVQLVE SGGGLVQAGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSSIRDNDGSTYYADSVKGRFTISSD NDKNTVYLQMNSLKPEDTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSS (SEQ ID NO: 194) VEGFANGBII00010 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQAGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSSIRDNDGSTYYADSVKGR FTISSDNDKNTVYLQMNSLKPEDTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSSGGGGS GGGSEVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADS VKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVE SGGGLVQAGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSSIRDNDGSTYYADSVKGRFTISSD NDKNTVYLQMNSLKPEDTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSS (SEQ ID NO: 195) VEGFANGBII00011 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQAGGSLRLSCAASGFTFDDYALGWFRQAAGKEREGVSCIRCSDGSTYYADSVKGR FTISSDNAKNTVYLQMNSLKPEDTAVYYCAASIVPRSKLEPYEYDAWGQGTLVTVSSGGGGSGGGSE VQLVESGGGLVQAGGSLRLSCAASGFTFDDYALGWFRQAAGKEREGVSCIRCSDGSTYYADSVKGRF TISSDNAKNTVYLQMNSLKPEDTAVYYCAASIVPRSKLEPYEYDAWGQGTLVTVSSGGGGSGGGSEV QLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFT ISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS (SEQ ID NO: 196) VEGFANGBII00012 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGR FTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGG LVQAGGSLRLSCAASGFTFDDYALGWFRQAAGKEREGVSCIRCSDGSTYYADSVKGRFTISSDNAKN TVYLQMNSLKPEDTAVYYCAASIVPRSKLEPYEYDAWGQGTLVTVSSGGGGSGGGSEVQLVESGGGL VQAGGSLRLSCAASGFTFDDYALGWFRQAAGKEREGVSCIRCSDGSTYYADSVKGRFTISSDNAKNT VYLQMNSLKPEDTAVYYCAASIVPRSKLEPYEYDAWGQGTLVTVSS (SEQ ID NO: 197) VEGFANGBII00013 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQAGGSLRLSCAASGFTFDDYALGWFRQAAGKEREGVSCIRCSDGSTYYADSVKGR FTISSDNAKNTVYLQMNSLKPEDTAVYYCAASIVPRSKLEPYEYDAWGQGTLVTVSSGGGGSGGGSE VQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRF TISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGGL VQAGGSLRLSCAASGFTFDDYALGWFRQAAGKEREGVSCIRCSDGSTYYADSVKGRFTISSDNAKNT VYLQMNSLKPEDTAVYYCAASIVPRSKLEPYEYDAWGQGTLVTVSS (SEQ ID NO: 198) VEGFANGBII00014 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGR FTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGG LVQAGGSLRLSCAASGFTFDDYALGWFRQAAGKEREGVSCIRCSDGSTYYADSVKGRFTISSDNAKN TVYLQMNSLKPEDTAVYYCAASIVPRSKLEPYEYDAWGQGTLVTVSS (SEQ ID NO: 199)

[0430] To explore the anti-VEGF blocking properties in comparison with the monovalent building block VEGFBII00038, all ten bispecific VHHs are analyzed in the VEGF/VEGFR2-Fc (Example 10; FIG. 27-1) and VEGF/VEGFR1 (FIG. 27-2) competition AlphaScreen. The VEGFR1 assay is slightly adjusted compared to Example 12.4 as described in patent US 2011/0172398 A1. Human VEGF165 and human VEGFR1-Fc are added at 0.05 nM. These competition assays are also performed after preincubation of the VHH with 25 .mu.M human serum albumin. A summary of IC.sub.50 values is shown in FIG. 26C.

[0431] To explore the anti-Ang2 blocking properties in comparison with their respective monovalent building block 7G08 (SEQ ID No:215), 1D01 (SEQ ID No:214) and 00027 (SEQ ID No:216), all ten bispecific VHHs are analyzed in the human Ang2/hTie2-Fc (see Example 5.1; FIG. 28-1), mouse Ang2/mTie2-Fc (see Example 5.2; FIG. 28-2) and cyno Ang2/cTie2-Fc (see Example 5.2; FIG. 28-3) competition ELISA. The human assay is also performed after incubation of the VHH with 0.5 .mu.M human serum albumin. Additionally, a hAng2 mediated HUVEC survival assay is performed (see Example 5.5; FIG. 29A-F). A summary of IC.sub.50 values and % inhibition is shown in FIG. 29G.

[0432] Affinities of for human serum albumin have been determined and are shown in Table 44. Briefly, human serum albumin (Sigma, St Louis, Mo., USA) is immobilized on a CM5 chip via amine coupling. A multicycle kinetic approach is used: increasing concentrations of VHH (2-8-31-125-500 nM) are injected and allowed to associate for 2 min and to dissociate for 10 min at a flow rate of 100 .mu.L/min. Between VHH injections, the surfaces are regenerated with a 10 sec pulse of 10 mM Glycine-HCl pH 1.5 and 60 sec stabilization period. Association/dissociation data are evaluated by fitting a 1:1 interaction model (Langmuir binding) or Heterogeneous Ligand model. The affinity constant KD is calculated from resulting association and dissociation rate constants k.sub.a and k.sub.d (Table 44)

TABLE-US-00043 TABLE 44 Affinity K.sub.D of purified VHHs for human (HSA), cyno (CSA) and mouse serum albumin (MSA) HSA CSA MSA k.sub.a k.sub.d K.sub.D k.sub.a k.sub.d K.sub.D k.sub.a k.sub.d K.sub.D (1/Ms) (1/s) (nM) (1/Ms) (1/s) (nM) (1/Ms) (1/s) (nM) ALB11 4.5E+05 1.8E-03 4 4.3E+05 1.6E-03 4 6.6E+05 3.2E-02 49 VEGFANGBII00001 2.3E+05 4.8E-03 22 1.8E+05 4.3E-03 24 n.d. n.d. n.d. VEGFANGBII00005 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. VEGFANGBII00006 2.0E+05 4.6E-03 22 1.5E+05 4.5E-03 30 1.7E+05 6.0E-02 360 VEGFANGBII00007 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. VEGFANGBII00008 1.3E+05 4.3E-03 34 n.d. n.d. n.d. n.d. n.d. n.d. VEGFANGBII00009 1.5E+05 4.6E-03 30 1.1E+05 4.2E-03 39 1.2E+05 4.0E-02 340 VEGFANGBII00010 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. VEGFANGBII00011 1.3E+05 4.0E-03 31 n.d. n.d. n.d. n.d. n.d. n.d. VEGFANGBII00012 1.5E+05 4.3E-03 31 1.2E+05 4.2E-03 24 1.0E+05 2.5E-02 240 VEGFANGBII0013 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. VEGFANGBII0014 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d., not determined

Example 12

[0433] Construction, Production and Characterization of Sequence Optimized and Affinity Matured Bispecific VHHs Targeting VEGF and Ang2 Using Anti-Serum Albumin Binding as Half-Life Extension

[0434] 14 bispecific VHHs targeting VEGF and Ang2 are constructed (VEGFANGBII00015-00028). In these constructs bivalent 00921 (a sequence optimized 1D01 variant) (SEQ ID No:220), monovalent VHHs 00908-00932-00933-00934-00935-0093600937-00938 (sequence optimized/affinity matured 28D10 variants) (SEQ ID No:222), bivalent 00956 (SEQ ID NO:223) (sequence optimized 28D10 variant) and monovalent 00928 (SEQ ID NO:221) (sequence optimized 37F02 variant) anti-Ang2 building blocks are included. A genetic fusion to a serum albumin binding VHH is used as half-life extension methodology. Building blocks are linked via a 9 Gly-Ser flexible linker (SEQ ID NO: 170). An overview of the format and sequence of all 14 bispecific VHHs is depicted in FIG. 30A and Table 45 (linker sequences underlined), SEQ ID Nos 200-213.

[0435] Expression levels are indicated in FIG. 30B.

TABLE-US-00044 TABLE 45 Sequences of bispecific VHH targeting VEGF and Ang2 VHH ID AA sequence VEGFANGBII00015 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGR FTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGG LVQPGGSLRLSCAASGITLDDYAIGWFRQAPGKEREGVSSIRDNGGSTYYADSVKGRFTISSDNSKN TVYLQMNSLRPEDTAVYYCAAVPAGRLRYGEQWYPIYEYDAWGQGTLVTVSS (SEQ ID NO: 200) VEGFANGBII00016 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGR FTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGG LVQPGGSLRLSCAVSGITLDDYAIGWFRQAPGKEREGVSSIRDNGGSTYYADSVKGRFTISSDNSKN TVYLQMNSLRPEDTAVYYCAAVPAGRLRYGEQWYPIYEYDAWGQGTLVTVSS SEQ ID NO: 201) VEGFANGBII00017 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGR FTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGG LVQPGGSLRLSCAASGITLDDYAIGWFRQAPGKEREGVSAIRDNGGSTYYADSVKGRFTISSDNSKN TVYLQMNSLRPEDTAVYYCAAVPAGRLRYGEQWYPIYEYDAWGQGTLVTVSS SEQ ID NO: 202) VEGFANGBII00018 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGR FTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGG LVQPGGSLRLSCAASGITLDDYAIGWFRQAPGKEREGVSAIRESGGSTYYADSVKGRFTISSDNSKN TVYLQMNSLRPEDTAVYYCAAVPAGRLRYGEQWYPIYEYDAWGQGTLVTVSS SEQ ID NO: 203) VEGFANGBII00019 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGR FTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGG LVQPGGSLRLSCAASGITLDDYAIGWFRQAPGKEREGVSAIRSSGGSTYYADSVKGRFTISSDNSKN TVYLQMNSLRPEDTAVYYCAAVPAGRLRYGEQWYPIYEYDAWGQGTLVTVSS SEQ ID NO: 204) VEGFANGBII00020 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGR FTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGG LVQPGGSLRLSCAVSGITLDDYAIGWFRQAPGKEREGVSAIRDNGGSTYYADSVKGRFTISSDNSKN TVYLQMNSLRPEDTAVYYCAAVPAGRLRYGEQWYPIYEYDAWGQGTLVTVSS SEQ ID NO: 205) VEGFANGBII00021 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGR FTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGG LVQPGGSLRLSCAVSGITLDDYAIGWFRQAPGKEREGVSAIRESGGSTYYADSVKGRFTISSDNSKN TVYLQMNSLRPEDTAVYYCAAVPAGRLRYGEQWYPIYEYDAWGQGTLVTVSS SEQ ID NO: 206) VEGFANGBII00022 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGR FTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGG LVQPGGSLRLSCAVSGITLDDYAIGWFRQAPGKEREGVSAIRSSGGSTYYADSVKGRFTISSDNSKN TVYLQMNSLRPEDTAVYYCAAVPAGRLRYGEQWYPIYEYDAWGQGTLVTVSS SEQ ID NO: 207) VEGFANGBII00023 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGR FTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGG LVQPGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSAIRDNGGSTYYADSVKGRFTISSDNSKN TVYLQMNSLRPEDTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSSGGGGSGGGSEVQLVE SGGGLVQPGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSAIRDNGGSTYYADSVKGRFTISSD NSKNTVYLQMNSLRPEDTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSS SEQ ID NO: 208) VEGFANGBII00024 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSAIRDNGGSTYYADSVKGR FTISSDNSKNTVYLQMNSLRPEDTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSSGGGGS GGGSEVQLVESGGGLVQPGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSAIRDNGGSTYYADS VKGRFTISSDNSKNTVYLQMNSLRPEDTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSSG GGGSGGGSEVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTL YADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS SEQ ID NO: 209) VEGFANGBII00025 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGR FTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGG LVQPGGSLRLSCAASGFTFDDYALGWFRQAPGKEREGVSCIRCSGGSTYYADSVKGRFTISSDNSKN TVYLQMNSLRPEDTAVYYCAASIVPRSKLEPYEYDAWGQGTLVTVSSGGGGSGGGSEVQLVESGGGL VQPGGSLRLSCAASGFTFDDYALGWFRQAPGKEREGVSCIRCSGGSTYYADSVKGRFTISSDNSKNT VYLQMNSLRPEDTAVYYCAASIVPRSKLEPYEYDAWGQGTLVTVSS SEQ ID NO: 210) VEGFANGBII00026 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGGSLRLSCAASGFTFDDYALGWFRQAPGKEREGVSCIRCSGGSTYYADSVKGR FTISSDNSKNTVYLQMNSLRPEDTAVYYCAASIVPRSKLEPYEYDAWGQGTLVTVSSGGGGSGGGSE VQLVESGGGLVQPGGSLRLSCAASGFTFDDYALGWFRQAPGKEREGVSCIRCSGGSTYYADSVKGRF TISSDNSKNTVYLQMNSLRPEDTAVYYCAASIVPRSKLEPYEYDAWGQGTLVTVSSGGGGSGGGSEV QLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFT ISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS SEQ ID NO: 211) VEGFANGBII00027 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGR FTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGG LVQPGGSLRLSCAASGFALDYYAIGWFRQAPGKEREGVSCISSSGGITYYADSVKGRFTISRDNSKN TVYLQMNSLRPEDTAVYYCATDSGGYIDYDCSGLGYDYWGQGTLVTVSS SEQ ID NO: 212) VEGFANGBII00028 DVQLVESGGGLVQPGGSLRLSCAASGRTFSSYSMGWFRQAPGKEREFVVAISKGGYKYDAVSLEGRF TISRDNAKNTVYLQINSLRPEDTAVYYCASSRAYGSSRLRLADTYEYWGQGTLVTVSSGGGGSGGGS EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGR FTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSSGGGGSGGGSEVQLVESGGG LVQPGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSAIRSSGGSTYYADSVKGRFTISSDNSKN TVYLQMNSLRPEDTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSSGGGGSGGGSEVQLVE SGGGLVQPGGSLRLSCAASGFTLDDYAIGWFRQAPGKEREGVSAIRSSGGSTYYADSVKGRFTISSD NSKNTVYLQMNSLRPEDTAVYYCAAVPAGRLRFGEQWYPLYEYDAWGQGTLVTVSS SEQ ID NO: 213)

[0436] To explore the anti-VEGF blocking properties in comparison with the monovalent building block VEGFBII00038, the bispecific VHHs are analyzed in the VEGF/VEGFR2-Fc (Example 10; FIG. 31-1) and VEGF/VEGFR1 (Example 11; FIG. 31-2) competition AlphaScreen. These competition assays are also performed after preincubation of the VHH with 25 .mu.M human serum albumin. A summary of IC.sub.50 values is shown in FIG. 30C.

[0437] Binding kinetics of the bispecific VHHs on human VEGF165 is analyzed by SPR on a Biacore T100 instrument (see Example 12.5 described in patent US 2011/0172398 A1). Monovalent Nanobody VEGFBII00038 is taken along as reference (FIG. 30D).

TABLE-US-00045 TABLE 46-B Overview of kinetic parameters in hVEGF165 Biacore assay. ka1 kd1 ka2 kd2 KD1 (1/Ms) (1/s) (1/s) (1/s) (M) VEGFBII00038 2.6E + 05 1.3E - 02 1.3E - 02 1.9E - 04 7.5E - 10 VEGFANG- 1.6E + 05 1.4E - 02 1.4E - 02 2.2E - 04 1.4E - 09 BII00022 VEGFANG- 1.1E + 05 1.4E - 02 1.4E - 02 2.1E - 04 1.9E - 09 BII00025 VEGFANG- 1.7E + 05 1.3E - 02 1.3E - 02 2.1E - 04 1.1E - 09 BII00028

[0438] The ability of the VHHs to bind to human isoform VEGF121 is determined in a binding ELISA. Binding of a dilution series of VHH to 1 .mu.g/mL directly coated human VEGF121 (R&D) (human VEGF165 as reference) is detected using biotinylated anti-VHH 1A4 followed by extravidin-HRP. 1A4 is a anti-VHH VHH (generated in-house by Ablynx N V). The benchmark Avastin serves as positive control and is detected using a HRP conjugated anti-human Fc antibody. An irrelevant VHH serves as negative control. Representative binding response curves on VEGF165 and VEGF121 are shown in FIG. 46 corresponding EC.sub.50 values are summarized in Table 46-C.

TABLE-US-00046 TABLE 46-C Overview of EC.sub.50 values in hVEGF165 and hVEGF121 binding ELISA. hVEGF165 hVEGF121 EC.sub.50 (M) EC.sub.50 (M) VEGFANGBII00022 1.4E - 09 2.3E - 09 VEGFANGBII00025 1.5E - 09 2.5E - 09 VEGFANGBII00028 1.2E - 09 2.1E - 09

[0439] Binding to rat and mouse VEGF164 is assessed in a binding ELISA. VHHs binding to 1 .mu.g/mL directly coated murine or rat VEGF164 (R&D) are detected using biotinylated anti-VHH 1A4 followed by extravidin-HRP. As positive control the mouse/rat cross-reactive monoclonal antibody B20-4.1 (Genentech) is titrated and detected with an HRP conjugated anti-human Fc antibody. An irrelevant VHH serves as negative control. Results are shown in FIG. 33. All 3 bispecific VHH are not cross-reactive to mouse and rat VEGF.

[0440] Binding to human VEGF-B, VEGF-C, VEGF-D and PIGF is assessed via a binding ELISA. Binding of VHHs to 1 .mu.g/mL directly coated VEGF-B (R&D), VEGF-C (R&D), VEGF-D (R&D) and PIGF (R&D) was detected using biotinylated anti-VHH 1A4 followed by extravidin-HRP. As positive controls a series of dilutions of the appropriate receptors (hVEGFR1-Fc for hVEGF-B and hPIGF, hVEGFR2-Fc for hVEGF-C, anti-hVEGF-D mAb (R&D) for hVEGF-D) are taken along. An irrelevant VHH serves as negative control. Results are shown in FIG. 34. All 3 bispecific VHH are not binding to VEGF family members.

[0441] To explore the anti-Ang2 blocking properties in comparison with their respective monovalent building block 00921 (SEQ ID NO:220) and 00938 (SEQ ID NO:222), all 3 bispecific VHHs are analyzed in the human Ang2/hTie2-Fc (see Example 5.1; FIG. 35-1), mouse Ang2/mTie2-Fc (see Example 5.2; FIG. 35-2) and cyno Ang2/cTie2-Fc (see Example 5.2; FIG. 35-3) competition ELISA. The human assay is also performed after incubation of the VHH with 0.5 .mu.M human serum albumin. Additionally, bispecific VHHs are tested in the hAng1/hTie2 competition ELISA (see Example 5.3; FIG. 36) and the Ang2 mediated HUVEC survival assay (see Example 5.5; FIG. 37). A summary of IC50 values and % inhibition is shown in FIG. 38.

[0442] Affinities of VEGFANGBII00022-25-28 for human, mouse, cyno and rat Ang2 (see Example 5.4) have been determined and are shown in Table 47.

TABLE-US-00047 TABLE 47 Affinity KD of purified VHHs for recombinant human, cyno, mouse and rat Ang2 human Ang2-FLD cyno Ang2-FLD k.sub.a k.sub.d K.sub.D k.sub.a k.sub.d K.sub.D (1/Ms) (1/s) (M) (1/Ms) (1/s) (M) VEGFANGBII00022 9.7E+05 1.5E-05 1.6E-11 1.5E+06 1.3E-05 8.1E-12 VEGFANGBII00025 2.7E+06 1.2E-02 4.5E-09 4.3E+06 1.1E-02 2.7E-09 VEGFANGBII00028 5.9E+05 9.6E-04 1.6E-09 8.4E+05 8.7E-04 1.0E-09 mouse Ang2-FLD rat Ang2-FLD k.sub.a k.sub.d K.sub.D k.sub.a k.sub.d K.sub.D (1/Ms) (1/s) (M) (1/Ms) (1/s) (M) VEGFANGBII00022 5.5E+05 2.8E-05 5.1E-11 3.9E+05 3.8E-05 9.9E-11 VEGFANGBII00025 1.3E+06 1.4E-02 1.1E-08 8.7E+05 2.9E-02 3.3E-08 VEGFANGBII00028 3.6E+05 2.0E-03 5.6E-09 2.5E+05 3.1E-03 1.2E-08

[0443] Affinities of VEGFANGBII00022-25-28 for human, mouse and cyno serum albumin have been determined (Example 11) and are shown in Table 48. The affinity constant K.sub.D is calculated from resulting association and dissociation rate constants k.sub.a and k.sub.d (Table 48).

TABLE-US-00048 TABLE 48 Affinity KD (nM) of purified VHHs for recombinant human, mouse and cyno serum albumin using (A) 1:1 interaction model or (B) heterogeneous ligand model HSA CSA k.sub.a k.sub.d K.sub.D k.sub.a k.sub.d K.sub.D (A) (1/Ms) (1/s) (nM) (1/Ms) (1/s) (nM) ALB11 5.6E+05 1.9E-03 4 4.5E+05 1.7E-03 4 VEGFANGBII00022 6.7E+05 6.0E-03 9 6.2E+05 5.4E-03 9 VEGFANGBII00025 5.6E+05 5.6E-03 12 4.3E+05 5.1E-03 12 VEGFANGBII00028 5.6E+05 5.8E-03 10 5.2E+05 5.3E-03 10 MSA k.sub.a k.sub.d K.sub.D (1/Ms) (1/s) (nM) ALB11 5.9E+05 3.0E-02 51 VEGFANGBII00022 5.2E+05 5.4E-03 150 VEGFANGBII00025 -- -- -- VEGFANGBII00028 -- -- -- MSA k.sub.a1 K.sub.d1 k.sub.a2 K.sub.d2 K.sub.D1 K.sub.D2 (B) (1/Ms) (1/s) (1/s) (1/s) (nM) (nM) VEGFANGBII00025 6.2E+05 9.9E-02 4.7E+04 5.7E-04 160 * 12 VEGFANGBII00028 5.9E+04 6.9E-04 5.7E+05 9.4E-02 12 160 * * describes 70% or more of the interaction

TABLE-US-00049 TABLE 49 Ang2-binding components (1D01 (SEQ ID No: 214 (CDRs 1-3 disclosed as SEQ ID NOS 224-226, respectively) (FRs 1-4 disclosed as SEQ ID NOS 689, 676, 677 and 603, respectively)); 7G08 (SEQ ID No: 215 (CDRs 1-3 disclosed as SEQ ID NOS 227-229, respectively) (FRs 1-4 disclosed as SEQ ID NOS 678, 679, 680 and 603, respectively)); 027 (SEQ ID No: 216 (CDRs 1-3 disclosed as SEQ ID NOS 230-232, respectively) (FRs 1-4 disclosed as SEQ ID NOS 681, 682, 683 and 603, respectively)); 00042 (SEQ ID No: 217 (CDRs 1-3 disclosed as SEQ ID NOS 233-235, respectively) (FRs 1-4 disclosed as SEQ ID NOS 684, 694, 685 and 664, respectively)); 00050 (SEQ DI No: 218 (CDRs 1-3 disclosed as SEQ ID NOS 224, 237, and 226, respectively) (FRs 1-4 disclosed as SEQ ID NOS 686, 694, 685 and 664, respectively); 00045 (SEQ ID No: 219 (CDRs 1-3 disclosed as SEQ ID NOS 227, 240, and 241, respectively) (FRs 1-4 disclosed as SEQ ID NOS 693, 694, 687 and 664, respectively)); 00921 (SEQ ID No: 220 (CDRs 1-3 disclosed as SEQ ID NOS 242-244, respectively) (FRs 1-4 disclosed as SEQ ID NOS 686, 694, 685 and 664, respectively)); 00928 (SEQ ID No: 221 (CDRs 1-3 disclosed as SEQ ID NOS 245-247, respectively) (FRs 1-4 disclosed as SEQ ID NOS 693, 694, 687 and 664, respectively)); 00938 (SEQ ID No: 222 (CDRs 1-3 disclosed as SEQ ID NOS 248-250, respectively) (FRs 1-4 disclosed as SEQ ID NOS 688, 694, 685 and 664, respectively)); 00956 (SEQ ID No: 223 (CDRs 1-3 disclosed as SEQ ID NOS 251-253, respectively) (FRs 1-4 disclosed as SEQ ID NOS 684, 694, 685 and 664, respectively)). FR1 CDR1 FR2 CDR2 1D01 EVQLVESGGGLVQAGGSLRLSCAASGFTFD DYALG WFRQAAGKEREGVS CIRCSDGSTYYADSVKG 7G08 EVQLVESGGGLVQPGGSLRLSCAASGFALD YYAIG WFRQVPGKEREGVS CISSSDGITYYVDSVKG 027 EVQLVESGGGLVQAGGSLRLSCAASGFTLD DYAIG WFRQAPGKEREGVS CIRDSDGSTYYADSVKG FR3 CDR3 FR4 1D01 RFTISSDNAKNTVYLQMNSLKPEDTAVYYCAA SIVPRSKLEPYEYDA WGQGTQVTVSS 7G08 RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAT DSGGYIDYDCMGLGYDY WGQGTQVTVSS 027 RFTISSDNDKNTVYLQMNSLKPEDTAVYYCAA VPAGRLRFGEQWYPLYEYDA WGQGTQVTVSS FR1 CDR1 FR2 CDR2 00042 EVQLVESGGGLVQPGGSLRLSCAASGFTLD DYAIG WFRQAPGKEREGVS SIRDNDGSTYYADSVKG 00050 EVQLVESGGGLVQPGGSLRLSCAASGFTFD DYALG WFRQAPGKEREGVS CIRCSDGSTYYADSVKG 00045 EVQLVESGGGLVQPGGSLRLSCAASGFALD YYAIG WFRQAPGKEREGVS CISSSDGITYYADSVKG FR3 CDR3 FR4 00042 RFTISSDNSKNTVYLQMNSLRPEDTAVYYCAA VPAGRLRFGEQWYPLYEYDA WGQGTLVTVSS 00050 RFTISSDNSKNTVYLQMNSLRPEDTAVYYCAA SIVPRSKLEPYEYDA WGQGTLVTVSS 00045 RFTISRDNSKNTVYLQMNSLRPEDTAVYYCAT DSGGYIDYDCMGLGYDY WGQGTLVTVSS FR1 CDR1 FR2 CDR2 00921 EVQLVESGGGLVQPGGSLRLSCAASGFTFD DYALG WFRQAPGKEREGVS CIRCSGGSTYYADSVKG 00928 EVQLVESGGGLVQPGGSLRLSCAASGFALD YYAIG WFRQAPGKEREGVS CISSSGGITYYADSVKG 00938 EVQLVESGGGLVQPGGSLRLSCAVSGITLD DYAIG WFRQAPGKEREGVS AIRSSGGSTYYADSVKG 00956 EVQLVESGGGLVQPGGSLRLSCAASGFTLD DYAIG WFRQAPGKEREGVS AIRSSGGSTYYADSVKG FR3 CDR3 FR4 00921 RFTISSDNSKNTVYLQMNSLRPEDTAVYYCAA SIVPRSKLEPYEYDA WGQGTLVTVSS 00928 RFTISRDNSKNTVYLQMNSLRPEDTAVYYCAT DSGGYIDYDCSGLGYDY WGQGTLVTVSS 00938 RFTISSDNSKNTVYLQMNSLRPEDTAVYYCAA VPAGRLRYGEQWYPIYEYDA WGQGTLVTVSS 00956 RFTISSDNSKNTVYLQMNSLRPEDTAVYYCAA VPAGRLRFGEQWYPLYEYDA WGQGTLVTVSS

Sequence CWU 1

1

694117PRTLama glamaMOD_RES(5)..(5)Gly or AlaMOD_RES(7)..(7)Ser or GlyMOD_RES(12)..(12)Gly, Ala or ProMOD_RES(13)..(13)Asp or GlyMOD_RES(16)..(16)Asp or Glu 1Ser Arg Ala Tyr Xaa Ser Xaa Arg Leu Arg Leu Xaa Xaa Thr Tyr Xaa1 5 10 15Tyr217PRTLama glama 2Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Gly Asp Thr Tyr Asp1 5 10 15Tyr317PRTLama glama 3Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr Asp1 5 10 15Tyr417PRTLama glama 4Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr Glu1 5 10 15Tyr517PRTLama glama 5Ser Arg Ala Tyr Gly Ser Gly Arg Leu Arg Leu Ala Asp Thr Tyr Asp1 5 10 15Tyr617PRTLama glama 6Ser Arg Ala Tyr Ala Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr Asp1 5 10 15Tyr717PRTLama glama 7Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Pro Asp Thr Tyr Asp1 5 10 15Tyr817PRTLama glama 8Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Pro Gly Thr Tyr Asp1 5 10 15Tyr9126PRTLama glama 9Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr65 70 75 80Leu Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Asp Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12510125PRTLama glama 10Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Ala Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Gly Gly Phe Ile Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu65 70 75 80Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12511126PRTLama glama 11Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr65 70 75 80Leu Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12512126PRTLama glama 12Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Asn Tyr Lys Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr65 70 75 80Leu Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Gly Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12513125PRTLama glama 13Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Val Ala Ser Gly Arg Thr Ser Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Gly Gly Ser Ile Tyr Asp Ser Val Ser Leu Gln 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu65 70 75 80Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ala Ser Arg Ala Tyr Ala Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12514125PRTLama glama 14Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu Gln 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu65 70 75 80Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12515125PRTLama glama 15Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Gly Gly Phe Ile Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu65 70 75 80Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12516125PRTLama glama 16Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Asn Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12517126PRTLama glama 17Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Gly Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr65 70 75 80Leu Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Pro Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12518125PRTLama glama 18Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12519125PRTLama glama 19Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Ala Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Gly Gly Phe Ile Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu65 70 75 80Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12520125PRTLama glama 20Glu Val Gln Leu Val Glu Ser Glu Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Val Ala Ser Gly Arg Thr Ser Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu Gln 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu65 70 75 80Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12521126PRTLama glama 21Glu Met Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr65 70 75 80Leu Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Asp Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12522126PRTLama glama 22Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Asn Tyr Lys Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr65 70 75 80Leu Gln Ile Asn Ser Leu Lys Pro Lys Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Gly Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12523126PRTLama glama 23Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Gly Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr65 70 75 80Leu Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Asp Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12524126PRTLama glama 24Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Gly Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr65 70 75 80Leu Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Pro Gly Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12525125PRTLama glama 25Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Val Ala Ser Gly Arg Thr Ser Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu Gln 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu65 70 75 80Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12526125PRTLama glama 26Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Gln Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ala Ser Arg Ala Tyr Gly Ser Gly Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Asp Tyr Trp Gly Gln Gly

Thr Gln Val Thr Val Ser Ser 115 120 12527125PRTLama glama 27Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Val Ala Ser Gly Arg Thr Ser Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Gln Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu Gln 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu65 70 75 80Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12528125PRTLama glama 28Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ile Ala Ser Gly Arg Thr Ser Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Gln Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu Gln 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu65 70 75 80Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12529126PRTLama glama 29Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Asn Tyr Lys Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr65 70 75 80Leu Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Gly Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Arg Val Thr Val Ser Ser 115 120 12530126PRTLama glama 30Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr65 70 75 80Leu Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Asp Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12531126PRTLama glama 31Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Pro Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr65 70 75 80Leu Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Asp Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12532126PRTLama glama 32Glu Val Pro Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Asn Tyr Lys Tyr Asp Ser Ala Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr65 70 75 80Leu Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Gly Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12533125PRTLama glama 33Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Ala Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Gly Gly Phe Ile Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu65 70 75 80Gln Thr Pro Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12534126PRTLama glama 34Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Ala Val Tyr65 70 75 80Leu Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Asp Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12535126PRTLama glama 35Glu Val Gln Leu Met Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr65 70 75 80Leu Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Asp Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12536125PRTLama glama 36Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Gly Gly Phe Ile Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu65 70 75 80Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12537125PRTLama glama 37Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Ala Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Gly Gly Phe Ile Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Glu Asn Thr Lys Asn Thr Val Tyr Leu65 70 75 80Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12538126PRTLama glama 38Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Pro Ser Leu Lys Pro Glu Asp Thr Ala Asp Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12539126PRTLama glama 39Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr65 70 75 80Leu Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12540125PRTLama glama 40Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Val Ala Ser Gly Arg Thr Ser Ser Ser Tyr 20 25 30Ser Val Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu Gln 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu65 70 75 80Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12541126PRTLama glama 41Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr65 70 75 80Leu Gln Thr Pro Ser Leu Lys Pro Glu Asp Ala Ala Asp Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12542126PRTLama glama 42Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Arg Asn Thr Val Tyr65 70 75 80Leu Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Asp Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12543125PRTLama glama 43Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu65 70 75 80Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ala Ser Arg Ala Tyr Ala Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12544126PRTLama glama 44Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr65 70 75 80Leu Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12545126PRTLama glama 45Glu Val Gln Leu Val Glu Ser Glu Gly Gly Leu Val Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Ser Ser Gly Asn Tyr Lys Tyr Asp Ser Val Ser Leu 50 55 60Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr65 70 75 80Leu Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Gly Asp Thr 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12546125PRTLama glama 46Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser Ser Tyr

20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ala Ser Gly Gly Tyr Ile Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asp Thr Val Tyr Leu65 70 75 80Gln Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ala Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12547125PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama glama sequence 47Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 12548125PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama glama sequence 48Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 12549125PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama glama sequence 49Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 12550125PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama glama sequence 50Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 12551125PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama glama sequence 51Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 12552125PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama glama sequence 52Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 12553125PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama glama sequence 53Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 12554125PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama glama sequence 54Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 12555125PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama glama sequence 55Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12556125PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama glama sequence 56Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 12557125PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama glama sequence 57Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 12558122PRTLama glama 58Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Gly Ser Phe Ser Ser Tyr 20 25 30Gly Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ser Ala Ile Ser Glu Tyr Ser Asn Thr Tyr Cys Ser Asp Ser Val Arg 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu65 70 75 80Gln Met Asn Ser Leu Thr Pro Asp Asp Thr Ala Ile Tyr Tyr Cys Ala 85 90 95Ala Ser Pro Thr Ile Leu Leu Thr Thr Glu Gln Trp Tyr Lys Tyr Trp 100 105 110Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 12059126PRTLama glama 59Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Thr Gly Arg Thr Phe Arg Ala Ser 20 25 30Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Ala Ile Asn Trp Ser Gly Leu Ser Thr Phe Tyr Thr Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Asp Asn Gly Ala Leu Tyr65 70 75 80Leu Gln Met Asn Thr Leu Lys Pro Glu Asp Thr Ala Val Tyr Ser Cys 85 90 95Ala Ala Gly Arg Ile Pro Ser Ser Ser Arg Phe Ser Ser Pro Ala Ala 100 105 110Tyr Ala Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12560125PRTLama glama 60Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Thr Ser Ile Tyr Thr Ile Thr 20 25 30Val Met Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Ala Ile Thr Trp Ser Ala Pro Thr Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Arg Met Asn Ser Leu Lys Pro Glu Asp Ser Ala Ile Tyr Tyr Cys 85 90 95Ala Ala Asp Arg Phe Lys Gly Arg Ser Ile Val Thr Pro Ser Asp Tyr 100 105 110Arg Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12561111PRTLama glama 61Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ala Val Gly Asp Ile 20 25 30Thr Val Ala Trp Tyr Arg Gln Ala Pro Gly Ile Gln Arg Gln Leu Val 35 40 45Ala Thr Ile Thr Pro Ser Gly Tyr Thr Tyr Tyr Trp Asp Phe Val Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ile Val Tyr Leu65 70 75 80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ala Tyr Tyr Cys Asn 85 90 95Thr Gln Phe Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 100 105 11062128PRTLama glama 62Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Thr Asp 20 25 30Asp Val Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Val Ile Arg Trp Ser Thr Gly Gly Thr Tyr Thr Ser Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Thr Met Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Arg Ser Arg Pro Leu Gly Ala Gly Ala Trp Tyr Ser Gly Glu 100 105 110Lys His Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12563121PRTLama glama 63Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ala Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ser Phe Ser His Tyr 20 25 30Asn Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Ser Ile Arg Gly Gly Gly Gly Ser Thr Thr Tyr Ala Asn Ser Val 50 55 60Lys Asp Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Thr Ala Phe Tyr Arg Gly Pro Tyr Asp Tyr Asp Tyr Trp Gly 100 105 110Gln Gly Thr Gln Val Thr Val Ser Ser 115 12064113PRTLama glama 64Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ile Arg Phe Met Ser Met 20 25 30Ala Trp Tyr Arg Gln Ala Pro Gly Lys His Arg Glu Leu Val Ala Arg 35 40 45Ile Ser Ser Gly Gly Thr Thr Ala Tyr Val

Asp Ser Val Lys Gly Arg 50 55 60Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met65 70 75 80Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Asn Thr Phe 85 90 95Ser Ser Arg Pro Asn Pro Trp Gly Ala Gly Thr Gln Val Thr Val Ser 100 105 110Ser65116PRTLama glama 65Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Ile Phe Ser Asn Asn 20 25 30Ala Met Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45Ala Arg Ile Ser Ser Gly Gly Gly Phe Thr Tyr Tyr Leu Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Asn Ala Ala Tyr Arg Thr Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val 100 105 110Thr Val Ser Ser 11566125PRTLama glama 66Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Thr Ser Ile Tyr Ser Ile Thr 20 25 30Val Met Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Ser Glu Phe Val 35 40 45Ala Ala Ile Thr Trp Ser Ala Pro Ser Ser Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Ser Ala Ile Tyr Tyr Cys 85 90 95Ala Ala Asp Arg Phe Lys Gly Arg Ser Ile Val Thr Arg Ser Asp Tyr 100 105 110Lys Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12567125PRTLama glama 67Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Val Ser Thr Ser Ile Tyr Ser Ile Ser 20 25 30Val Met Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Ala Phe Val 35 40 45Ala Ala Ile Thr Trp Ser Ala Pro Thr Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Thr Asn Ser Leu Lys Pro Glu Asp Ser Ala Ile Tyr Tyr Cys 85 90 95Ala Ala Asp Arg Phe Lys Gly Arg Ser Ile Val Thr Arg Ser Asp Tyr 100 105 110Arg Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12568126PRTLama glama 68Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Asn Tyr 20 25 30Ala Met Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ser Ala Ile Asn Gln Arg Gly Ser Asn Thr Asn Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Ala Lys Asn Ser Val Phe65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Thr Trp Tyr Gly Tyr Ser Thr Tyr Ala Arg Arg Glu Glu 100 105 110Tyr Arg Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12569123PRTLama glama 69Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ser Phe Ser Asp Asn 20 25 30Val Met Gly Trp Phe Arg Gln Ala Ala Gly Lys Glu Arg Glu Phe Val 35 40 45Ala His Ile Ser Arg Gly Gly Ser Arg Thr Glu Tyr Ala Glu Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Lys Thr Met Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Arg Ser Val Ala Leu Ala Thr Ala Arg Pro Tyr Asp Tyr 100 105 110Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 12070121PRTLama glama 70Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ala Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Thr Thr Ser Gly Leu Thr Phe Ser Ser Tyr 20 25 30Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Thr Ile Ser Trp Asn Lys Ile Ser Thr Ile Tyr Thr Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Asn Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Asp Ala Ser Arg Pro Thr Leu Arg Ile Pro Gln Tyr Trp Gly 100 105 110Gln Gly Thr Gln Val Thr Val Ser Ser 115 12071115PRTLama glama 71Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Val Arg Ser Asp 20 25 30Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45Ala Phe Ile Arg Ser Leu Gly Ser Thr Tyr Tyr Ala Gly Ser Val Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asp Ala Ala Asn Thr Val Tyr Leu65 70 75 80Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn 85 90 95Ala Arg Phe Ser Gly Glu Ser Tyr Trp Gly Gln Gly Thr Pro Val Thr 100 105 110Val Ser Ser 11572124PRTLama glama 72Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Ser Thr Phe Gly Leu Tyr 20 25 30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Arg Glu Arg Glu Phe Leu 35 40 45Ser Ala Ile Thr Trp Ser Ala Gly Asp Thr Gln Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Val Asn65 70 75 80Leu Gln Met Asn Gly Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Gly Arg Gln Trp Gly Gly Thr Tyr Tyr Tyr His Gly Ser Tyr Ala 100 105 110Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 12073113PRTLama glama 73Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ile Arg Phe Met Ser Met 20 25 30Ala Trp Tyr Arg Gln Ala Pro Gly Lys His Arg Glu Leu Val Ala Arg 35 40 45Ile Ser Ser Glu Gly Thr Thr Ala Tyr Val Asp Ser Val Lys Gly Arg 50 55 60Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met65 70 75 80Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Asn Thr Phe 85 90 95Ser Ser Arg Pro Asn Pro Trp Gly Ala Gly Thr Thr Val Thr Val Ser 100 105 110Ser74128PRTLama glama 74Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Thr Asp 20 25 30Asp Val Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Val Ile Arg Trp Ser Thr Gly Gly Thr Tyr Thr Ser Asp Ser Val 50 55 60Ala Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Thr Met Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Arg Ser Arg Pro Leu Gly Ala Gly Ala Trp Tyr Thr Gly Glu 100 105 110Thr Arg Tyr Asp Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12575122PRTLama glama 75Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ser Phe Ser Arg Tyr 20 25 30Gly Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ile Ala Ile Ser Glu Tyr Asp Asn Val Tyr Thr Ala Asp Ser Val Arg 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Val Tyr Leu65 70 75 80Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ala Ser Pro Thr Ile Leu Leu Ser Thr Asp Glu Trp Tyr Lys Tyr Trp 100 105 110Gly Arg Gly Thr Gln Val Thr Val Ser Ser 115 12076128PRTLama glama 76Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Thr Asp 20 25 30Asp Val Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Val Ile Arg Trp Ser Thr Gly Gly Thr Tyr Thr Ser Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Thr Met Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Arg Ser Arg Pro Leu Gly Ala Gly Ala Trp Tyr Thr Gly Glu 100 105 110Thr Arg Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12577127PRTLama glama 77Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Ser Leu Ser Cys Ala Ala Ser Ala Arg Ala Phe Ser Asn Tyr 20 25 30Ala Met Gly Trp Phe Arg Gln Val Pro Gly Arg Glu Arg Glu Phe Val 35 40 45Ala Val Ile Thr Arg Ser Pro Ser Asn Thr Tyr Tyr Thr Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ile Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala His Tyr Trp Asn Ser Asp Ser Tyr Thr Tyr Thr Asp Ser Arg 100 105 110Trp Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12578124PRTLama glama 78Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Asn Tyr 20 25 30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Val Leu Val 35 40 45Ala Asp Ile Ser Ser Ser Gly Ile Asn Thr Tyr Val Ala Asp Ala Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Ala Trp Trp Tyr Ser Gln Met Ala Arg Asp Asn Tyr Arg 100 105 110Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 12079125PRTLama glama 79Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asp Thr Leu Ser Arg Tyr 20 25 30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Ser Ile Asn Thr Ser Gly Lys Arg Thr Ser Tyr Ala Asp Ser Met 50 55 60Lys Gly Arg Phe Ala Val Ser Arg Asp Asn Ala Lys Asn Thr Gly Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Leu Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95Ala Ala Asp Arg Phe Phe Gly Ser Asp Ser Asn Glu Pro Arg Ala Tyr 100 105 110Arg Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12580123PRTLama glama 80Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Glu1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ile Thr Phe Ser Asn Tyr 20 25 30Asn Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Thr Ile Arg His His Gly Tyr Asp Thr Tyr Tyr Ala Glu Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Leu Tyr Ser Cys 85 90 95Ala Lys Lys Leu Phe Trp Asp Met Asp Pro Lys Thr Gly Phe Ser Ser 100 105 110Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 12081126PRTLama glama 81Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Leu Ser Ser Tyr 20 25 30Gly Leu Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Ala Ile Gly Trp Ser Gly Ser Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Val Ser Val Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Lys Met Asn Ser Leu Glu Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Lys Val Arg Asn Phe Asn Ser Asp Trp Asp Leu Leu Thr Ser 100 105 110Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12582125PRTLama glama 82Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Met Leu Ser Cys Ala Ala Ser Gly Arg Ala Leu Ser Ser Tyr 20 25 30Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Arg Glu Arg Glu Phe Val 35 40 45Ala Arg Ile Ser Trp Ser Gly Ala Asn Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Gly Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ala Tyr Tyr Cys 85 90 95Ala Ala Gln Thr Thr Ser Lys Tyr Asp Asn Tyr Asp Ala Arg Ala Tyr 100 105 110Gly Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12583125PRTLama glama 83Glu Glu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Met Leu Ser Cys Ala Ala Ser Gly Arg Ala Leu Ser Ser Tyr 20 25 30Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Arg Glu Arg Glu Phe Val 35 40 45Ala Arg Ile Ser Trp Ser Gly Ala Asn Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Gly Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ala Tyr Tyr Cys 85 90 95Ala Ala Gln Thr Thr Ser Lys Tyr Asp Asn Tyr Asp Ala Arg Ala Tyr 100 105 110Gly Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12584123PRTLama glama 84Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr

20 25 30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Thr Ile Ser Gln Ser Gly Tyr Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Asn65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Asp Pro Phe Tyr Ser Tyr Gly Ser Pro Ser Pro Tyr Arg Tyr 100 105 110Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 12085125PRTLama glama 85Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ser Ser Gly Arg Leu Phe Ser Phe Ser 20 25 30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Ala Phe Lys Trp Ser Gly Ser Thr Thr Tyr Tyr Ala Asp Tyr Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Thr Asp Asn Ala Lys Asn Ile Leu Phe65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95Ala Val Asp Arg Phe Tyr Thr Gly Arg Tyr Tyr Ser Ser Asp Glu Tyr 100 105 110Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12586125PRTLama glama 86Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Thr Ser Ile Tyr Ser Ile Thr 20 25 30Val Met Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Ala Ile Thr Trp Ser Ala Pro Ser Ser Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Val Asn Ser Leu Lys Pro Glu Asp Ser Ala Ile Tyr Tyr Cys 85 90 95Ala Ala Asp Arg Phe Lys Gly Arg Ser Ile Val Thr Arg Ser Asp Tyr 100 105 110Arg Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12587125PRTLama glama 87Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ser Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ser Phe Ser Ser Leu 20 25 30Ala Met Gly Trp Phe Arg Gln Val Pro Gly Lys Asp Arg Glu Phe Val 35 40 45Ala Ser Ile Ser Gln Ser Gly Ile Thr Thr Ser Tyr Ala Asp Ser Val 50 55 60Lys Ser Arg Phe Thr Ile Ser Arg Asp Ser Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Leu Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Thr Ser Val Phe Tyr Ser Thr Ala Leu Thr Arg Pro Val Asp Tyr 100 105 110Arg Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12588125PRTLama glama 88Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Thr Ser Ile Tyr Ser Ile Thr 20 25 30Val Met Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Ala Ile Thr Trp Ser Ala Pro Thr Thr Tyr Ser Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Ser Ala Ile Tyr Tyr Cys 85 90 95Ala Ala Asp Arg Phe Lys Gly Arg Ser Ile Val Thr Arg Ser Asp Tyr 100 105 110Arg Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12589129PRTLama glama 89Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ser Val Thr Gly Arg Thr Phe Asn Lys Tyr 20 25 30Val Met Gly Trp Phe Arg Gln Ala Pro Gly Asn Asp Arg Glu Phe Val 35 40 45Ala Ala Ile Thr Ser Arg Asp Gly Pro Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Gly Asp Asn Thr Lys Asn Lys Ile Phe65 70 75 80Leu Gln Met Asn Ser Leu Met Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ile Asp Glu Asp Leu Tyr His Tyr Ser Ser Tyr His Phe Thr Arg 100 105 110Val Asp Leu Tyr His Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser 115 120 125Ser90117PRTLama glama 90Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ala Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Ser 20 25 30Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Arg Ile Ser Pro Gly Gly Leu Phe Thr Tyr Tyr Val Asp Ser Val 50 55 60Lys Gly Arg Phe Ser Val Ser Thr Asp Asn Ala Asn Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Leu Tyr Ser Cys 85 90 95Ala Lys Gly Gly Ala Pro Asn Tyr Thr Pro Arg Gly Arg Gly Thr Gln 100 105 110Val Thr Val Ser Ser 11591115PRTLama glama 91Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Val Arg Ser Asp 20 25 30Val Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45Ala Phe Ile Arg Ser Leu Gly Ser Thr Tyr Tyr Ala Gly Ser Val Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Ala Asn Thr Val Tyr Leu65 70 75 80Gln Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn 85 90 95Ala Arg Phe Ser Gly Glu Ser Tyr Trp Gly Gln Gly Thr Pro Val Thr 100 105 110Val Ser Ser 11592129PRTLama glama 92Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ala Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Arg Thr Phe Asn Asn Tyr 20 25 30Val Met Gly Trp Phe Arg Gln Ala Pro Gly Asn Glu Arg Glu Phe Val 35 40 45Ala Ala Ile Thr Ser Thr Asn Gly Pro Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Gly Asp Asn Thr Lys Asn Lys Val Phe65 70 75 80Leu Gln Met Asp Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ile Asp Glu Asp Leu Tyr His Tyr Ser Ser Tyr His Tyr Thr Arg 100 105 110Val Ala Leu Tyr His Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser 115 120 125Ser93124PRTLama glama 93Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ser Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Asn Thr Phe Gly Leu Tyr 20 25 30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Arg Glu Arg Glu Phe Val 35 40 45Ser Ala Ile Thr Trp Ser Ala Gly Asp Thr Gln Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Val Asn65 70 75 80Leu Gln Met Asn Gly Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Gly Arg Gln Trp Gly Gly Thr Tyr Tyr Tyr His Gly Ser Tyr Ala 100 105 110Trp Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 12094128PRTLama glama 94Glu Val Gln Leu Val Glu Ser Glu Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Thr Asp 20 25 30Asp Val Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Val Ile Arg Trp Ser Thr Gly Gly Thr Tyr Thr Ser Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Thr Met Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Arg Ser Arg Pro Leu Gly Ala Gly Ala Trp Tyr Thr Gly Glu 100 105 110Asn Tyr Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 12595126PRTLama glama 95Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Ser Ser Gly Tyr 20 25 30Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Thr Ala Ile Thr Trp Ser Gly Gly Ser Thr Tyr Ser Pro Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Asn Leu Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ser Gly Arg Ile Trp Arg Ser Arg Asp Tyr Asp Ser Glu Lys Tyr 100 105 110Tyr Asp Ile Trp Gly His Gly Thr Gln Val Thr Val Ser Ser 115 120 12596129PRTLama glama 96Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ala Tyr 20 25 30Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Val Ile Ser Trp Thr Asn Ser Met Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Val Asp Arg Arg Arg Thr Tyr Ser Arg Trp Arg Phe Tyr Thr Gly 100 105 110Val Asn Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser 115 120 125Ser97129PRTLama glama 97Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ala Tyr 20 25 30Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Val Ile Ser Trp Ser Gly Gly Met Thr Tyr Tyr Ala Asp Ser Val 50 55 60Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Pro Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Val Asp Arg Arg Arg Ala Tyr Ser Arg Trp Arg Tyr Tyr Thr Gly 100 105 110Val Asn Asp Tyr Glu Phe Trp Gly Gln Gly Thr Gln Val Thr Val Ser 115 120 125Ser98129PRTLama glama 98Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ala Tyr 20 25 30Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Val Ile Ser Trp Ser Gly Gly Met Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Val Asp Arg Arg Arg Leu Tyr Ser Arg Trp Arg Tyr Tyr Thr Gly 100 105 110Val Asn Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser 115 120 125Ser99129PRTLama glama 99Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ala Tyr 20 25 30Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Val Ile Ser Trp Thr Gly Gly Met Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Lys Ala Lys Asn Thr Val Ser65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Val Asp Arg Arg Arg Thr Tyr Ser Arg Trp Arg Tyr Tyr Thr Gly 100 105 110Val Asn Glu Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser 115 120 125Ser100129PRTLama glama 100Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ala Tyr 20 25 30Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Val Ile Ser Trp Thr Gly Asp Met Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Lys Ala Lys Asn Thr Val Ser65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Asp Arg Arg Arg Thr Tyr Ser Arg Trp Arg Tyr Tyr Thr Gly 100 105 110Val Asn Glu Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser 115 120 125Ser101123PRTLama glama 101Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Val Tyr 20 25 30Thr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Thr Ile Ser Arg Thr Gly Asp Arg Thr Ser Tyr Ala Asn Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Ser Cys 85 90 95Ala Ala Gly Pro Ile Ala Pro Ser Pro Arg Pro Arg Glu Tyr Tyr Tyr 100 105 110Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120102129PRTLama glama 102Glu Val Gln Leu Met Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ala Tyr 20 25 30Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Val Ile Ser Trp Thr Gly Gly Met Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Lys Ala Lys Asn Thr Val Ser65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Val Asp Arg Arg Arg Thr Tyr Ser Arg Trp Arg Tyr Tyr Thr Gly 100 105 110Val Asn Glu Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser 115 120 125Ser103129PRTLama glama 103Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ala Tyr 20 25 30Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Val Ile Ser Trp Ser Gly Gly Met Thr Asp Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Thr Gln Phe65

70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Val Gly Arg Arg Arg Ala Tyr Ser Arg Trp Arg Tyr Tyr Thr Gly 100 105 110Val Asn Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser 115 120 125Ser104125PRTLama glama 104Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Arg Thr Phe Asn Ser Tyr 20 25 30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ser Val 35 40 45Ala His Ile Asn Arg Ser Gly Ser Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Leu Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Gly Arg Tyr Tyr Ser Ser Asp Gly Val Pro Ser Ala Ser Phe 100 105 110Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125105128PRTLama glama 105Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Phe Thr Ser Ala Arg Thr Phe Asp Thr Trp 20 25 30Ala Met Ala Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Ile 35 40 45Ser Ala Ile Ser Trp Ser Gly Ser Met Thr Tyr Tyr Thr Asp Ser Val 50 55 60Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Ala Gln Asn Thr Leu Phe65 70 75 80Leu Gln Met Asn Asn Thr Ala Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Lys Thr Val Asp Tyr Cys Ser Ala Tyr Glu Cys Tyr Ala Arg 100 105 110Leu Glu Tyr Asp Tyr Trp Gly Arg Gly Ala Gln Val Thr Val Ser Ser 115 120 125106126PRTLama glama 106Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Met Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Arg Phe Thr Ser Thr 20 25 30Asn Met Gly Trp Phe Arg Gln Gly Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Ala Ile Thr Leu Ser Gly Thr Thr Tyr Tyr Ala Glu Ala Val Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Asp Lys Asn Thr Val Ala Leu65 70 75 80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Gly 85 90 95Ala Asp Pro Ser Tyr Tyr Ser Thr Ser Arg Tyr Thr Lys Ala Thr Glu 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125107126PRTLama glama 107Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Asn Thr Tyr 20 25 30Thr Met Gly Trp Phe Arg Gln Thr Pro Gly Thr Glu Arg Glu Phe Val 35 40 45Ala Ala Ile Arg Trp Thr Val Asn Ile Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Ile Val Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Gln Thr Ser Ala Pro Arg Ser Leu Ile Arg Met Ser Asn Glu 100 105 110Tyr Pro Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125108123PRTLama glama 108Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Leu Tyr 20 25 30Thr Val Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Tyr Ile Ser Arg Ser Gly Ser Asn Arg Tyr Tyr Val Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Thr Val Asp65 70 75 80Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Thr Ser Arg Gly Leu Ser Ser Leu Ala Gly Glu Tyr Asn Tyr 100 105 110Trp Gly Arg Gly Thr Gln Val Thr Val Ser Ser 115 120109123PRTLama glama 109Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Ser Ala Phe Lys Ser Tyr 20 25 30Arg Met Gly Trp Phe Arg Arg Thr Pro Gly Lys Glu Asp Glu Phe Val 35 40 45Ala Ser Ile Ser Trp Thr Tyr Gly Ser Thr Phe Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Met Ser Arg Asp Lys Ala Lys Asn Ala Gly Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95Ala Ala Gly Ala Gln Ser Asp Arg Tyr Asn Ile Arg Ser Tyr Asp Tyr 100 105 110Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120110115PRTLama glama 110Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Lys Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Ser 20 25 30Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Ile Pro Pro Val Gly His Phe Ala Asn Tyr Ala Pro Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Phe65 70 75 80Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Asp Ser Ala Gly Arg Thr Lys Gly Gln Gly Thr Gln Val Thr 100 105 110Val Ser Ser 115111124PRTLama glama 111Lys Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Arg Thr Phe Ser Asn Tyr 20 25 30Ala Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Ala Ile Thr Arg Ser Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Thr Arg Ser Ser Thr Ile Val Val Gly Val Gly Gly Met Glu 100 105 110Tyr Trp Gly Lys Gly Thr Leu Val Thr Val Ser Ser 115 120112128PRTLama glama 112Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Tyr 20 25 30Asp Ile Gly Trp Phe Arg Gln Ala Pro Gly Asn Glu Arg Glu Gly Val 35 40 45Ser Cys Ile Thr Thr Asp Val Gly Thr Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Ile Asn Asp Leu Lys Pro Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95Ala Val Asp Thr Gln Asp Leu Gly Leu Asp Ile Phe Cys Arg Gly Asn 100 105 110Gly Pro Phe Asp Gly Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125113134PRTLama glama 113Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Leu Asn Leu Asp Asp Tyr 20 25 30Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45Ser Cys Ile Ser Ser Tyr Asp Ser Val Thr Tyr Tyr Ala Asp His Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Ala Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Ser Ile Glu Asp Thr Gly Val Tyr Tyr Cys 85 90 95Ala Ala Glu Arg Glu Gln Leu Arg Arg Arg Glu Ser Pro His Asp Glu 100 105 110Leu Leu Arg Leu Cys Phe Tyr Gly Met Arg Tyr Ser Gly Lys Gly Thr 115 120 125Leu Val Thr Val Ser Ser 130114123PRTLama glama 114Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Arg Leu Asp Asp Tyr 20 25 30Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ala Val 35 40 45Ser Cys Ile Ser Ser Ser Asp Thr Ser Ile Asp Tyr Thr Asn Ser Val 50 55 60Lys Gly Arg Phe Thr Phe Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ala Phe Arg Cys Ser Gly Tyr Glu Leu Arg Gly Phe Pro Thr 100 105 110Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120115126PRTLama glama 115Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Thr Phe Ser Ser Leu 20 25 30Ala Val Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Arg Ile Thr Trp Ser Gly Ala Thr Thr Tyr Tyr Ala Asp Ala Val 50 55 60Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Met Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Asp Arg Ser Pro Asn Ile Ile Asn Val Val Thr Ala Tyr Glu 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125116126PRTLama glama 116Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Ala1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asp Gly Phe Thr Leu Tyr 20 25 30Asn Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Ala Ile Thr Ser Ser Pro Met Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Ser Ile Ser Ile Asn Asn Asp Lys Thr Thr Gly Phe65 70 75 80Leu Gln Met Asn Val Leu Lys Pro Glu Asp Thr Gly Val Tyr Phe Cys 85 90 95Ala Ala Pro Glu Gly Ser Phe Arg Arg Gln Tyr Ala Asp Arg Ala Met 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125117127PRTLama glama 117Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ala Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Gly Ser 20 25 30Asp Met Gly Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu Ile Val 35 40 45Ala Ala Ile Arg Leu Ser Gly Ser Ile Thr Tyr Tyr Pro Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Arg Ser Thr Tyr Ser Tyr Tyr Leu Ala Leu Ala Asp Arg Gly 100 105 110Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125118125PRTLama glama 118Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Gly Thr Tyr 20 25 30Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ala Val 35 40 45Ser Cys Met Ser Ala Gly Asp Ser Ile Pro Trp Tyr Thr Ala Ser Val 50 55 60Lys Gly Arg Phe Thr Thr Ser Thr Asp Asn Ala Arg Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala His Tyr Tyr Cys 85 90 95Ala Ala Ala Arg Tyr His Gly Asp Tyr Cys Tyr Tyr Glu Gly Tyr Tyr 100 105 110Pro Phe Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125119117PRTLama glama 119Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Thr Ser Ile Ser Ser Thr Asn 20 25 30Phe Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45Ala Thr Ile Thr Ser Ser Ser Ile Thr Asn Tyr Val Asp Ser Val Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Met Thr Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys His 85 90 95Ala Arg Trp Arg Trp Ser Asp Val Glu Tyr Trp Gly Lys Gly Thr Leu 100 105 110Val Thr Val Ser Ser 115120121PRTLama glama 120Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Thr Thr Ser Ser Ile Phe 20 25 30Ala Met Arg Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45Ala Ser Ile Thr Arg Ser Ser Ile Thr Thr Tyr Ala Asp Ser Val Lys 50 55 60Gly Arg Phe Thr Pro Ser Arg Asp Asn Ala Lys Asn Thr Val Ser Leu65 70 75 80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn 85 90 95Ala Ala Ile Arg Pro Glu Leu Tyr Ser Val Val Asn Asp Tyr Trp Gly 100 105 110Gln Gly Thr Gln Val Thr Val Ser Ser 115 120121127PRTLama glama 121Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Leu Thr Phe Ser Asp Tyr 20 25 30Asn Leu Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Gln Phe Val 35 40 45Ala Val Ile Ser Trp Arg Asp Ser Phe Ala Tyr Tyr Ala Glu Pro Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Asp Arg Val Ser Ser Arg Leu Val Leu Pro Asn Thr Ser Pro 100 105 110Asp Phe Gly Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125122129PRTLama glama 122Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Asn Asn Ala 20 25 30Ile Met Gly Trp Phe Arg Gln Ala Pro Gly Gln Glu Arg Glu Phe Val 35 40 45Ala Ala Met Asn Trp Arg Gly Gly Pro Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Gly Asp Asn Thr Lys Asn Thr Val Phe65 70 75 80Leu Gln Met Asn Phe Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Asp Glu Asp Leu Tyr His Tyr Ser Ser Tyr His Tyr Ser Arg 100 105 110Val Asp Leu Tyr His Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser 115 120 125Ser123121PRTLama glama 123Glu Val Gln Leu Val

Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Thr Thr Ser Ser Ile Phe 20 25 30Ala Met Arg Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45Ala Ser Ile Thr Arg Ser Ser Ile Thr Thr Tyr Ala Asp Ser Val Lys 50 55 60Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Thr Val Ser Leu65 70 75 80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn 85 90 95Ala Ala Ile Arg Pro Glu Leu Tyr Ser Val Val Asn Asp Tyr Trp Gly 100 105 110Gln Gly Thr Gln Val Thr Val Ser Ser 115 120124123PRTLama glama 124Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Ser Phe Ser Ser Tyr 20 25 30Ala Pro Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Ala Phe Thr Arg Ser Ser Asn Ile Pro Tyr Tyr Lys Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala His Thr Val Tyr Leu65 70 75 80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ala 85 90 95Val Asn Leu Gly Ser Thr Trp Ser Arg Asp Gln Arg Thr Tyr Asp Tyr 100 105 110Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120125113PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama glama sequence 125Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Arg Phe Met Ser Met 20 25 30Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Arg 35 40 45Ile Ser Ser Gly Gly Thr Thr Ala Tyr Ala Asp Ser Val Lys Gly Arg 50 55 60Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met65 70 75 80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Asn Thr Phe 85 90 95Ser Ser Arg Pro Asn Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser126113PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama glama sequence 126Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ile Arg Phe Ile Ser Met 20 25 30Ala Trp Tyr Arg Gln Ala Pro Gly Lys His Arg Glu Leu Val Ala Arg 35 40 45Ile Ser Ser Gly Gly Thr Thr Ala Tyr Val Asp Ser Val Lys Gly Arg 50 55 60Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met65 70 75 80Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Asn Thr Phe 85 90 95Ser Ser Arg Pro Asn Pro Trp Gly Ala Gly Thr Gln Val Thr Val Ser 100 105 110Ser127113PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama glama sequence 127Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Arg Phe Ile Ser Met 20 25 30Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Arg 35 40 45Ile Ser Ser Gly Gly Thr Thr Ala Tyr Ala Asp Ser Val Lys Gly Arg 50 55 60Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met65 70 75 80Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Asn Thr Phe 85 90 95Ser Ser Arg Pro Asn Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser 100 105 110Ser128285PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 128Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser145 150 155 160Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp 165 170 175Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 180 185 190Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 195 200 205Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 210 215 220Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu225 230 235 240Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 245 250 255Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 260 265 270Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 275 280 285129245PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 129Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Ser Ala Val Gly Asp Ile Thr Val Ala Trp Tyr Arg Gln Ala Pro Gly 165 170 175Ile Gln Arg Gln Leu Val Ala Thr Ile Thr Pro Ser Gly Tyr Thr Tyr 180 185 190Tyr Trp Asp Phe Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser 195 200 205Lys Asn Ile Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr 210 215 220Ala Ala Tyr Tyr Cys Asn Thr Gln Phe Tyr Trp Gly Gln Gly Thr Gln225 230 235 240Val Thr Val Ser Ser 245130255PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 130Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Ala Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Arg Ser Phe Ser His Tyr Asn Met Gly Trp Phe Arg Gln Ala Pro Gly 165 170 175Lys Glu Arg Glu Phe Val Ala Ser Ile Arg Gly Gly Gly Gly Ser Thr 180 185 190Thr Tyr Ala Asn Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Glu Asn 195 200 205Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Ala Ala Thr Ala Phe Tyr Arg Gly Pro Tyr225 230 235 240Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 245 250 255131247PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 131Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Val Ala Ser Gly145 150 155 160Ile Arg Phe Met Ser Met Ala Trp Tyr Arg Gln Ala Pro Gly Lys His 165 170 175Arg Glu Leu Val Ala Arg Ile Ser Ser Gly Gly Thr Thr Ala Tyr Val 180 185 190Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn 195 200 205Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val 210 215 220Tyr Tyr Cys Asn Thr Phe Ser Ser Arg Pro Asn Pro Trp Gly Ala Gly225 230 235 240Thr Gln Val Thr Val Ser Ser 245132250PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 132Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Asn Ile Phe Ser Asn Asn Ala Met Ala Trp Tyr Arg Gln Ala Pro Gly 165 170 175Lys Gln Arg Glu Leu Val Ala Arg Ile Ser Ser Gly Gly Gly Phe Thr 180 185 190Tyr Tyr Leu Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn 195 200 205Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Asn Ala Ala Tyr Arg Thr Tyr Asn Tyr Trp225 230 235 240Gly Gln Gly Thr Gln Val Thr Val Ser Ser 245 250133258PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 133Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Arg Thr Phe Ser Asn Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly 165 170 175Lys Glu Arg Val Leu Val Ala Asp Ile Ser Ser Ser Gly Ile Asn Thr 180 185 190Tyr Val Ala Asp Ala Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Ala Ala Ser Ala Trp Trp Tyr Ser Gln Met225 230 235 240Ala Arg Asp Asn Tyr Arg Tyr Trp Gly Gln Gly Thr Gln Val Thr Val 245 250 255Ser Ser134251PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 134Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ala Cys Ala Ala Ser Gly145 150

155 160Phe Thr Leu Ser Ser Ser Trp Met Tyr Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Arg Ile Ser Pro Gly Gly Leu Phe Thr 180 185 190Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Ser Val Ser Thr Asp Asn 195 200 205Ala Asn Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp 210 215 220Thr Ala Leu Tyr Ser Cys Ala Lys Gly Gly Ala Pro Asn Tyr Thr Pro225 230 235 240Arg Gly Arg Gly Thr Gln Val Thr Val Ser Ser 245 250135259PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 135Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly145 150 155 160Arg Thr Phe Asn Ser Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly 165 170 175Lys Glu Arg Glu Ser Val Ala His Ile Asn Arg Ser Gly Ser Ser Thr 180 185 190Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Asn Thr Val Tyr Leu Gln Leu Asn Ser Leu Lys Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Ala Ala Gly Arg Tyr Tyr Ser Ser Asp Gly225 230 235 240Val Pro Ser Ala Ser Phe Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr 245 250 255Val Ser Ser136257PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 136Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly145 150 155 160Ser Ala Phe Lys Ser Tyr Arg Met Gly Trp Phe Arg Arg Thr Pro Gly 165 170 175Lys Glu Asp Glu Phe Val Ala Ser Ile Ser Trp Thr Tyr Gly Ser Thr 180 185 190Phe Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Met Ser Arg Asp Lys 195 200 205Ala Lys Asn Ala Gly Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp 210 215 220Thr Ala Leu Tyr Tyr Cys Ala Ala Gly Ala Gln Ser Asp Arg Tyr Asn225 230 235 240Ile Arg Ser Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser 245 250 255Ser137249PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 137Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Thr Ala Ser Gly145 150 155 160Phe Thr Phe Ser Thr Ser Trp Met His Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Ser Ile Pro Pro Val Gly His Phe Ala 180 185 190Asn Tyr Ala Pro Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Lys Ser Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Ala Lys Asp Ser Ala Gly Arg Thr Lys Gly225 230 235 240Gln Gly Thr Gln Val Thr Val Ser Ser 245138258PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 138Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu145 150 155 160Arg Thr Phe Ser Asn Tyr Ala Met Asp Trp Phe Arg Gln Ala Pro Gly 165 170 175Lys Glu Arg Glu Phe Val Ala Ala Ile Thr Arg Ser Gly Gly Gly Thr 180 185 190Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Ala Ala Thr Arg Ser Ser Thr Ile Val Val225 230 235 240Gly Val Gly Gly Met Glu Tyr Trp Gly Lys Gly Thr Gln Val Thr Val 245 250 255Ser Ser139276PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 139Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser145 150 155 160Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 165 170 175Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser 180 185 190Ala Val Gly Asp Ile Thr Val Ala Trp Tyr Arg Gln Ala Pro Gly Ile 195 200 205Gln Arg Gln Leu Val Ala Thr Ile Thr Pro Ser Gly Tyr Thr Tyr Tyr 210 215 220Trp Asp Phe Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys225 230 235 240Asn Ile Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala 245 250 255Ala Tyr Tyr Cys Asn Thr Gln Phe Tyr Trp Gly Gln Gly Thr Gln Val 260 265 270Thr Val Ser Ser 275140286PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 140Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser145 150 155 160Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 165 170 175Ala Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg 180 185 190Ser Phe Ser His Tyr Asn Met Gly Trp Phe Arg Gln Ala Pro Gly Lys 195 200 205Glu Arg Glu Phe Val Ala Ser Ile Arg Gly Gly Gly Gly Ser Thr Thr 210 215 220Tyr Ala Asn Ser Val Lys Asp Arg Phe Thr Ile Ser Arg Glu Asn Ala225 230 235 240Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr 245 250 255Ala Val Tyr Tyr Cys Ala Ala Thr Ala Phe Tyr Arg Gly Pro Tyr Asp 260 265 270Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 275 280 285141278PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 141Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser145 150 155 160Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 165 170 175Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ile 180 185 190Arg Phe Met Ser Met Ala Trp Tyr Arg Gln Ala Pro Gly Lys His Arg 195 200 205Glu Leu Val Ala Arg Ile Ser Ser Gly Gly Thr Thr Ala Tyr Val Asp 210 215 220Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr225 230 235 240Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr 245 250 255Tyr Cys Asn Thr Phe Ser Ser Arg Pro Asn Pro Trp Gly Ala Gly Thr 260 265 270Gln Val Thr Val Ser Ser 275142281PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 142Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser145 150 155 160Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 165 170 175Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn 180 185 190Ile Phe Ser Asn Asn Ala Met Ala Trp Tyr Arg Gln Ala Pro Gly Lys 195 200 205Gln Arg Glu Leu Val Ala Arg Ile Ser Ser Gly Gly Gly Phe Thr Tyr 210 215 220Tyr Leu Asp Ser Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala225 230 235 240Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr 245 250 255Ala Val Tyr Tyr Cys Asn Ala Ala Tyr Arg Thr Tyr Asn Tyr Trp Gly 260 265 270Gln Gly Thr Gln Val Thr Val Ser Ser 275 280143289PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 143Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile

Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser145 150 155 160Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 165 170 175Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg 180 185 190Thr Phe Ser Asn Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys 195 200 205Glu Arg Val Leu Val Ala Asp Ile Ser Ser Ser Gly Ile Asn Thr Tyr 210 215 220Val Ala Asp Ala Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala225 230 235 240Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr 245 250 255Ala Val Tyr Tyr Cys Ala Ala Ser Ala Trp Trp Tyr Ser Gln Met Ala 260 265 270Arg Asp Asn Tyr Arg Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser 275 280 285Ser144282PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 144Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser145 150 155 160Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 165 170 175Val Gln Pro Gly Gly Ser Leu Arg Leu Ala Cys Ala Ala Ser Gly Phe 180 185 190Thr Leu Ser Ser Ser Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys 195 200 205Gly Leu Glu Trp Val Ser Arg Ile Ser Pro Gly Gly Leu Phe Thr Tyr 210 215 220Tyr Val Asp Ser Val Lys Gly Arg Phe Ser Val Ser Thr Asp Asn Ala225 230 235 240Asn Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr 245 250 255Ala Leu Tyr Ser Cys Ala Lys Gly Gly Ala Pro Asn Tyr Thr Pro Arg 260 265 270Gly Arg Gly Thr Gln Val Thr Val Ser Ser 275 280145290PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 145Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser145 150 155 160Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 165 170 175Val Gln Ala Gly Asp Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Arg 180 185 190Thr Phe Asn Ser Tyr Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys 195 200 205Glu Arg Glu Ser Val Ala His Ile Asn Arg Ser Gly Ser Ser Thr Tyr 210 215 220Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala225 230 235 240Lys Asn Thr Val Tyr Leu Gln Leu Asn Ser Leu Lys Pro Glu Asp Thr 245 250 255Ala Val Tyr Tyr Cys Ala Ala Gly Arg Tyr Tyr Ser Ser Asp Gly Val 260 265 270Pro Ser Ala Ser Phe Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr Val 275 280 285Ser Ser 290146288PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 146Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser145 150 155 160Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 165 170 175Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Ser 180 185 190Ala Phe Lys Ser Tyr Arg Met Gly Trp Phe Arg Arg Thr Pro Gly Lys 195 200 205Glu Asp Glu Phe Val Ala Ser Ile Ser Trp Thr Tyr Gly Ser Thr Phe 210 215 220Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Met Ser Arg Asp Lys Ala225 230 235 240Lys Asn Ala Gly Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr 245 250 255Ala Leu Tyr Tyr Cys Ala Ala Gly Ala Gln Ser Asp Arg Tyr Asn Ile 260 265 270Arg Ser Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 275 280 285147280PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 147Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser145 150 155 160Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 165 170 175Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Thr Ala Ser Gly Phe 180 185 190Thr Phe Ser Thr Ser Trp Met His Trp Val Arg Gln Ala Pro Gly Lys 195 200 205Gly Leu Glu Trp Val Ser Ser Ile Pro Pro Val Gly His Phe Ala Asn 210 215 220Tyr Ala Pro Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala225 230 235 240Lys Asn Thr Leu Phe Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr 245 250 255Ala Val Tyr Tyr Cys Ala Lys Asp Ser Ala Gly Arg Thr Lys Gly Gln 260 265 270Gly Thr Gln Val Thr Val Ser Ser 275 280148289PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 148Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser145 150 155 160Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 165 170 175Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Arg 180 185 190Thr Phe Ser Asn Tyr Ala Met Asp Trp Phe Arg Gln Ala Pro Gly Lys 195 200 205Glu Arg Glu Phe Val Ala Ala Ile Thr Arg Ser Gly Gly Gly Thr Tyr 210 215 220Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala225 230 235 240Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr 245 250 255Ala Val Tyr Tyr Cys Ala Ala Thr Arg Ser Ser Thr Ile Val Val Gly 260 265 270Val Gly Gly Met Glu Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser 275 280 285Ser149245PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 149Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ala Val Gly Asp Ile 20 25 30Thr Val Ala Trp Tyr Arg Gln Ala Pro Gly Ile Gln Arg Gln Leu Val 35 40 45Ala Thr Ile Thr Pro Ser Gly Tyr Thr Tyr Tyr Trp Asp Phe Val Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ile Val Tyr Leu65 70 75 80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ala Tyr Tyr Cys Asn 85 90 95Thr Gln Phe Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly 100 105 110Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly 115 120 125Gly Gly Leu Val Gln Thr Gly Asp Ser Leu Arg Leu Ser Cys Glu Val 130 135 140Ser Gly Arg Thr Phe Ser Ser Tyr Ser Met Gly Trp Phe Arg Gln Ala145 150 155 160Gln Gly Lys Glu Arg Glu Phe Val Val Ala Ile Ser Lys Gly Gly Tyr 165 170 175Lys Tyr Asp Ser Val Ser Leu Glu Gly Arg Phe Thr Ile Ser Lys Asp 180 185 190Asn Ala Lys Asn Thr Val Tyr Leu Gln Ile Asn Ser Leu Lys Pro Glu 195 200 205Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ser Arg Ala Tyr Gly Ser Ser 210 215 220Arg Leu Arg Leu Ala Asp Thr Tyr Glu Tyr Trp Gly Gln Gly Thr Gln225 230 235 240Val Thr Val Ser Ser 245150255PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 150Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ala Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ser Phe Ser His Tyr 20 25 30Asn Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Ser Ile Arg Gly Gly Gly Gly Ser Thr Thr Tyr Ala Asn Ser Val 50 55 60Lys Asp Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Thr Ala Phe Tyr Arg Gly Pro Tyr Asp Tyr Asp Tyr Trp Gly 100 105 110Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr 130 135 140Gly Asp Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser145 150 155 160Ser Tyr Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu 165 170 175Phe Val Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser 180 185 190Leu Glu Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val 195 200 205Tyr Leu Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr 210 215 220Cys Ala Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp225 230 235 240Thr Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 245 250 255151247PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 151Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ile Arg Phe Met Ser Met 20 25 30Ala Trp Tyr Arg Gln Ala Pro Gly Lys His Arg Glu Leu Val Ala Arg 35 40 45Ile Ser Ser Gly Gly Thr Thr Ala Tyr Val Asp Ser Val Lys Gly Arg 50 55 60Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met65 70 75 80Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Asn Thr Phe 85 90 95Ser Ser Arg Pro Asn Pro Trp Gly Ala Gly Thr Gln Val Thr Val Ser 100 105 110Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu 115 120 125Ser Gly Gly Gly Leu Val Gln Thr Gly Asp Ser Leu Arg Leu Ser Cys

130 135 140Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr Ser Met Gly Trp Phe Arg145 150 155 160Gln Ala Gln Gly Lys Glu Arg Glu Phe Val Val Ala Ile Ser Lys Gly 165 170 175Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu Gly Arg Phe Thr Ile Ser 180 185 190Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Ile Asn Ser Leu Lys 195 200 205Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ser Arg Ala Tyr Gly 210 215 220Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr Glu Tyr Trp Gly Gln Gly225 230 235 240Thr Gln Val Thr Val Ser Ser 245152250PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 152Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Ile Phe Ser Asn Asn 20 25 30Ala Met Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45Ala Arg Ile Ser Ser Gly Gly Gly Phe Thr Tyr Tyr Leu Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Asn Ala Ala Tyr Arg Thr Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val 100 105 110Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln 115 120 125Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp Ser Leu Arg 130 135 140Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr Ser Met Gly145 150 155 160Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val Val Ala Ile 165 170 175Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu Gly Arg Phe 180 185 190Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Ile Asn 195 200 205Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ser Arg 210 215 220Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr Glu Tyr Trp225 230 235 240Gly Gln Gly Thr Gln Val Thr Val Ser Ser 245 250153258PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 153Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Asn Tyr 20 25 30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Val Leu Val 35 40 45Ala Asp Ile Ser Ser Ser Gly Ile Asn Thr Tyr Val Ala Asp Ala Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Ala Trp Trp Tyr Ser Gln Met Ala Arg Asp Asn Tyr Arg 100 105 110Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly 115 120 125Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 130 135 140Val Gln Thr Gly Asp Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg145 150 155 160Thr Phe Ser Ser Tyr Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys 165 170 175Glu Arg Glu Phe Val Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp 180 185 190Ser Val Ser Leu Glu Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys 195 200 205Asn Thr Val Tyr Leu Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala 210 215 220Val Tyr Tyr Cys Ala Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg225 230 235 240Leu Ala Asp Thr Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val 245 250 255Ser Ser154251PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 154Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ala Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Ser 20 25 30Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Arg Ile Ser Pro Gly Gly Leu Phe Thr Tyr Tyr Val Asp Ser Val 50 55 60Lys Gly Arg Phe Ser Val Ser Thr Asp Asn Ala Asn Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Leu Tyr Ser Cys 85 90 95Ala Lys Gly Gly Ala Pro Asn Tyr Thr Pro Arg Gly Arg Gly Thr Gln 100 105 110Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val 115 120 125Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp Ser Leu 130 135 140Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr Ser Met145 150 155 160Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val Val Ala 165 170 175Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu Gly Arg 180 185 190Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Ile 195 200 205Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ser 210 215 220Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr Glu Tyr225 230 235 240Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 245 250155259PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 155Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Arg Thr Phe Asn Ser Tyr 20 25 30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ser Val 35 40 45Ala His Ile Asn Arg Ser Gly Ser Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Leu Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Gly Arg Tyr Tyr Ser Ser Asp Gly Val Pro Ser Ala Ser Phe 100 105 110Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Thr Gly Asp Ser Leu Arg Leu Ser Cys Glu Val Ser Gly145 150 155 160Arg Thr Phe Ser Ser Tyr Ser Met Gly Trp Phe Arg Gln Ala Gln Gly 165 170 175Lys Glu Arg Glu Phe Val Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr 180 185 190Asp Ser Val Ser Leu Glu Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala 195 200 205Lys Asn Thr Val Tyr Leu Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr 210 215 220Ala Val Tyr Tyr Cys Ala Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu225 230 235 240Arg Leu Ala Asp Thr Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr 245 250 255Val Ser Ser156257PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 156Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Ser Ala Phe Lys Ser Tyr 20 25 30Arg Met Gly Trp Phe Arg Arg Thr Pro Gly Lys Glu Asp Glu Phe Val 35 40 45Ala Ser Ile Ser Trp Thr Tyr Gly Ser Thr Phe Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Met Ser Arg Asp Lys Ala Lys Asn Ala Gly Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95Ala Ala Gly Ala Gln Ser Asp Arg Tyr Asn Ile Arg Ser Tyr Asp Tyr 100 105 110Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 130 135 140Gln Thr Gly Asp Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr145 150 155 160Phe Ser Ser Tyr Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu 165 170 175Arg Glu Phe Val Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser 180 185 190Val Ser Leu Glu Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn 195 200 205Thr Val Tyr Leu Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val 210 215 220Tyr Tyr Cys Ala Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu225 230 235 240Ala Asp Thr Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser 245 250 255Ser157249PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 157Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Lys Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Ser 20 25 30Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Ile Pro Pro Val Gly His Phe Ala Asn Tyr Ala Pro Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Phe65 70 75 80Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Asp Ser Ala Gly Arg Thr Lys Gly Gln Gly Thr Gln Val Thr 100 105 110Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu 115 120 125Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp Ser Leu Arg Leu 130 135 140Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr Ser Met Gly Trp145 150 155 160Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val Val Ala Ile Ser 165 170 175Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu Gly Arg Phe Thr 180 185 190Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Ile Asn Ser 195 200 205Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ser Arg Ala 210 215 220Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr Glu Tyr Trp Gly225 230 235 240Gln Gly Thr Gln Val Thr Val Ser Ser 245158258PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 158Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Arg Thr Phe Ser Asn Tyr 20 25 30Ala Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Ala Ile Thr Arg Ser Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Thr Arg Ser Ser Thr Ile Val Val Gly Val Gly Gly Met Glu 100 105 110Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly 115 120 125Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 130 135 140Val Gln Thr Gly Asp Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg145 150 155 160Thr Phe Ser Ser Tyr Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys 165 170 175Glu Arg Glu Phe Val Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp 180 185 190Ser Val Ser Leu Glu Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys 195 200 205Asn Thr Val Tyr Leu Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala 210 215 220Val Tyr Tyr Cys Ala Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg225 230 235 240Leu Ala Asp Thr Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val 245 250 255Ser Ser159276PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 159Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ala Val Gly Asp Ile 20 25 30Thr Val Ala Trp Tyr Arg Gln Ala Pro Gly Ile Gln Arg Gln Leu Val 35 40 45Ala Thr Ile Thr Pro Ser Gly Tyr Thr Tyr Tyr Trp Asp Phe Val Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ile Val Tyr Leu65 70 75 80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ala Tyr Tyr Cys Asn 85 90 95Thr Gln Phe Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly 100 105 110Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 130 135 140Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly145 150 155 160Gly Leu Val Gln Thr Gly Asp Ser Leu Arg Leu Ser Cys Glu Val Ser 165 170 175Gly Arg Thr Phe Ser Ser Tyr Ser Met Gly Trp Phe Arg Gln Ala Gln 180 185 190Gly Lys Glu Arg Glu Phe Val Val Ala Ile Ser Lys Gly Gly Tyr Lys 195 200 205Tyr Asp Ser Val Ser Leu Glu Gly Arg Phe Thr Ile Ser Lys Asp Asn 210 215 220Ala Lys Asn Thr Val Tyr Leu Gln Ile Asn Ser Leu Lys Pro Glu Asp225 230 235 240Thr Ala Val Tyr Tyr Cys Ala Ser Ser Arg Ala Tyr Gly Ser Ser Arg 245 250 255Leu Arg Leu Ala Asp Thr Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val 260 265 270Thr Val Ser Ser 275160286PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 160Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ala Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ser Phe Ser His Tyr 20 25 30Asn Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Ser Ile Arg Gly Gly Gly Gly Ser Thr Thr Tyr Ala Asn Ser Val 50 55 60Lys Asp Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Thr Ala Phe Tyr Arg Gly Pro Tyr Asp Tyr Asp Tyr Trp Gly 100 105 110Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115

120 125Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 130 135 140Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly145 150 155 160Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly 165 170 175Asp Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser 180 185 190Tyr Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe 195 200 205Val Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu 210 215 220Glu Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr225 230 235 240Leu Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 245 250 255Ala Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr 260 265 270Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 275 280 285161278PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 161Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ile Arg Phe Met Ser Met 20 25 30Ala Trp Tyr Arg Gln Ala Pro Gly Lys His Arg Glu Leu Val Ala Arg 35 40 45Ile Ser Ser Gly Gly Thr Thr Ala Tyr Val Asp Ser Val Lys Gly Arg 50 55 60Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met65 70 75 80Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Asn Thr Phe 85 90 95Ser Ser Arg Pro Asn Pro Trp Gly Ala Gly Thr Gln Val Thr Val Ser 100 105 110Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 130 135 140Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser145 150 155 160Gly Gly Gly Leu Val Gln Thr Gly Asp Ser Leu Arg Leu Ser Cys Glu 165 170 175Val Ser Gly Arg Thr Phe Ser Ser Tyr Ser Met Gly Trp Phe Arg Gln 180 185 190Ala Gln Gly Lys Glu Arg Glu Phe Val Val Ala Ile Ser Lys Gly Gly 195 200 205Tyr Lys Tyr Asp Ser Val Ser Leu Glu Gly Arg Phe Thr Ile Ser Lys 210 215 220Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Ile Asn Ser Leu Lys Pro225 230 235 240Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ser Arg Ala Tyr Gly Ser 245 250 255Ser Arg Leu Arg Leu Ala Asp Thr Tyr Glu Tyr Trp Gly Gln Gly Thr 260 265 270Gln Val Thr Val Ser Ser 275162281PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 162Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Ile Phe Ser Asn Asn 20 25 30Ala Met Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45Ala Arg Ile Ser Ser Gly Gly Gly Phe Thr Tyr Tyr Leu Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Asn Ala Ala Tyr Arg Thr Tyr Asn Tyr Trp Gly Gln Gly Thr Gln Val 100 105 110Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 130 135 140Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu145 150 155 160Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp Ser Leu Arg Leu 165 170 175Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr Ser Met Gly Trp 180 185 190Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val Val Ala Ile Ser 195 200 205Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu Gly Arg Phe Thr 210 215 220Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Ile Asn Ser225 230 235 240Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ser Arg Ala 245 250 255Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr Glu Tyr Trp Gly 260 265 270Gln Gly Thr Gln Val Thr Val Ser Ser 275 280163289PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 163Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Asn Tyr 20 25 30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Val Leu Val 35 40 45Ala Asp Ile Ser Ser Ser Gly Ile Asn Thr Tyr Val Ala Asp Ala Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Ala Trp Trp Tyr Ser Gln Met Ala Arg Asp Asn Tyr Arg 100 105 110Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly 115 120 125Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 130 135 140Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly145 150 155 160Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 165 170 175Gln Thr Gly Asp Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr 180 185 190Phe Ser Ser Tyr Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu 195 200 205Arg Glu Phe Val Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser 210 215 220Val Ser Leu Glu Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn225 230 235 240Thr Val Tyr Leu Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val 245 250 255Tyr Tyr Cys Ala Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu 260 265 270Ala Asp Thr Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser 275 280 285Ser164282PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 164Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ala Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Ser 20 25 30Trp Met Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Arg Ile Ser Pro Gly Gly Leu Phe Thr Tyr Tyr Val Asp Ser Val 50 55 60Lys Gly Arg Phe Ser Val Ser Thr Asp Asn Ala Asn Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Leu Tyr Ser Cys 85 90 95Ala Lys Gly Gly Ala Pro Asn Tyr Thr Pro Arg Gly Arg Gly Thr Gln 100 105 110Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 115 120 125Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 130 135 140Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln145 150 155 160Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp Ser Leu Arg 165 170 175Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr Ser Met Gly 180 185 190Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val Val Ala Ile 195 200 205Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu Gly Arg Phe 210 215 220Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Ile Asn225 230 235 240Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ser Arg 245 250 255Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr Glu Tyr Trp 260 265 270Gly Gln Gly Thr Gln Val Thr Val Ser Ser 275 280165290PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 165Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Arg Thr Phe Asn Ser Tyr 20 25 30Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ser Val 35 40 45Ala His Ile Asn Arg Ser Gly Ser Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Leu Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Gly Arg Tyr Tyr Ser Ser Asp Gly Val Pro Ser Ala Ser Phe 100 105 110Asn Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser145 150 155 160Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 165 170 175Val Gln Thr Gly Asp Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg 180 185 190Thr Phe Ser Ser Tyr Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys 195 200 205Glu Arg Glu Phe Val Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp 210 215 220Ser Val Ser Leu Glu Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys225 230 235 240Asn Thr Val Tyr Leu Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala 245 250 255Val Tyr Tyr Cys Ala Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg 260 265 270Leu Ala Asp Thr Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val 275 280 285Ser Ser 290166288PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 166Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Ser Ala Phe Lys Ser Tyr 20 25 30Arg Met Gly Trp Phe Arg Arg Thr Pro Gly Lys Glu Asp Glu Phe Val 35 40 45Ala Ser Ile Ser Trp Thr Tyr Gly Ser Thr Phe Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Met Ser Arg Asp Lys Ala Lys Asn Ala Gly Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95Ala Ala Gly Ala Gln Ser Asp Arg Tyr Asn Ile Arg Ser Tyr Asp Tyr 100 105 110Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 130 135 140Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly145 150 155 160Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln 165 170 175Thr Gly Asp Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe 180 185 190Ser Ser Tyr Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg 195 200 205Glu Phe Val Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val 210 215 220Ser Leu Glu Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr225 230 235 240Val Tyr Leu Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr 245 250 255Tyr Cys Ala Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala 260 265 270Asp Thr Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 275 280 285167280PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 167Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Lys Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Thr Ser 20 25 30Trp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Ile Pro Pro Val Gly His Phe Ala Asn Tyr Ala Pro Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Phe65 70 75 80Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Asp Ser Ala Gly Arg Thr Lys Gly Gln Gly Thr Gln Val Thr 100 105 110Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val145 150 155 160Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp Ser Leu Arg Leu Ser 165 170 175Cys Glu Val Ser Gly Arg Thr Phe Ser Ser Tyr Ser Met Gly Trp Phe 180 185 190Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val Val Ala Ile Ser Lys 195 200 205Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu Gly Arg Phe Thr Ile 210 215 220Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Ile Asn Ser Leu225 230 235 240Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ser Arg Ala Tyr 245 250 255Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr Glu Tyr Trp Gly Gln 260 265 270Gly Thr Gln Val Thr Val Ser Ser 275 280168289PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideArtificial polypeptide comprising lama glama sequences 168Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Arg Thr Phe Ser Asn Tyr 20 25 30Ala Met Asp Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala Ala Ile Thr Arg Ser Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Thr Arg Ser Ser Thr Ile Val Val Gly Val Gly Gly Met Glu 100 105 110Tyr Trp Gly Lys Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly 115 120 125Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 130 135 140Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly145

150 155 160Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 165 170 175Gln Thr Gly Asp Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr 180 185 190Phe Ser Ser Tyr Ser Met Gly Trp Phe Arg Gln Ala Gln Gly Lys Glu 195 200 205Arg Glu Phe Val Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser 210 215 220Val Ser Leu Glu Gly Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn225 230 235 240Thr Val Tyr Leu Gln Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val 245 250 255Tyr Tyr Cys Ala Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu 260 265 270Ala Asp Thr Tyr Glu Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser 275 280 285Ser16935PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideSynthetic linker 169Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1 5 10 15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 20 25 30Gly Gly Ser 351709PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptideSynthetic linker 170Gly Gly Gly Gly Ser Gly Gly Gly Ser1 517140PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideSynthetic linker 171Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1 5 10 15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 20 25 30Gly Gly Ser Gly Gly Gly Gly Ser 35 401729PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptideSynthetic linker 172Gly Gly Gly Gly Cys Gly Gly Gly Ser1 517325PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptideSynthetic linker 173Gly Gly Gly Gly Cys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1 5 10 15Gly Gly Gly Ser Gly Gly Gly Gly Ser 20 2517427PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptideSynthetic linker 174Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Cys Gly Gly1 5 10 15Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 20 2517535PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideSynthetic linker 175Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Cys Gly1 5 10 15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 20 25 30Gly Gly Ser 3517635PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideSynthetic linker 176Gly Gly Gly Gly Cys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1 5 10 15Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 20 25 30Gly Gly Ser 35177115PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama glama sequence 177Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asn1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 115178585PRTHomo sapiens 178Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu1 5 10 15Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50 55 60Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu65 70 75 80Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro 85 90 95Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu 100 105 110Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His 115 120 125Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg145 150 155 160Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180 185 190Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu 195 200 205Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro 210 215 220Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys225 230 235 240Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala305 310 315 320Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg 325 330 335Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr 340 345 350Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu 355 360 365Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro 370 375 380Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu385 390 395 400Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425 430Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys 435 440 445Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His 450 455 460Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser465 470 475 480Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr 485 490 495Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys545 550 555 560Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val 565 570 575Ala Ala Ser Gln Ala Ala Leu Gly Leu 580 585179109PRTHomo sapiens 179Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 100 105180257PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated Lama sequence 180Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30Ala Leu Gly Trp Phe Arg Gln Ala Ala Gly Lys Glu Arg Glu Gly Val 35 40 45Ser Cys Ile Arg Cys Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Ile Val Pro Arg Ser Lys Leu Glu Pro Tyr Glu Tyr Asp 100 105 110Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly 115 120 125Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 130 135 140Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe145 150 155 160Thr Phe Asp Asp Tyr Ala Leu Gly Trp Phe Arg Gln Ala Ala Gly Lys 165 170 175Glu Arg Glu Gly Val Ser Cys Ile Arg Cys Ser Asp Gly Ser Thr Tyr 180 185 190Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala 195 200 205Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr 210 215 220Ala Val Tyr Tyr Cys Ala Ala Ser Ile Val Pro Arg Ser Lys Leu Glu225 230 235 240Pro Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser 245 250 255Ser181288PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 181Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30Ala Leu Gly Trp Phe Arg Gln Ala Ala Gly Lys Glu Arg Glu Gly Val 35 40 45Ser Cys Ile Arg Cys Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Ile Val Pro Arg Ser Lys Leu Glu Pro Tyr Glu Tyr Asp 100 105 110Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly 115 120 125Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 130 135 140Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly145 150 155 160Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 165 170 175Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr 180 185 190Phe Asp Asp Tyr Ala Leu Gly Trp Phe Arg Gln Ala Ala Gly Lys Glu 195 200 205Arg Glu Gly Val Ser Cys Ile Arg Cys Ser Asp Gly Ser Thr Tyr Tyr 210 215 220Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Lys225 230 235 240Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala 245 250 255Val Tyr Tyr Cys Ala Ala Ser Ile Val Pro Arg Ser Lys Leu Glu Pro 260 265 270Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 275 280 285182255PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 182Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Val Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Thr Tyr 20 25 30Leu Met Val Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe 35 40 45Ala Ala Gly Ile Trp Ser Ser Gly Asp Thr Ala Tyr Ala Asp Ser Val 50 55 60Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Gly Ser Tyr Asp Gly Asn Tyr Tyr Ile Pro Gly Phe Tyr Lys Asp 100 105 110Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser 115 120 125Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val 130 135 140Gln Val Gly Asp Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr145 150 155 160Phe Ser Thr Tyr Leu Met Val Gly Trp Phe Arg Gln Ala Pro Gly Lys 165 170 175Glu Arg Glu Phe Ala Ala Gly Ile Trp Ser Ser Gly Asp Thr Ala Tyr 180 185 190Ala Asp Ser Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys 195 200 205Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala 210 215 220Val Tyr Tyr Cys Ala Gly Ser Tyr Asp Gly Asn Tyr Tyr Ile Pro Gly225 230 235 240Phe Tyr Lys Asp Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 245 250 255183267PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 183Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp Asp Tyr 20 25 30Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45Ser Ser Ile Arg Asp Asn Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Asp Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Val Pro Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp Tyr Pro 100 105 110Leu Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser 115 120 125Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu 130 135 140Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys145 150 155 160Ala Ala Ser Gly Phe Thr Leu Asp Asp Tyr Ala Ile Gly Trp Phe Arg 165 170 175Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Ser Ile Arg Asp Asn 180 185 190Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile 195 200 205Ser Ser Asp Asn Asp Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu 210 215 220Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Pro Ala Gly225 230 235 240Arg Leu Arg Phe Gly Glu Gln Trp Tyr Pro Leu Tyr Glu Tyr Asp Ala 245 250 255Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 260 265184298PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 184Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10

15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp Asp Tyr 20 25 30Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45Ser Ser Ile Arg Asp Asn Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Asp Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Val Pro Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp Tyr Pro 100 105 110Leu Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser 115 120 125Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 130 135 140Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly145 150 155 160Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser 165 170 175Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala 180 185 190Ala Ser Gly Phe Thr Leu Asp Asp Tyr Ala Ile Gly Trp Phe Arg Gln 195 200 205Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Ser Ile Arg Asp Asn Asp 210 215 220Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser225 230 235 240Ser Asp Asn Asp Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys 245 250 255Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Pro Ala Gly Arg 260 265 270Leu Arg Phe Gly Glu Gln Trp Tyr Pro Leu Tyr Glu Tyr Asp Ala Trp 275 280 285Gly Gln Gly Thr Leu Val Thr Val Ser Ser 290 295185267PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 185Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Leu Asp Asp Tyr 20 25 30Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45Ser Ser Ile Arg Asp Asn Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Val Pro Ala Gly Arg Leu Arg Tyr Gly Glu Gln Trp Tyr Pro 100 105 110Ile Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser 115 120 125Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Leu Glu 130 135 140Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys145 150 155 160Ala Ala Ser Gly Ile Thr Leu Asp Asp Tyr Ala Ile Gly Trp Phe Arg 165 170 175Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Ser Ile Arg Asp Asn 180 185 190Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile 195 200 205Ser Ser Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu 210 215 220Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Pro Ala Gly225 230 235 240Arg Leu Arg Tyr Gly Glu Gln Trp Tyr Pro Ile Tyr Glu Tyr Asp Ala 245 250 255Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 260 265186387PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 186Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180 185 190Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser225 230 235 240Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala 260 265 270Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp 275 280 285Asp Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu 290 295 300Gly Val Ser Ser Ile Arg Asp Asn Asp Gly Ser Thr Tyr Tyr Ala Asp305 310 315 320Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Asp Lys Asn Thr 325 330 335Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr 340 345 350Tyr Cys Ala Ala Val Pro Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp 355 360 365Tyr Pro Leu Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr 370 375 380Val Ser Ser385187387PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 187Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp Asp Tyr 20 25 30Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45Ser Ser Ile Arg Asp Asn Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Asp Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Val Pro Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp Tyr Pro 100 105 110Leu Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser 115 120 125Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu 130 135 140Ser Gly Gly Gly Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys145 150 155 160Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg 165 170 175Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser 180 185 190Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile 195 200 205Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu 210 215 220Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu225 230 235 240Ser Arg Ser Ser Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 245 250 255Gly Ser Gly Gly Gly Ser Asp Val Gln Leu Val Glu Ser Gly Gly Gly 260 265 270Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 275 280 285Arg Thr Phe Ser Ser Tyr Ser Met Gly Trp Phe Arg Gln Ala Pro Gly 290 295 300Lys Glu Arg Glu Phe Val Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr305 310 315 320Asp Ala Val Ser Leu Glu Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala 325 330 335Lys Asn Thr Val Tyr Leu Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr 340 345 350Ala Val Tyr Tyr Cys Ala Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu 355 360 365Arg Leu Ala Asp Thr Tyr Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr 370 375 380Val Ser Ser385188387PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 188Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp Asp Tyr 20 25 30Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45Ser Ser Ile Arg Asp Asn Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Asp Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Val Pro Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp Tyr Pro 100 105 110Leu Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser 115 120 125Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Asp Val Gln Leu Val Glu 130 135 140Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys145 150 155 160Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr Ser Met Gly Trp Phe Arg 165 170 175Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Val Ala Ile Ser Lys Gly 180 185 190Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu Gly Arg Phe Thr Ile Ser 195 200 205Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Ile Asn Ser Leu Arg 210 215 220Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Ser Arg Ala Tyr Gly225 230 235 240Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr Glu Tyr Trp Gly Gln Gly 245 250 255Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser 260 265 270Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asn 275 280 285Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 290 295 300Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val305 310 315 320Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 325 330 335Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr 340 345 350Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 355 360 365Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr 370 375 380Val Ser Ser385189375PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 189Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ala Ala 115 120 125Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asn 130 135 140Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe145 150 155 160Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 165 170 175Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 180 185 190Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr 195 200 205Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 210 215 220Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr225 230 235 240Val Ser Ser Ala Ala Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly 245 250 255Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 260 265 270Phe Thr Leu Asp Asp Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly 275 280 285Lys Glu Arg Glu Gly Val Ser Ser Ile Arg Asp Asn Asp Gly Ser Thr 290 295 300Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn305 310 315 320Asp Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp 325 330 335Thr Ala Val Tyr Tyr Cys Ala Ala Val Pro Ala Gly Arg Leu Arg Phe 340 345 350Gly Glu Gln Trp Tyr Pro Leu Tyr Glu Tyr Asp Ala Trp Gly Gln Gly 355 360 365Thr Leu Val Thr Val Ser Ser 370 375190384PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 190Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Ala Leu Asp Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Val Pro Gly 165 170 175Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Ser Asp Gly Ile Thr 180 185 190Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Ala Thr Asp Ser Gly Gly Tyr Ile Asp Tyr225 230 235 240Asp Cys Met Gly Leu Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val 245 250 255Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln 260 265 270Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asn Ser Leu Arg

275 280 285Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Gly Met Ser 290 295 300Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile305 310 315 320Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val Lys Gly Arg 325 330 335Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr Leu Gln Met 340 345 350Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Thr Ile Gly 355 360 365Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr Val Ser Ser 370 375 380191384PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 191Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180 185 190Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser225 230 235 240Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro 260 265 270Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Leu Asp 275 280 285Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Val Pro Gly Lys Glu Arg Glu 290 295 300Gly Val Ser Cys Ile Ser Ser Ser Asp Gly Ile Thr Tyr Tyr Val Asp305 310 315 320Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr 325 330 335Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr 340 345 350Tyr Cys Ala Thr Asp Ser Gly Gly Tyr Ile Asp Tyr Asp Cys Met Gly 355 360 365Leu Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 370 375 380192519PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 192Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Ala Leu Asp Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Val Pro Gly 165 170 175Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Ser Asp Gly Ile Thr 180 185 190Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Ala Thr Asp Ser Gly Gly Tyr Ile Asp Tyr225 230 235 240Asp Cys Met Gly Leu Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val 245 250 255Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln 260 265 270Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asn Ser Leu Arg 275 280 285Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Gly Met Ser 290 295 300Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile305 310 315 320Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val Lys Gly Arg 325 330 335Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr Leu Gln Met 340 345 350Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Thr Ile Gly 355 360 365Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr Val Ser Ser 370 375 380Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser385 390 395 400Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala 405 410 415Ala Ser Gly Phe Ala Leu Asp Tyr Tyr Ala Ile Gly Trp Phe Arg Gln 420 425 430Val Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Ser Ser Ser Asp 435 440 445Gly Ile Thr Tyr Tyr Val Asp Ser Val Lys Gly Arg Phe Thr Ile Ser 450 455 460Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys465 470 475 480Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Asp Ser Gly Gly Tyr 485 490 495Ile Asp Tyr Asp Cys Met Gly Leu Gly Tyr Asp Tyr Trp Gly Gln Gly 500 505 510Thr Leu Val Thr Val Ser Ser 515193525PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMuttaed lama sequence 193Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Leu Asp Asp Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly 165 170 175Lys Glu Arg Glu Gly Val Ser Ser Ile Arg Asp Asn Asp Gly Ser Thr 180 185 190Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn 195 200 205Asp Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Ala Ala Val Pro Ala Gly Arg Leu Arg Phe225 230 235 240Gly Glu Gln Trp Tyr Pro Leu Tyr Glu Tyr Asp Ala Trp Gly Gln Gly 245 250 255Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser 260 265 270Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly 275 280 285Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp Asp Tyr 290 295 300Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val305 310 315 320Ser Ser Ile Arg Asp Asn Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val 325 330 335Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Asp Lys Asn Thr Val Tyr 340 345 350Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 355 360 365Ala Ala Val Pro Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp Tyr Pro 370 375 380Leu Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser385 390 395 400Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu 405 410 415Ser Gly Gly Gly Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys 420 425 430Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg 435 440 445Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser 450 455 460Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile465 470 475 480Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu 485 490 495Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu 500 505 510Ser Arg Ser Ser Gln Gly Thr Leu Val Thr Val Ser Ser 515 520 525194525PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 194Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180 185 190Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser225 230 235 240Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala 260 265 270Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp 275 280 285Asp Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu 290 295 300Gly Val Ser Ser Ile Arg Asp Asn Asp Gly Ser Thr Tyr Tyr Ala Asp305 310 315 320Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Asp Lys Asn Thr 325 330 335Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr 340 345 350Tyr Cys Ala Ala Val Pro Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp 355 360 365Tyr Pro Leu Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr 370 375 380Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu385 390 395 400Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu 405 410 415Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp Asp Tyr Ala Ile Gly Trp 420 425 430Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Ser Ile Arg 435 440 445Asp Asn Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe 450 455 460Thr Ile Ser Ser Asp Asn Asp Lys Asn Thr Val Tyr Leu Gln Met Asn465 470 475 480Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Pro 485 490 495Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp Tyr Pro Leu Tyr Glu Tyr 500 505 510Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 515 520 525195525PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 195Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Leu Asp Asp Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly 165 170 175Lys Glu Arg Glu Gly Val Ser Ser Ile Arg Asp Asn Asp Gly Ser Thr 180 185 190Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn 195 200 205Asp Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Ala Ala Val Pro Ala Gly Arg Leu Arg Phe225 230 235 240Gly Glu Gln Trp Tyr Pro Leu Tyr Glu Tyr Asp Ala Trp Gly Gln Gly 245 250 255Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser 260 265 270Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asn 275 280 285Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 290 295 300Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val305 310 315 320Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 325 330 335Lys Gly Arg Phe

Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr 340 345 350Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 355 360 365Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr 370 375 380Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu385 390 395 400Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu 405 410 415Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp Asp Tyr Ala Ile Gly Trp 420 425 430Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Ser Ile Arg 435 440 445Asp Asn Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe 450 455 460Thr Ile Ser Ser Asp Asn Asp Lys Asn Thr Val Tyr Leu Gln Met Asn465 470 475 480Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Pro 485 490 495Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp Tyr Pro Leu Tyr Glu Tyr 500 505 510Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 515 520 525196515PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 196Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Asp Asp Tyr Ala Leu Gly Trp Phe Arg Gln Ala Ala Gly 165 170 175Lys Glu Arg Glu Gly Val Ser Cys Ile Arg Cys Ser Asp Gly Ser Thr 180 185 190Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn 195 200 205Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Ala Ala Ser Ile Val Pro Arg Ser Lys Leu225 230 235 240Glu Pro Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val 245 250 255Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val 260 265 270Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser 275 280 285Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Leu Gly Trp Phe 290 295 300Arg Gln Ala Ala Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Arg Cys305 310 315 320Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr 325 330 335Ile Ser Ser Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser 340 345 350Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ser Ile Val 355 360 365Pro Arg Ser Lys Leu Glu Pro Tyr Glu Tyr Asp Ala Trp Gly Gln Gly 370 375 380Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser385 390 395 400Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asn 405 410 415Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 420 425 430Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 435 440 445Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 450 455 460Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr465 470 475 480Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 485 490 495Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr 500 505 510Val Ser Ser 515197515PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 197Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180 185 190Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser225 230 235 240Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala 260 265 270Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp 275 280 285Asp Tyr Ala Leu Gly Trp Phe Arg Gln Ala Ala Gly Lys Glu Arg Glu 290 295 300Gly Val Ser Cys Ile Arg Cys Ser Asp Gly Ser Thr Tyr Tyr Ala Asp305 310 315 320Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Lys Asn Thr 325 330 335Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr 340 345 350Tyr Cys Ala Ala Ser Ile Val Pro Arg Ser Lys Leu Glu Pro Tyr Glu 355 360 365Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 370 375 380Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly385 390 395 400Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 405 410 415Gly Phe Thr Phe Asp Asp Tyr Ala Leu Gly Trp Phe Arg Gln Ala Ala 420 425 430Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Arg Cys Ser Asp Gly Ser 435 440 445Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp 450 455 460Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu465 470 475 480Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ser Ile Val Pro Arg Ser Lys 485 490 495Leu Glu Pro Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr 500 505 510Val Ser Ser 515198515PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 198Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Asp Asp Tyr Ala Leu Gly Trp Phe Arg Gln Ala Ala Gly 165 170 175Lys Glu Arg Glu Gly Val Ser Cys Ile Arg Cys Ser Asp Gly Ser Thr 180 185 190Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn 195 200 205Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Ala Ala Ser Ile Val Pro Arg Ser Lys Leu225 230 235 240Glu Pro Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val 245 250 255Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val 260 265 270Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser 275 280 285Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val 290 295 300Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly305 310 315 320Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr 325 330 335Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser 340 345 350Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser 355 360 365Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 370 375 380Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly385 390 395 400Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 405 410 415Gly Phe Thr Phe Asp Asp Tyr Ala Leu Gly Trp Phe Arg Gln Ala Ala 420 425 430Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Arg Cys Ser Asp Gly Ser 435 440 445Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp 450 455 460Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu465 470 475 480Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ser Ile Val Pro Arg Ser Lys 485 490 495Leu Glu Pro Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr 500 505 510Val Ser Ser 515199382PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 199Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180 185 190Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser225 230 235 240Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala 260 265 270Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp 275 280 285Asp Tyr Ala Leu Gly Trp Phe Arg Gln Ala Ala Gly Lys Glu Arg Glu 290 295 300Gly Val Ser Cys Ile Arg Cys Ser Asp Gly Ser Thr Tyr Tyr Ala Asp305 310 315 320Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Lys Asn Thr 325 330 335Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr 340 345 350Tyr Cys Ala Ala Ser Ile Val Pro Arg Ser Lys Leu Glu Pro Tyr Glu 355 360 365Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 370 375 380200387PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 200Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180 185 190Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser225 230 235 240Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro 260 265 270Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala

Ser Gly Ile Thr Leu Asp 275 280 285Asp Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu 290 295 300Gly Val Ser Ser Ile Arg Asp Asn Gly Gly Ser Thr Tyr Tyr Ala Asp305 310 315 320Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr 325 330 335Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr 340 345 350Tyr Cys Ala Ala Val Pro Ala Gly Arg Leu Arg Tyr Gly Glu Gln Trp 355 360 365Tyr Pro Ile Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr 370 375 380Val Ser Ser385201387PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 201Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180 185 190Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser225 230 235 240Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro 260 265 270Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Ile Thr Leu Asp 275 280 285Asp Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu 290 295 300Gly Val Ser Ser Ile Arg Asp Asn Gly Gly Ser Thr Tyr Tyr Ala Asp305 310 315 320Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr 325 330 335Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr 340 345 350Tyr Cys Ala Ala Val Pro Ala Gly Arg Leu Arg Tyr Gly Glu Gln Trp 355 360 365Tyr Pro Ile Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr 370 375 380Val Ser Ser385202387PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 202Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180 185 190Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser225 230 235 240Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro 260 265 270Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Leu Asp 275 280 285Asp Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu 290 295 300Gly Val Ser Ala Ile Arg Asp Asn Gly Gly Ser Thr Tyr Tyr Ala Asp305 310 315 320Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr 325 330 335Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr 340 345 350Tyr Cys Ala Ala Val Pro Ala Gly Arg Leu Arg Tyr Gly Glu Gln Trp 355 360 365Tyr Pro Ile Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr 370 375 380Val Ser Ser385203387PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 203Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180 185 190Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser225 230 235 240Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro 260 265 270Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Leu Asp 275 280 285Asp Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu 290 295 300Gly Val Ser Ala Ile Arg Glu Ser Gly Gly Ser Thr Tyr Tyr Ala Asp305 310 315 320Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr 325 330 335Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr 340 345 350Tyr Cys Ala Ala Val Pro Ala Gly Arg Leu Arg Tyr Gly Glu Gln Trp 355 360 365Tyr Pro Ile Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr 370 375 380Val Ser Ser385204387PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 204Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180 185 190Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser225 230 235 240Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro 260 265 270Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Leu Asp 275 280 285Asp Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu 290 295 300Gly Val Ser Ala Ile Arg Ser Ser Gly Gly Ser Thr Tyr Tyr Ala Asp305 310 315 320Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr 325 330 335Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr 340 345 350Tyr Cys Ala Ala Val Pro Ala Gly Arg Leu Arg Tyr Gly Glu Gln Trp 355 360 365Tyr Pro Ile Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr 370 375 380Val Ser Ser385205387PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 205Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180 185 190Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser225 230 235 240Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro 260 265 270Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Ile Thr Leu Asp 275 280 285Asp Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu 290 295 300Gly Val Ser Ala Ile Arg Asp Asn Gly Gly Ser Thr Tyr Tyr Ala Asp305 310 315 320Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr 325 330 335Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr 340 345 350Tyr Cys Ala Ala Val Pro Ala Gly Arg Leu Arg Tyr Gly Glu Gln Trp 355 360 365Tyr Pro Ile Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr 370 375 380Val Ser Ser385206387PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 206Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180 185 190Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser225 230 235 240Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro 260 265 270Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Ile Thr Leu Asp 275 280 285Asp Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu 290 295 300Gly Val Ser Ala Ile Arg Glu Ser Gly Gly Ser Thr Tyr Tyr Ala Asp305 310 315 320Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr

325 330 335Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr 340 345 350Tyr Cys Ala Ala Val Pro Ala Gly Arg Leu Arg Tyr Gly Glu Gln Trp 355 360 365Tyr Pro Ile Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr 370 375 380Val Ser Ser385207387PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 207Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180 185 190Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser225 230 235 240Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro 260 265 270Gly Gly Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Ile Thr Leu Asp 275 280 285Asp Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu 290 295 300Gly Val Ser Ala Ile Arg Ser Ser Gly Gly Ser Thr Tyr Tyr Ala Asp305 310 315 320Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr 325 330 335Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr 340 345 350Tyr Cys Ala Ala Val Pro Ala Gly Arg Leu Arg Tyr Gly Glu Gln Trp 355 360 365Tyr Pro Ile Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr 370 375 380Val Ser Ser385208525PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 208Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180 185 190Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser225 230 235 240Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro 260 265 270Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp 275 280 285Asp Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu 290 295 300Gly Val Ser Ala Ile Arg Asp Asn Gly Gly Ser Thr Tyr Tyr Ala Asp305 310 315 320Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr 325 330 335Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr 340 345 350Tyr Cys Ala Ala Val Pro Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp 355 360 365Tyr Pro Leu Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr 370 375 380Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu385 390 395 400Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu 405 410 415Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp Asp Tyr Ala Ile Gly Trp 420 425 430Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Ala Ile Arg 435 440 445Asp Asn Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe 450 455 460Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn465 470 475 480Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Pro 485 490 495Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp Tyr Pro Leu Tyr Glu Tyr 500 505 510Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 515 520 525209525PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 209Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Leu Asp Asp Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly 165 170 175Lys Glu Arg Glu Gly Val Ser Ala Ile Arg Asp Asn Gly Gly Ser Thr 180 185 190Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn 195 200 205Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Ala Ala Val Pro Ala Gly Arg Leu Arg Phe225 230 235 240Gly Glu Gln Trp Tyr Pro Leu Tyr Glu Tyr Asp Ala Trp Gly Gln Gly 245 250 255Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser 260 265 270Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 275 280 285Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp Asp Tyr 290 295 300Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val305 310 315 320Ser Ala Ile Arg Asp Asn Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 325 330 335Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr Val Tyr 340 345 350Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 355 360 365Ala Ala Val Pro Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp Tyr Pro 370 375 380Leu Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser385 390 395 400Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu 405 410 415Ser Gly Gly Gly Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys 420 425 430Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg 435 440 445Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser 450 455 460Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile465 470 475 480Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu 485 490 495Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu 500 505 510Ser Arg Ser Ser Gln Gly Thr Leu Val Thr Val Ser Ser 515 520 525210515PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 210Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180 185 190Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser225 230 235 240Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro 260 265 270Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp 275 280 285Asp Tyr Ala Leu Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu 290 295 300Gly Val Ser Cys Ile Arg Cys Ser Gly Gly Ser Thr Tyr Tyr Ala Asp305 310 315 320Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr 325 330 335Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr 340 345 350Tyr Cys Ala Ala Ser Ile Val Pro Arg Ser Lys Leu Glu Pro Tyr Glu 355 360 365Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 370 375 380Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly385 390 395 400Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser 405 410 415Gly Phe Thr Phe Asp Asp Tyr Ala Leu Gly Trp Phe Arg Gln Ala Pro 420 425 430Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Arg Cys Ser Gly Gly Ser 435 440 445Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp 450 455 460Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu465 470 475 480Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ser Ile Val Pro Arg Ser Lys 485 490 495Leu Glu Pro Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr 500 505 510Val Ser Ser 515211515PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 211Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Asp Asp Tyr Ala Leu Gly Trp Phe Arg Gln Ala Pro Gly 165 170 175Lys Glu Arg Glu Gly Val Ser Cys Ile Arg Cys Ser Gly Gly Ser Thr 180 185 190Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn 195 200 205Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Ala Ala Ser Ile Val Pro Arg Ser Lys Leu225 230 235 240Glu Pro Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val 245 250 255Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val 260 265 270Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser 275 280 285Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Leu Gly Trp Phe 290 295 300Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Cys Ile Arg Cys305 310 315 320Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr 325 330 335Ile Ser Ser Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn Ser 340 345 350Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Ser Ile Val 355 360 365Pro Arg Ser Lys Leu Glu Pro Tyr Glu Tyr Asp Ala Trp Gly Gln Gly 370

375 380Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser385 390 395 400Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asn 405 410 415Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 420 425 430Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 435 440 445Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 450 455 460Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr465 470 475 480Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 485 490 495Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr 500 505 510Val Ser Ser 515212384PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 212Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180 185 190Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser225 230 235 240Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro 260 265 270Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Leu Asp 275 280 285Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu 290 295 300Gly Val Ser Cys Ile Ser Ser Ser Gly Gly Ile Thr Tyr Tyr Ala Asp305 310 315 320Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr 325 330 335Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr 340 345 350Tyr Cys Ala Thr Asp Ser Gly Gly Tyr Ile Asp Tyr Asp Cys Ser Gly 355 360 365Leu Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 370 375 380213525PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 213Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Tyr 20 25 30Ser Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Val Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu65 70 75 80Gln Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Ser Ser Arg Ala Tyr Gly Ser Ser Arg Leu Arg Leu Ala Asp Thr Tyr 100 105 110Glu Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140Leu Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly145 150 155 160Phe Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180 185 190Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 195 200 205Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser225 230 235 240Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 245 250 255Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro 260 265 270Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp 275 280 285Asp Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu 290 295 300Gly Val Ser Ala Ile Arg Ser Ser Gly Gly Ser Thr Tyr Tyr Ala Asp305 310 315 320Ser Val Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr 325 330 335Val Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr 340 345 350Tyr Cys Ala Ala Val Pro Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp 355 360 365Tyr Pro Leu Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr 370 375 380Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu385 390 395 400Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu 405 410 415Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp Asp Tyr Ala Ile Gly Trp 420 425 430Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser Ala Ile Arg 435 440 445Ser Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe 450 455 460Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn465 470 475 480Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Pro 485 490 495Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp Tyr Pro Leu Tyr Glu Tyr 500 505 510Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 515 520 525214124PRTLama glama 214Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30Ala Leu Gly Trp Phe Arg Gln Ala Ala Gly Lys Glu Arg Glu Gly Val 35 40 45Ser Cys Ile Arg Cys Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Ile Val Pro Arg Ser Lys Leu Glu Pro Tyr Glu Tyr Asp 100 105 110Ala Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120215126PRTLama glama 215Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Leu Asp Tyr Tyr 20 25 30Ala Ile Gly Trp Phe Arg Gln Val Pro Gly Lys Glu Arg Glu Gly Val 35 40 45Ser Cys Ile Ser Ser Ser Asp Gly Ile Thr Tyr Tyr Val Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Thr Asp Ser Gly Gly Tyr Ile Asp Tyr Asp Cys Met Gly Leu Gly 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser 115 120 125216129PRTLama glama 216Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp Asp Tyr 20 25 30Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45Ser Cys Ile Arg Asp Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Asp Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Val Pro Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp Tyr Pro 100 105 110Leu Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Gln Val Thr Val Ser 115 120 125Ser217129PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 217Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp Asp Tyr 20 25 30Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45Ser Ser Ile Arg Asp Asn Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Val Pro Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp Tyr Pro 100 105 110Leu Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser 115 120 125Ser218124PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 218Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30Ala Leu Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45Ser Cys Ile Arg Cys Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Ile Val Pro Arg Ser Lys Leu Glu Pro Tyr Glu Tyr Asp 100 105 110Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120219126PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 219Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Leu Asp Tyr Tyr 20 25 30Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45Ser Cys Ile Ser Ser Ser Asp Gly Ile Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Thr Asp Ser Gly Gly Tyr Ile Asp Tyr Asp Cys Met Gly Leu Gly 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125220124PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 220Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30Ala Leu Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45Ser Cys Ile Arg Cys Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ser Ile Val Pro Arg Ser Lys Leu Glu Pro Tyr Glu Tyr Asp 100 105 110Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120221126PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 221Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Leu Asp Tyr Tyr 20 25 30Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45Ser Cys Ile Ser Ser Ser Gly Gly Ile Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Thr Asp Ser Gly Gly Tyr Ile Asp Tyr Asp Cys Ser Gly Leu Gly 100 105 110Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125222129PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 222Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Ile Thr Leu Asp Asp Tyr 20 25 30Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45Ser Ala Ile Arg Ser Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Val Pro Ala Gly Arg Leu Arg Tyr Gly Glu Gln Trp Tyr Pro 100 105 110Ile Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser 115 120 125Ser223129PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 223Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp Asp Tyr 20 25 30Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45Ser Ala Ile Arg Ser Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr Val Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Val Pro Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp Tyr Pro 100 105 110Leu Tyr Glu Tyr Asp Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser 115 120 125Ser2245PRTLama glama 224Asp Tyr Ala Leu Gly1

522517PRTLama glama 225Cys Ile Arg Cys Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly22615PRTLama glama 226Ser Ile Val Pro Arg Ser Lys Leu Glu Pro Tyr Glu Tyr Asp Ala1 5 10 152275PRTLama glama 227Tyr Tyr Ala Ile Gly1 522817PRTLama glama 228Cys Ile Ser Ser Ser Asp Gly Ile Thr Tyr Tyr Val Asp Ser Val Lys1 5 10 15Gly22917PRTLama glama 229Asp Ser Gly Gly Tyr Ile Asp Tyr Asp Cys Met Gly Leu Gly Tyr Asp1 5 10 15Tyr2305PRTLama glama 230Asp Tyr Ala Ile Gly1 523117PRTLama glama 231Cys Ile Arg Asp Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly23220PRTLama glama 232Val Pro Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp Tyr Pro Leu Tyr1 5 10 15Glu Tyr Asp Ala 202335PRTLama glama 233Asp Tyr Ala Ile Gly1 523417PRTLama glama 234Ser Ile Arg Asp Asn Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly23520PRTLama glama 235Val Pro Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp Tyr Pro Leu Tyr1 5 10 15Glu Tyr Asp Ala 202365PRTLama glama 236Asp Tyr Ala Leu Gly1 523717PRTLama glama 237Cys Ile Arg Cys Ser Asp Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly23815PRTLama glama 238Ser Ile Val Pro Arg Ser Lys Leu Glu Pro Tyr Glu Tyr Asp Ala1 5 10 152395PRTLama glama 239Tyr Tyr Ala Ile Gly1 524017PRTLama glama 240Cys Ile Ser Ser Ser Asp Gly Ile Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly24117PRTLama glama 241Asp Ser Gly Gly Tyr Ile Asp Tyr Asp Cys Met Gly Leu Gly Tyr Asp1 5 10 15Tyr2425PRTLama glama 242Asp Tyr Ala Leu Gly1 524317PRTLama glama 243Cys Ile Arg Cys Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly24415PRTLama glama 244Ser Ile Val Pro Arg Ser Lys Leu Glu Pro Tyr Glu Tyr Asp Ala1 5 10 152455PRTLama glama 245Tyr Tyr Ala Ile Gly1 524617PRTLama glama 246Cys Ile Ser Ser Ser Gly Gly Ile Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly24717PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptideMutated lama sequence 247Asp Ser Gly Gly Tyr Ile Asp Tyr Asp Cys Ser Gly Leu Gly Tyr Asp1 5 10 15Tyr2485PRTLama glama 248Asp Tyr Ala Ile Gly1 524917PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptideMutated lama sequence 249Ala Ile Arg Ser Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly25020PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptideMutated lama sequence 250Val Pro Ala Gly Arg Leu Arg Tyr Gly Glu Gln Trp Tyr Pro Ile Tyr1 5 10 15Glu Tyr Asp Ala 202515PRTLama glama 251Asp Tyr Ala Ile Gly1 525217PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptideMutated lama sequence 252Ala Ile Arg Ser Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly25320PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptideMutated lama sequence 253Val Pro Ala Gly Arg Leu Arg Phe Gly Glu Gln Trp Tyr Pro Leu Tyr1 5 10 15Glu Tyr Asp Ala 20254115PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptideMutated lama sequence 254Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asn1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser 1152555PRTLama glama 255Ser Phe Gly Met Ser1 525617PRTLama glama 256Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val Lys1 5 10 15Gly2576PRTLama glama 257Gly Gly Ser Leu Ser Arg1 52585PRTLama glama 258Leu Asn Leu Met Gly1 525916PRTLama glama 259Thr Ile Thr Val Gly Asp Ser Thr Asn Tyr Ala Asp Ser Val Lys Gly1 5 10 152608PRTLama glama 260Arg Arg Thr Trp His Ser Glu Leu1 52615PRTLama glama 261Ile Asn Leu Leu Gly1 526216PRTLama glama 262Thr Ile Thr Val Gly Asp Ser Thr Ser Tyr Ala Asp Ser Val Lys Gly1 5 10 152638PRTLama glama 263Arg Arg Thr Trp His Ser Glu Leu1 52645PRTLama glama 264Ser Phe Gly Met Ser1 526517PRTLama glama 265Ser Ile Asn Gly Arg Gly Asp Asp Thr Arg Tyr Ala Asp Ser Val Lys1 5 10 15Gly2667PRTLama glama 266Gly Arg Ser Val Ser Arg Ser1 52675PRTLama glama 267Ser Phe Gly Met Ser1 526817PRTLama glama 268Ala Ile Ser Ala Asp Ser Ser Asp Lys Arg Tyr Ala Asp Ser Val Lys1 5 10 15Gly2695PRTLama glama 269Gly Arg Gly Ser Pro1 52705PRTLama glama 270Ser Phe Gly Met Ser1 527117PRTLama glama 271Ala Ile Ser Ala Asp Ser Ser Asp Lys Arg Tyr Ala Asp Ser Val Lys1 5 10 15Gly2725PRTLama glama 272Gly Arg Gly Ser Pro1 52735PRTLama glama 273Asn Tyr Trp Met Tyr1 527417PRTLama glama 274Arg Ile Ser Thr Gly Gly Gly Tyr Ser Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly27513PRTLama glama 275Asp Arg Glu Ala Gln Val Asp Thr Leu Asp Phe Asp Tyr1 5 102764PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 276Lys Glu Arg Glu12774PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 277Gly Leu Glu Trp127815PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 278Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser1 5 10 1527920PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 279Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly1 5 10 15Gly Gly Gly Ser 202805PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 280Gly Gly Gly Gly Ser1 52814PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 281Gly Gly Gly Ser128215PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 282Gly Gly Gly Ser Ser Gly Gly Gly Ser Ser Gly Gly Gly Ser Ser1 5 10 152836PRTArtificial SequenceDescription of Artificial Sequence Synthetic 6xHis tag 283His His His His His His1 52845PRTLama glama 284Ser Tyr Gly Met Gly1 52855PRTLama glama 285Ala Ser Asp Met Gly1 52865PRTLama glama 286Ile Thr Val Met Ala1 52875PRTLama glama 287Asp Ile Thr Val Ala1 52885PRTLama glama 288Thr Asp Asp Val Gly1 52895PRTLama glama 289His Tyr Asn Met Gly1 52903PRTLama glama 290Ser Met Ala12915PRTLama glama 291Asn Asn Ala Met Ala1 52925PRTLama glama 292Ile Ser Val Met Ala1 52935PRTLama glama 293Asn Tyr Ala Met Ala1 52945PRTLama glama 294Asp Asn Val Met Gly1 52955PRTLama glama 295Ser Tyr Tyr Met Gly1 52965PRTLama glama 296Ser Asp Val Met Gly1 52975PRTLama glama 297Leu Tyr Ala Met Gly1 52985PRTLama glama 298Arg Tyr Gly Met Gly1 52995PRTLama glama 299Asn Tyr Ala Met Gly1 53005PRTLama glama 300Arg Tyr Ala Met Gly1 53015PRTLama glama 301Asn Tyr Asn Met Gly1 53025PRTLama glama 302Ser Tyr Gly Leu Gly1 53035PRTLama glama 303Ser Tyr Ala Ile Gly1 53045PRTLama glama 304Ser Tyr Ala Met Gly1 53055PRTLama glama 305Phe Ser Ala Met Gly1 53065PRTLama glama 306Ser Leu Ala Met Gly1 53075PRTLama glama 307Lys Tyr Val Met Gly1 53085PRTLama glama 308Ser Ser Trp Met Tyr1 53095PRTLama glama 309Asn Tyr Val Met Gly1 53105PRTLama glama 310Gly Tyr Asp Met Gly1 53115PRTLama glama 311Ala Tyr Asp Met Gly1 53125PRTLama glama 312Val Tyr Thr Met Gly1 53135PRTLama glama 313Thr Trp Ala Met Ala1 53145PRTLama glama 314Ser Thr Asn Met Gly1 53155PRTLama glama 315Thr Tyr Thr Met Gly1 53165PRTLama glama 316Leu Tyr Thr Val Gly1 53175PRTLama glama 317Ser Tyr Arg Met Gly1 53185PRTLama glama 318Thr Ser Trp Met His1 53195PRTLama glama 319Asn Tyr Ala Met Asp1 53205PRTLama glama 320Asp Tyr Asp Ile Gly1 53215PRTLama glama 321Ser Leu Ala Val Gly1 53225PRTLama glama 322Leu Tyr Asn Met Gly1 53235PRTLama glama 323Gly Ser Asp Met Gly1 53245PRTLama glama 324Thr Tyr Ala Ile Gly1 53255PRTLama glama 325Thr Asn Phe Met Gly1 53265PRTLama glama 326Ile Phe Ala Met Arg1 53275PRTLama glama 327Asp Tyr Asn Leu Gly1 53285PRTLama glama 328Asn Ala Ile Met Gly1 53295PRTLama glama 329Ser Tyr Ala Pro Gly1 533016PRTLama glama 330Ala Ile Ser Glu Tyr Ser Asn Thr Tyr Cys Ser Asp Ser Val Arg Gly1 5 10 1533117PRTLama glama 331Ala Ile Asn Trp Ser Gly Leu Ser Thr Phe Tyr Thr Asp Ser Val Lys1 5 10 15Gly33217PRTLama glama 332Ala Ile Thr Trp Ser Ala Pro Thr Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly33316PRTLama glama 333Thr Ile Thr Pro Ser Gly Tyr Thr Tyr Tyr Trp Asp Phe Val Lys Gly1 5 10 1533417PRTLama glama 334Val Ile Arg Trp Ser Thr Gly Gly Thr Tyr Thr Ser Asp Ser Val Lys1 5 10 15Gly33517PRTLama glama 335Ser Ile Arg Gly Gly Gly Gly Ser Thr Thr Tyr Ala Asn Ser Val Lys1 5 10 15Asp33616PRTLama glama 336Arg Ile Ser Ser Gly Gly Thr Thr Ala Tyr Val Asp Ser Val Lys Gly1 5 10 1533717PRTLama glama 337Arg Ile Ser Ser Gly Gly Gly Phe Thr Tyr Tyr Leu Asp Ser Val Lys1 5 10 15Gly33817PRTLama glama 338Ala Ile Thr Trp Ser Ala Pro Ser Ser Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly33917PRTLama glama 339Ala Ile Asn Gln Arg Gly Ser Asn Thr Asn Tyr Ala Asp Ser Val Lys1 5 10 15Gly34017PRTLama glama 340His Ile Ser Arg Gly Gly Ser Arg Thr Glu Tyr Ala Glu Ser Val Lys1 5 10 15Gly34117PRTLama glama 341Thr Ile Ser Trp Asn Lys Ile Ser Thr Ile Tyr Thr Asp Ser Val Lys1 5 10 15Gly34216PRTLama glama 342Phe Ile Arg Ser Leu Gly Ser Thr Tyr Tyr Ala Gly Ser Val Lys Gly1 5 10 1534317PRTLama glama 343Ala Ile Thr Trp Ser Ala Gly Asp Thr Gln Tyr Ala Asp Ser Val Lys1 5 10 15Gly34416PRTLama glama 344Arg Ile Ser Ser Glu Gly Thr Thr Ala Tyr Val Asp Ser Val Lys Gly1 5 10 1534517PRTLama glama 345Val Ile Arg Trp Ser Thr Gly Gly Thr Tyr Thr Ser Asp Ser Val Ala1 5 10 15Gly34616PRTLama glama 346Ala Ile Ser Glu Tyr Asp Asn Val Tyr Thr Ala Asp Ser Val Arg Gly1 5 10 1534717PRTLama glama 347Val Ile Thr Arg Ser Pro Ser Asn Thr Tyr Tyr Thr Asp Ser Val Lys1 5 10 15Gly34817PRTLama glama 348Asp Ile Ser Ser Ser Gly Ile Asn Thr Tyr Val Ala Asp Ala Val Lys1 5 10 15Gly34917PRTLama glama 349Ser Ile Asn Thr Ser Gly Lys Arg Thr Ser Tyr Ala Asp Ser Met Lys1 5 10 15Gly35017PRTLama glama 350Thr Ile Arg His His Gly Tyr Asp Thr Tyr Tyr Ala Glu Ser Val Lys1 5 10 15Gly35117PRTLama glama 351Ala Ile Gly Trp Ser Gly Ser Ser Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly35217PRTLama glama 352Arg Ile Ser Trp Ser Gly Ala Asn Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly35317PRTLama glama 353Thr Ile Ser Gln Ser Gly Tyr Ser Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly35417PRTLama glama 354Ala Phe Lys Trp Ser Gly Ser Thr Thr Tyr Tyr Ala Asp Tyr Val Lys1 5 10 15Gly35517PRTLama glama 355Ala Ile Thr Trp Ser Ala Pro Ser Ser Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly35617PRTLama glama 356Ser Ile Ser Gln Ser Gly Ile Thr Thr Ser Tyr Ala Asp Ser Val Lys1 5 10 15Ser35717PRTLama glama 357Ala Ile Thr Trp Ser Ala Pro Thr Thr Tyr Ser Ala Asp Ser Val Lys1 5 10 15Gly35817PRTLama glama 358Ala Ile Thr Ser Arg Asp Gly Pro Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly35917PRTLama glama 359Arg Ile Ser Pro Gly Gly Leu Phe Thr Tyr Tyr Val Asp Ser Val Lys1 5 10 15Gly36017PRTLama glama 360Ala Ile Thr Ser Thr Asn Gly Pro Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly36117PRTLama glama 361Ala Ile Thr Trp Ser Gly Gly Ser Thr Tyr Ser Pro Asp Ser Val Lys1 5 10 15Gly36217PRTLama glama 362Val Ile Ser Trp Thr Asn Ser Met Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly36317PRTLama glama 363Val Ile Ser Trp Ser Gly Gly Met Thr Tyr Tyr Ala Asp Ser Val Gln1 5 10 15Gly36417PRTLama glama 364Val Ile Ser Trp Ser Gly Gly Met Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly36517PRTLama glama 365Val Ile Ser Trp Thr Gly Gly Met Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly36617PRTLama glama 366Val Ile Ser Trp Thr Gly Asp Met Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly36717PRTLama glama 367Thr Ile Ser Arg Thr Gly Asp Arg Thr Ser Tyr Ala Asn Ser Val Lys1 5 10 15Gly36817PRTLama glama 368Val Ile Ser Trp Ser Gly Gly Met Thr Asp Tyr Ala Asp Ser Val Lys1 5 10 15Gly36917PRTLama glama 369His Ile Asn Arg Ser Gly Ser Ser Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly37017PRTLama glama 370Ala Ile Ser Trp Ser Gly Ser Met Thr Tyr Tyr Thr Asp Ser Val Lys1 5 10 15Gly37116PRTLama glama 371Ala Ile Thr Leu Ser Gly Thr Thr Tyr Tyr Ala Glu Ala Val Lys Gly1 5 10 1537217PRTLama glama 372Ala Ile Arg Trp Thr Val Asn Ile Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly37317PRTLama glama 373Tyr Ile Ser Arg Ser Gly Ser Asn Arg Tyr Tyr Val Asp Ser Val Lys1 5 10 15Gly37417PRTLama glama 374Ser Ile Ser Trp Thr Tyr Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys1 5 10 15Gly37517PRTLama glama 375Ser Ile Pro Pro Val Gly His Phe Ala Asn Tyr Ala Pro Ser Val Lys1 5 10 15Gly37617PRTLama glama 376Ala Ile Thr Arg Ser Gly Gly Gly Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly37717PRTLama glama 377Cys Ile Thr Thr Asp Val Gly Thr Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly37817PRTLama glama 378Cys Ile Ser Ser Tyr Asp Ser Val Thr Tyr Tyr Ala Asp His Val Lys1 5 10 15Gly37917PRTLama glama 379Cys Ile Ser Ser Ser Asp Thr Ser Ile Asp Tyr Thr Asn Ser Val Lys1 5 10 15Gly38017PRTLama glama 380Arg Ile Thr Trp Ser Gly Ala Thr Thr Tyr Tyr Ala Asp Ala Val Lys1 5 10 15Asp38117PRTLama glama 381Ala Ile Thr Ser Ser Pro Met Ser Thr Tyr Tyr

Ala Asp Ser Val Lys1 5 10 15Gly38217PRTLama glama 382Ala Ile Arg Leu Ser Gly Ser Ile Thr Tyr Tyr Pro Asp Ser Val Lys1 5 10 15Gly38317PRTLama glama 383Cys Met Ser Ala Gly Asp Ser Ile Pro Trp Tyr Thr Ala Ser Val Lys1 5 10 15Gly38416PRTLama glama 384Thr Ile Thr Ser Ser Ser Ile Thr Asn Tyr Val Asp Ser Val Lys Gly1 5 10 1538516PRTLama glama 385Ser Ile Thr Arg Ser Ser Ile Thr Thr Tyr Ala Asp Ser Val Lys Gly1 5 10 1538617PRTLama glama 386Val Ile Ser Trp Arg Asp Ser Phe Ala Tyr Tyr Ala Glu Pro Val Lys1 5 10 15Gly38717PRTLama glama 387Ala Met Asn Trp Arg Gly Gly Pro Thr Tyr Tyr Ala Asp Ser Val Lys1 5 10 15Gly38817PRTLama glama 388Ala Phe Thr Arg Ser Ser Asn Ile Pro Tyr Tyr Lys Asp Ser Val Lys1 5 10 15Gly38914PRTLama glama 389Ser Pro Thr Ile Leu Leu Thr Thr Glu Gln Trp Tyr Lys Tyr1 5 1039017PRTLama glama 390Gly Arg Ile Pro Ser Ser Ser Arg Phe Ser Ser Pro Ala Ala Tyr Ala1 5 10 15Ser39116PRTLama glama 391Asp Arg Phe Lys Gly Arg Ser Ile Val Thr Pro Ser Asp Tyr Arg Tyr1 5 10 153923PRTLama glama 392Gln Phe Tyr139319PRTLama glama 393Arg Ser Arg Pro Leu Gly Ala Gly Ala Trp Tyr Ser Gly Glu Lys His1 5 10 15Tyr Asn Tyr39412PRTLama glama 394Thr Ala Phe Tyr Arg Gly Pro Tyr Asp Tyr Asp Tyr1 5 103957PRTLama glama 395Phe Ser Ser Arg Pro Asn Pro1 53967PRTLama glama 396Ala Tyr Arg Thr Tyr Asn Tyr1 539716PRTLama glama 397Asp Arg Phe Lys Gly Arg Ser Ile Val Thr Arg Ser Asp Tyr Lys Tyr1 5 10 1539816PRTLama glama 398Asp Arg Phe Lys Gly Arg Ser Ile Val Thr Arg Ser Asp Tyr Arg Tyr1 5 10 1539917PRTLama glama 399Ser Thr Trp Tyr Gly Tyr Ser Thr Tyr Ala Arg Arg Glu Glu Tyr Arg1 5 10 15Tyr40014PRTLama glama 400Ser Arg Ser Val Ala Leu Ala Thr Ala Arg Pro Tyr Asp Tyr1 5 1040112PRTLama glama 401Asp Ala Ser Arg Pro Thr Leu Arg Ile Pro Gln Tyr1 5 104027PRTLama glama 402Arg Phe Ser Gly Glu Ser Tyr1 540315PRTLama glama 403Arg Gln Trp Gly Gly Thr Tyr Tyr Tyr His Gly Ser Tyr Ala Tyr1 5 10 1540416PRTLama glama 404Arg Ile Ser Ser Gly Gly Thr Thr Ala Tyr Ala Asp Ser Val Lys Gly1 5 10 1540519PRTLama glama 405Arg Ser Arg Pro Leu Gly Ala Gly Ala Trp Tyr Thr Gly Glu Thr Arg1 5 10 15Tyr Asp Ser40614PRTLama glama 406Ser Pro Thr Ile Leu Leu Ser Thr Asp Glu Trp Tyr Lys Tyr1 5 1040719PRTLama glama 407Arg Ser Arg Pro Leu Gly Ala Gly Ala Trp Tyr Thr Gly Glu Thr Arg1 5 10 15Tyr Asn Tyr40818PRTLama glama 408His Tyr Trp Asn Ser Asp Ser Tyr Thr Tyr Thr Asp Ser Arg Trp Tyr1 5 10 15Asn Tyr40915PRTLama glama 409Ser Ala Trp Trp Tyr Ser Gln Met Ala Arg Asp Asn Tyr Arg Tyr1 5 10 1541016PRTLama glama 410Asp Arg Phe Phe Gly Ser Asp Ser Asn Glu Pro Arg Ala Tyr Arg Tyr1 5 10 1541114PRTLama glama 411Lys Leu Phe Trp Asp Met Asp Pro Lys Thr Gly Phe Ser Ser1 5 1041217PRTLama glama 412Lys Val Arg Asn Phe Asn Ser Asp Trp Asp Leu Leu Thr Ser Tyr Asn1 5 10 15Tyr41316PRTLama glama 413Gln Thr Thr Ser Lys Tyr Asp Asn Tyr Asp Ala Arg Ala Tyr Gly Tyr1 5 10 1541414PRTLama glama 414Asp Pro Phe Tyr Ser Tyr Gly Ser Pro Ser Pro Tyr Arg Tyr1 5 1041516PRTLama glama 415Asp Arg Phe Tyr Thr Gly Arg Tyr Tyr Ser Ser Asp Glu Tyr Asp Tyr1 5 10 1541616PRTLama glama 416Asp Arg Phe Lys Gly Arg Ser Ile Val Thr Arg Ser Asp Tyr Arg Tyr1 5 10 1541716PRTLama glama 417Ser Val Phe Tyr Ser Thr Ala Leu Thr Arg Pro Val Asp Tyr Arg Tyr1 5 10 1541820PRTLama glama 418Asp Glu Asp Leu Tyr His Tyr Ser Ser Tyr His Phe Thr Arg Val Asp1 5 10 15Leu Tyr His Tyr 204198PRTLama glama 419Gly Gly Ala Pro Asn Tyr Thr Pro1 542020PRTLama glama 420Asp Glu Asp Leu Tyr His Tyr Ser Ser Tyr His Tyr Thr Arg Val Ala1 5 10 15Leu Tyr His Tyr 2042115PRTLama glama 421Arg Gln Trp Gly Gly Thr Tyr Tyr Tyr His Gly Ser Tyr Ala Trp1 5 10 1542219PRTLama glama 422Arg Ser Arg Pro Leu Gly Ala Gly Ala Trp Tyr Thr Gly Glu Asn Tyr1 5 10 15Tyr Asn Tyr42317PRTLama glama 423Gly Arg Ile Trp Arg Ser Arg Asp Tyr Asp Ser Glu Lys Tyr Tyr Asp1 5 10 15Ile42420PRTLama glama 424Asp Arg Arg Arg Thr Tyr Ser Arg Trp Arg Phe Tyr Thr Gly Val Asn1 5 10 15Asp Tyr Asp Tyr 2042520PRTLama glama 425Asp Arg Arg Arg Ala Tyr Ser Arg Trp Arg Tyr Tyr Thr Gly Val Asn1 5 10 15Asp Tyr Glu Phe 2042620PRTLama glama 426Asp Arg Arg Arg Leu Tyr Ser Arg Trp Arg Tyr Tyr Thr Gly Val Asn1 5 10 15Asp Tyr Asp Tyr 2042720PRTLama glama 427Asp Arg Arg Arg Thr Tyr Ser Arg Trp Arg Tyr Tyr Thr Gly Val Asn1 5 10 15Glu Tyr Glu Tyr 2042814PRTLama glama 428Gly Pro Ile Ala Pro Ser Pro Arg Pro Arg Glu Tyr Tyr Tyr1 5 1042920PRTLama glama 429Gly Arg Arg Arg Ala Tyr Ser Arg Trp Arg Tyr Tyr Thr Gly Val Asn1 5 10 15Glu Tyr Asp Tyr 2043016PRTLama glama 430Gly Arg Tyr Tyr Ser Ser Asp Gly Val Pro Ser Ala Ser Phe Asn Tyr1 5 10 1543119PRTLama glama 431Lys Thr Val Asp Tyr Cys Ser Ala Tyr Glu Cys Tyr Ala Arg Leu Glu1 5 10 15Tyr Asp Tyr43218PRTLama glama 432Asp Pro Ser Tyr Tyr Ser Thr Ser Arg Tyr Thr Lys Ala Thr Glu Tyr1 5 10 15Asp Tyr43317PRTLama glama 433Gln Thr Ser Ala Pro Arg Ser Leu Ile Arg Met Ser Asn Glu Tyr Pro1 5 10 15Tyr43414PRTLama glama 434Thr Ser Arg Gly Leu Ser Ser Leu Ala Gly Glu Tyr Asn Tyr1 5 1043514PRTLama glama 435Gly Ala Gln Ser Asp Arg Tyr Asn Ile Arg Ser Tyr Asp Tyr1 5 104366PRTLama glama 436Asp Ser Ala Gly Arg Thr1 543715PRTLama glama 437Thr Arg Ser Ser Thr Ile Val Val Gly Val Gly Gly Met Glu Tyr1 5 10 1543819PRTLama glama 438Asp Thr Gln Asp Leu Gly Leu Asp Ile Phe Cys Arg Gly Asn Gly Pro1 5 10 15Phe Asp Gly43925PRTLama glama 439Glu Arg Glu Gln Leu Arg Arg Arg Glu Ser Pro His Asp Glu Leu Leu1 5 10 15Arg Leu Cys Phe Tyr Gly Met Arg Tyr 20 2544014PRTLama glama 440Ala Phe Arg Cys Ser Gly Tyr Glu Leu Arg Gly Phe Pro Thr1 5 1044117PRTLama glama 441Asp Arg Ser Pro Asn Ile Ile Asn Val Val Thr Ala Tyr Glu Tyr Asp1 5 10 15Tyr44217PRTLama glama 442Pro Glu Gly Ser Phe Arg Arg Gln Tyr Ala Asp Arg Ala Met Tyr Asp1 5 10 15Tyr44318PRTLama glama 443Arg Ser Thr Tyr Ser Tyr Tyr Leu Ala Leu Ala Asp Arg Gly Gly Tyr1 5 10 15Asp Tyr44416PRTLama glama 444Ala Arg Tyr His Gly Asp Tyr Cys Tyr Tyr Glu Gly Tyr Tyr Pro Phe1 5 10 154459PRTLama glama 445Arg Trp Arg Trp Ser Asp Val Glu Tyr1 544613PRTLama glama 446Ala Ile Arg Pro Glu Leu Tyr Ser Val Val Asn Asp Tyr1 5 1044718PRTLama glama 447Asp Arg Val Ser Ser Arg Leu Val Leu Pro Asn Thr Ser Pro Asp Phe1 5 10 15Gly Ser44820PRTLama glama 448Asp Glu Asp Leu Tyr His Tyr Ser Ser Tyr His Tyr Ser Arg Val Asp1 5 10 15Leu Tyr His Tyr 2044915PRTLama glama 449Asn Leu Gly Ser Thr Trp Ser Arg Asp Gln Arg Thr Tyr Asp Tyr1 5 10 154505PRTLama glama 450Ser Tyr Ser Met Gly1 54515PRTLama glama 451Ser Tyr Ser Met Ala1 54525PRTLama glama 452Ser Tyr Ser Val Gly1 545317PRTLama glama 453Ala Ile Ser Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu Glu1 5 10 15Gly45416PRTLama glama 454Ala Ile Ser Ser Gly Gly Phe Ile Tyr Asp Ala Val Ser Leu Glu Gly1 5 10 1545517PRTLama glama 455Ala Ile Ser Ser Ser Gly Asn Tyr Lys Tyr Asp Ser Val Ser Leu Glu1 5 10 15Gly45616PRTLama glama 456Ala Ile Ser Ser Gly Gly Ser Ile Tyr Asp Ser Val Ser Leu Gln Gly1 5 10 1545716PRTLama glama 457Ala Ile Ser Ser Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu Gln Gly1 5 10 1545816PRTLama glama 458Ala Ile Ser Asn Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu Gly1 5 10 1545916PRTLama glama 459Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu Gly1 5 10 1546017PRTLama glama 460Ala Ile Ser Ser Gly Gly Gly Tyr Ile Tyr Asp Ser Val Ser Leu Glu1 5 10 15Gly46116PRTLama glama 461Ala Ile Ser Ser Gly Gly Tyr Lys Tyr Asp Ser Val Ser Leu Glu Gly1 5 10 1546217PRTLama glama 462Ala Ile Ser Ser Ser Gly Asn Tyr Lys Tyr Asp Ser Ala Ser Leu Glu1 5 10 15Gly46316PRTLama glama 463Ala Ile Ser Ser Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu Gly1 5 10 1546416PRTLama glama 464Ala Ile Ala Ser Gly Gly Tyr Ile Tyr Asp Ala Val Ser Leu Glu Gly1 5 10 1546516PRTLama glama 465Ala Ile Ser Lys Gly Gly Tyr Lys Tyr Asp Ala Val Ser Leu Glu Gly1 5 10 1546630PRTLama glama 466Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Gly Ser Phe Ser 20 25 3046730PRTLama glama 467Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Thr Gly Arg Thr Phe Arg 20 25 3046830PRTLama glama 468Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Thr Ser Ile Tyr Thr 20 25 3046930PRTLama glama 469Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ala Val Gly 20 25 3047030PRTLama glama 470Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser 20 25 3047130PRTLama glama 471Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ala Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ser Phe Ser 20 25 3047230PRTLama glama 472Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ile Arg Phe Met 20 25 3047330PRTLama glama 473Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asn Ile Phe Ser 20 25 3047430PRTLama glama 474Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Thr Ser Ile Tyr Ser 20 25 3047530PRTLama glama 475Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Val Ser Thr Ser Ile Tyr Ser 20 25 3047630PRTLama glama 476Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser 20 25 3047730PRTLama glama 477Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ser Phe Ser 20 25 3047830PRTLama glama 478Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ala Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Thr Thr Ser Gly Leu Thr Phe Ser 20 25 3047930PRTLama glama 479Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Val Arg 20 25 3048030PRTLama glama 480Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Ser Thr Phe Gly 20 25 3048130PRTLama glama 481Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Ser Phe Ser 20 25 3048230PRTLama glama 482Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Ser Leu Ser Cys Ala Ala Ser Ala Arg Ala Phe Ser 20 25 3048330PRTLama glama 483Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asp Thr Leu Ser 20 25 3048430PRTLama glama 484Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Glu1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ile Thr Phe Ser 20 25 3048530PRTLama glama 485Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Leu Ser 20 25 3048630PRTLama glama 486Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Met Leu Ser Cys Ala Ala Ser Gly Arg Ala Leu Ser 20 25 3048730PRTLama glama 487Glu Glu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Met Leu Ser Cys Ala Ala Ser Gly Arg Ala Leu Ser 20 25 3048830PRTLama glama 488Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ser Ser Gly Arg Leu Phe Ser 20 25 3048930PRTLama glama 489Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ser Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Ser Phe Ser 20 25 3049030PRTLama glama 490Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ser Val Thr Gly Arg Thr Phe Asn 20 25 3049130PRTLama glama 491Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ala Cys Ala Ala Ser Gly Phe Thr Leu Ser 20 25 3049230PRTLama glama 492Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ala Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Arg Thr Phe Asn 20 25 3049330PRTLama glama 493Glu Val Gln

Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ser Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Asn Thr Phe Gly 20 25 3049430PRTLama glama 494Glu Val Gln Leu Val Glu Ser Glu Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser 20 25 3049530PRTLama glama 495Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Ser Ser 20 25 3049630PRTLama glama 496Glu Val Gln Leu Met Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser 20 25 3049730PRTLama glama 497Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Arg Thr Phe Asn 20 25 3049830PRTLama glama 498Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Phe Thr Ser Ala Arg Thr Phe Asp 20 25 3049930PRTLama glama 499Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Met Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Arg Phe Thr 20 25 3050030PRTLama glama 500Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Asn 20 25 3050130PRTLama glama 501Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser 20 25 3050230PRTLama glama 502Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Ser Ala Phe Lys 20 25 3050330PRTLama glama 503Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Lys Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser 20 25 3050430PRTLama glama 504Lys Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu Arg Thr Phe Ser 20 25 3050530PRTLama glama 505Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly 20 25 3050630PRTLama glama 506Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Leu Asn Leu Asp 20 25 3050730PRTLama glama 507Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Arg Leu Asp 20 25 3050830PRTLama glama 508Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Thr Phe Ser 20 25 3050930PRTLama glama 509Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Ala1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Asp Gly Phe Thr 20 25 3051030PRTLama glama 510Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Ala Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser 20 25 3051130PRTLama glama 511Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Phe Thr Leu Gly 20 25 3051230PRTLama glama 512Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Thr Ser Ile Ser Ser 20 25 3051330PRTLama glama 513Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Thr Thr Ser Ser 20 25 3051430PRTLama glama 514Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Leu Thr Phe Ser 20 25 3051530PRTLama glama 515Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Asn 20 25 3051630PRTLama glama 516Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Ser Phe Ser 20 25 3051714PRTLama glama 517Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu Phe Val Ser1 5 1051814PRTLama glama 518Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala1 5 1051914PRTLama glama 519Trp Tyr Arg Gln Ala Pro Gly Ile Gln Arg Gln Leu Val Ala1 5 1052014PRTLama glama 520Trp Tyr Arg Gln Ala Pro Gly Lys His Arg Glu Leu Val Ala1 5 1052114PRTLama glama 521Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala1 5 1052214PRTLama glama 522Trp Phe Arg Gln Ala Pro Gly Lys Glu Ser Glu Phe Val Ala1 5 1052314PRTLama glama 523Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Ala Phe Val Ala1 5 1052414PRTLama glama 524Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ser1 5 1052514PRTLama glama 525Trp Phe Arg Gln Ala Ala Gly Lys Glu Arg Glu Phe Val Ala1 5 1052614PRTLama glama 526Trp Phe Arg Gln Ala Pro Gly Arg Glu Arg Glu Phe Leu Ser1 5 1052714PRTLama glama 527Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ile1 5 1052814PRTLama glama 528Trp Phe Arg Gln Val Pro Gly Arg Glu Arg Glu Phe Val Ala1 5 1052914PRTLama glama 529Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Val Leu Val Ala1 5 1053014PRTLama glama 530Trp Phe Arg Gln Ala Pro Gly Arg Glu Arg Glu Phe Val Ala1 5 1053114PRTLama glama 531Trp Phe Arg Gln Val Pro Gly Lys Asp Arg Glu Phe Val Ala1 5 1053214PRTLama glama 532Trp Phe Arg Gln Ala Pro Gly Asn Asp Arg Glu Phe Val Ala1 5 1053314PRTLama glama 533Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser1 5 1053414PRTLama glama 534Trp Phe Arg Gln Ala Pro Gly Asn Glu Arg Glu Phe Val Ala1 5 1053514PRTLama glama 535Trp Phe Arg Gln Ala Pro Gly Arg Glu Arg Glu Phe Val Ser1 5 1053614PRTLama glama 536Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Thr1 5 1053714PRTLama glama 537Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ser Val Ala1 5 1053814PRTLama glama 538Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Ile Ser1 5 1053914PRTLama glama 539Trp Phe Arg Gln Gly Pro Gly Lys Glu Arg Glu Phe Val Ala1 5 1054014PRTLama glama 540Trp Phe Arg Gln Thr Pro Gly Thr Glu Arg Glu Phe Val Ala1 5 1054114PRTLama glama 541Trp Phe Arg Arg Thr Pro Gly Lys Glu Asp Glu Phe Val Ala1 5 1054214PRTLama glama 542Trp Phe Arg Gln Ala Pro Gly Asn Glu Arg Glu Gly Val Ser1 5 1054314PRTLama glama 543Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser1 5 1054414PRTLama glama 544Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ala Val Ser1 5 1054514PRTLama glama 545Trp Phe Arg Gln Ser Pro Gly Lys Glu Arg Glu Ile Val Ala1 5 1054614PRTLama glama 546Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Gln Phe Val Ala1 5 1054714PRTLama glama 547Trp Phe Arg Gln Ala Pro Gly Gln Glu Arg Glu Phe Val Ala1 5 1054832PRTLama glama 548Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Thr Pro Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Ala 20 25 3054932PRTLama glama 549Arg Phe Thr Ile Ser Arg Asp Asn Asp Asn Gly Ala Leu Tyr Leu Gln1 5 10 15Met Asn Thr Leu Lys Pro Glu Asp Thr Ala Val Tyr Ser Cys Ala Ala 20 25 3055032PRTLama glama 550Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Arg1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Ser Ala Ile Tyr Tyr Cys Ala Ala 20 25 3055132PRTLama glama 551Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ile Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ala Tyr Tyr Cys Asn Thr 20 25 3055232PRTLama glama 552Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Thr Met Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3055332PRTLama glama 553Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3055432PRTLama glama 554Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Asn Thr 20 25 3055532PRTLama glama 555Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn Ala 20 25 3055632PRTLama glama 556Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Ser Ala Ile Tyr Tyr Cys Ala Ala 20 25 3055732PRTLama glama 557Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Thr Asn Ser Leu Lys Pro Glu Asp Ser Ala Ile Tyr Tyr Cys Ala Ala 20 25 3055832PRTLama glama 558Arg Phe Thr Ile Ser Arg Asp Ser Ala Lys Asn Ser Val Phe Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3055932PRTLama glama 559Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Lys Thr Met Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3056032PRTLama glama 560Arg Phe Thr Val Ser Arg Asp Asn Asn Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3056132PRTLama glama 561Arg Phe Thr Ile Ser Arg Asp Asp Ala Ala Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn Ala 20 25 3056232PRTLama glama 562Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Val Asn Leu Gln1 5 10 15Met Asn Gly Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Gly 20 25 3056332PRTLama glama 563Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Ser Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3056432PRTLama glama 564Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ile Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3056532PRTLama glama 565Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3056632PRTLama glama 566Arg Phe Ala Val Ser Arg Asp Asn Ala Lys Asn Thr Gly Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Leu Glu Asp Thr Ala Thr Tyr Tyr Cys Ala Ala 20 25 3056732PRTLama glama 567Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Leu Tyr Ser Cys Ala Lys 20 25 3056832PRTLama glama 568Arg Phe Thr Val Ser Val Asp Asn Ala Lys Asn Thr Val Tyr Leu Lys1 5 10 15Met Asn Ser Leu Glu Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3056932PRTLama glama 569Arg Phe Thr Ile Ser Arg Gly Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ala Tyr Tyr Cys Ala Ala 20 25 3057032PRTLama glama 570Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Asn Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3057132PRTLama glama 571Arg Phe Thr Ile Ser Thr Asp Asn Ala Lys Asn Ile Leu Phe Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Val 20 25 3057232PRTLama glama 572Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Val Asn Ser Leu Lys Pro Glu Asp Ser Ala Ile Tyr Tyr Cys Ala Ala 20 25 3057332PRTLama glama 573Arg Phe Thr Ile Ser Arg Asp Ser Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Leu Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr 20 25 3057432PRTLama glama 574Arg Phe Thr Ile Ser Gly Asp Asn Thr Lys Asn Lys Ile Phe Leu Gln1 5 10 15Met Asn Ser Leu Met Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ile 20 25 3057532PRTLama glama 575Arg Phe Ser Val Ser Thr Asp Asn Ala Asn Asn Thr Leu Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Leu Tyr Ser Cys Ala Lys 20 25 3057632PRTLama glama 576Arg Phe Thr Ile Ser Arg Asp Asn Ala Ala Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Asn Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn Ala 20 25 3057732PRTLama glama 577Arg Phe Thr Ile Ser Gly Asp Asn Thr Lys Asn Lys Val Phe Leu Gln1 5 10 15Met Asp Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ile 20 25 3057832PRTLama glama 578Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Asn Leu Thr Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser 20 25 3057932PRTLama glama 579Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val 20 25 3058032PRTLama glama 580Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Pro Lys Pro Glu Asp Thr Ala Val Tyr

Tyr Cys Ala Val 20 25 3058132PRTLama glama 581Arg Phe Thr Ile Ser Arg Asp Lys Ala Lys Asn Thr Val Ser Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val 20 25 3058232PRTLama glama 582Arg Phe Thr Ile Ser Arg Asp Lys Ala Lys Asn Thr Val Ser Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3058332PRTLama glama 583Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Ser Cys Ala Ala 20 25 3058432PRTLama glama 584Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Thr Gln Phe Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Val 20 25 3058532PRTLama glama 585Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Leu Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3058632PRTLama glama 586Arg Phe Ile Ile Ser Arg Asp Asn Ala Gln Asn Thr Leu Phe Leu Gln1 5 10 15Met Asn Asn Thr Ala Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3058732PRTLama glama 587Arg Phe Thr Ile Ser Arg Asp Asn Asp Lys Asn Thr Val Ala Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Gly Ala 20 25 3058832PRTLama glama 588Arg Phe Thr Ile Ser Arg Asp Ile Val Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3058932PRTLama glama 589Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Thr Val Asp Leu Gln1 5 10 15Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3059032PRTLama glama 590Arg Phe Thr Met Ser Arg Asp Lys Ala Lys Asn Ala Gly Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Ala 20 25 3059132PRTLama glama 591Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Phe Leu Gln1 5 10 15Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys 20 25 3059232PRTLama glama 592Arg Phe Thr Ile Ser Ser Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Ile Asn Asp Leu Lys Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Val 20 25 3059332PRTLama glama 593Arg Phe Thr Ile Ser Arg Asp Ser Ala Lys Asn Thr Leu Tyr Leu Gln1 5 10 15Met Asn Ser Leu Ser Ile Glu Asp Thr Gly Val Tyr Tyr Cys Ala Ala 20 25 3059432PRTLama glama 594Arg Phe Thr Phe Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3059532PRTLama glama 595Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Met Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3059632PRTLama glama 596Arg Phe Ser Ile Ser Ile Asn Asn Asp Lys Thr Thr Gly Phe Leu Gln1 5 10 15Met Asn Val Leu Lys Pro Glu Asp Thr Gly Val Tyr Phe Cys Ala Ala 20 25 3059732PRTLama glama 597Arg Phe Thr Thr Ser Thr Asp Asn Ala Arg Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala His Tyr Tyr Cys Ala Ala 20 25 3059832PRTLama glama 598Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Thr Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys His Ala 20 25 3059932PRTLama glama 599Arg Phe Thr Pro Ser Arg Asp Asn Ala Lys Asn Thr Val Ser Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn Ala 20 25 3060032PRTLama glama 600Arg Phe Thr Ile Ser Gly Asp Asn Thr Lys Asn Thr Val Phe Leu Gln1 5 10 15Met Asn Phe Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3060132PRTLama glama 601Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Thr Val Ser Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Asn Ala 20 25 3060231PRTLama glama 602Arg Phe Thr Ile Ser Arg Asp Asn Ala His Thr Val Tyr Leu Gln Met1 5 10 15Asn Ser Leu Lys Pro Glu Asp Thr Ala Ile Tyr Tyr Cys Ala Val 20 25 3060311PRTLama glama 603Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser1 5 1060411PRTLama glama 604Trp Gly Ala Gly Thr Gln Val Thr Val Ser Ser1 5 1060511PRTLama glama 605Trp Gly Gln Gly Thr Pro Val Thr Val Ser Ser1 5 1060611PRTLama glama 606Trp Gly Ala Gly Thr Thr Val Thr Val Ser Ser1 5 1060711PRTLama glama 607Trp Gly Arg Gly Thr Gln Val Thr Val Ser Ser1 5 1060811PRTLama glama 608Arg Gly Arg Gly Thr Gln Val Thr Val Ser Ser1 5 1060911PRTLama glama 609Trp Gly His Gly Thr Gln Val Thr Val Ser Ser1 5 1061011PRTLama glama 610Trp Gly Arg Gly Ala Gln Val Thr Val Ser Ser1 5 1061111PRTLama glama 611Lys Gly Gln Gly Thr Gln Val Thr Val Ser Ser1 5 1061211PRTLama glama 612Trp Gly Lys Gly Thr Leu Val Thr Val Ser Ser1 5 1061311PRTLama glama 613Ser Gly Lys Gly Thr Leu Val Thr Val Ser Ser1 5 1061430PRTLama glama 614Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser 20 25 3061530PRTLama glama 615Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser 20 25 3061630PRTLama glama 616Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser 20 25 3061730PRTLama glama 617Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Val Ala Ser Gly Arg Thr Ser Ser 20 25 3061830PRTLama glama 618Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Ser 20 25 3061930PRTLama glama 619Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser 20 25 3062030PRTLama glama 620Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe Ser 20 25 3062130PRTLama glama 621Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Gly 20 25 3062230PRTLama glama 622Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser 20 25 3062330PRTLama glama 623Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser 20 25 3062430PRTLama glama 624Glu Val Gln Leu Val Glu Ser Glu Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Val Ala Ser Gly Arg Thr Ser Ser 20 25 3062530PRTLama glama 625Glu Met Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser 20 25 3062630PRTLama glama 626Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser 20 25 3062730PRTLama glama 627Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ile Ala Ser Gly Arg Thr Ser Ser 20 25 3062830PRTLama glama 628Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Gly Thr Phe Ser 20 25 3062930PRTLama glama 629Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Pro Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser 20 25 3063030PRTLama glama 630Glu Val Pro Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser 20 25 3063130PRTLama glama 631Glu Val Gln Leu Met Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser 20 25 3063230PRTLama glama 632Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser 20 25 3063330PRTLama glama 633Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Phe Ser Gly Arg Thr Phe Ser 20 25 3063430PRTLama glama 634Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser 20 25 3063530PRTLama glama 635Glu Val Gln Leu Val Glu Ser Glu Gly Gly Leu Val Gln Ala Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser 20 25 3063614PRTLama glama 636Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val Val1 5 1063714PRTLama glama 637Trp Phe Arg Gln Ala Gln Gly Gln Glu Arg Glu Phe Val Val1 5 1063832PRTLama glama 638Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu Gln1 5 10 15Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Asp Tyr Tyr Cys Ala Ala 20 25 3063932PRTLama glama 639Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu Gln1 5 10 15Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3064032PRTLama glama 640Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu Gln1 5 10 15Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3064132PRTLama glama 641Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln1 5 10 15Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3064232PRTLama glama 642Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser 20 25 3064332PRTLama glama 643Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu Gln1 5 10 15Ile Asn Ser Leu Lys Pro Lys Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3064432PRTLama glama 644Arg Phe Thr Ile Ser Arg Asp Asn Thr Gln Asn Thr Val Tyr Leu Gln1 5 10 15Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3064532PRTLama glama 645Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu Gln1 5 10 15Thr Pro Ser Leu Lys Pro Glu Gly Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3064632PRTLama glama 646Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Ala Val Tyr Leu Gln1 5 10 15Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Asp Tyr Tyr Cys Ala Ala 20 25 3064732PRTLama glama 647Arg Phe Thr Ile Ser Arg Glu Asn Thr Lys Asn Thr Val Tyr Leu Gln1 5 10 15Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3064832PRTLama glama 648Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Pro Ser Leu Lys Pro Glu Asp Thr Ala Asp Tyr Tyr Cys Ala Ala 20 25 3064932PRTLama glama 649Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asn Thr Val Tyr Leu Gln1 5 10 15Thr Pro Ser Leu Lys Pro Glu Asp Ala Ala Asp Tyr Tyr Cys Ala Ala 20 25 3065032PRTLama glama 650Arg Phe Thr Ile Ser Arg Asp Asn Thr Arg Asn Thr Val Tyr Leu Gln1 5 10 15Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Asp Tyr Tyr Cys Ala Ala 20 25 3065132PRTLama glama 651Arg Phe Thr Ile Ser Arg Asp Asn Thr Lys Asp Thr Val Tyr Leu Gln1 5 10 15Thr Pro Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3065211PRTLama glama 652Trp Gly Gln Gly Thr Arg Val Thr Val Ser Ser1 5 1065330PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 653Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Arg Thr Phe Ser 20 25 3065430PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 654Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser 20 25 3065530PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 655Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Arg Thr Phe Ser 20 25 3065630PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 656Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser 20 25 3065730PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 657Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser 20 25 3065830PRTArtificial SequenceDescription of Artificial Sequence Synthetic

polypeptide 658Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Arg Thr Phe Ser 20 25 3065914PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 659Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Val1 5 1066032PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 660Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser 20 25 3066132PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 661Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser 20 25 3066232PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 662Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Ile Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser 20 25 3066332PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 663Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser 20 25 3066411PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 664Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser1 5 1066511PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 665Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser1 5 1066630PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 666Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser 20 25 3066730PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 667Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Arg Phe Met 20 25 3066830PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 668Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Ile Arg Phe Ile 20 25 3066914PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 669Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala1 5 1067014PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 670Trp Tyr Arg Gln Ala Pro Gly Lys His Arg Glu Leu Val Ala1 5 1067132PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 671Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Asn Thr 20 25 3067232PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 672Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr Tyr Cys Asn Thr 20 25 3067311PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 673Trp Gly Ala Gly Thr Gln Val Thr Val Ser Ser1 5 1067430PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 674Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Arg Phe Ile 20 25 3067514PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 675Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala1 5 1067614PRTLama glama 676Trp Phe Arg Gln Ala Ala Gly Lys Glu Arg Glu Gly Val Ser1 5 1067732PRTLama glama 677Arg Phe Thr Ile Ser Ser Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3067830PRTLama glama 678Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Leu Asp 20 25 3067914PRTLama glama 679Trp Phe Arg Gln Val Pro Gly Lys Glu Arg Glu Gly Val Ser1 5 1068032PRTLama glama 680Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr 20 25 3068130PRTLama glama 681Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp 20 25 3068214PRTLama glama 682Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser1 5 1068332PRTLama glama 683Arg Phe Thr Ile Ser Ser Asp Asn Asp Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3068430PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 684Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Asp 20 25 3068532PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 685Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala 20 25 3068630PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 686Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp 20 25 3068732PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 687Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln1 5 10 15Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr 20 25 3068830PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 688Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Val Ser Gly Ile Thr Leu Asp 20 25 3068930PRTLama glama 689Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp 20 25 3069030PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 690Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Thr Gly Asp1 5 10 15Ser Leu Arg Leu Ser Cys Glu Val Ser Gly Arg Thr Phe Ser 20 25 3069114PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 691Trp Phe Arg Gln Ala Gln Gly Lys Glu Arg Glu Phe Val Val1 5 1069232PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 692Arg Phe Thr Ile Ser Lys Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln1 5 10 15Ile Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser 20 25 3069330PRTArtificial SequenceDescription of Artificial Sequence Synthetic polypeptide 693Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Leu Asp 20 25 3069414PRTArtificial SequenceDescription of Artificial Sequence Synthetic peptide 694Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Ser1 5 10

Claims

1. A bispecific binding molecule comprising at least one VEGF-binding component, at least one Ang2-binding component and at least one serum albumin binding component, wherein said Ang2-binding component binds to Ang2 with a potency at least 5,000 times higher than to Ang1 or to Ang4.

2. A bispecific binding molecule of claim 1, wherein said VEGF-binding component comprises at least a variable domain with four framework regions and three complementarity determining regions CDR1, CDR2 and CDR3, respectively, wherein said CDR3 has the amino acid sequence Ser Arg Ala Tyr Xaa Ser Xaa Arg Leu Arg Leu Xaa Xaa Thr Tyr Xaa Tyr as shown in SEQ ID NO: 1, wherein Xaa at position 5 is Gly or Ala; Xaa at position 7 is Ser or Gly; Xaa at position 12 is Gly, Ala or Pro; Xaa at position 13 is Asp or Gly; Xaa at position 16 is Asp or Glu; and wherein said VEGF-binding component is capable of blocking the interaction of human recombinant VEGF165 with the human recombinant VEGFR-2 with an inhibition rate of .gtoreq.60.degree. %.

3. A bispecific binding molecule of claim 2, wherein said CDR3 has a sequence selected from TABLE-US-00050 SEQ ID NO: 2 SRAYGSSRLRLGDTYDY, SEQ ID NO: 3 SRAYGSSRLRLADTYDY; SEQ ID NO: 4 SRAYGSSRLRLADTYEY; SEQ ID NO: 5 SRAYGSGRLRLADTYDY; SEQ ID NO: 6 SRAYASSRLRLADTYDY; SEQ ID NO: 7 SRAYGSSRLRLPDTYDY; SEQ ID NO: 8 SRAYGSSRLRLPGTYDY.

4. A bispecific binding molecule of claim 3, wherein said VEGF-binding component comprises one or more immunoglobulin single variable domains each containing a. a CDR3 with an amino acid sequence selected from a first group of sequences shown in SEQ ID NO: 2 to 8; b. a CDR1 and a CDR2 with an amino acid sequences that is contained, as indicated in Table 3, in a sequence selected from a second group of sequences shown in SEQ ID NOs: 9 to 46, wherein said second sequence contains the respective CDR3 in said selected sequence according to a).

5. A bispecific binding molecule of claim 4, wherein said one or more immunoglobulin single variable domains are VHHs.

6. A bispecific binding molecule of claim 5, wherein said one or more VHHs have amino acid sequences selected from the amino acid sequences shown in SEQ ID NOs: 9-46.

7. A bispecific binding molecule of claim 6, which comprises one or more VHHs having amino acid sequences selected from SEQ ID NO: 15, SEQ ID NO: 18 and SEQ ID NO: 25.

8. A bispecific binding molecule, the VEGF-binding component of which has been obtained by affinity maturation and/or sequence optimization of a VHH defined in claim 7.

9. A bispecific binding molecule according to claim 8, the VEGF-binding component of which has been obtained by sequence optimization of a VHH having an amino acid sequence shown in SEQ ID NO: 18.

10. A bispecific binding molecule according to claim 9, the VEGF-binding component of which having an amino acid sequence selected from sequences shown in SEQ ID NOs: 47-57.

11. A bispecific binding molecule according to claim 5, the VEGF-binding component of which comprising two or more VHHs, which are a. identical VHHs that are capable of blocking the interaction between recombinant human VEGF and the recombinant human VEGFR-2 with an inhibition rate of 60% or b. different VHHs that bind to non-overlapping epitopes of VEGF, wherein at least one VHH is capable of blocking the interaction between recombinant human VEGF and the recombinant human VEGFR-2 with an inhibition rate of .gtoreq.60% and wherein at least one VHH is capable of blocking said interaction with an inhibition rate of .ltoreq.60%.

12. A bispecific binding molecule according to claim 11, wherein said identical VHHs a) are selected from VHHs having amino acid sequences shown in SEQ ID NOs: 9-46 or VHHs that have been obtained by affinity maturation and/or sequence optimization of such VHH.

13. A bispecific binding molecule according to claim 12, wherein said VHH is selected from VHHs having the amino acid shown in SEQ ID NO: 18 or SEQ ID NO: 47-57.

14. A bispecific binding molecule according to claim 13 comprising two VHHs each having the amino acid sequence shown in SEQ ID NO: 57.

15. A bispecific binding molecule according to claim 14, wherein a. said one or more VHHs with an inhibition rate of .gtoreq.60% are selected from i. VHHs having an amino acid sequence selected from amino acid sequences shown in SEQ ID NOs: 9-46 or ii. VHHs that have been obtained by affinity maturation and/or sequence optimization of such VHHs, and wherein b. said one or more VHHs with an inhibition rate of .ltoreq.60% are selected from i. SEQ ID NOs: 58-124 or ii. VHHs that have been obtained by affinity maturation and/or sequence optimization of such VHH.

16. A bispecific binding molecule according to claim 15, wherein two VHHs are contained in polypeptides with amino acid sequences shown in SEQ ID NOs: 128-168, separated by linker sequences as indicated in Table 13.

17. A bispecific binding molecule according to claim 16, wherein said VHH a) i. has an amino acid sequence shown in SEQ ID NO: 18 and said VHH b) i. has an amino acid sequence shown in SEQ ID NO: 64.

18. A bispecific binding molecule according to claim 17, wherein said VHHs according to a) ii) are selected from VHHs having an amino acid sequence shown in SEQ ID NOs: 47-57 and wherein said VHHs according to b) ii) are selected from VHHs having an amino acid sequence shown in SEQ ID NOs: 125-127.

19. A bispecific binding molecule according to claim 18, comprising two VHHs, one of them having the amino acid shown in SEQ ID NO: 57 and one of them having the amino acid shown in SEQ ID NO: 127.

20. The bispecific binding molecule of claim 1, comprising an Ang2-binding component comprising at least a variable domain with four framework regions and three complementarity determining regions CDR1, CDR2 and CDR3, respectively, wherein said CDR3 has an amino acid sequence selected from amino acid sequences shown in SEQ IDs NOs: 226, 229, 232, 235, 238, 241, 244, 247, 250, or 253.

21. The bispecific binding molecule of claim 20, the Ang2-binding component of which is an isolated immunoglobulin single variable domain or a polypeptide containing one or more of said immunoglobulin single variable domains, wherein said immunoglobulin single variable domain consists of four framework regions and three complementarity determining regions CDR1, CDR2 and CDR3, respectively, and wherein said CDR3 has an amino acid sequence selected from amino acid sequences shown in SEQ IDs NOs: 226, 229, 232, 235, 238, 241, 244, 247, 250, or 253.

22. The bispecific binding molecule of claim 21, wherein said one or more immunoglobulin single variable domain contain a. a CDR3 with an amino acid sequence selected from a first group of amino acid sequences shown in SEQ ID NOs: SEQ IDs NOs: 226, 229, 232, 235, 238, 241, 244, 247, 250, or 253 (Table 49); b. a CDR1 with an amino acid sequences that is contained, as indicated in Table 36-A, 38-A, 41-A, or 45-A, as partial sequence in a sequence selected from a second group of amino acid sequences shown SEQ ID NOs: 224, 227, 230, 233, 236, 239, 242, 245, 248, or 251 (Table 49); c. a CDR2 with an amino acid sequences that is contained, as indicated in Table 36-A, 38-A, 41-A, or 45-A, as partial sequence in a sequence selected from a second group of amino acid sequences shown SEQ ID NOs:225, 228, 231, 234, 237, 240, 243, 246, 249, or 252 (Table 49).

23. The bispecific binding molecule of claim 20, wherein said one or more immunoglobulin single variable domains are VHHs.

24. The bispecific binding molecule of claim 23, wherein said one or more VHHs have an amino acid sequence selected from amino acid sequences shown in SEQ ID NOs: 214, 215, 216, 217, 218, 219, 220, 221, 222, or 223.

25. An immunoglobulin single variable domain which has been obtained by affinity maturation of an immunoglobulin single variable domain as defined in claim 22.

26. A VHH which has been obtained by affinity maturation of a VHH as defined in claim 24.

27. An Ang2-binding VHH with an amino acid sequence selected from acid sequences shown in SEQ ID NOs: 214, 215, 216, 217, 218, 219, 220, 221, 222, or 223.

28. An immunoglobulin single variable domain which has been obtained by humanization of a VHH defined in claim 27.

29. An immunoglobulin single variable domain which has been obtained by humanization of an immunoglobulin single variable domain as defined in claim 22.

30. The binding molecule of claim 1, the serum albumin binding component of which is an isolated immunoglobulin single variable domain or a polypeptide containing one or more of said immunoglobulin single variable domains, wherein said immunoglobulin single variable domain consists of four framework regions and three complementarity determining regions CDR1, CDR2 and CDR3, respectively, and wherein said CDR3 has an amino acid sequence selected from amino acid sequences shown in SEQ ID NOs: 257, 260, 263, 266, 269, 272, or 275.

31. The binding molecule of claim 30, wherein said one or more immunoglobulin single variable domain contain a. a CDR3 with an amino acid sequence selected from a first group of amino acid sequences shown in SEQ ID NOs: SEQ IDs NOs: 257, 260, 263, 266, 269, 272, or 275; b. a CDR1 with an amino acid sequences selected from a second group of amino acid sequences shown SEQ ID NOs: 255, 258, 261, 264, 267, 270, or 273; c. a CDR2 with an amino acid sequences selected from a second group of amino acid sequences shown SEQ ID NOs: 256, 259, 262, 265, 268, 271, or 274.

32. The bispecific binding molecule of claim 30, wherein said one or more immunoglobulin single variable domains are VHHs.

33. The bispecific binding molecule of claim 32, wherein said one or more VHHs have an amino acid sequence shown in SEQ ID NOs: 98 or 254.

34. The bispecific binding molecule of claim 1 having the amino acid sequence selected from amino acid sequences shown in SEQ ID NOs: 180-213.

35. A nucleic acid molecule encoding a bispecific binding molecule of claim 1 or a vector containing same.

36. A host cell comprising a nucleic acid molecule of claim 35.

37. A pharmaceutical composition comprising at least one bispecific binding molecule of claim 1 as the active ingredient.

38. A method of treating a disease that is associated with VEGF- and/or Ang2-mediated effects on angiogenesis comprising administering to a patient an effective amount of a pharmaceutical composition according to claim 37.

39. The method of claim 38 wherein the disease is selected from cancer and cancerous diseases.

40. The method of claim 38 wherein the disease is eye diseases.